words,sentence_id,labels
Two,0,O
distinct,0,O
mutations,0,O
at,0,O
a,0,O
single,0,O
BamHI,0,O
site,0,O
in,0,O
phenylketonuria,0,B-DiseaseOrPhenotypicFeature
.,0,O
Classical,1,B-DiseaseOrPhenotypicFeature
phenylketonuria,1,I-DiseaseOrPhenotypicFeature
is,1,O
an,1,O
autosomal,1,B-DiseaseOrPhenotypicFeature
recessive,1,I-DiseaseOrPhenotypicFeature
disease,1,I-DiseaseOrPhenotypicFeature
caused,1,O
by,1,O
a,1,O
deficiency,1,B-DiseaseOrPhenotypicFeature
of,1,I-DiseaseOrPhenotypicFeature
hepatic,1,I-DiseaseOrPhenotypicFeature
phenylalanine,1,I-DiseaseOrPhenotypicFeature
hydroxylase,1,I-DiseaseOrPhenotypicFeature
(,1,O
PAH,1,B-GeneOrGeneProduct
),1,O
.,1,O
The,2,O
abolition,2,O
of,2,O
an,2,O
invariant,2,O
BamHI,2,O
site,2,O
located,2,O
in,2,O
the,2,O
coding,2,O
sequence,2,O
of,2,O
the,2,O
PAH,2,B-GeneOrGeneProduct
gene,2,O
(,2,O
exon,2,O
7,2,O
),2,O
led,2,O
to,2,O
the,2,O
recognition,2,O
of,2,O
two,2,O
new,2,O
point,2,O
mutations,2,O
at,2,O
codon,2,O
272,2,O
and,2,O
273,2,O
(,2,O
272gly,2,B-SequenceVariant
--,2,I-SequenceVariant
--,2,I-SequenceVariant
stop,2,I-SequenceVariant
and,2,O
273ser,2,B-SequenceVariant
--,2,I-SequenceVariant
--,2,I-SequenceVariant
phe,2,I-SequenceVariant
",",2,O
respectively,2,O
),2,O
.,2,O
Both,3,O
mutations,3,O
were,3,O
detected,3,O
in,3,O
north,3,O
eastern,3,O
France,3,O
or,3,O
Belgium,3,O
and,3,O
occurred,3,O
on,3,O
the,3,O
background,3,O
of,3,O
RFLP,3,O
haplotype,3,O
7,3,O
alleles,3,O
.,3,O
The,4,O
present,4,O
study,4,O
supports,4,O
the,4,O
view,4,O
that,4,O
the,4,O
clinical,4,O
heterogeneity,4,O
in,4,O
PKU,4,B-DiseaseOrPhenotypicFeature
is,4,O
accounted,4,O
for,4,O
by,4,O
the,4,O
large,4,O
variety,4,O
of,4,O
mutant,4,O
genotypes,4,O
associated,4,O
with,4,O
PAH,4,B-DiseaseOrPhenotypicFeature
deficiencies,4,I-DiseaseOrPhenotypicFeature
..,4,O
Localisation,5,O
of,5,O
the,5,O
Becker,5,B-GeneOrGeneProduct
muscular,5,I-GeneOrGeneProduct
dystrophy,5,I-GeneOrGeneProduct
gene,5,I-GeneOrGeneProduct
on,5,O
the,5,O
short,5,O
arm,5,O
of,5,O
the,5,O
X,5,O
chromosome,5,O
by,5,O
linkage,5,O
to,5,O
cloned,5,O
DNA,5,O
sequences,5,O
.,5,O
A,6,O
linkage,6,O
study,6,O
in,6,O
30,6,O
Becker,6,B-DiseaseOrPhenotypicFeature
muscular,6,I-DiseaseOrPhenotypicFeature
dystrophy,6,I-DiseaseOrPhenotypicFeature
(,6,O
BMD,6,B-DiseaseOrPhenotypicFeature
),6,O
kindreds,6,O
using,6,O
three,6,O
cloned,6,O
DNA,6,O
sequences,6,O
from,6,O
the,6,O
X,6,O
chromosome,6,O
which,6,O
demonstrate,6,O
restriction,6,O
fragment,6,O
length,6,O
polymorphisms,6,O
(,6,O
RFLPs,6,O
),6,O
",",6,O
suggests,6,O
that,6,O
the,6,O
BMD,6,B-GeneOrGeneProduct
gene,6,O
is,6,O
located,6,O
on,6,O
the,6,O
short,6,O
arm,6,O
of,6,O
the,6,O
X,6,O
chromosome,6,O
",",6,O
in,6,O
the,6,O
p21,6,O
region,6,O
.,6,O
The,7,O
genes,7,O
for,7,O
Becker,7,B-DiseaseOrPhenotypicFeature
and,7,I-DiseaseOrPhenotypicFeature
Duchenne,7,I-DiseaseOrPhenotypicFeature
dystrophies,7,I-DiseaseOrPhenotypicFeature
must,7,O
therefore,7,O
be,7,O
closely,7,O
linked,7,O
",",7,O
if,7,O
not,7,O
allelic,7,O
",",7,O
and,7,O
any,7,O
future,7,O
DNA,7,O
probes,7,O
found,7,O
to,7,O
be,7,O
of,7,O
practical,7,O
use,7,O
in,7,O
one,7,O
disorder,7,O
should,7,O
be,7,O
equally,7,O
applicable,7,O
to,7,O
the,7,O
other,7,O
.,7,O
The,8,O
linkage,8,O
analysis,8,O
also,8,O
provides,8,O
data,8,O
on,8,O
the,8,O
frequency,8,O
of,8,O
recombination,8,O
along,8,O
the,8,O
short,8,O
arm,8,O
of,8,O
the,8,O
X,8,O
chromosome,8,O
",",8,O
and,8,O
across,8,O
the,8,O
centromeric,8,O
region,8,O
..,8,O
X-linked,9,B-DiseaseOrPhenotypicFeature
adrenoleukodystrophy,9,I-DiseaseOrPhenotypicFeature
(,9,O
ALD,9,B-DiseaseOrPhenotypicFeature
),9,O
:,9,O
a,9,O
novel,9,O
mutation,9,O
of,9,O
the,9,O
ALD,9,B-GeneOrGeneProduct
gene,9,O
in,9,O
6,9,O
members,9,O
of,9,O
a,9,O
family,9,O
presenting,9,O
with,9,O
5,9,O
different,9,O
phenotypes,9,O
.,9,O
Fragments,10,O
of,10,O
the,10,O
adrenoleukodystrophy,10,B-DiseaseOrPhenotypicFeature
(,10,O
ALD,10,B-DiseaseOrPhenotypicFeature
),10,O
cDNA,10,O
from,10,O
a,10,O
patient,10,B-OrganismTaxon
with,10,O
adolescent,10,O
ALD,10,B-DiseaseOrPhenotypicFeature
were,10,O
amplified,10,O
by,10,O
polymerase,10,O
chain,10,O
reaction,10,O
and,10,O
subcloned,10,O
.,10,O
Bidirectional,11,O
sequencing,11,O
of,11,O
the,11,O
entire,11,O
coding,11,O
ALD,11,B-GeneOrGeneProduct
gene,11,O
disclosed,11,O
a,11,O
cytosine,11,B-SequenceVariant
to,11,I-SequenceVariant
guanine,11,I-SequenceVariant
transversion,11,I-SequenceVariant
at,11,I-SequenceVariant
nucleotide,11,I-SequenceVariant
1451,11,I-SequenceVariant
in,11,O
exon,11,O
five,11,O
",",11,O
resulting,11,O
in,11,O
substitution,11,O
of,11,O
proline,11,B-SequenceVariant
484,11,I-SequenceVariant
by,11,I-SequenceVariant
arginine,11,I-SequenceVariant
.,11,O
Five,12,O
of,12,O
nine,12,O
siblings,12,O
of,12,O
the,12,O
patient,12,B-OrganismTaxon
",",12,O
comprising,12,O
two,12,O
cerebral,12,O
ALD,12,B-DiseaseOrPhenotypicFeature
",",12,O
one,12,O
adrenomyeloneuropathy,12,B-DiseaseOrPhenotypicFeature
",",12,O
one,12,O
Addison,12,B-DiseaseOrPhenotypicFeature
only,12,O
as,12,O
well,12,O
as,12,O
the,12,O
symptomatic,12,O
mother,12,O
(,12,O
all,12,O
accumulating,12,O
very,12,O
long,12,B-ChemicalEntity
chain,12,I-ChemicalEntity
fatty,12,I-ChemicalEntity
acids,12,I-ChemicalEntity
),12,O
carried,12,O
this,12,O
mutation,12,O
",",12,O
which,12,O
was,12,O
not,12,O
found,12,O
in,12,O
the,12,O
unaffected,12,O
persons,12,O
",",12,O
in,12,O
five,12,O
unrelated,12,O
ALD,12,B-DiseaseOrPhenotypicFeature
patients,12,B-OrganismTaxon
",",12,O
and,12,O
in,12,O
twenty,12,O
controls,12,O
.,12,O
We,13,O
propose,13,O
that,13,O
this,13,O
missense,13,O
mutation,13,O
generated,13,O
the,13,O
disease,13,O
per,13,O
se,13,O
as,13,O
well,13,O
as,13,O
the,13,O
metabolic,13,O
defect,13,O
;,13,O
the,13,O
different,13,O
phenotypes,13,O
",",13,O
however,13,O
",",13,O
must,13,O
have,13,O
originated,13,O
by,13,O
means,13,O
of,13,O
additional,13,O
pathogenetic,13,O
factors,13,O
..,13,O
Detection,14,O
of,14,O
heterozygous,14,O
mutations,14,O
in,14,O
BRCA1,14,B-GeneOrGeneProduct
using,14,O
high,14,O
density,14,O
oligonucleotide,14,O
arrays,14,O
and,14,O
two-colour,14,O
fluorescence,14,O
analysis,14,O
.,14,O
The,15,O
ability,15,O
to,15,O
scan,15,O
a,15,O
large,15,O
gene,15,O
rapidly,15,O
and,15,O
accurately,15,O
for,15,O
all,15,O
possible,15,O
heterozygous,15,O
mutations,15,O
in,15,O
large,15,O
numbers,15,O
of,15,O
patient,15,B-OrganismTaxon
samples,15,O
will,15,O
be,15,O
critical,15,O
for,15,O
the,15,O
future,15,O
of,15,O
medicine,15,O
.,15,O
We,16,O
have,16,O
designed,16,O
high-density,16,O
arrays,16,O
consisting,16,O
of,16,O
over,16,O
96,16,O
",",16,O
600,16,O
oligonucleotides,16,O
20-nucleotides,16,O
(,16,O
nt,16,O
),16,O
in,16,O
length,16,O
to,16,O
screen,16,O
for,16,O
a,16,O
wide,16,O
range,16,O
of,16,O
heterozygous,16,O
mutations,16,O
in,16,O
the,16,O
3,16,O
.,16,O
45-kilobases,17,O
(,17,O
kb,17,O
),17,O
exon,17,O
11,17,O
of,17,O
the,17,O
hereditary,17,O
breast,17,B-GeneOrGeneProduct
and,17,I-GeneOrGeneProduct
ovarian,17,I-GeneOrGeneProduct
cancer,17,I-GeneOrGeneProduct
gene,17,I-GeneOrGeneProduct
BRCA1,17,B-GeneOrGeneProduct
.,17,O
Reference,18,O
and,18,O
test,18,O
samples,18,O
were,18,O
co-hybridized,18,O
to,18,O
these,18,O
arrays,18,O
and,18,O
differences,18,O
in,18,O
hybridization,18,O
patterns,18,O
quantitated,18,O
by,18,O
two-colour,18,O
analysis,18,O
.,18,O
Fourteen,19,O
of,19,O
fifteen,19,O
patient,19,B-OrganismTaxon
samples,19,O
with,19,O
known,19,O
mutations,19,O
were,19,O
accurately,19,O
diagnosed,19,O
",",19,O
and,19,O
no,19,O
false,19,O
positive,19,O
mutations,19,O
were,19,O
identified,19,O
in,19,O
20,19,O
control,19,O
samples,19,O
.,19,O
Eight,20,O
single,20,O
nucleotide,20,O
polymorphisms,20,O
were,20,O
also,20,O
readily,20,O
detected,20,O
.,20,O
DNA,21,O
chip-based,21,O
assays,21,O
may,21,O
provide,21,O
a,21,O
valuable,21,O
new,21,O
technology,21,O
for,21,O
high-throughput,21,O
cost-efficient,21,O
detection,21,O
of,21,O
genetic,21,O
alterations,21,O
.,21,O
Congenital,22,B-DiseaseOrPhenotypicFeature
hypothyroidism,22,I-DiseaseOrPhenotypicFeature
due,22,O
to,22,O
a,22,O
new,22,O
deletion,22,O
in,22,O
the,22,O
sodium/iodide,22,B-GeneOrGeneProduct
symporter,22,I-GeneOrGeneProduct
protein,22,O
.,22,O
OBJECTIVE,23,O
:,23,O
Iodide,23,B-DiseaseOrPhenotypicFeature
transport,23,I-DiseaseOrPhenotypicFeature
defect,23,I-DiseaseOrPhenotypicFeature
(,23,O
ITD,23,B-DiseaseOrPhenotypicFeature
),23,O
is,23,O
a,23,O
rare,23,O
disorder,23,O
characterised,23,O
by,23,O
an,23,O
inability,23,B-DiseaseOrPhenotypicFeature
of,23,I-DiseaseOrPhenotypicFeature
the,23,I-DiseaseOrPhenotypicFeature
thyroid,23,I-DiseaseOrPhenotypicFeature
to,23,O
maintain,23,O
an,23,O
iodide,23,B-ChemicalEntity
gradient,23,O
across,23,O
the,23,O
basolateral,23,O
membrane,23,O
of,23,O
thyroid,23,O
follicular,23,O
cells,23,O
",",23,O
that,23,O
often,23,O
results,23,O
in,23,O
congenital,23,B-DiseaseOrPhenotypicFeature
hypothyroidism,23,I-DiseaseOrPhenotypicFeature
.,23,O
When,24,O
present,24,O
the,24,O
defect,24,O
is,24,O
also,24,O
found,24,O
in,24,O
the,24,O
salivary,24,O
glands,24,O
and,24,O
gastric,24,O
mucosa,24,O
and,24,O
it,24,O
has,24,O
been,24,O
shown,24,O
to,24,O
arise,24,O
from,24,O
abnormalities,24,O
of,24,O
the,24,O
sodium/iodide,24,B-GeneOrGeneProduct
symporter,24,I-GeneOrGeneProduct
(,24,O
NIS,24,B-GeneOrGeneProduct
),24,O
.,24,O
PATIENT,25,B-OrganismTaxon
:,25,O
We,25,O
describe,25,O
a,25,O
woman,25,B-OrganismTaxon
with,25,O
hypothyroidism,25,B-DiseaseOrPhenotypicFeature
identified,25,O
at,25,O
the,25,O
3rd,25,O
month,25,O
of,25,O
life,25,O
.,25,O
The,26,O
diagnosis,26,O
of,26,O
ITD,26,B-DiseaseOrPhenotypicFeature
was,26,O
suspected,26,O
because,26,O
of,26,O
nodular,26,B-DiseaseOrPhenotypicFeature
goitre,26,I-DiseaseOrPhenotypicFeature
",",26,O
and,26,O
little,26,O
if,26,O
any,26,O
iodide,26,B-ChemicalEntity
uptake,26,O
by,26,O
the,26,O
thyroid,26,O
and,26,O
salivary,26,O
glands,26,O
.,26,O
Treatment,27,O
with,27,O
iodide,27,B-ChemicalEntity
partially,27,O
corrected,27,O
the,27,O
hypothyroidism,27,B-DiseaseOrPhenotypicFeature
;,27,O
however,27,O
",",27,O
long-term,27,O
substitution,27,O
therapy,27,O
with,27,O
L-thyroxine,27,B-ChemicalEntity
was,27,O
started,27,O
.,27,O
MEASUREMENTS,28,O
:,28,O
Thyroid,28,O
radioiodide,28,B-ChemicalEntity
uptake,28,O
was,28,O
only,28,O
1.4,28,O
%,28,O
and,28,O
0.3,28,O
%,28,O
at,28,O
1,28,O
and,28,O
24,28,O
h,28,O
after,28,O
the,28,O
administration,28,O
of,28,O
recombinant,28,O
human,28,B-OrganismTaxon
TSH,28,B-GeneOrGeneProduct
.,28,O
The,29,O
saliva,29,O
to,29,O
plasma,29,O
I-,29,B-ChemicalEntity
ratio,29,O
was,29,O
1.1,29,O
indicating,29,O
that,29,O
the,29,O
inability,29,O
of,29,O
the,29,O
thyroid,29,O
gland,29,O
to,29,O
concentrate,29,O
I-,29,B-ChemicalEntity
was,29,O
also,29,O
present,29,O
in,29,O
the,29,O
salivary,29,O
glands,29,O
.,29,O
RESULTS,30,O
:,30,O
Analysis,30,O
of,30,O
the,30,O
patient,30,B-OrganismTaxon
's,30,O
NIS,30,B-GeneOrGeneProduct
gene,30,O
revealed,30,O
a,30,O
15,30,O
nucleotide,30,O
(,30,O
nt,30,O
),30,O
deletion,30,B-SequenceVariant
of,30,I-SequenceVariant
the,30,I-SequenceVariant
coding,30,I-SequenceVariant
sequence,30,I-SequenceVariant
(,30,I-SequenceVariant
nt,30,I-SequenceVariant
1314,30,I-SequenceVariant
through,30,I-SequenceVariant
nt,30,I-SequenceVariant
1328,30,I-SequenceVariant
),30,I-SequenceVariant
and,30,O
the,30,O
insertion,30,B-SequenceVariant
of,30,I-SequenceVariant
15,30,I-SequenceVariant
nt,30,I-SequenceVariant
duplicating,30,I-SequenceVariant
the,30,I-SequenceVariant
first,30,I-SequenceVariant
15,30,I-SequenceVariant
nt,30,O
of,30,O
the,30,O
adjacent,30,O
intron,30,O
.,30,O
The,31,O
patient,31,B-OrganismTaxon
was,31,O
homozygous,31,O
for,31,O
this,31,O
insertion/deletion,31,O
",",31,O
while,31,O
both,31,O
consanguineous,31,O
parents,31,O
were,31,O
heterozygous,31,O
.,31,O
This,32,O
deletion,32,O
predicts,32,O
the,32,O
production,32,O
of,32,O
a,32,O
protein,32,O
lacking,32,B-SequenceVariant
the,32,I-SequenceVariant
five,32,I-SequenceVariant
terminal,32,I-SequenceVariant
amino,32,I-SequenceVariant
acids,32,I-SequenceVariant
of,32,I-SequenceVariant
exon,32,I-SequenceVariant
XI,32,I-SequenceVariant
(,32,I-SequenceVariant
439-443,32,I-SequenceVariant
),32,I-SequenceVariant
which,32,O
are,32,O
located,32,O
in,32,O
the,32,O
6th,32,O
intracellular,32,O
loop,32,O
.,32,O
COS-7,33,B-CellLine
cells,33,O
transfected,33,O
with,33,O
a,33,O
vector,33,O
expressing,33,O
the,33,O
mutant,33,O
del-,33,B-SequenceVariant
(,33,I-SequenceVariant
439-443,33,I-SequenceVariant
),33,I-SequenceVariant
NIS,33,B-GeneOrGeneProduct
failed,33,O
to,33,O
concentrate,33,O
iodide,33,B-ChemicalEntity
",",33,O
suggesting,33,O
that,33,O
the,33,O
mutation,33,O
was,33,O
the,33,O
direct,33,O
cause,33,O
of,33,O
the,33,O
ITD,33,B-DiseaseOrPhenotypicFeature
in,33,O
this,33,O
patient,33,B-OrganismTaxon
.,33,O
CONCLUSION,34,O
:,34,O
In,34,O
conclusion,34,O
we,34,O
describe,34,O
the,34,O
first,34,O
Italian,34,O
case,34,O
of,34,O
congenital,34,B-DiseaseOrPhenotypicFeature
hypothyroidism,34,I-DiseaseOrPhenotypicFeature
due,34,O
to,34,O
a,34,O
new,34,O
deletion,34,O
in,34,O
the,34,O
NIS,34,B-GeneOrGeneProduct
gene,34,O
.,34,O
Comparison,35,O
of,35,O
sequential,35,O
cytomegalovirus,35,B-OrganismTaxon
isolates,35,O
in,35,O
a,35,O
patient,35,B-OrganismTaxon
with,35,O
lymphoma,35,B-DiseaseOrPhenotypicFeature
and,35,O
failing,35,O
antiviral,35,O
therapy,35,O
.,35,O
BACKGROUND,36,O
:,36,O
Long-term,36,B-DiseaseOrPhenotypicFeature
anti-cytomegalovirus,36,I-DiseaseOrPhenotypicFeature
(,36,O
CMV,36,B-DiseaseOrPhenotypicFeature
),36,O
treatments,36,O
in,36,O
immunocompromised,36,O
patients,36,B-OrganismTaxon
are,36,O
hampered,36,O
by,36,O
resistance,36,O
to,36,O
antiviral,36,O
drugs,36,O
.,36,O
Longitudinal,37,O
changes,37,O
in,37,O
the,37,O
resistance,37,O
genotype,37,O
may,37,O
depend,37,O
on,37,O
changes,37,O
in,37,O
selective,37,O
pressure,37,O
and,37,O
the,37,O
complexity,37,O
of,37,O
CMV,37,B-DiseaseOrPhenotypicFeature
isolates,37,O
.,37,O
OBJECTIVE,38,O
:,38,O
To,38,O
evaluate,38,O
longitudinal,38,O
changes,38,O
in,38,O
the,38,O
CMV,38,B-DiseaseOrPhenotypicFeature
resistance,38,O
genotype,38,O
and,38,O
phenotype,38,O
along,38,O
with,38,O
strain-specific,38,O
variability,38,O
in,38,O
a,38,O
patient,38,B-OrganismTaxon
with,38,O
non-Hodgkin,38,B-DiseaseOrPhenotypicFeature
's,38,I-DiseaseOrPhenotypicFeature
lymphoma,38,I-DiseaseOrPhenotypicFeature
in,38,O
whom,38,O
successive,38,O
anti-CMV,38,O
treatments,38,O
failed,38,O
.,38,O
STUDY,39,O
DESIGN,39,O
:,39,O
The,39,O
resistance,39,O
phenotype,39,O
and,39,O
genotype,39,O
of,39,O
seven,39,O
CMV,39,B-DiseaseOrPhenotypicFeature
isolates,39,O
collected,39,O
from,39,O
one,39,O
patient,39,B-OrganismTaxon
during,39,O
a,39,O
2-year,39,O
follow-up,39,O
period,39,O
were,39,O
retrospectively,39,O
analysed,39,O
.,39,O
In,40,O
parallel,40,O
",",40,O
we,40,O
used,40,O
glycoprotein,40,B-GeneOrGeneProduct
B,40,I-GeneOrGeneProduct
(,40,O
gB,40,B-GeneOrGeneProduct
),40,O
genotyping,40,O
",",40,O
and,40,O
a-,40,O
and,40,O
UL10-13-sequence,40,O
analysis,40,O
to,40,O
study,40,O
CMV,40,B-DiseaseOrPhenotypicFeature
interstrain,40,O
variability,40,O
.,40,O
RESULTS,41,O
:,41,O
The,41,O
patient,41,B-OrganismTaxon
was,41,O
infected,41,O
by,41,O
at,41,O
least,41,O
three,41,O
CMV,41,B-DiseaseOrPhenotypicFeature
strains,41,O
plus,41,O
variants,41,O
of,41,O
the,41,O
parental,41,O
strains,41,O
.,41,O
Resistance,42,O
to,42,O
ganciclovir,42,B-ChemicalEntity
",",42,O
cidofovir,42,B-ChemicalEntity
and,42,O
foscarnet,42,B-ChemicalEntity
was,42,O
successively,42,O
detected,42,O
during,42,O
the,42,O
follow-up,42,O
period,42,O
.,42,O
UL97,43,B-GeneOrGeneProduct
protein,43,I-GeneOrGeneProduct
kinase,43,I-GeneOrGeneProduct
changes,43,O
responsible,43,O
for,43,O
resistance,43,O
to,43,O
ganciclovir,43,B-ChemicalEntity
were,43,O
initially,43,O
detected,43,O
at,43,O
residues,43,O
591,43,O
and,43,O
592,43,O
",",43,O
and,43,O
then,43,O
at,43,O
position,43,O
594,43,O
.,43,O
Decreased,44,O
sensitivity,44,O
to,44,O
foscarnet,44,B-ChemicalEntity
coincided,44,O
with,44,O
the,44,O
appearance,44,O
of,44,O
amino,44,O
acid,44,O
substitution,44,O
N495K,44,B-SequenceVariant
in,44,O
DNA,44,O
polymerase,44,O
",",44,O
whereas,44,O
cross-resistance,44,O
to,44,O
ganciclovir,44,B-ChemicalEntity
and,44,O
cidofovir,44,B-ChemicalEntity
was,44,O
due,44,O
to,44,O
the,44,O
L501I,44,B-SequenceVariant
substitution,44,O
.,44,O
CONCLUSIONS,45,O
:,45,O
The,45,O
CMV,45,B-DiseaseOrPhenotypicFeature
isolates,45,O
obtained,45,O
from,45,O
our,45,O
patient,45,B-OrganismTaxon
were,45,O
complex,45,O
mixtures,45,O
of,45,O
strains,45,O
.,45,O
Changes,46,O
in,46,O
resistance,46,O
genotypes,46,O
depended,46,O
on,46,O
resistance,46,O
selective,46,O
pressure,46,O
and,46,O
were,46,O
not,46,O
linked,46,O
to,46,O
interstrain,46,O
variation,46,O
.,46,O
A,47,O
first,47,O
Taiwanese,47,O
Chinese,47,O
family,47,O
of,47,O
type,47,B-DiseaseOrPhenotypicFeature
2B,47,I-DiseaseOrPhenotypicFeature
von,47,I-DiseaseOrPhenotypicFeature
Willebrand,47,I-DiseaseOrPhenotypicFeature
disease,47,I-DiseaseOrPhenotypicFeature
with,47,O
R1306W,47,B-SequenceVariant
mutation,47,O
.,47,O
Clinical,48,O
",",48,O
laboratory,48,O
and,48,O
genetic,48,B-DiseaseOrPhenotypicFeature
defect,48,I-DiseaseOrPhenotypicFeature
of,48,O
a,48,O
Taiwanese,48,O
family,48,O
with,48,O
type,48,B-DiseaseOrPhenotypicFeature
2B,48,I-DiseaseOrPhenotypicFeature
von,48,I-DiseaseOrPhenotypicFeature
Willebrand,48,I-DiseaseOrPhenotypicFeature
disease,48,I-DiseaseOrPhenotypicFeature
(,48,O
VWD,48,B-DiseaseOrPhenotypicFeature
),48,O
were,48,O
studied,48,O
.,48,O
The,49,O
proband,49,O
was,49,O
a,49,O
55-year-old,49,O
woman,49,B-OrganismTaxon
who,49,O
gave,49,O
birth,49,O
to,49,O
two,49,O
daughters,49,O
and,49,O
one,49,O
son,49,O
aged,49,O
30,49,O
",",49,O
29,49,O
and,49,O
27,49,O
",",49,O
respectively,49,O
.,49,O
All,50,O
had,50,O
abnormal,50,O
mucocutaneous,50,O
bleedings,50,B-DiseaseOrPhenotypicFeature
since,50,O
their,50,O
childhood,50,O
.,50,O
In,51,O
proband,51,O
",",51,O
PT,51,O
",",51,O
PTT,51,O
and,51,O
platelet,51,O
count,51,O
were,51,O
normal,51,O
;,51,O
template,51,O
bleeding,51,B-DiseaseOrPhenotypicFeature
time,51,O
was,51,O
14,51,O
min,51,O
;,51,O
VIII,51,B-GeneOrGeneProduct
:,51,O
C,51,O
was,51,O
51,51,O
%,51,O
",",51,O
von,51,B-GeneOrGeneProduct
Willebrand,51,I-GeneOrGeneProduct
factor,51,I-GeneOrGeneProduct
antigen,51,O
(,51,O
VWF,51,B-GeneOrGeneProduct
:,51,O
Ag,51,O
),51,O
",",51,O
42,51,O
%,51,O
and,51,O
von,51,B-GeneOrGeneProduct
Willerand,51,I-GeneOrGeneProduct
factor,51,I-GeneOrGeneProduct
ristocetin-cofactor,51,B-ChemicalEntity
(,51,O
VWF,51,B-GeneOrGeneProduct
:,51,O
RCo,51,O
",",51,O
15,51,O
%,51,O
),51,O
;,51,O
ristocetin-induced,51,B-DiseaseOrPhenotypicFeature
platelet,51,I-DiseaseOrPhenotypicFeature
aggregation,51,I-DiseaseOrPhenotypicFeature
(,51,O
RIPA,51,B-DiseaseOrPhenotypicFeature
),51,O
at,51,O
0.3,51,O
and,51,O
0.6,51,O
mg/ml,51,O
of,51,O
ristocetin,51,B-ChemicalEntity
was,51,O
16,51,O
%,51,O
and,51,O
68,51,O
%,51,O
",",51,O
respectively,51,O
.,51,O
The,52,O
enhanced,52,O
response,52,O
to,52,O
ristocetin,52,B-ChemicalEntity
was,52,O
identified,52,O
to,52,O
be,52,O
in,52,O
plasma,52,O
",",52,O
not,52,O
in,52,O
platelet,52,O
itself,52,O
",",52,O
by,52,O
mixing,52,O
studies,52,O
.,52,O
Analysis,53,O
of,53,O
von,53,B-GeneOrGeneProduct
Willebrand,53,I-GeneOrGeneProduct
factor,53,I-GeneOrGeneProduct
(,53,O
VWF,53,B-GeneOrGeneProduct
),53,O
multimer,53,O
of,53,O
plasma,53,O
but,53,O
not,53,O
of,53,O
platelets,53,O
showed,53,O
absence,53,O
of,53,O
high-molecular,53,O
weight,53,O
(,53,O
HMW,53,O
),53,O
multimer,53,O
.,53,O
All,54,O
three,54,O
children,54,O
had,54,O
similar,54,O
laboratory,54,O
findings,54,O
.,54,O
Exon,55,O
28,55,O
of,55,O
VWF,55,B-GeneOrGeneProduct
gene,55,O
was,55,O
amplified,55,O
using,55,O
polymerase,55,O
chain,55,O
reaction,55,O
(,55,O
PCR,55,O
),55,O
and,55,O
sequenced,55,O
.,55,O
The,56,O
proband,56,O
and,56,O
three,56,O
children,56,O
were,56,O
all,56,O
found,56,O
to,56,O
be,56,O
heterozygous,56,O
for,56,O
C,56,B-SequenceVariant
to,56,I-SequenceVariant
T,56,I-SequenceVariant
transition,56,I-SequenceVariant
at,56,I-SequenceVariant
nucleotide,56,I-SequenceVariant
3916,56,I-SequenceVariant
resulting,56,O
in,56,O
Arg,56,B-SequenceVariant
1306,56,I-SequenceVariant
Trp,56,I-SequenceVariant
(,56,O
R1306W,56,B-SequenceVariant
),56,O
substitution,56,O
.,56,O
This,57,O
mutation,57,O
in,57,O
the,57,O
glycoprotein,57,B-GeneOrGeneProduct
Ib,57,I-GeneOrGeneProduct
(,57,O
GPIb,57,B-GeneOrGeneProduct
),57,O
-binding,57,O
site,57,O
has,57,O
been,57,O
found,57,O
to,57,O
increase,57,O
the,57,O
affinity,57,O
of,57,O
plasma,57,O
VWF,57,B-GeneOrGeneProduct
for,57,O
platelets,57,O
",",57,O
and,57,O
thus,57,O
cause,57,O
loss,57,O
of,57,O
HMW,57,O
multimers,57,O
and,57,O
often,57,O
thrombocytopenia,57,B-DiseaseOrPhenotypicFeature
.,57,O
In,58,O
conclusion,58,O
",",58,O
a,58,O
first,58,O
report,58,O
of,58,O
type,58,B-DiseaseOrPhenotypicFeature
2B,58,I-DiseaseOrPhenotypicFeature
VWD,58,I-DiseaseOrPhenotypicFeature
in,58,O
a,58,O
Taiwanese,58,O
Chinese,58,O
family,58,O
who,58,O
show,58,O
R1306W,58,B-SequenceVariant
mutation,58,O
in,58,O
VWF,58,B-GeneOrGeneProduct
gene,58,O
was,58,O
described,58,O
.,58,O
Four,59,O
novel,59,O
mutations,59,O
in,59,O
the,59,O
thiazide-sensitive,59,B-ChemicalEntity
Na-Cl,59,B-GeneOrGeneProduct
co-transporter,59,I-GeneOrGeneProduct
gene,59,O
in,59,O
Japanese,59,O
patients,59,B-OrganismTaxon
with,59,O
Gitelman,59,B-DiseaseOrPhenotypicFeature
's,59,I-DiseaseOrPhenotypicFeature
syndrome,59,I-DiseaseOrPhenotypicFeature
.,59,O
BACKGROUND,60,O
:,60,O
Gitelman,60,B-DiseaseOrPhenotypicFeature
's,60,I-DiseaseOrPhenotypicFeature
syndrome,60,I-DiseaseOrPhenotypicFeature
(,60,O
GS,60,B-DiseaseOrPhenotypicFeature
),60,O
is,60,O
an,60,O
autosomal,60,B-DiseaseOrPhenotypicFeature
recessive,60,I-DiseaseOrPhenotypicFeature
disorder,60,I-DiseaseOrPhenotypicFeature
resulting,60,O
from,60,O
inactivating,60,O
mutations,60,O
in,60,O
the,60,O
thiazide-sensitive,60,B-ChemicalEntity
Na-Cl,60,B-GeneOrGeneProduct
co-transporter,60,I-GeneOrGeneProduct
(,60,O
NCCT,60,B-GeneOrGeneProduct
),60,O
gene,60,O
.,60,O
To,61,O
date,61,O
",",61,O
almost,61,O
90,61,O
mutations,61,O
have,61,O
been,61,O
identified,61,O
.,61,O
It,62,O
is,62,O
possible,62,O
that,62,O
there,62,O
is,62,O
a,62,O
population-specific,62,O
distribution,62,O
of,62,O
mutations,62,O
.,62,O
In,63,O
this,63,O
study,63,O
",",63,O
we,63,O
analysed,63,O
mutations,63,O
in,63,O
the,63,O
NCCT,63,B-GeneOrGeneProduct
gene,63,O
of,63,O
seven,63,O
Japanese,63,O
patients,63,B-OrganismTaxon
with,63,O
GS,63,B-DiseaseOrPhenotypicFeature
.,63,O
METHODS,64,O
:,64,O
Peripheral,64,O
blood,64,O
mononuclear,64,O
cells,64,O
were,64,O
isolated,64,O
from,64,O
patients,64,B-OrganismTaxon
with,64,O
GS,64,B-DiseaseOrPhenotypicFeature
",",64,O
their,64,O
family,64,O
members,64,O
and,64,O
healthy,64,O
control,64,O
subjects,64,O
.,64,O
A,65,O
mutation,65,O
analysis,65,O
of,65,O
the,65,O
NCCT,65,B-GeneOrGeneProduct
gene,65,O
was,65,O
performed,65,O
completely,65,O
by,65,O
direct,65,O
automated,65,O
sequencing,65,O
of,65,O
polymerase,65,O
chain,65,O
reaction-amplified,65,O
DNA,65,O
products,65,O
.,65,O
In,66,O
patients,66,B-OrganismTaxon
with,66,O
a,66,O
deletion,66,O
or,66,O
splice,66,O
site,66,O
mutation,66,O
",",66,O
we,66,O
undertook,66,O
cDNA,66,O
sequence,66,O
analysis,66,O
.,66,O
RESULTS,67,O
:,67,O
We,67,O
identified,67,O
nine,67,O
mutations,67,O
.,67,O
Five,68,O
of,68,O
them,68,O
[,68,O
c.185C,68,B-SequenceVariant
>,68,I-SequenceVariant
T,68,I-SequenceVariant
(,68,O
Thr60Met,68,B-SequenceVariant
),68,O
",",68,O
c.1712C,68,B-SequenceVariant
>,68,I-SequenceVariant
T,68,I-SequenceVariant
(,68,O
Ala569Val,68,B-SequenceVariant
),68,O
",",68,O
c.1930C,68,B-SequenceVariant
>,68,I-SequenceVariant
T,68,I-SequenceVariant
(,68,O
Arg642Cys,68,B-SequenceVariant
),68,O
",",68,O
c.2552T,68,B-SequenceVariant
>,68,I-SequenceVariant
A,68,I-SequenceVariant
(,68,O
Leu849His,68,B-SequenceVariant
),68,O
and,68,O
c.1932delC,68,B-SequenceVariant
],68,O
have,68,O
been,68,O
reported,68,O
in,68,O
Japanese,68,O
patients,68,B-OrganismTaxon
",",68,O
but,68,O
not,68,O
in,68,O
GS,68,B-DiseaseOrPhenotypicFeature
patients,68,B-OrganismTaxon
from,68,O
other,68,O
ethnic,68,O
groups,68,O
.,68,O
The,69,O
remaining,69,O
four,69,O
mutations,69,O
[,69,O
c.7A,69,B-SequenceVariant
>,69,I-SequenceVariant
T,69,I-SequenceVariant
(,69,O
Met1Leu,69,B-SequenceVariant
),69,O
",",69,O
c.1181_1186+20del26,69,B-SequenceVariant
",",69,O
c.1811_1812delAT,69,B-SequenceVariant
and,69,O
IVS16+1G,69,B-SequenceVariant
>,69,I-SequenceVariant
A,69,I-SequenceVariant
],69,O
were,69,O
novel,69,O
.,69,O
In,70,O
cDNA,70,O
derived,70,O
from,70,O
a,70,O
patient,70,B-OrganismTaxon
with,70,O
c.1181_1186+20del26,70,B-SequenceVariant
",",70,O
a,70,O
deletion,70,O
of,70,O
exon,70,O
9,70,O
and,70,O
a,70,O
frameshift,70,O
at,70,O
the,70,O
start,70,O
of,70,O
exon,70,O
10,70,O
were,70,O
observed,70,O
.,70,O
In,71,O
cDNA,71,O
derived,71,O
from,71,O
patients,71,B-OrganismTaxon
with,71,O
IVS16+1G,71,B-SequenceVariant
>,71,I-SequenceVariant
A,71,I-SequenceVariant
",",71,O
an,71,O
additional,71,O
96,71,B-SequenceVariant
bp,71,I-SequenceVariant
insertion,71,I-SequenceVariant
between,71,O
exons,71,O
16,71,O
and,71,O
17,71,O
was,71,O
observed,71,O
.,71,O
Six,72,O
out,72,O
of,72,O
seven,72,O
patients,72,B-OrganismTaxon
were,72,O
compound,72,O
heterozygotes,72,O
",",72,O
and,72,O
the,72,O
remaining,72,O
one,72,O
carried,72,O
a,72,O
single,72,O
heterozygous,72,O
mutation,72,O
.,72,O
CONCLUSIONS,73,O
:,73,O
We,73,O
found,73,O
four,73,O
novel,73,O
mutations,73,O
in,73,O
the,73,O
NCCT,73,B-GeneOrGeneProduct
gene,73,O
in,73,O
seven,73,O
Japanese,73,O
patients,73,B-OrganismTaxon
with,73,O
GS,73,B-DiseaseOrPhenotypicFeature
.,73,O
Moreover,74,O
",",74,O
our,74,O
study,74,O
suggests,74,O
that,74,O
the,74,O
distribution,74,O
of,74,O
mutations,74,O
in,74,O
the,74,O
NCCT,74,B-GeneOrGeneProduct
gene,74,O
in,74,O
Japanese,74,O
GS,74,B-DiseaseOrPhenotypicFeature
patients,74,B-OrganismTaxon
potentially,74,O
differs,74,O
from,74,O
that,74,O
in,74,O
other,74,O
populations,74,O
.,74,O
Identification,75,O
of,75,O
three,75,O
F5,75,B-GeneOrGeneProduct
gene,75,O
mutations,75,O
associated,75,O
with,75,O
inherited,75,B-DiseaseOrPhenotypicFeature
coagulation,75,I-DiseaseOrPhenotypicFeature
factor,75,I-DiseaseOrPhenotypicFeature
V,75,I-DiseaseOrPhenotypicFeature
deficiency,75,I-DiseaseOrPhenotypicFeature
in,75,O
two,75,O
Chinese,75,O
pedigrees,75,O
.,75,O
To,76,O
investigate,76,O
the,76,O
molecular,76,O
defects,76,O
in,76,O
two,76,O
Chinese,76,O
pedigrees,76,O
with,76,O
inherited,76,B-DiseaseOrPhenotypicFeature
factor,76,I-DiseaseOrPhenotypicFeature
V,76,I-DiseaseOrPhenotypicFeature
(,76,I-DiseaseOrPhenotypicFeature
FV,76,I-DiseaseOrPhenotypicFeature
),76,I-DiseaseOrPhenotypicFeature
deficiency,76,I-DiseaseOrPhenotypicFeature
.,76,O
A,77,O
37-year-old,77,O
male,77,O
(,77,O
proband,77,O
1,77,O
),77,O
and,77,O
an,77,O
18-month-old,77,O
boy,77,O
(,77,O
proband,77,O
2,77,O
),77,O
were,77,O
diagnosed,77,O
as,77,O
inherited,77,B-DiseaseOrPhenotypicFeature
coagulation,77,I-DiseaseOrPhenotypicFeature
FV,77,I-DiseaseOrPhenotypicFeature
deficiency,77,I-DiseaseOrPhenotypicFeature
by,77,O
severely,77,O
reduced,77,O
plasma,77,O
levels,77,O
of,77,O
FV,77,B-GeneOrGeneProduct
activity,77,O
and,77,O
antigen,77,O
.,77,O
All,78,O
25,78,O
exons,78,O
and,78,O
their,78,O
flanking,78,O
sequence,78,O
of,78,O
F5,78,B-GeneOrGeneProduct
gene,78,O
were,78,O
amplified,78,O
by,78,O
polymerase,78,O
chain,78,O
reaction,78,O
(,78,O
PCR,78,O
),78,O
for,78,O
both,78,O
probands,78,O
and,78,O
the,78,O
PCR,78,O
products,78,O
were,78,O
directly,78,O
sequenced,78,O
.,78,O
Total,79,O
RNA,79,O
was,79,O
extracted,79,O
from,79,O
the,79,O
peripheral,79,O
lymphocytes,79,O
of,79,O
proband,79,O
1,79,O
for,79,O
detecting,79,O
the,79,O
changes,79,O
at,79,O
mRNA,79,O
level,79,O
.,79,O
The,80,O
homozygous,80,O
deletion,80,O
IVS8,80,B-SequenceVariant
-2A,80,I-SequenceVariant
>,80,I-SequenceVariant
G,80,I-SequenceVariant
was,80,O
identified,80,O
in,80,O
the,80,O
F5,80,B-GeneOrGeneProduct
gene,80,O
of,80,O
proband,80,O
1,80,O
and,80,O
complementary,80,O
DNA,80,O
(,80,O
cDNA,80,O
),80,O
analysis,80,O
revealed,80,O
the,80,O
abolishment,80,O
of,80,O
the,80,O
canonical,80,O
splicing,80,O
site,80,O
by,80,O
the,80,O
mutation,80,O
and,80,O
the,80,O
activation,80,O
of,80,O
the,80,O
cryptic,80,O
acceptor,80,O
site,80,O
24,80,O
bp,80,O
upstream,80,O
instead,80,O
.,80,O
The,81,O
insertion,81,B-SequenceVariant
introduced,81,I-SequenceVariant
eight,81,I-SequenceVariant
additional,81,I-SequenceVariant
amino,81,I-SequenceVariant
acids,81,I-SequenceVariant
(,81,O
AA,81,O
),81,O
into,81,O
the,81,O
FV,81,B-GeneOrGeneProduct
protein,81,O
.,81,O
Two,82,O
heterozygous,82,O
mutations,82,O
of,82,O
F5,82,B-GeneOrGeneProduct
gene,82,O
were,82,O
discovered,82,O
in,82,O
proband,82,O
2,82,O
.,82,O
The,83,O
2238-9del,83,B-SequenceVariant
AG,83,I-SequenceVariant
in,83,O
exon,83,O
13,83,O
introduced,83,O
a,83,O
premature,83,O
termination,83,O
code,83,O
at,83,O
689,83,B-SequenceVariant
AA,83,I-SequenceVariant
and,83,O
the,83,O
substitution,83,O
of,83,O
G6410,83,B-SequenceVariant
by,83,I-SequenceVariant
T,83,I-SequenceVariant
in,83,O
exon,83,O
23,83,O
lead,83,O
to,83,O
the,83,O
missense,83,O
mutation,83,O
Gly2079Val,83,B-SequenceVariant
.,83,O
Three,84,O
F5,84,B-GeneOrGeneProduct
gene,84,O
mutations,84,O
",",84,O
IVS8,84,B-SequenceVariant
-2A,84,I-SequenceVariant
>,84,I-SequenceVariant
G,84,I-SequenceVariant
",",84,O
2238-9del,84,B-SequenceVariant
AG,84,I-SequenceVariant
and,84,O
G6410T,84,B-SequenceVariant
",",84,O
have,84,O
been,84,O
identified,84,O
in,84,O
two,84,O
Chinese,84,O
pedigree,84,O
with,84,O
congenital,84,B-DiseaseOrPhenotypicFeature
FV,84,I-DiseaseOrPhenotypicFeature
deficiency,84,I-DiseaseOrPhenotypicFeature
",",84,O
respectively,84,O
.,84,O
Pallidal,85,O
stimulation,85,O
:,85,O
an,85,O
alternative,85,O
to,85,O
pallidotomy,85,O
?,85,O
A,86,O
resurgence,86,O
of,86,O
interest,86,O
in,86,O
the,86,O
surgical,86,O
treatment,86,O
of,86,O
Parkinson,86,B-DiseaseOrPhenotypicFeature
's,86,I-DiseaseOrPhenotypicFeature
disease,86,I-DiseaseOrPhenotypicFeature
(,86,O
PD,86,B-DiseaseOrPhenotypicFeature
),86,O
came,86,O
with,86,O
the,86,O
rediscovery,86,O
of,86,O
posteroventral,86,O
pallidotomy,86,O
by,86,O
Laitinen,86,O
in,86,O
1985,86,O
.,86,O
Laitinen,87,O
's,87,O
procedure,87,O
improved,87,O
most,87,O
symptoms,87,O
in,87,O
drug-resistant,87,O
PD,87,B-DiseaseOrPhenotypicFeature
",",87,O
which,87,O
engendered,87,O
wide,87,O
interest,87,O
in,87,O
the,87,O
neurosurgical,87,O
community,87,O
.,87,O
Another,88,O
lesioning,88,O
procedure,88,O
",",88,O
ventrolateral,88,O
thalamotomy,88,O
",",88,O
has,88,O
become,88,O
a,88,O
powerful,88,O
alternative,88,O
to,88,O
stimulate,88,O
the,88,O
nucleus,88,O
ventralis,88,O
intermedius,88,O
",",88,O
producing,88,O
high,88,O
long-term,88,O
success,88,O
rates,88,O
and,88,O
low,88,O
morbidity,88,O
rates,88,O
.,88,O
Pallidal,89,O
stimulation,89,O
has,89,O
not,89,O
met,89,O
with,89,O
the,89,O
same,89,O
success,89,O
.,89,O
According,90,O
to,90,O
the,90,O
literature,90,O
pallidotomy,90,O
improves,90,O
the,90,O
``,90,O
on,90,O
'',90,O
symptoms,90,O
of,90,O
PD,90,B-DiseaseOrPhenotypicFeature
",",90,O
such,90,O
as,90,O
dyskinesias,90,B-DiseaseOrPhenotypicFeature
",",90,O
as,90,O
well,90,O
as,90,O
the,90,O
``,90,O
off,90,O
'',90,O
symptoms,90,O
",",90,O
such,90,O
as,90,O
rigidity,90,B-DiseaseOrPhenotypicFeature
",",90,O
bradykinesia,90,B-DiseaseOrPhenotypicFeature
",",90,O
and,90,O
on-off,90,O
fluctuations,90,O
.,90,O
Pallidal,91,O
stimulation,91,O
improves,91,O
bradykinesia,91,B-DiseaseOrPhenotypicFeature
and,91,O
rigidity,91,B-DiseaseOrPhenotypicFeature
to,91,O
a,91,O
minor,91,O
extent,91,O
;,91,O
however,91,O
",",91,O
its,91,O
strength,91,O
seems,91,O
to,91,O
be,91,O
in,91,O
improving,91,O
levodopa-induced,91,B-ChemicalEntity
dyskinesias,91,B-DiseaseOrPhenotypicFeature
.,91,O
Stimulation,92,O
often,92,O
produces,92,O
an,92,O
improvement,92,O
in,92,O
the,92,O
hyper-,92,B-DiseaseOrPhenotypicFeature
or,92,I-DiseaseOrPhenotypicFeature
dyskinetic,92,I-DiseaseOrPhenotypicFeature
upper,92,O
limbs,92,O
",",92,O
but,92,O
increases,92,O
the,92,O
``,92,O
freezing,92,O
'',92,O
phenomenon,92,O
in,92,O
the,92,O
lower,92,O
limbs,92,O
at,92,O
the,92,O
same,92,O
time,92,O
.,92,O
Considering,93,O
the,93,O
small,93,O
increase,93,O
in,93,O
the,93,O
patient,93,B-OrganismTaxon
's,93,O
independence,93,O
",",93,O
the,93,O
high,93,O
costs,93,O
of,93,O
bilateral,93,O
implants,93,O
",",93,O
and,93,O
the,93,O
difficulty,93,O
most,93,O
patients,93,B-OrganismTaxon
experience,93,O
in,93,O
handling,93,O
the,93,O
devices,93,O
",",93,O
the,93,O
question,93,O
arises,93,O
as,93,O
to,93,O
whether,93,O
bilateral,93,O
pallidal,93,O
stimulation,93,O
is,93,O
a,93,O
real,93,O
alternative,93,O
to,93,O
pallidotomy,93,O
.,93,O
Hypoxia,94,B-DiseaseOrPhenotypicFeature
in,94,O
renal,94,B-DiseaseOrPhenotypicFeature
disease,94,I-DiseaseOrPhenotypicFeature
with,94,O
proteinuria,94,B-DiseaseOrPhenotypicFeature
and/or,94,O
glomerular,94,O
hypertension,94,B-DiseaseOrPhenotypicFeature
.,94,O
Despite,95,O
the,95,O
increasing,95,O
need,95,O
to,95,O
identify,95,O
and,95,O
quantify,95,O
tissue,95,O
oxygenation,95,O
at,95,O
the,95,O
cellular,95,O
level,95,O
",",95,O
relatively,95,O
few,95,O
methods,95,O
have,95,O
been,95,O
available,95,O
.,95,O
In,96,O
this,96,O
study,96,O
",",96,O
we,96,O
developed,96,O
a,96,O
new,96,O
hypoxia-responsive,96,B-DiseaseOrPhenotypicFeature
reporter,96,O
vector,96,O
using,96,O
a,96,O
hypoxia-responsive,96,B-DiseaseOrPhenotypicFeature
element,96,O
of,96,O
the,96,O
5,96,O
',96,O
vascular,96,B-GeneOrGeneProduct
endothelial,96,I-GeneOrGeneProduct
growth,96,I-GeneOrGeneProduct
factor,96,I-GeneOrGeneProduct
untranslated,96,O
region,96,O
and,96,O
generated,96,O
a,96,O
novel,96,O
hypoxia-sensing,96,B-DiseaseOrPhenotypicFeature
transgenic,96,O
rat,96,B-OrganismTaxon
.,96,O
We,97,O
then,97,O
applied,97,O
this,97,O
animal,97,O
model,97,O
to,97,O
the,97,O
detection,97,O
of,97,O
tubulointerstitial,97,O
hypoxia,97,B-DiseaseOrPhenotypicFeature
in,97,O
the,97,O
diseased,97,B-DiseaseOrPhenotypicFeature
kidney,97,I-DiseaseOrPhenotypicFeature
.,97,O
With,98,O
this,98,O
model,98,O
",",98,O
we,98,O
were,98,O
able,98,O
to,98,O
identify,98,O
diffuse,98,O
cortical,98,O
hypoxia,98,B-DiseaseOrPhenotypicFeature
in,98,O
the,98,O
puromycin,98,B-ChemicalEntity
aminonucleoside-induced,98,O
nephrotic,98,B-DiseaseOrPhenotypicFeature
syndrome,98,I-DiseaseOrPhenotypicFeature
and,98,O
focal,98,O
and,98,O
segmental,98,O
hypoxia,98,B-DiseaseOrPhenotypicFeature
in,98,O
the,98,O
remnant,98,O
kidney,98,O
model,98,O
.,98,O
Expression,99,O
of,99,O
the,99,O
hypoxia-responsive,99,B-DiseaseOrPhenotypicFeature
transgene,99,O
increased,99,O
throughout,99,O
the,99,O
observation,99,O
period,99,O
",",99,O
reaching,99,O
2.2-fold,99,O
at,99,O
2,99,O
weeks,99,O
in,99,O
the,99,O
puromycin,99,B-ChemicalEntity
aminonucleoside,99,I-ChemicalEntity
model,99,O
and,99,O
2.6-fold,99,O
at,99,O
4,99,O
weeks,99,O
in,99,O
the,99,O
remnant,99,O
kidney,99,O
model,99,O
",",99,O
whereas,99,O
that,99,O
of,99,O
vascular,99,B-GeneOrGeneProduct
endothelial,99,I-GeneOrGeneProduct
growth,99,I-GeneOrGeneProduct
factor,99,I-GeneOrGeneProduct
showed,99,O
a,99,O
mild,99,O
decrease,99,O
",",99,O
reflecting,99,O
distinct,99,O
behaviors,99,O
of,99,O
the,99,O
two,99,O
genes,99,O
.,99,O
The,100,O
degree,100,O
of,100,O
hypoxia,100,B-DiseaseOrPhenotypicFeature
showed,100,O
a,100,O
positive,100,O
correlation,100,O
with,100,O
microscopic,100,O
tubulointerstitial,100,B-DiseaseOrPhenotypicFeature
injury,100,I-DiseaseOrPhenotypicFeature
in,100,O
both,100,O
models,100,O
.,100,O
Finally,101,O
",",101,O
we,101,O
identified,101,O
the,101,O
localization,101,O
of,101,O
proliferating,101,O
cell,101,O
nuclear,101,O
antigen-positive,101,O
",",101,O
ED-1-positive,101,B-GeneOrGeneProduct
",",101,O
and,101,O
terminal,101,O
dUTP,101,B-ChemicalEntity
nick-end,101,O
labeled-positive,101,O
cells,101,O
in,101,O
the,101,O
hypoxic,101,B-DiseaseOrPhenotypicFeature
cortical,101,O
area,101,O
in,101,O
the,101,O
remnant,101,O
kidney,101,O
model,101,O
.,101,O
We,102,O
propose,102,O
here,102,O
a,102,O
possible,102,O
pathological,102,O
tie,102,O
between,102,O
chronic,102,O
tubulointerstitial,102,O
hypoxia,102,B-DiseaseOrPhenotypicFeature
and,102,O
progressive,102,O
glomerular,102,B-DiseaseOrPhenotypicFeature
diseases,102,I-DiseaseOrPhenotypicFeature
.,102,O
Novel,103,O
somatic,103,O
MEN1,103,B-GeneOrGeneProduct
gene,103,O
alterations,103,O
in,103,O
sporadic,103,O
primary,103,B-DiseaseOrPhenotypicFeature
hyperparathyroidism,103,I-DiseaseOrPhenotypicFeature
and,103,O
correlation,103,O
with,103,O
clinical,103,O
characteristics,103,O
.,103,O
Primary,104,B-DiseaseOrPhenotypicFeature
hyperparathyroidism,104,I-DiseaseOrPhenotypicFeature
(,104,O
pHPT,104,B-DiseaseOrPhenotypicFeature
),104,O
is,104,O
a,104,O
common,104,O
endocrine,104,B-DiseaseOrPhenotypicFeature
disease,104,I-DiseaseOrPhenotypicFeature
that,104,O
in,104,O
more,104,O
than,104,O
95,104,O
%,104,O
of,104,O
cases,104,O
is,104,O
sporadic,104,O
and,104,O
only,104,O
in,104,O
some,104,O
cases,104,O
is,104,O
caused,104,O
by,104,O
inherited,104,B-DiseaseOrPhenotypicFeature
disorders,104,I-DiseaseOrPhenotypicFeature
",",104,O
isolated,104,O
or,104,O
as,104,O
part,104,O
of,104,O
multiple,104,B-DiseaseOrPhenotypicFeature
endocrine,104,I-DiseaseOrPhenotypicFeature
neoplasia,104,I-DiseaseOrPhenotypicFeature
(,104,O
MEN1,104,B-DiseaseOrPhenotypicFeature
and,104,I-DiseaseOrPhenotypicFeature
2,104,I-DiseaseOrPhenotypicFeature
),104,O
.,104,O
Somatic,105,O
mutations,105,O
of,105,O
MEN1,105,B-GeneOrGeneProduct
gene,105,O
have,105,O
also,105,O
been,105,O
described,105,O
in,105,O
sporadic,105,O
parathyroid,105,B-DiseaseOrPhenotypicFeature
tumors,105,I-DiseaseOrPhenotypicFeature
.,105,O
In,106,O
our,106,O
study,106,O
",",106,O
we,106,O
examined,106,O
the,106,O
presence,106,O
of,106,O
alterations,106,O
in,106,O
MEN1,106,B-GeneOrGeneProduct
gene,106,O
in,106,O
a,106,O
series,106,O
of,106,O
39,106,O
patients,106,B-OrganismTaxon
who,106,O
had,106,O
undergone,106,O
surgery,106,O
for,106,O
sporadic,106,O
pHPT,106,B-DiseaseOrPhenotypicFeature
(,106,O
35,106,O
with,106,O
parathyroid,106,B-DiseaseOrPhenotypicFeature
adenoma,106,I-DiseaseOrPhenotypicFeature
or,106,I-DiseaseOrPhenotypicFeature
hyperplasia,106,I-DiseaseOrPhenotypicFeature
",",106,O
4,106,O
with,106,O
a,106,O
carcinoma,106,B-DiseaseOrPhenotypicFeature
),106,O
.,106,O
A,107,O
genotype-phenotype,107,O
correlation,107,O
was,107,O
also,107,O
analysed,107,O
.,107,O
After,108,O
DNA,108,O
extraction,108,O
from,108,O
paraffin-embedded,108,B-ChemicalEntity
tissues,108,O
",",108,O
we,108,O
amplified,108,O
by,108,O
PCR,108,O
and,108,O
sequenced,108,O
the,108,O
exons,108,O
2-10,108,O
of,108,O
the,108,O
MEN1,108,B-GeneOrGeneProduct
gene,108,O
.,108,O
Somatic,109,O
MEN1,109,B-GeneOrGeneProduct
mutations,109,O
were,109,O
detected,109,O
in,109,O
6,109,O
of,109,O
the,109,O
35,109,O
patients,109,B-OrganismTaxon
with,109,O
a,109,O
benign,109,B-DiseaseOrPhenotypicFeature
parathyroid,109,I-DiseaseOrPhenotypicFeature
lesion,109,I-DiseaseOrPhenotypicFeature
examined,109,O
(,109,O
17.1,109,O
%,109,O
),109,O
",",109,O
whereas,109,O
no,109,O
alterations,109,O
were,109,O
found,109,O
in,109,O
the,109,O
carcinomas,109,B-DiseaseOrPhenotypicFeature
.,109,O
Four,110,O
novel,110,O
MEN1,110,B-GeneOrGeneProduct
gene,110,O
mutations,110,O
were,110,O
identified,110,O
as,110,O
follows,110,O
:,110,O
one,110,O
frameshift,110,O
mutation,110,O
(,110,O
222insT,110,B-SequenceVariant
",",110,O
exon,110,O
2,110,O
),110,O
",",110,O
one,110,O
frameshift,110,O
deletion,110,O
(,110,O
912delTA,110,B-SequenceVariant
",",110,O
exon,110,O
5,110,O
),110,O
",",110,O
one,110,O
in-frame,110,O
deletion,110,O
(,110,O
835del18,110,B-SequenceVariant
",",110,O
exon,110,O
4,110,O
),110,O
and,110,O
one,110,O
missense,110,O
mutation,110,O
(,110,O
P291A,110,B-SequenceVariant
",",110,O
exon,110,O
6,110,O
),110,O
.,110,O
In,111,O
addition,111,O
",",111,O
one,111,O
missense,111,O
mutation,111,O
(,111,O
L89R,111,B-SequenceVariant
",",111,O
exon,111,O
2,111,O
),111,O
and,111,O
one,111,O
nonsense,111,O
mutation,111,O
(,111,O
Q536X,111,B-SequenceVariant
",",111,O
exon,111,O
10,111,O
),111,O
were,111,O
previously,111,O
reported,111,O
.,111,O
Moreover,112,O
",",112,O
two,112,O
polymorphisms,112,O
were,112,O
also,112,O
found,112,O
:,112,O
one,112,O
allele,112,O
carried,112,O
a,112,O
R171Q,112,B-SequenceVariant
polymorphism,112,O
(,112,O
1/39,112,O
tumors,112,B-DiseaseOrPhenotypicFeature
),112,O
",",112,O
while,112,O
a,112,O
D418D,112,B-SequenceVariant
polymorphism,112,O
(,112,O
GAC/GAT,112,B-SequenceVariant
),112,O
was,112,O
found,112,O
in,112,O
15,112,O
and,112,O
8,112,O
tumors,112,B-DiseaseOrPhenotypicFeature
in,112,O
hetero,112,O
(,112,O
CT,112,O
),112,O
and,112,O
homozygosity,112,O
(,112,O
TT,112,O
),112,O
",",112,O
respectively,112,O
.,112,O
In,113,O
no,113,O
case,113,O
(,113,O
mutations,113,O
and/or,113,O
polymorphisms,113,O
),113,O
did,113,O
we,113,O
find,113,O
a,113,O
genotype-phenotype,113,O
correlation,113,O
.,113,O
In,114,O
conclusion,114,O
",",114,O
our,114,O
data,114,O
demonstrate,114,O
the,114,O
presence,114,O
of,114,O
somatic,114,O
alterations,114,O
of,114,O
the,114,O
MEN1,114,B-GeneOrGeneProduct
tumor,114,B-DiseaseOrPhenotypicFeature
suppressor,114,O
gene,114,O
in,114,O
about,114,O
one,114,O
fifth,114,O
of,114,O
benign,114,O
sporadic,114,O
parathyroid,114,B-DiseaseOrPhenotypicFeature
tumors,114,I-DiseaseOrPhenotypicFeature
.,114,O
The,115,O
absence,115,O
of,115,O
a,115,O
genotype-phenotype,115,O
correlation,115,O
",",115,O
however,115,O
",",115,O
suggests,115,O
the,115,O
involvement,115,O
of,115,O
other,115,O
genetic/epigenetic,115,O
factors,115,O
for,115,O
the,115,O
full,115,O
expression,115,O
of,115,O
the,115,O
disease,115,O
.,115,O
Genetic,116,O
variants,116,O
of,116,O
the,116,O
T-cell,116,B-GeneOrGeneProduct
immunoglobulin,116,I-GeneOrGeneProduct
mucin,116,I-GeneOrGeneProduct
1,116,I-GeneOrGeneProduct
but,116,O
not,116,O
the,116,O
T-cell,116,B-GeneOrGeneProduct
immunoglobulin,116,I-GeneOrGeneProduct
mucin,116,I-GeneOrGeneProduct
3,116,I-GeneOrGeneProduct
gene,116,O
are,116,O
associated,116,O
with,116,O
asthma,116,B-DiseaseOrPhenotypicFeature
in,116,O
an,116,O
African,116,O
American,116,O
population,116,O
.,116,O
BACKGROUND,117,O
:,117,O
The,117,O
T-cell,117,B-GeneOrGeneProduct
immunoglobulin,117,I-GeneOrGeneProduct
mucin,117,I-GeneOrGeneProduct
(,117,O
TIM,117,B-GeneOrGeneProduct
),117,O
proteins,117,O
and,117,O
their,117,O
genetic,117,O
variants,117,O
have,117,O
been,117,O
suggested,117,O
to,117,O
play,117,O
a,117,O
role,117,O
in,117,O
regulating,117,O
allergic,117,B-DiseaseOrPhenotypicFeature
diseases,117,I-DiseaseOrPhenotypicFeature
.,117,O
OBJECTIVE,118,O
:,118,O
Genetic,118,O
association,118,O
of,118,O
the,118,O
sequence,118,O
variants,118,O
for,118,O
TIM-1,118,B-GeneOrGeneProduct
and,118,O
TIM-3,118,B-GeneOrGeneProduct
genes,118,O
with,118,O
asthma,118,B-DiseaseOrPhenotypicFeature
in,118,O
an,118,O
African,118,O
American,118,O
population,118,O
was,118,O
investigated,118,O
.,118,O
METHODS,119,O
:,119,O
Both,119,O
case-control,119,O
and,119,O
family-based,119,O
association,119,O
analyses,119,O
were,119,O
performed,119,O
for,119,O
a,119,O
total,119,O
of,119,O
7,119,O
polymorphisms,119,O
",",119,O
including,119,O
3,119,O
single,119,O
nucleotide,119,O
polymorphism,119,O
(,119,O
SNPs,119,O
),119,O
and,119,O
1,119,O
insertion/deletion,119,O
polymorphism,119,O
in,119,O
the,119,O
TIM-1,119,B-GeneOrGeneProduct
and,119,I-GeneOrGeneProduct
3,119,I-GeneOrGeneProduct
SNPs,119,O
in,119,O
the,119,O
TIM-3,119,B-GeneOrGeneProduct
genes,119,O
.,119,O
The,120,O
exposure,120,O
to,120,O
hepatitis,120,B-OrganismTaxon
A,120,I-OrganismTaxon
virus,120,I-OrganismTaxon
as,120,O
judged,120,O
by,120,O
seropositivity,120,O
was,120,O
also,120,O
examined,120,O
.,120,O
RESULTS,121,O
:,121,O
In,121,O
the,121,O
case-control,121,O
design,121,O
",",121,O
the,121,O
frequencies,121,O
of,121,O
the,121,O
TT,121,O
genotype,121,O
for,121,O
SNP,121,O
rs2277025,121,B-SequenceVariant
and,121,O
the,121,O
homozygous,121,O
deletion,121,O
variant,121,O
(,121,O
157delMTTTVP,121,B-SequenceVariant
),121,O
in,121,O
the,121,O
fourth,121,O
exon,121,O
of,121,O
the,121,O
TIM-1,121,B-GeneOrGeneProduct
gene,121,O
were,121,O
higher,121,O
among,121,O
patients,121,B-OrganismTaxon
with,121,O
patients,121,B-OrganismTaxon
with,121,O
asthma,121,B-DiseaseOrPhenotypicFeature
compared,121,O
with,121,O
the,121,O
controls,121,O
(,121,O
odds,121,O
ratio,121,O
[,121,O
OR,121,O
],121,O
",",121,O
2.779,121,O
",",121,O
P,121,O
=,121,O
.016,121,O
;,121,O
and,121,O
OR,121,O
",",121,O
3.09,121,O
",",121,O
P,121,O
=,121,O
.022,121,O
",",121,O
respectively,121,O
),121,O
.,121,O
This,122,O
association,122,O
was,122,O
substantiated,122,O
by,122,O
haplotype,122,O
analysis,122,O
of,122,O
these,122,O
and,122,O
2,122,O
additional,122,O
SNPs,122,O
(,122,O
OR,122,O
",",122,O
2.48,122,O
;,122,O
P,122,O
=,122,O
.004,122,O
),122,O
",",122,O
and,122,O
also,122,O
by,122,O
family-based,122,O
tests,122,O
for,122,O
the,122,O
allele,122,O
and,122,O
haplotype,122,O
carrying,122,O
157delMTTTVP,122,B-SequenceVariant
(,122,O
P,122,O
=,122,O
.009,122,O
and,122,O
P,122,O
=,122,O
.048,122,O
",",122,O
respectively,122,O
),122,O
.,122,O
Furthermore,123,O
",",123,O
this,123,O
association,123,O
seems,123,O
to,123,O
exist,123,O
even,123,O
in,123,O
the,123,O
hepatitis,123,B-OrganismTaxon
A,123,I-OrganismTaxon
virus-seronegative,123,O
subjects,123,O
in,123,O
our,123,O
data,123,O
.,123,O
None,124,O
of,124,O
the,124,O
3,124,O
variants,124,O
in,124,O
TIM-3,124,B-GeneOrGeneProduct
genes,124,O
yielded,124,O
significant,124,O
association,124,O
with,124,O
either,124,O
asthma,124,B-DiseaseOrPhenotypicFeature
or,124,O
asthma-related,124,B-DiseaseOrPhenotypicFeature
phenotypes,124,O
.,124,O
CONCLUSION,125,O
:,125,O
Our,125,O
findings,125,O
suggest,125,O
that,125,O
the,125,O
genetic,125,O
variants,125,O
of,125,O
the,125,O
TIM-1,125,B-GeneOrGeneProduct
but,125,O
not,125,O
the,125,O
TIM-3,125,B-GeneOrGeneProduct
gene,125,O
contribute,125,O
to,125,O
asthma,125,B-DiseaseOrPhenotypicFeature
susceptibility,125,O
in,125,O
this,125,O
African-American,125,O
population,125,O
.,125,O
Screening,126,O
for,126,O
exonic,126,O
copy,126,O
number,126,O
mutations,126,O
at,126,O
MSH2,126,B-GeneOrGeneProduct
and,126,O
MLH1,126,B-GeneOrGeneProduct
by,126,O
MAPH,126,O
.,126,O
BACKGROUND,127,O
:,127,O
Exonic,127,O
deletions,127,O
in,127,O
MSH2,127,B-GeneOrGeneProduct
and,127,O
MLH1,127,B-GeneOrGeneProduct
are,127,O
significant,127,O
contributors,127,O
to,127,O
the,127,O
mutation,127,O
spectrum,127,O
in,127,O
HNPCC,127,B-DiseaseOrPhenotypicFeature
",",127,O
and,127,O
heterozygous,127,O
changes,127,O
in,127,O
exon,127,O
copy,127,O
number,127,O
are,127,O
not,127,O
detected,127,O
by,127,O
conventional,127,O
mutation,127,O
screening,127,O
methods,127,O
.,127,O
AIMS,128,O
:,128,O
We,128,O
aimed,128,O
to,128,O
develop,128,O
methods,128,O
for,128,O
screening,128,O
copy,128,O
number,128,O
changes,128,O
in,128,O
all,128,O
the,128,O
exons,128,O
of,128,O
the,128,O
MLH1,128,B-GeneOrGeneProduct
and,128,O
MSH2,128,B-GeneOrGeneProduct
genes,128,O
using,128,O
a,128,O
single,128,O
multiplex,128,O
amplifiable,128,O
probe,128,O
hybridisation,128,O
(,128,O
MAPH,128,O
),128,O
assay,128,O
.,128,O
METHODS,129,O
:,129,O
We,129,O
developed,129,O
a,129,O
probe,129,O
set,129,O
consisting,129,O
of,129,O
probes,129,O
from,129,O
the,129,O
19,129,O
exons,129,O
of,129,O
MLH1,129,B-GeneOrGeneProduct
and,129,O
16,129,O
exons,129,O
of,129,O
MSH2,129,B-GeneOrGeneProduct
",",129,O
and,129,O
3,129,O
control,129,O
probes,129,O
",",129,O
and,129,O
applied,129,O
it,129,O
to,129,O
screening,129,O
for,129,O
deletions,129,O
and,129,O
duplications,129,O
using,129,O
fluorescent,129,O
detection,129,O
of,129,O
amplified,129,O
fragments,129,O
.,129,O
RESULTS,130,O
:,130,O
We,130,O
tested,130,O
73,130,O
DNA,130,O
samples,130,O
from,130,O
controls,130,O
and,130,O
50,130,O
from,130,O
HNPCC,130,B-DiseaseOrPhenotypicFeature
patients,130,B-OrganismTaxon
in,130,O
whom,130,O
no,130,O
point,130,O
mutations,130,O
had,130,O
been,130,O
found,130,O
",",130,O
and,130,O
detected,130,O
10,130,O
copy,130,O
number,130,O
changes,130,O
among,130,O
the,130,O
patient,130,B-OrganismTaxon
samples,130,O
.,130,O
A,131,O
deletion,131,O
of,131,O
about,131,O
1.4,131,O
kb,131,O
including,131,O
exon,131,O
3,131,O
of,131,O
MSH2,131,B-GeneOrGeneProduct
was,131,O
confirmed,131,O
by,131,O
amplification,131,O
of,131,O
a,131,O
junction,131,O
fragment,131,O
",",131,O
and,131,O
was,131,O
shown,131,O
to,131,O
be,131,O
the,131,O
result,131,O
of,131,O
an,131,O
unequal,131,O
recombination,131,O
between,131,O
intronic,131,O
Alu,131,O
elements,131,O
.,131,O
CONCLUSIONS,132,O
:,132,O
MAPH,132,O
can,132,O
detect,132,O
exonic,132,O
copy,132,O
number,132,O
changes,132,O
in,132,O
MLH1,132,B-GeneOrGeneProduct
and,132,O
MSH2,132,B-GeneOrGeneProduct
in,132,O
DNA,132,O
from,132,O
HNPCC,132,B-DiseaseOrPhenotypicFeature
patients,132,B-OrganismTaxon
.,132,O
Since,133,O
finding,133,O
an,133,O
exonic,133,O
deletion,133,O
or,133,O
duplication,133,O
makes,133,O
full,133,O
sequence,133,O
analysis,133,O
unnecessary,133,O
",",133,O
it,133,O
may,133,O
be,133,O
most,133,O
cost-effective,133,O
to,133,O
pre-screen,133,O
samples,133,O
by,133,O
MAPH,133,O
or,133,O
MLPA,133,O
before,133,O
screening,133,O
for,133,O
point,133,O
mutations,133,O
.,133,O
Nicotine,134,B-ChemicalEntity
antagonizes,134,O
caffeine-,134,B-ChemicalEntity
but,134,O
not,134,O
pentylenetetrazole-induced,134,B-ChemicalEntity
anxiogenic,134,B-DiseaseOrPhenotypicFeature
effect,134,I-DiseaseOrPhenotypicFeature
in,134,O
mice,134,B-OrganismTaxon
.,134,O
RATIONALE,135,O
:,135,O
Nicotine,135,B-ChemicalEntity
and,135,O
caffeine,135,B-ChemicalEntity
are,135,O
widely,135,O
consumed,135,O
licit,135,O
psychoactive,135,B-ChemicalEntity
drugs,135,I-ChemicalEntity
worldwide,135,O
.,135,O
Epidemiological,136,O
studies,136,O
showed,136,O
that,136,O
they,136,O
were,136,O
generally,136,O
used,136,O
concurrently,136,O
.,136,O
Although,137,O
some,137,O
studies,137,O
in,137,O
experimental,137,O
animals,137,O
indicate,137,O
clear,137,O
pharmacological,137,O
interactions,137,O
between,137,O
them,137,O
",",137,O
no,137,O
studies,137,O
have,137,O
shown,137,O
a,137,O
specific,137,O
interaction,137,O
on,137,O
anxiety,137,B-DiseaseOrPhenotypicFeature
responses,137,O
.,137,O
OBJECTIVES,138,O
:,138,O
The,138,O
present,138,O
study,138,O
investigates,138,O
the,138,O
effects,138,O
of,138,O
nicotine,138,B-ChemicalEntity
on,138,O
anxiety,138,B-DiseaseOrPhenotypicFeature
induced,138,O
by,138,O
caffeine,138,B-ChemicalEntity
and,138,O
another,138,O
anxiogenic,138,B-ChemicalEntity
drug,138,I-ChemicalEntity
",",138,O
pentylenetetrazole,138,B-ChemicalEntity
",",138,O
in,138,O
mice,138,B-OrganismTaxon
.,138,O
The,139,O
elevated,139,O
plus-maze,139,O
(,139,O
EPM,139,O
),139,O
test,139,O
was,139,O
used,139,O
to,139,O
evaluate,139,O
the,139,O
effects,139,O
of,139,O
drugs,139,O
on,139,O
anxiety,139,B-DiseaseOrPhenotypicFeature
.,139,O
METHODS,140,O
:,140,O
Adult,140,O
male,140,O
Swiss,140,O
Webster,140,O
mice,140,B-OrganismTaxon
(,140,O
25-32,140,O
g,140,O
),140,O
were,140,O
given,140,O
nicotine,140,B-ChemicalEntity
(,140,O
0.05-0.25,140,O
mg/kg,140,O
s.c.,140,O
),140,O
or,140,O
saline,140,O
10,140,O
min,140,O
before,140,O
caffeine,140,B-ChemicalEntity
(,140,O
70,140,O
mg/kg,140,O
i.p,140,O
.,140,O
),140,O
or,141,O
pentylenetetrazole,141,B-ChemicalEntity
(,141,O
15,141,O
and,141,O
30,141,O
mg/kg,141,O
i.p,141,O
.,141,O
),141,O
injections,142,O
.,142,O
After,143,O
15,143,O
min,143,O
",",143,O
mice,143,B-OrganismTaxon
were,143,O
evaluated,143,O
for,143,O
their,143,O
open-,143,O
and,143,O
closed-arm,143,O
time,143,O
and,143,O
entries,143,O
on,143,O
the,143,O
EPM,143,O
for,143,O
a,143,O
10-min,143,O
session,143,O
.,143,O
Locomotor,144,O
activity,144,O
was,144,O
recorded,144,O
for,144,O
individual,144,O
groups,144,O
by,144,O
using,144,O
the,144,O
same,144,O
treatment,144,O
protocol,144,O
with,144,O
the,144,O
EPM,144,O
test,144,O
.,144,O
RESULTS,145,O
:,145,O
Nicotine,145,B-ChemicalEntity
(,145,O
0.05-0.25,145,O
mg/kg,145,O
),145,O
itself,145,O
did,145,O
not,145,O
produce,145,O
any,145,O
significant,145,O
effect,145,O
in,145,O
the,145,O
EPM,145,O
test,145,O
",",145,O
whereas,145,O
caffeine,145,B-ChemicalEntity
(,145,O
70,145,O
mg/kg,145,O
),145,O
and,145,O
pentylenetetrazole,145,B-ChemicalEntity
(,145,O
30,145,O
mg/kg,145,O
),145,O
produced,145,O
an,145,O
anxiogenic,145,B-DiseaseOrPhenotypicFeature
effect,145,I-DiseaseOrPhenotypicFeature
",",145,O
apparent,145,O
with,145,O
decreases,145,O
in,145,O
open-arm,145,O
time,145,O
and,145,O
entry,145,O
.,145,O
Nicotine,146,B-ChemicalEntity
(,146,O
0.25,146,O
mg/kg,146,O
),146,O
pretreatment,146,O
blocked,146,O
the,146,O
caffeine-,146,B-ChemicalEntity
but,146,O
not,146,O
pentylenetetrazole-induced,146,B-ChemicalEntity
anxiety,146,B-DiseaseOrPhenotypicFeature
.,146,O
Administration,147,O
of,147,O
each,147,O
drug,147,O
and,147,O
their,147,O
combinations,147,O
did,147,O
not,147,O
produce,147,O
any,147,O
effect,147,O
on,147,O
locomotor,147,O
activity,147,O
.,147,O
CONCLUSIONS,148,O
:,148,O
Our,148,O
results,148,O
suggest,148,O
that,148,O
the,148,O
antagonistic,148,O
effect,148,O
of,148,O
nicotine,148,B-ChemicalEntity
on,148,O
caffeine-induced,148,B-ChemicalEntity
anxiety,148,B-DiseaseOrPhenotypicFeature
is,148,O
specific,148,O
to,148,O
caffeine,148,B-ChemicalEntity
",",148,O
instead,148,O
of,148,O
a,148,O
non-specific,148,O
anxiolytic,148,O
effect,148,O
.,148,O
Thus,149,O
",",149,O
it,149,O
may,149,O
extend,149,O
the,149,O
current,149,O
findings,149,O
on,149,O
the,149,O
interaction,149,O
between,149,O
nicotine,149,B-ChemicalEntity
and,149,O
caffeine,149,B-ChemicalEntity
.,149,O
Successful,150,O
therapy,150,O
with,150,O
argatroban,150,B-ChemicalEntity
for,150,O
superior,150,O
mesenteric,150,O
vein,150,B-DiseaseOrPhenotypicFeature
thrombosis,150,I-DiseaseOrPhenotypicFeature
in,150,O
a,150,O
patient,150,B-OrganismTaxon
with,150,O
congenital,150,B-DiseaseOrPhenotypicFeature
antithrombin,150,I-DiseaseOrPhenotypicFeature
deficiency,150,I-DiseaseOrPhenotypicFeature
.,150,O
A,151,O
38-year-old,151,O
woman,151,B-OrganismTaxon
was,151,O
admitted,151,O
with,151,O
superior,151,B-DiseaseOrPhenotypicFeature
mesenteric,151,I-DiseaseOrPhenotypicFeature
vein,151,I-DiseaseOrPhenotypicFeature
(,151,I-DiseaseOrPhenotypicFeature
SMV,151,I-DiseaseOrPhenotypicFeature
),151,I-DiseaseOrPhenotypicFeature
thrombosis,151,I-DiseaseOrPhenotypicFeature
",",151,O
which,151,O
was,151,O
refractory,151,O
to,151,O
anticoagulation,151,O
therapy,151,O
.,151,O
The,152,O
plasma,152,O
antithrombin,152,B-GeneOrGeneProduct
activity,152,O
was,152,O
decreased,152,O
and,152,O
hardly,152,O
compensated,152,O
by,152,O
concentrated,152,O
antithrombin,152,B-GeneOrGeneProduct
preparation,152,O
due,152,O
to,152,O
high,152,O
consumption,152,O
rate,152,O
.,152,O
However,153,O
",",153,O
successful,153,O
anticoagulation,153,O
was,153,O
achieved,153,O
by,153,O
administration,153,O
of,153,O
direct,153,O
thrombin,153,B-GeneOrGeneProduct
inhibitor,153,O
",",153,O
argatroban,153,B-ChemicalEntity
.,153,O
Family,154,O
studies,154,O
of,154,O
antithrombin,154,B-GeneOrGeneProduct
activity,154,O
revealed,154,O
that,154,O
she,154,O
had,154,O
type,154,B-DiseaseOrPhenotypicFeature
I,154,I-DiseaseOrPhenotypicFeature
congenital,154,I-DiseaseOrPhenotypicFeature
antithrombin,154,I-DiseaseOrPhenotypicFeature
deficiency,154,I-DiseaseOrPhenotypicFeature
.,154,O
A,155,O
novel,155,O
heterozygous,155,O
mutation,155,O
in,155,O
the,155,O
gene,155,O
for,155,O
antithrombin,155,B-GeneOrGeneProduct
(,155,O
single,155,O
nucleotide,155,B-SequenceVariant
T,155,I-SequenceVariant
insertion,155,I-SequenceVariant
at,155,I-SequenceVariant
7916,155,I-SequenceVariant
and,155,I-SequenceVariant
7917,155,I-SequenceVariant
",",155,O
Glu,155,B-SequenceVariant
272,155,I-SequenceVariant
to,155,I-SequenceVariant
stop,155,I-SequenceVariant
in,155,O
exon,155,O
4,155,O
),155,O
was,155,O
identified,155,O
.,155,O
Argatroban,156,B-ChemicalEntity
administration,156,O
would,156,O
be,156,O
effective,156,O
in,156,O
the,156,O
treatment,156,O
of,156,O
congenital,156,B-DiseaseOrPhenotypicFeature
antithrombin,156,I-DiseaseOrPhenotypicFeature
deficiency,156,I-DiseaseOrPhenotypicFeature
with,156,O
SMV,156,B-DiseaseOrPhenotypicFeature
thrombosis,156,I-DiseaseOrPhenotypicFeature
.,156,O
Two,157,O
novel,157,O
mutations,157,O
in,157,O
SRY,157,B-GeneOrGeneProduct
gene,157,O
form,157,O
Chinese,157,O
sex,157,B-DiseaseOrPhenotypicFeature
reversal,157,I-DiseaseOrPhenotypicFeature
XY,157,I-DiseaseOrPhenotypicFeature
females,157,O
.,157,O
The,158,O
SRY,158,B-GeneOrGeneProduct
gene,158,O
(,158,O
sex,158,O
determining,158,O
region,158,O
on,158,O
Y,158,O
chromosome,158,O
),158,O
acts,158,O
as,158,O
TDF,158,O
and,158,O
is,158,O
required,158,O
for,158,O
regulating,158,O
male,158,O
sex,158,O
determination,158,O
.,158,O
SRY,159,B-GeneOrGeneProduct
represents,159,O
a,159,O
transcription,159,O
factor,159,O
belonging,159,O
to,159,O
the,159,O
superfamily,159,O
of,159,O
genes,159,O
sharing,159,O
the,159,O
HMG-box,159,O
motif,159,O
(,159,O
high-mobility,159,O
group-box,159,O
),159,O
",",159,O
which,159,O
acts,159,O
as,159,O
DNA,159,O
binding,159,O
region,159,O
.,159,O
Deletion,160,O
and,160,O
inactivating,160,O
mutations,160,O
of,160,O
SRY,160,B-GeneOrGeneProduct
are,160,O
among,160,O
the,160,O
known,160,O
causes,160,O
of,160,O
XY,160,B-DiseaseOrPhenotypicFeature
sex,160,I-DiseaseOrPhenotypicFeature
reversal,160,I-DiseaseOrPhenotypicFeature
.,160,O
Here,161,O
",",161,O
we,161,O
described,161,O
the,161,O
screening,161,O
of,161,O
10,161,O
patients,161,B-OrganismTaxon
who,161,O
presented,161,O
with,161,O
46,161,B-DiseaseOrPhenotypicFeature
",",161,I-DiseaseOrPhenotypicFeature
XY,161,I-DiseaseOrPhenotypicFeature
sex,161,I-DiseaseOrPhenotypicFeature
reversal,161,I-DiseaseOrPhenotypicFeature
for,161,O
mutations,161,O
in,161,O
open,161,O
reading,161,O
frame,161,O
(,161,O
ORF,161,O
),161,O
of,161,O
SRY,161,B-GeneOrGeneProduct
gene,161,O
.,161,O
DNA,162,O
was,162,O
isolated,162,O
from,162,O
blood,162,O
samples,162,O
using,162,O
standard,162,O
techniques,162,O
.,162,O
A,163,O
609,163,O
bp,163,O
fragment,163,O
from,163,O
the,163,O
central,163,O
portion,163,O
of,163,O
the,163,O
SRY,163,B-GeneOrGeneProduct
gene,163,O
was,163,O
amplified,163,O
",",163,O
using,163,O
primers,163,O
XES-2,163,O
and,163,O
XES-7,163,O
.,163,O
The,164,O
amplified,164,O
PCR,164,O
fragments,164,O
were,164,O
cloned,164,O
into,164,O
the,164,O
pUCm-T,164,O
vectors,164,O
",",164,O
and,164,O
direct,164,O
sequencing,164,O
were,164,O
carried,164,O
out,164,O
on,164,O
an,164,O
ABI,164,O
377-3,164,O
automated,164,O
DNA,164,O
sequencer,164,O
to,164,O
detect,164,O
the,164,O
mutation,164,O
.,164,O
PCR-restriction,165,O
enzyme,165,O
digestion,165,O
was,165,O
applied,165,O
to,165,O
detect,165,O
the,165,O
results,165,O
of,165,O
DNA,165,O
sequencing,165,O
.,165,O
In,166,O
two,166,O
patients,166,B-OrganismTaxon
",",166,O
de,166,O
novo,166,O
mutations,166,O
led,166,O
to,166,O
an,166,O
amino,166,O
acid,166,O
substitution,166,O
.,166,O
An,167,O
A,167,B-SequenceVariant
was,167,I-SequenceVariant
replaced,167,I-SequenceVariant
by,167,I-SequenceVariant
a,167,I-SequenceVariant
G,167,I-SequenceVariant
in,167,I-SequenceVariant
codon,167,I-SequenceVariant
38,167,I-SequenceVariant
upstream,167,O
of,167,O
the,167,O
5,167,O
',167,O
border,167,O
outside,167,O
the,167,O
HMG,167,O
box,167,O
of,167,O
the,167,O
SRY,167,B-GeneOrGeneProduct
gene,167,O
",",167,O
resulting,167,O
in,167,O
the,167,O
replacement,167,O
of,167,O
the,167,O
amino,167,O
acid,167,O
glutamate,167,B-SequenceVariant
by,167,I-SequenceVariant
glycine,167,I-SequenceVariant
.,167,O
Another,168,O
heterozygous,168,O
T,168,B-SequenceVariant
to,168,I-SequenceVariant
A,168,I-SequenceVariant
transition,168,I-SequenceVariant
at,168,I-SequenceVariant
the,168,I-SequenceVariant
nucleotide,168,I-SequenceVariant
position,168,I-SequenceVariant
+387,168,I-SequenceVariant
which,168,O
encodes,168,O
for,168,O
a,168,O
Tyrosine,168,B-SequenceVariant
(,168,I-SequenceVariant
Tyr,168,I-SequenceVariant
),168,I-SequenceVariant
instead,168,I-SequenceVariant
of,168,I-SequenceVariant
a,168,I-SequenceVariant
Term,168,I-SequenceVariant
",",168,O
whereas,168,O
her,168,O
father,168,O
was,168,O
proven,168,O
to,168,O
have,168,O
the,168,O
wild-type,168,O
sequence,168,O
.,168,O
These,169,O
point,169,O
mutations,169,O
have,169,O
been,169,O
confirmed,169,O
with,169,O
PCR-restrict,169,O
enzyme,169,O
method,169,O
.,169,O
As,170,O
demonstrated,170,O
by,170,O
the,170,O
Human,170,B-OrganismTaxon
Gene,170,O
Mutation,170,O
Database,170,O
analysis,170,O
",",170,O
homology,170,O
search,170,O
",",170,O
and,170,O
review,170,O
of,170,O
the,170,O
literature,170,O
",",170,O
these,170,O
two,170,O
mutations,170,O
were,170,O
not,170,O
described,170,O
previously,170,O
and,170,O
brought,170,O
the,170,O
total,170,O
number,170,O
of,170,O
SRY,170,B-GeneOrGeneProduct
gene,170,O
nucleotide,170,O
substitutions,170,O
(,170,O
missense/nonsense,170,O
),170,O
to,170,O
45,170,O
.,170,O
These,171,O
findings,171,O
indicated,171,O
that,171,O
these,171,O
amino,171,O
acid,171,O
substitutions,171,O
may,171,O
be,171,O
responsible,171,O
for,171,O
the,171,O
sex,171,B-DiseaseOrPhenotypicFeature
reversal,171,I-DiseaseOrPhenotypicFeature
",",171,O
not,171,O
only,171,O
inside,171,O
the,171,O
HMG-box,171,O
but,171,O
also,171,O
outside,171,O
the,171,O
HMG-box,171,O
.,171,O
The,172,O
two,172,O
novel,172,O
mutations,172,O
in,172,O
SRY,172,B-GeneOrGeneProduct
gene,172,O
provided,172,O
valuable,172,O
information,172,O
for,172,O
understanding,172,O
the,172,O
molecular,172,O
mechanism,172,O
of,172,O
the,172,O
patient,172,B-OrganismTaxon
with,172,O
46,172,B-DiseaseOrPhenotypicFeature
",",172,I-DiseaseOrPhenotypicFeature
XY,172,I-DiseaseOrPhenotypicFeature
female,172,I-DiseaseOrPhenotypicFeature
sex,172,I-DiseaseOrPhenotypicFeature
reversal,172,I-DiseaseOrPhenotypicFeature
.,172,O
Polymorphism,173,O
of,173,O
the,173,O
PEMT,173,B-GeneOrGeneProduct
gene,173,O
and,173,O
susceptibility,173,O
to,173,O
nonalcoholic,173,B-DiseaseOrPhenotypicFeature
fatty,173,I-DiseaseOrPhenotypicFeature
liver,173,I-DiseaseOrPhenotypicFeature
disease,173,I-DiseaseOrPhenotypicFeature
(,173,O
NAFLD,173,B-DiseaseOrPhenotypicFeature
),173,O
.,173,O
Phosphatidylethanolamine,174,B-GeneOrGeneProduct
N-methyltransferase,174,I-GeneOrGeneProduct
(,174,O
PEMT,174,B-GeneOrGeneProduct
),174,O
catalyzes,174,O
phosphatidylcholine,174,B-ChemicalEntity
synthesis,174,O
.,174,O
PEMT,175,B-GeneOrGeneProduct
knockout,175,O
mice,175,B-OrganismTaxon
have,175,O
fatty,175,B-DiseaseOrPhenotypicFeature
livers,175,I-DiseaseOrPhenotypicFeature
",",175,O
and,175,O
it,175,O
is,175,O
possible,175,O
that,175,O
",",175,O
in,175,O
humans,175,B-OrganismTaxon
",",175,O
nonalcoholic,175,B-DiseaseOrPhenotypicFeature
fatty,175,I-DiseaseOrPhenotypicFeature
liver,175,I-DiseaseOrPhenotypicFeature
disease,175,I-DiseaseOrPhenotypicFeature
(,175,O
NAFLD,175,B-DiseaseOrPhenotypicFeature
),175,O
might,175,O
be,175,O
associated,175,O
with,175,O
PEMT,175,B-GeneOrGeneProduct
gene,175,O
polymorphisms,175,O
.,175,O
DNA,176,O
samples,176,O
from,176,O
59,176,O
humans,176,B-OrganismTaxon
without,176,O
fatty,176,B-DiseaseOrPhenotypicFeature
liver,176,I-DiseaseOrPhenotypicFeature
and,176,O
from,176,O
28,176,O
humans,176,B-OrganismTaxon
with,176,O
NAFLD,176,B-DiseaseOrPhenotypicFeature
were,176,O
genotyped,176,O
for,176,O
a,176,O
single,176,O
nucleotide,176,O
polymorphism,176,O
in,176,O
exon,176,O
8,176,O
of,176,O
PEMT,176,B-GeneOrGeneProduct
",",176,O
which,176,O
leads,176,O
to,176,O
a,176,O
V175M,176,B-SequenceVariant
substitution,176,O
.,176,O
V175M,177,B-SequenceVariant
is,177,O
a,177,O
loss,177,O
of,177,O
function,177,O
mutation,177,O
",",177,O
as,177,O
determined,177,O
by,177,O
transiently,177,O
transfecting,177,O
McArdle-RH7777,177,B-CellLine
cells,177,O
with,177,O
constructs,177,O
of,177,O
wild-type,177,O
PEMT,177,B-GeneOrGeneProduct
open,177,O
reading,177,O
frame,177,O
or,177,O
the,177,O
V175M,177,B-SequenceVariant
mutant,177,O
.,177,O
Met/Met,178,B-SequenceVariant
at,178,I-SequenceVariant
residue,178,I-SequenceVariant
175,178,I-SequenceVariant
(,178,O
loss,178,O
of,178,O
function,178,O
SNP,178,O
),178,O
occurred,178,O
in,178,O
67.9,178,O
%,178,O
of,178,O
the,178,O
NAFLD,178,B-DiseaseOrPhenotypicFeature
subjects,178,O
and,178,O
in,178,O
only,178,O
40.7,178,O
%,178,O
of,178,O
control,178,O
subjects,178,O
(,178,O
P,178,O
<,178,O
0.03,178,O
),178,O
.,178,O
For,179,O
the,179,O
first,179,O
time,179,O
we,179,O
report,179,O
that,179,O
a,179,O
polymorphism,179,O
of,179,O
the,179,O
human,179,B-OrganismTaxon
PEMT,179,B-GeneOrGeneProduct
gene,179,O
(,179,O
V175M,179,B-SequenceVariant
),179,O
is,179,O
associated,179,O
with,179,O
diminished,179,O
activity,179,O
and,179,O
may,179,O
confer,179,O
susceptibility,179,O
to,179,O
NAFLD,179,B-DiseaseOrPhenotypicFeature
.,179,O
Carrier,180,O
frequency,180,O
of,180,O
mutation,180,O
657del5,180,B-SequenceVariant
in,180,O
the,180,O
NBS1,180,B-GeneOrGeneProduct
gene,180,O
in,180,O
a,180,O
population,180,O
of,180,O
Polish,180,O
pediatric,180,O
patients,180,B-OrganismTaxon
with,180,O
sporadic,180,B-DiseaseOrPhenotypicFeature
lymphoid,180,I-DiseaseOrPhenotypicFeature
malignancies,180,I-DiseaseOrPhenotypicFeature
.,180,O
Nijmegen,181,B-DiseaseOrPhenotypicFeature
breakage,181,I-DiseaseOrPhenotypicFeature
syndrome,181,I-DiseaseOrPhenotypicFeature
(,181,O
NBS,181,B-DiseaseOrPhenotypicFeature
),181,O
is,181,O
a,181,O
human,181,B-OrganismTaxon
autosomal,181,B-DiseaseOrPhenotypicFeature
recessive,181,I-DiseaseOrPhenotypicFeature
disease,181,I-DiseaseOrPhenotypicFeature
characterized,181,O
by,181,O
genomic,181,O
instability,181,O
and,181,O
enhanced,181,O
cancer,181,B-DiseaseOrPhenotypicFeature
predisposition,181,O
",",181,O
in,181,O
particular,181,O
to,181,O
lymphoma,181,B-DiseaseOrPhenotypicFeature
and,181,O
leukemia,181,B-DiseaseOrPhenotypicFeature
.,181,O
Recently,182,O
",",182,O
significantly,182,O
higher,182,O
frequencies,182,O
of,182,O
heterozygous,182,O
carriers,182,O
of,182,O
the,182,O
Slavic,182,O
founder,182,O
NBS1,182,B-GeneOrGeneProduct
mutation,182,O
",",182,O
657del5,182,B-SequenceVariant
",",182,O
were,182,O
found,182,O
in,182,O
Russian,182,O
children,182,O
with,182,O
sporadic,182,B-DiseaseOrPhenotypicFeature
lymphoid,182,I-DiseaseOrPhenotypicFeature
malignancies,182,I-DiseaseOrPhenotypicFeature
",",182,O
and,182,O
in,182,O
Polish,182,O
adults,182,O
with,182,O
non-Hodgkin,182,B-DiseaseOrPhenotypicFeature
lymphoma,182,I-DiseaseOrPhenotypicFeature
(,182,O
NHL,182,B-DiseaseOrPhenotypicFeature
),182,O
.,182,O
In,183,O
addition,183,O
",",183,O
the,183,O
substitution,183,O
643C,183,B-SequenceVariant
>,183,I-SequenceVariant
T,183,I-SequenceVariant
(,183,O
R215W,183,B-SequenceVariant
),183,O
has,183,O
also,183,O
been,183,O
found,183,O
in,183,O
excess,183,O
among,183,O
children,183,O
with,183,O
acute,183,B-DiseaseOrPhenotypicFeature
lymphoblastic,183,I-DiseaseOrPhenotypicFeature
leukemia,183,I-DiseaseOrPhenotypicFeature
(,183,O
ALL,183,B-DiseaseOrPhenotypicFeature
),183,O
.,183,O
In,184,O
an,184,O
attempt,184,O
to,184,O
asses,184,O
the,184,O
contribution,184,O
of,184,O
both,184,O
mutations,184,O
to,184,O
the,184,O
development,184,O
of,184,O
sporadic,184,B-DiseaseOrPhenotypicFeature
lymphoid,184,I-DiseaseOrPhenotypicFeature
malignancies,184,I-DiseaseOrPhenotypicFeature
",",184,O
we,184,O
analyzed,184,O
DNA,184,O
samples,184,O
from,184,O
a,184,O
large,184,O
group,184,O
of,184,O
Polish,184,O
pediatric,184,O
patients,184,B-OrganismTaxon
.,184,O
The,185,O
NBS1,185,B-GeneOrGeneProduct
mutation,185,O
657del5,185,B-SequenceVariant
on,185,O
one,185,O
allele,185,O
was,185,O
found,185,O
in,185,O
3,185,O
of,185,O
270,185,O
patients,185,B-OrganismTaxon
with,185,O
ALL,185,B-DiseaseOrPhenotypicFeature
and,185,O
2,185,O
of,185,O
212,185,O
children,185,O
and,185,O
adolescents,185,O
with,185,O
NHL,185,B-DiseaseOrPhenotypicFeature
;,185,O
no,185,O
carrier,185,O
was,185,O
found,185,O
among,185,O
63,185,O
patients,185,B-OrganismTaxon
with,185,O
Hodgkin,185,B-DiseaseOrPhenotypicFeature
lymphoma,185,I-DiseaseOrPhenotypicFeature
(,185,O
HL,185,B-DiseaseOrPhenotypicFeature
),185,O
.,185,O
No,186,O
carriers,186,O
of,186,O
the,186,O
variant,186,O
R215W,186,B-SequenceVariant
were,186,O
detected,186,O
in,186,O
any,186,O
studied,186,O
group,186,O
.,186,O
The,187,O
relative,187,O
frequency,187,O
of,187,O
the,187,O
657del5,187,B-SequenceVariant
mutation,187,O
was,187,O
calculated,187,O
from,187,O
a,187,O
total,187,O
of,187,O
"6,984",187,O
controls,187,O
matched,187,O
by,187,O
place,187,O
of,187,O
patient,187,B-OrganismTaxon
residence,187,O
",",187,O
of,187,O
whom,187,O
42,187,O
were,187,O
found,187,O
to,187,O
be,187,O
carriers,187,O
(,187,O
frequency,187,O
=,187,O
0.006,187,O
),187,O
.,187,O
In,188,O
the,188,O
analyzed,188,O
population,188,O
with,188,O
malignancies,188,B-DiseaseOrPhenotypicFeature
",",188,O
an,188,O
increased,188,O
odds,188,O
ratio,188,O
for,188,O
the,188,O
occurrence,188,O
of,188,O
mutation,188,O
657del5,188,B-SequenceVariant
was,188,O
found,188,O
in,188,O
comparison,188,O
with,188,O
the,188,O
control,188,O
Polish,188,O
population,188,O
(,188,O
OR,188,O
range,188,O
1.48-1.85,188,O
",",188,O
95,188,O
%,188,O
confidence,188,O
interval,188,O
1.18-2.65,188,O
),188,O
.,188,O
This,189,O
finding,189,O
indicates,189,O
that,189,O
the,189,O
frequency,189,O
of,189,O
the,189,O
mutation,189,O
carriers,189,O
was,189,O
indeed,189,O
increased,189,O
in,189,O
patients,189,B-OrganismTaxon
with,189,O
ALL,189,B-DiseaseOrPhenotypicFeature
and,189,O
NHL,189,B-DiseaseOrPhenotypicFeature
(,189,O
p,189,O
<,189,O
0.05,189,O
),189,O
.,189,O
Nonetheless,190,O
",",190,O
NBS1,190,B-GeneOrGeneProduct
gene,190,O
heterozygosity,190,O
is,190,O
not,190,O
a,190,O
major,190,O
risk,190,O
factor,190,O
for,190,O
lymphoid,190,B-DiseaseOrPhenotypicFeature
malignancies,190,I-DiseaseOrPhenotypicFeature
in,190,O
childhood,190,O
and,190,O
adolescence,190,O
.,190,O
Mono-allelic,191,O
POLG,191,B-GeneOrGeneProduct
expression,191,O
resulting,191,O
from,191,O
nonsense-mediated,191,O
decay,191,O
and,191,O
alternative,191,O
splicing,191,O
in,191,O
a,191,O
patient,191,B-OrganismTaxon
with,191,O
Alpers,191,B-DiseaseOrPhenotypicFeature
syndrome,191,I-DiseaseOrPhenotypicFeature
.,191,O
Alpers,192,B-DiseaseOrPhenotypicFeature
syndrome,192,I-DiseaseOrPhenotypicFeature
is,192,O
an,192,O
autosomal,192,O
recessive,192,O
mitochondrial,192,B-DiseaseOrPhenotypicFeature
DNA,192,I-DiseaseOrPhenotypicFeature
depletion,192,I-DiseaseOrPhenotypicFeature
disorder,192,O
that,192,O
affects,192,O
children,192,O
and,192,O
young,192,O
adults,192,O
.,192,O
It,193,O
is,193,O
characterized,193,O
by,193,O
a,193,O
progressive,193,O
",",193,O
fatal,193,O
brain,193,O
and,193,O
liver,193,B-DiseaseOrPhenotypicFeature
disease,193,I-DiseaseOrPhenotypicFeature
.,193,O
This,194,O
syndrome,194,O
has,194,O
been,194,O
associated,194,O
with,194,O
mutations,194,O
in,194,O
POLG,194,B-GeneOrGeneProduct
",",194,O
the,194,O
gene,194,O
encoding,194,O
the,194,O
mitochondrial,194,O
DNA,194,O
polymerase,194,O
(,194,O
pol,194,B-GeneOrGeneProduct
gamma,194,I-GeneOrGeneProduct
),194,O
.,194,O
Most,195,O
patients,195,B-OrganismTaxon
with,195,O
Alpers,195,B-DiseaseOrPhenotypicFeature
syndrome,195,I-DiseaseOrPhenotypicFeature
have,195,O
been,195,O
found,195,O
to,195,O
be,195,O
compound,195,O
heterozygotes,195,O
",",195,O
carrying,195,O
two,195,O
pathogenic,195,O
mutations,195,O
in,195,O
trans,195,O
at,195,O
the,195,O
POLG,195,B-GeneOrGeneProduct
locus,195,O
.,195,O
POLG,196,B-GeneOrGeneProduct
is,196,O
a,196,O
nuclear-encoded,196,O
gene,196,O
whose,196,O
protein,196,O
product,196,O
is,196,O
imported,196,O
into,196,O
mitochondria,196,O
",",196,O
where,196,O
it,196,O
is,196,O
essential,196,O
for,196,O
mtDNA,196,O
replication,196,O
and,196,O
repair,196,O
.,196,O
We,197,O
studied,197,O
the,197,O
skin,197,O
fibroblasts,197,O
of,197,O
a,197,O
patient,197,B-OrganismTaxon
with,197,O
Alpers,197,B-DiseaseOrPhenotypicFeature
syndrome,197,I-DiseaseOrPhenotypicFeature
having,197,O
the,197,O
genotype,197,O
E873stop/A467T,197,B-SequenceVariant
.,197,O
The,198,O
E873stop,198,B-SequenceVariant
mutation,198,O
produces,198,O
a,198,O
premature,198,O
termination,198,O
codon,198,O
(,198,O
TAG,198,O
),198,O
in,198,O
exon,198,O
17,198,O
.,198,O
The,199,O
A467T,199,B-SequenceVariant
mutation,199,O
produces,199,O
a,199,O
threonine,199,B-SequenceVariant
to,199,I-SequenceVariant
alanine,199,I-SequenceVariant
substitution,199,O
at,199,O
a,199,O
highly,199,O
conserved,199,O
site,199,O
in,199,O
exon,199,O
7,199,O
.,199,O
The,200,O
allele,200,O
bearing,200,O
the,200,O
stop,200,O
codon,200,O
(,200,O
E873-TAG,200,B-SequenceVariant
),200,O
is,200,O
predicted,200,O
to,200,O
produce,200,O
a,200,O
truncated,200,O
",",200,O
catalytically,200,O
inactive,200,O
polymerase,200,O
.,200,O
However,201,O
",",201,O
only,201,O
full-length,201,O
pol,201,B-GeneOrGeneProduct
gamma,201,I-GeneOrGeneProduct
protein,201,O
was,201,O
detected,201,O
by,201,O
Western,201,O
blot,201,O
analysis,201,O
.,201,O
Here,202,O
",",202,O
we,202,O
show,202,O
that,202,O
transcripts,202,O
containing,202,O
this,202,O
stop,202,O
codon,202,O
undergo,202,O
nonsense-associated,202,O
alternative,202,O
splicing,202,O
and,202,O
nonsense-mediated,202,O
decay,202,O
.,202,O
More,203,O
than,203,O
95,203,O
%,203,O
of,203,O
the,203,O
functional,203,O
POLG,203,B-GeneOrGeneProduct
mRNA,203,O
was,203,O
derived,203,O
from,203,O
the,203,O
allele,203,O
bearing,203,O
the,203,O
A467T,203,B-SequenceVariant
mutation,203,O
and,203,O
less,203,O
than,203,O
5,203,O
%,203,O
contained,203,O
the,203,O
E873stop,203,B-SequenceVariant
mutation,203,O
.,203,O
These,204,O
events,204,O
ensured,204,O
that,204,O
virtually,204,O
all,204,O
POLG,204,B-GeneOrGeneProduct
protein,204,O
in,204,O
the,204,O
cell,204,O
was,204,O
expressed,204,O
from,204,O
the,204,O
A467T,204,B-SequenceVariant
allele,204,O
.,204,O
Therefore,205,O
",",205,O
the,205,O
Alpers,205,O
phenotype,205,O
in,205,O
this,205,O
patient,205,B-OrganismTaxon
was,205,O
a,205,O
consequence,205,O
of,205,O
a,205,O
single-copy,205,O
gene,205,O
dose,205,O
of,205,O
the,205,O
A467T,205,B-SequenceVariant
allele,205,O
",",205,O
and,205,O
selective,205,O
elimination,205,O
of,205,O
transcripts,205,O
bearing,205,O
the,205,O
E873stop,205,B-SequenceVariant
mutation,205,O
.,205,O
Amisulpride,206,B-ChemicalEntity
related,206,O
tic-like,206,B-DiseaseOrPhenotypicFeature
symptoms,206,I-DiseaseOrPhenotypicFeature
in,206,O
an,206,O
adolescent,206,O
schizophrenic,206,B-DiseaseOrPhenotypicFeature
.,206,O
Tic,207,B-DiseaseOrPhenotypicFeature
disorders,207,I-DiseaseOrPhenotypicFeature
can,207,O
be,207,O
effectively,207,O
treated,207,O
by,207,O
atypical,207,O
antipsychotics,207,B-ChemicalEntity
such,207,O
as,207,O
risperidone,207,B-ChemicalEntity
",",207,O
olanzapine,207,B-ChemicalEntity
and,207,O
ziprasidone,207,B-ChemicalEntity
.,207,O
However,208,O
",",208,O
there,208,O
are,208,O
two,208,O
case,208,O
reports,208,O
that,208,O
show,208,O
tic-like,208,B-DiseaseOrPhenotypicFeature
symptoms,208,I-DiseaseOrPhenotypicFeature
",",208,O
including,208,O
motor,208,O
and,208,O
phonic,208,O
variants,208,O
",",208,O
occurring,208,O
during,208,O
treatment,208,O
with,208,O
quetiapine,208,B-ChemicalEntity
or,208,O
clozapine,208,B-ChemicalEntity
.,208,O
We,209,O
present,209,O
a,209,O
15-year-old,209,O
girl,209,O
schizophrenic,209,B-DiseaseOrPhenotypicFeature
who,209,O
developed,209,O
frequent,209,O
involuntary,209,B-DiseaseOrPhenotypicFeature
eye-blinking,209,I-DiseaseOrPhenotypicFeature
movements,209,I-DiseaseOrPhenotypicFeature
after,209,O
5,209,O
months,209,O
of,209,O
amisulpride,209,B-ChemicalEntity
treatment,209,O
(,209,O
1000,209,O
mg,209,O
per,209,O
day,209,O
),209,O
.,209,O
The,210,O
tic-like,210,B-DiseaseOrPhenotypicFeature
symptoms,210,I-DiseaseOrPhenotypicFeature
resolved,210,O
completely,210,O
after,210,O
we,210,O
reduced,210,O
the,210,O
dose,210,O
of,210,O
amisulpride,210,B-ChemicalEntity
down,210,O
to,210,O
800,210,O
mg,210,O
per,210,O
day,210,O
.,210,O
However,211,O
",",211,O
her,211,O
psychosis,211,B-DiseaseOrPhenotypicFeature
recurred,211,O
after,211,O
the,211,O
dose,211,O
reduction,211,O
.,211,O
We,212,O
then,212,O
placed,212,O
her,212,O
on,212,O
an,212,O
additional,212,O
100,212,O
mg,212,O
per,212,O
day,212,O
of,212,O
quetiapine,212,B-ChemicalEntity
.,212,O
She,213,O
has,213,O
been,213,O
in,213,O
complete,213,O
remission,213,O
under,213,O
the,213,O
combined,213,O
medications,213,O
for,213,O
more,213,O
than,213,O
one,213,O
year,213,O
and,213,O
maintains,213,O
a,213,O
fair,213,O
role,213,O
function,213,O
.,213,O
No,214,O
more,214,O
tic-like,214,B-DiseaseOrPhenotypicFeature
symptoms,214,I-DiseaseOrPhenotypicFeature
or,214,O
other,214,O
side,214,O
effects,214,O
have,214,O
been,214,O
reported,214,O
.,214,O
Together,215,O
with,215,O
previously,215,O
reported,215,O
cases,215,O
",",215,O
our,215,O
patient,215,B-OrganismTaxon
suggests,215,O
that,215,O
tic-like,215,B-DiseaseOrPhenotypicFeature
symptoms,215,I-DiseaseOrPhenotypicFeature
might,215,O
occur,215,O
in,215,O
certain,215,O
vulnerable,215,O
individuals,215,O
during,215,O
treatment,215,O
with,215,O
atypical,215,O
antipsychotics,215,B-ChemicalEntity
such,215,O
as,215,O
quetiapine,215,B-ChemicalEntity
",",215,O
clozapine,215,B-ChemicalEntity
",",215,O
or,215,O
amisulpride,215,B-ChemicalEntity
.,215,O
Segregation,216,O
of,216,O
a,216,O
M404V,216,B-SequenceVariant
mutation,216,O
of,216,O
the,216,O
p62/sequestosome,216,B-GeneOrGeneProduct
1,216,I-GeneOrGeneProduct
(,216,O
p62/SQSTM1,216,B-GeneOrGeneProduct
),216,O
gene,216,O
with,216,O
polyostotic,216,O
Paget,216,B-DiseaseOrPhenotypicFeature
's,216,I-DiseaseOrPhenotypicFeature
disease,216,I-DiseaseOrPhenotypicFeature
of,216,I-DiseaseOrPhenotypicFeature
bone,216,I-DiseaseOrPhenotypicFeature
in,216,O
an,216,O
Italian,216,O
family,216,O
.,216,O
Mutations,217,O
of,217,O
the,217,O
p62/Sequestosome,217,B-GeneOrGeneProduct
1,217,I-GeneOrGeneProduct
gene,217,O
(,217,O
p62/SQSTM1,217,B-GeneOrGeneProduct
),217,O
account,217,O
for,217,O
both,217,O
sporadic,217,O
and,217,O
familial,217,O
forms,217,O
of,217,O
Paget,217,B-DiseaseOrPhenotypicFeature
's,217,I-DiseaseOrPhenotypicFeature
disease,217,I-DiseaseOrPhenotypicFeature
of,217,I-DiseaseOrPhenotypicFeature
bone,217,I-DiseaseOrPhenotypicFeature
(,217,O
PDB,217,B-DiseaseOrPhenotypicFeature
),217,O
.,217,O
We,218,O
originally,218,O
described,218,O
a,218,O
methionine,218,B-SequenceVariant
--,218,I-SequenceVariant
>,218,I-SequenceVariant
valine,218,I-SequenceVariant
substitution,218,I-SequenceVariant
at,218,I-SequenceVariant
codon,218,I-SequenceVariant
404,218,I-SequenceVariant
(,218,O
M404V,218,B-SequenceVariant
),218,O
of,218,O
exon,218,O
8,218,O
",",218,O
in,218,O
the,218,O
ubiquitin,218,O
protein-binding,218,O
domain,218,O
of,218,O
p62/SQSTM1,218,B-GeneOrGeneProduct
gene,218,O
in,218,O
an,218,O
Italian,218,O
PDB,218,B-DiseaseOrPhenotypicFeature
patient,218,B-OrganismTaxon
.,218,O
The,219,O
collection,219,O
of,219,O
data,219,O
from,219,O
the,219,O
patient,219,B-OrganismTaxon
's,219,O
pedigree,219,O
provided,219,O
evidence,219,O
for,219,O
a,219,O
familial,219,O
form,219,O
of,219,O
PDB,219,B-DiseaseOrPhenotypicFeature
.,219,O
Extension,220,O
of,220,O
the,220,O
genetic,220,O
analysis,220,O
to,220,O
other,220,O
relatives,220,O
in,220,O
this,220,O
family,220,O
demonstrated,220,O
segregation,220,O
of,220,O
the,220,O
M404V,220,B-SequenceVariant
mutation,220,O
with,220,O
the,220,O
polyostotic,220,O
PDB,220,B-DiseaseOrPhenotypicFeature
phenotype,220,O
and,220,O
provided,220,O
the,220,O
identification,220,O
of,220,O
six,220,O
asymptomatic,220,O
gene,220,O
carriers,220,O
.,220,O
DNA,221,O
for,221,O
mutational,221,O
analysis,221,O
of,221,O
the,221,O
exon,221,O
8,221,O
coding,221,O
sequence,221,O
was,221,O
obtained,221,O
from,221,O
22,221,O
subjects,221,O
",",221,O
4,221,O
PDB,221,B-DiseaseOrPhenotypicFeature
patients,221,B-OrganismTaxon
and,221,O
18,221,O
clinically,221,O
unaffected,221,O
members,221,O
.,221,O
Of,222,O
the,222,O
five,222,O
clinically,222,O
ascertained,222,O
affected,222,O
members,222,O
of,222,O
the,222,O
family,222,O
",",222,O
four,222,O
possessed,222,O
the,222,O
M404V,222,B-SequenceVariant
mutation,222,O
and,222,O
exhibited,222,O
the,222,O
polyostotic,222,O
form,222,O
of,222,O
PDB,222,B-DiseaseOrPhenotypicFeature
",",222,O
except,222,O
one,222,O
patient,222,B-OrganismTaxon
with,222,O
a,222,O
single,222,O
X-ray-assessed,222,O
skeletal,222,O
localization,222,O
and,222,O
one,222,O
with,222,O
a,222,O
polyostotic,222,B-DiseaseOrPhenotypicFeature
disease,222,I-DiseaseOrPhenotypicFeature
who,222,O
had,222,O
died,222,O
several,222,O
years,222,O
before,222,O
the,222,O
DNA,222,O
analysis,222,O
.,222,O
By,223,O
both,223,O
reconstitution,223,O
and,223,O
mutational,223,O
analysis,223,O
of,223,O
the,223,O
pedigree,223,O
",",223,O
six,223,O
unaffected,223,O
subjects,223,O
were,223,O
shown,223,O
to,223,O
bear,223,O
the,223,O
M404V,223,B-SequenceVariant
mutation,223,O
",",223,O
representing,223,O
potential,223,O
asymptomatic,223,O
gene,223,O
carriers,223,O
whose,223,O
circulating,223,O
levels,223,O
of,223,O
alkaline,223,B-ChemicalEntity
phosphatase,223,I-ChemicalEntity
were,223,O
recently,223,O
assessed,223,O
as,223,O
still,223,O
within,223,O
the,223,O
normal,223,O
range,223,O
.,223,O
Taken,224,O
together,224,O
",",224,O
these,224,O
results,224,O
support,224,O
a,224,O
genotype-phenotype,224,O
correlation,224,O
between,224,O
the,224,O
M404V,224,B-SequenceVariant
mutation,224,O
in,224,O
the,224,O
p62/SQSTM1,224,B-GeneOrGeneProduct
gene,224,O
and,224,O
a,224,O
polyostotic,224,O
form,224,O
of,224,O
PDB,224,B-DiseaseOrPhenotypicFeature
in,224,O
this,224,O
family,224,O
.,224,O
The,225,O
high,225,O
penetrance,225,O
of,225,O
the,225,O
PDB,225,B-DiseaseOrPhenotypicFeature
trait,225,O
in,225,O
this,225,O
family,225,O
together,225,O
with,225,O
the,225,O
study,225,O
of,225,O
the,225,O
asymptomatic,225,O
gene,225,O
carriers,225,O
will,225,O
allow,225,O
us,225,O
to,225,O
confirm,225,O
the,225,O
proposed,225,O
genotype-phenotype,225,O
correlation,225,O
and,225,O
to,225,O
evaluate,225,O
the,225,O
potential,225,O
use,225,O
of,225,O
mutational,225,O
analysis,225,O
of,225,O
the,225,O
p62/SQSTM1,225,B-GeneOrGeneProduct
gene,225,O
in,225,O
the,225,O
early,225,O
detection,225,O
of,225,O
relatives,225,O
at,225,O
risk,225,O
for,225,O
PDB,225,B-DiseaseOrPhenotypicFeature
.,225,O
A,226,O
novel,226,O
missense,226,O
mutation,226,O
",",226,O
F826Y,226,B-SequenceVariant
",",226,O
in,226,O
the,226,O
mineralocorticoid,226,B-GeneOrGeneProduct
receptor,226,I-GeneOrGeneProduct
gene,226,O
in,226,O
Japanese,226,O
hypertensives,226,B-DiseaseOrPhenotypicFeature
:,226,O
its,226,O
implications,226,O
for,226,O
clinical,226,O
phenotypes,226,O
.,226,O
A,227,O
gain-of-function,227,O
mutation,227,O
resulting,227,O
in,227,O
the,227,O
S810L,227,B-SequenceVariant
amino,227,O
acid,227,O
substitution,227,O
in,227,O
the,227,O
hormone-binding,227,O
domain,227,O
of,227,O
the,227,O
mineralocorticoid,227,B-GeneOrGeneProduct
receptor,227,I-GeneOrGeneProduct
(,227,O
MR,227,B-GeneOrGeneProduct
",",227,O
locus,227,O
symbol,227,O
NR3C2,227,B-GeneOrGeneProduct
),227,O
is,227,O
responsible,227,O
for,227,O
early-onset,227,O
hypertension,227,B-DiseaseOrPhenotypicFeature
that,227,O
is,227,O
exacerbated,227,O
in,227,O
pregnancy,227,O
.,227,O
The,228,O
objective,228,O
of,228,O
this,228,O
study,228,O
was,228,O
to,228,O
test,228,O
whether,228,O
other,228,O
types,228,O
of,228,O
missense,228,O
mutations,228,O
in,228,O
the,228,O
hormone-binding,228,O
domain,228,O
could,228,O
be,228,O
implicated,228,O
in,228,O
hypertension,228,B-DiseaseOrPhenotypicFeature
in,228,O
Japanese,228,O
.,228,O
Here,229,O
",",229,O
we,229,O
screened,229,O
942,229,O
Japanese,229,O
patients,229,B-OrganismTaxon
with,229,O
hypertension,229,B-DiseaseOrPhenotypicFeature
for,229,O
the,229,O
S810L,229,B-SequenceVariant
mutation,229,O
in,229,O
exon,229,O
6,229,O
in,229,O
the,229,O
MR.,229,B-GeneOrGeneProduct
We,229,O
did,229,O
not,229,O
identify,229,O
the,229,O
S810L,229,B-SequenceVariant
mutation,229,O
in,229,O
our,229,O
hypertensive,229,B-DiseaseOrPhenotypicFeature
population,229,O
",",229,O
indicating,229,O
that,229,O
S810L,229,B-SequenceVariant
does,229,O
not,229,O
play,229,O
a,229,O
major,229,O
role,229,O
in,229,O
the,229,O
etiology,229,O
of,229,O
essential,229,B-DiseaseOrPhenotypicFeature
hypertension,229,I-DiseaseOrPhenotypicFeature
in,229,O
Japanese,229,O
.,229,O
However,230,O
",",230,O
we,230,O
identified,230,O
a,230,O
novel,230,O
missense,230,O
mutation,230,O
",",230,O
F826Y,230,B-SequenceVariant
",",230,O
in,230,O
three,230,O
patients,230,B-OrganismTaxon
in,230,O
a,230,O
heterozygous,230,O
state,230,O
",",230,O
in,230,O
addition,230,O
to,230,O
four,230,O
single,230,O
nucleotide,230,O
polymorphisms,230,O
",",230,O
including,230,O
one,230,O
synonymous,230,O
mutation,230,O
(,230,O
L809L,230,B-SequenceVariant
),230,O
.,230,O
The,231,O
F826Y,231,B-SequenceVariant
mutation,231,O
is,231,O
present,231,O
in,231,O
the,231,O
MR,231,B-GeneOrGeneProduct
hormone-binding,231,O
domain,231,O
and,231,O
might,231,O
affect,231,O
the,231,O
ligand,231,O
affinity,231,O
.,231,O
The,232,O
F826Y,232,B-SequenceVariant
mutation,232,O
was,232,O
also,232,O
identified,232,O
in,232,O
13,232,O
individuals,232,O
(,232,O
5,232,O
hypertensives,232,B-DiseaseOrPhenotypicFeature
and,232,O
8,232,O
normotensives,232,O
),232,O
in,232,O
a,232,O
Japanese,232,O
general,232,O
population,232,O
(,232,O
"n=3,655",232,O
),232,O
.,232,O
The,233,O
allele,233,O
frequency,233,O
was,233,O
0.00178,233,O
.,233,O
The,234,O
frequencies,234,O
of,234,O
the,234,O
F826Y,234,B-SequenceVariant
mutation,234,O
in,234,O
the,234,O
hypertensive,234,B-DiseaseOrPhenotypicFeature
population,234,O
(,234,O
3/942,234,O
),234,O
and,234,O
in,234,O
the,234,O
hypertensive,234,B-DiseaseOrPhenotypicFeature
group,234,O
(,234,O
5/,234,O
"1,480",234,O
),234,O
and,234,O
the,234,O
normotensive,234,O
group,234,O
(,234,O
"8/2,175",234,O
),234,O
in,234,O
the,234,O
general,234,O
population,234,O
were,234,O
not,234,O
significantly,234,O
different,234,O
",",234,O
suggesting,234,O
that,234,O
this,234,O
mutation,234,O
does,234,O
not,234,O
greatly,234,O
affect,234,O
hypertension,234,B-DiseaseOrPhenotypicFeature
.,234,O
Although,235,O
it,235,O
is,235,O
unclear,235,O
at,235,O
present,235,O
whether,235,O
or,235,O
not,235,O
the,235,O
F826Y,235,B-SequenceVariant
mutation,235,O
makes,235,O
a,235,O
substantial,235,O
contribution,235,O
to,235,O
the,235,O
mineralocorticoid,235,B-GeneOrGeneProduct
receptor,235,I-GeneOrGeneProduct
activity,235,O
",",235,O
this,235,O
missense,235,O
mutation,235,O
may,235,O
contribute,235,O
",",235,O
to,235,O
some,235,O
extent,235,O
",",235,O
to,235,O
clinical,235,O
phenotypes,235,O
through,235,O
its,235,O
effects,235,O
on,235,O
MR,235,B-GeneOrGeneProduct
.,235,O
The,236,O
influence,236,O
of,236,O
the,236,O
time,236,O
interval,236,O
between,236,O
monoHER,236,B-ChemicalEntity
and,236,O
doxorubicin,236,B-ChemicalEntity
administration,236,O
on,236,O
the,236,O
protection,236,O
against,236,O
doxorubicin-induced,236,B-ChemicalEntity
cardiotoxicity,236,B-DiseaseOrPhenotypicFeature
in,236,O
mice,236,B-OrganismTaxon
.,236,O
PURPOSE,237,O
:,237,O
Despite,237,O
its,237,O
well-known,237,O
cardiotoxicity,237,B-DiseaseOrPhenotypicFeature
",",237,O
the,237,O
anthracyclin,237,B-ChemicalEntity
doxorubicin,237,B-ChemicalEntity
(,237,O
DOX,237,B-ChemicalEntity
),237,O
continues,237,O
to,237,O
be,237,O
an,237,O
effective,237,O
and,237,O
widely,237,O
used,237,O
chemotherapeutic,237,O
agent,237,O
.,237,O
DOX-induced,238,B-ChemicalEntity
cardiac,238,B-DiseaseOrPhenotypicFeature
damage,238,I-DiseaseOrPhenotypicFeature
presumably,238,O
results,238,O
from,238,O
the,238,O
formation,238,O
of,238,O
free,238,O
radicals,238,O
by,238,O
DOX,238,B-ChemicalEntity
.,238,O
Reactive,239,O
oxygen,239,B-ChemicalEntity
species,239,O
particularly,239,O
affect,239,O
the,239,O
cardiac,239,O
myocytes,239,O
because,239,O
these,239,O
cells,239,O
seem,239,O
to,239,O
have,239,O
a,239,O
relatively,239,O
poor,239,O
antioxidant,239,O
defense,239,O
system,239,O
.,239,O
The,240,O
semisynthetic,240,O
flavonoid,240,B-ChemicalEntity
monohydroxyethylrutoside,240,B-ChemicalEntity
(,240,O
monoHER,240,B-ChemicalEntity
),240,O
showed,240,O
cardioprotection,240,O
against,240,O
DOX-induced,240,B-ChemicalEntity
cardiotoxicity,240,B-DiseaseOrPhenotypicFeature
through,240,O
its,240,O
radical,240,O
scavenging,240,O
and,240,O
iron,240,B-ChemicalEntity
chelating,240,O
properties,240,O
.,240,O
Because,241,O
of,241,O
the,241,O
relatively,241,O
short,241,O
final,241,O
half-life,241,O
of,241,O
monoHER,241,B-ChemicalEntity
(,241,O
about,241,O
30,241,O
min,241,O
),241,O
",",241,O
it,241,O
is,241,O
expected,241,O
that,241,O
the,241,O
time,241,O
interval,241,O
between,241,O
monoHER,241,B-ChemicalEntity
and,241,O
DOX,241,B-ChemicalEntity
might,241,O
be,241,O
of,241,O
influence,241,O
on,241,O
the,241,O
cardioprotective,241,O
effect,241,O
of,241,O
monoHER,241,B-ChemicalEntity
.,241,O
Therefore,242,O
",",242,O
the,242,O
aim,242,O
of,242,O
the,242,O
present,242,O
study,242,O
was,242,O
to,242,O
investigate,242,O
this,242,O
possible,242,O
effect,242,O
.,242,O
METHODS,243,O
:,243,O
Six,243,O
groups,243,O
of,243,O
6,243,O
BALB/c,243,O
mice,243,B-OrganismTaxon
were,243,O
treated,243,O
with,243,O
saline,243,O
",",243,O
DOX,243,B-ChemicalEntity
alone,243,O
or,243,O
DOX,243,B-ChemicalEntity
(,243,O
4,243,O
mg/kg,243,O
i.v,243,O
.,243,O
),243,O
preceded,244,O
by,244,O
monoHER,244,B-ChemicalEntity
(,244,O
500,244,O
mg/kg,244,O
i.p,244,O
.,244,O
),244,O
with,245,O
an,245,O
interval,245,O
of,245,O
10,245,O
",",245,O
30,245,O
",",245,O
60,245,O
or,245,O
120,245,O
min,245,O
.,245,O
After,246,O
a,246,O
6-week,246,O
treatment,246,O
period,246,O
and,246,O
additional,246,O
observation,246,O
for,246,O
2,246,O
weeks,246,O
",",246,O
the,246,O
mice,246,B-OrganismTaxon
were,246,O
sacrificed,246,O
.,246,O
Their,247,O
cardiac,247,O
tissues,247,O
were,247,O
processed,247,O
for,247,O
light,247,O
microscopy,247,O
",",247,O
after,247,O
which,247,O
cardiomyocyte,247,B-DiseaseOrPhenotypicFeature
damage,247,I-DiseaseOrPhenotypicFeature
was,247,O
evaluated,247,O
according,247,O
to,247,O
Billingham,247,O
(,247,O
in,247,O
Cancer,247,O
Treat,247,O
Rep,247,O
62,247,O
(,247,O
6,247,O
),247,O
:865-872,247,O
",",247,O
1978,247,O
),247,O
.,247,O
Microscopic,248,O
evaluation,248,O
revealed,248,O
that,248,O
treatment,248,O
with,248,O
DOX,248,B-ChemicalEntity
alone,248,O
induced,248,O
significant,248,O
cardiac,248,B-DiseaseOrPhenotypicFeature
damage,248,I-DiseaseOrPhenotypicFeature
in,248,O
comparison,248,O
to,248,O
the,248,O
saline,248,O
control,248,O
group,248,O
(,248,O
P,248,O
<,248,O
0.001,248,O
),248,O
.,248,O
RESULTS,249,O
:,249,O
The,249,O
number,249,O
of,249,O
damaged,249,O
cardiomyocytes,249,O
was,249,O
9.6-fold,249,O
(,249,O
95,249,O
%,249,O
CI,249,O
4.4-21.0,249,O
),249,O
higher,249,O
in,249,O
mice,249,B-OrganismTaxon
treated,249,O
with,249,O
DOX,249,B-ChemicalEntity
alone,249,O
than,249,O
that,249,O
in,249,O
animals,249,O
of,249,O
the,249,O
control,249,O
group,249,O
.,249,O
The,250,O
ratio,250,O
of,250,O
aberrant,250,O
cardiomyocytes,250,O
in,250,O
mice,250,B-OrganismTaxon
treated,250,O
with,250,O
DOX,250,B-ChemicalEntity
preceded,250,O
by,250,O
monoHER,250,B-ChemicalEntity
and,250,O
those,250,O
in,250,O
mice,250,B-OrganismTaxon
treated,250,O
with,250,O
saline,250,O
ranged,250,O
from,250,O
1.6,250,O
to,250,O
2.8,250,O
(,250,O
mean,250,O
2.2,250,O
",",250,O
95,250,O
%,250,O
CI,250,O
1.2-4.1,250,O
",",250,O
P=0.019,250,O
),250,O
.,250,O
The,251,O
mean,251,O
protective,251,O
effect,251,O
by,251,O
adding,251,O
monoHER,251,B-ChemicalEntity
before,251,O
DOX,251,B-ChemicalEntity
led,251,O
to,251,O
a,251,O
significant,251,O
4.4-fold,251,O
reduction,251,O
(,251,O
P,251,O
<,251,O
0.001,251,O
",",251,O
95,251,O
%,251,O
CI,251,O
2.3-8.2,251,O
),251,O
of,251,O
abnormal,251,O
cardiomyocytes,251,O
.,251,O
This,252,O
protective,252,O
effect,252,O
did,252,O
not,252,O
depend,252,O
on,252,O
the,252,O
time,252,O
interval,252,O
between,252,O
monoHER,252,B-ChemicalEntity
and,252,O
DOX,252,B-ChemicalEntity
administration,252,O
(,252,O
P=0.345,252,O
),252,O
.,252,O
CONCLUSION,253,O
:,253,O
The,253,O
results,253,O
indicate,253,O
that,253,O
in,253,O
an,253,O
outpatient,253,B-OrganismTaxon
clinical,253,O
setting,253,O
monoHER,253,B-ChemicalEntity
may,253,O
be,253,O
administered,253,O
shortly,253,O
before,253,O
DOX,253,B-ChemicalEntity
.,253,O
Gene,254,O
therapy,254,O
for,254,O
cystic,254,B-DiseaseOrPhenotypicFeature
fibrosis,254,I-DiseaseOrPhenotypicFeature
airway,254,O
disease-,254,O
is,254,O
clinical,254,O
success,254,O
imminent,254,O
?,254,O
Cystic,255,B-DiseaseOrPhenotypicFeature
fibrosis,255,I-DiseaseOrPhenotypicFeature
(,255,O
CF,255,B-DiseaseOrPhenotypicFeature
),255,O
was,255,O
one,255,O
of,255,O
the,255,O
first,255,O
inherited,255,B-DiseaseOrPhenotypicFeature
disorders,255,I-DiseaseOrPhenotypicFeature
for,255,O
which,255,O
gene,255,O
therapy,255,O
was,255,O
seriously,255,O
considered,255,O
as,255,O
a,255,O
realistic,255,O
option,255,O
for,255,O
treatment,255,O
",",255,O
and,255,O
as,255,O
such,255,O
",",255,O
it,255,O
has,255,O
long,255,O
provided,255,O
a,255,O
paradigm,255,O
for,255,O
gene,255,O
therapy,255,O
of,255,O
inherited,255,B-DiseaseOrPhenotypicFeature
diseases,255,I-DiseaseOrPhenotypicFeature
.,255,O
However,256,O
",",256,O
despite,256,O
the,256,O
cloning,256,O
of,256,O
the,256,O
cystic,256,B-GeneOrGeneProduct
fibrosis,256,I-GeneOrGeneProduct
transmembrane,256,I-GeneOrGeneProduct
conductance,256,I-GeneOrGeneProduct
regulator,256,I-GeneOrGeneProduct
gene,256,O
in,256,O
1989,256,O
",",256,O
over,256,O
15,256,O
years,256,O
later,256,O
a,256,O
practical,256,O
gene,256,O
therapy,256,O
for,256,O
CF,256,B-DiseaseOrPhenotypicFeature
has,256,O
not,256,O
eventuated,256,O
.,256,O
There,257,O
are,257,O
a,257,O
number,257,O
of,257,O
reasons,257,O
for,257,O
this,257,O
",",257,O
and,257,O
analysis,257,O
of,257,O
the,257,O
specific,257,O
issues,257,O
that,257,O
have,257,O
delayed,257,O
the,257,O
successful,257,O
development,257,O
of,257,O
gene,257,O
therapy,257,O
for,257,O
CF,257,B-DiseaseOrPhenotypicFeature
also,257,O
provides,257,O
general,257,O
insights,257,O
into,257,O
the,257,O
practical,257,O
complexities,257,O
involved,257,O
in,257,O
the,257,O
development,257,O
of,257,O
gene,257,O
therapy,257,O
for,257,O
inherited,257,B-DiseaseOrPhenotypicFeature
disorders,257,I-DiseaseOrPhenotypicFeature
.,257,O
The,258,O
issues,258,O
which,258,O
have,258,O
prevented,258,O
the,258,O
application,258,O
of,258,O
gene,258,O
therapy,258,O
for,258,O
CF,258,B-DiseaseOrPhenotypicFeature
to,258,O
date,258,O
include,258,O
the,258,O
lack,258,O
of,258,O
suitable,258,O
gene,258,O
delivery,258,O
technologies,258,O
",",258,O
the,258,O
complexities,258,O
of,258,O
the,258,O
interactions,258,O
between,258,O
the,258,O
host,258,O
and,258,O
vector,258,O
",",258,O
the,258,O
biology,258,O
of,258,O
the,258,O
lung,258,O
airways,258,O
",",258,O
and,258,O
the,258,O
nature,258,O
of,258,O
the,258,O
pathology,258,O
found,258,O
in,258,O
individuals,258,O
with,258,O
CF,258,B-DiseaseOrPhenotypicFeature
.,258,O
We,259,O
will,259,O
discuss,259,O
the,259,O
history,259,O
of,259,O
CF,259,B-DiseaseOrPhenotypicFeature
gene,259,O
therapy,259,O
with,259,O
specific,259,O
reference,259,O
to,259,O
these,259,O
and,259,O
other,259,O
issues,259,O
that,259,O
pre-occupy,259,O
the,259,O
field,259,O
at,259,O
present,259,O
:,259,O
namely,259,O
",",259,O
the,259,O
question,259,O
of,259,O
what,259,O
vectors,259,O
appear,259,O
to,259,O
be,259,O
suitable,259,O
for,259,O
airway,259,O
gene,259,O
delivery,259,O
in,259,O
CF,259,B-DiseaseOrPhenotypicFeature
",",259,O
what,259,O
cells,259,O
must,259,O
be,259,O
targeted,259,O
",",259,O
how,259,O
airway,259,O
epithelium,259,O
defences,259,O
can,259,O
be,259,O
overcome,259,O
or,259,O
eluded,259,O
to,259,O
allow,259,O
efficient,259,O
gene,259,O
delivery,259,O
",",259,O
how,259,O
to,259,O
ensure,259,O
safe,259,O
and,259,O
long-term,259,O
transgene,259,O
expression,259,O
and,259,O
the,259,O
need,259,O
to,259,O
identify,259,O
relevant,259,O
surrogate,259,O
success,259,O
measures,259,O
that,259,O
can,259,O
be,259,O
used,259,O
to,259,O
assess,259,O
the,259,O
outcome,259,O
of,259,O
gene,259,O
therapy,259,O
in,259,O
CF,259,B-DiseaseOrPhenotypicFeature
patients,259,B-OrganismTaxon
.,259,O
Pharmacokinetics,260,O
of,260,O
desipramine,260,B-ChemicalEntity
HCl,260,I-ChemicalEntity
when,260,O
administered,260,O
with,260,O
cinacalcet,260,B-ChemicalEntity
HCl,260,I-ChemicalEntity
.,260,O
OBJECTIVE,261,O
:,261,O
In,261,O
vitro,261,O
work,261,O
has,261,O
demonstrated,261,O
that,261,O
cinacalcet,261,B-ChemicalEntity
is,261,O
a,261,O
strong,261,O
inhibitor,261,O
of,261,O
cytochrome,261,B-GeneOrGeneProduct
P450,261,I-GeneOrGeneProduct
isoenzyme,261,I-GeneOrGeneProduct
(,261,I-GeneOrGeneProduct
CYP,261,I-GeneOrGeneProduct
),261,I-GeneOrGeneProduct
2D6,261,I-GeneOrGeneProduct
.,261,O
The,262,O
purpose,262,O
of,262,O
this,262,O
study,262,O
was,262,O
to,262,O
evaluate,262,O
the,262,O
effect,262,O
of,262,O
cinacalcet,262,B-ChemicalEntity
on,262,O
CYP2D6,262,B-GeneOrGeneProduct
activity,262,O
",",262,O
using,262,O
desipramine,262,B-ChemicalEntity
as,262,O
a,262,O
probe,262,O
substrate,262,O
",",262,O
in,262,O
healthy,262,O
subjects,262,O
.,262,O
METHODS,263,O
:,263,O
Seventeen,263,O
subjects,263,O
who,263,O
were,263,O
genotyped,263,O
as,263,O
CYP2D6,263,B-GeneOrGeneProduct
extensive,263,O
metabolizers,263,O
were,263,O
enrolled,263,O
in,263,O
this,263,O
randomized,263,O
",",263,O
open-label,263,O
",",263,O
crossover,263,O
study,263,O
to,263,O
receive,263,O
a,263,O
single,263,O
oral,263,O
dose,263,O
of,263,O
desipramine,263,B-ChemicalEntity
(,263,O
50,263,O
mg,263,O
),263,O
on,263,O
two,263,O
separate,263,O
occasions,263,O
",",263,O
once,263,O
alone,263,O
and,263,O
once,263,O
after,263,O
multiple,263,O
doses,263,O
of,263,O
cinacalcet,263,B-ChemicalEntity
(,263,O
90,263,O
mg,263,O
for,263,O
7,263,O
days,263,O
),263,O
.,263,O
Blood,264,O
samples,264,O
were,264,O
obtained,264,O
predose,264,O
and,264,O
up,264,O
to,264,O
72,264,O
h,264,O
postdose,264,O
.,264,O
RESULTS,265,O
:,265,O
Fourteen,265,O
subjects,265,O
completed,265,O
both,265,O
treatment,265,O
arms,265,O
.,265,O
Relative,266,O
to,266,O
desipramine,266,B-ChemicalEntity
alone,266,O
",",266,O
mean,266,O
AUC,266,O
and,266,O
C,266,O
(,266,O
max,266,O
),266,O
of,266,O
desipramine,266,B-ChemicalEntity
increased,266,O
3.6-,266,O
and,266,O
1.8-fold,266,O
when,266,O
coadministered,266,O
with,266,O
cinacalcet,266,B-ChemicalEntity
.,266,O
The,267,O
t,267,O
(,267,O
1/2,267,O
",",267,O
z,267,O
),267,O
of,267,O
desipramine,267,B-ChemicalEntity
was,267,O
longer,267,O
when,267,O
desipramine,267,B-ChemicalEntity
was,267,O
coadministered,267,O
with,267,O
cinacalcet,267,B-ChemicalEntity
(,267,O
21.0,267,O
versus,267,O
43.3,267,O
hs,267,O
),267,O
.,267,O
The,268,O
t,268,O
(,268,O
max,268,O
),268,O
was,268,O
similar,268,O
between,268,O
the,268,O
regimens,268,O
.,268,O
Fewer,269,O
subjects,269,O
reported,269,O
adverse,269,O
events,269,O
following,269,O
treatment,269,O
with,269,O
desipramine,269,B-ChemicalEntity
alone,269,O
than,269,O
when,269,O
receiving,269,O
desipramine,269,B-ChemicalEntity
with,269,O
cinacalcet,269,B-ChemicalEntity
(,269,O
33,269,O
versus,269,O
86,269,O
%,269,O
),269,O
",",269,O
the,269,O
most,269,O
frequent,269,O
of,269,O
which,269,O
(,269,O
nausea,269,B-DiseaseOrPhenotypicFeature
and,269,O
headache,269,B-DiseaseOrPhenotypicFeature
),269,O
have,269,O
been,269,O
reported,269,O
for,269,O
patients,269,B-OrganismTaxon
treated,269,O
with,269,O
either,269,O
desipramine,269,B-ChemicalEntity
or,269,O
cinacalcet,269,B-ChemicalEntity
.,269,O
CONCLUSION,270,O
:,270,O
This,270,O
study,270,O
demonstrates,270,O
that,270,O
cinacalcet,270,B-ChemicalEntity
is,270,O
a,270,O
strong,270,O
inhibitor,270,O
of,270,O
CYP2D6,270,B-GeneOrGeneProduct
.,270,O
These,271,O
data,271,O
suggest,271,O
that,271,O
during,271,O
concomitant,271,O
treatment,271,O
with,271,O
cinacalcet,271,B-ChemicalEntity
",",271,O
dose,271,O
adjustment,271,O
may,271,O
be,271,O
necessary,271,O
for,271,O
drugs,271,O
that,271,O
demonstrate,271,O
a,271,O
narrow,271,O
therapeutic,271,O
index,271,O
and,271,O
are,271,O
metabolized,271,O
by,271,O
CYP2D6,271,B-GeneOrGeneProduct
.,271,O
Single,272,O
nucleotide,272,O
polymorphisms,272,O
of,272,O
the,272,O
HNF4alpha,272,B-GeneOrGeneProduct
gene,272,O
are,272,O
associated,272,O
with,272,O
the,272,O
conversion,272,O
to,272,O
type,272,B-DiseaseOrPhenotypicFeature
2,272,I-DiseaseOrPhenotypicFeature
diabetes,272,I-DiseaseOrPhenotypicFeature
mellitus,272,I-DiseaseOrPhenotypicFeature
:,272,O
the,272,O
STOP-NIDDM,272,O
trial,272,O
.,272,O
Hepatocyte,273,B-GeneOrGeneProduct
nuclear,273,I-GeneOrGeneProduct
factor,273,I-GeneOrGeneProduct
4alpha,273,I-GeneOrGeneProduct
(,273,O
HNF4alpha,273,B-GeneOrGeneProduct
),273,O
is,273,O
a,273,O
transcription,273,O
factor,273,O
",",273,O
which,273,O
is,273,O
necessary,273,O
for,273,O
normal,273,O
function,273,O
of,273,O
human,273,B-OrganismTaxon
liver,273,O
and,273,O
pancreatic,273,O
islets,273,O
.,273,O
We,274,O
investigated,274,O
whether,274,O
single,274,O
nucleotide,274,O
polymorphisms,274,O
(,274,O
SNPs,274,O
),274,O
of,274,O
HNF4A,274,B-GeneOrGeneProduct
",",274,O
encoding,274,O
HNF4alpha,274,B-GeneOrGeneProduct
",",274,O
influenced,274,O
the,274,O
conversion,274,O
from,274,O
impaired,274,B-DiseaseOrPhenotypicFeature
glucose,274,I-DiseaseOrPhenotypicFeature
tolerance,274,I-DiseaseOrPhenotypicFeature
(,274,O
IGT,274,B-DiseaseOrPhenotypicFeature
),274,O
to,274,O
type,274,B-DiseaseOrPhenotypicFeature
2,274,I-DiseaseOrPhenotypicFeature
diabetes,274,I-DiseaseOrPhenotypicFeature
mellitus,274,I-DiseaseOrPhenotypicFeature
in,274,O
subjects,274,O
of,274,O
the,274,O
STOP-NIDDM,274,O
trial,274,O
.,274,O
This,275,O
trial,275,O
aimed,275,O
at,275,O
evaluating,275,O
the,275,O
effect,275,O
of,275,O
acarbose,275,B-ChemicalEntity
compared,275,O
to,275,O
placebo,275,O
in,275,O
the,275,O
prevention,275,O
of,275,O
type,275,B-DiseaseOrPhenotypicFeature
2,275,I-DiseaseOrPhenotypicFeature
diabetes,275,I-DiseaseOrPhenotypicFeature
mellitus,275,I-DiseaseOrPhenotypicFeature
.,275,O
Eight,276,O
SNPs,276,O
covering,276,O
the,276,O
intragenic,276,O
and,276,O
alternate,276,O
P2,276,O
promoter,276,O
regions,276,O
of,276,O
HNF4A,276,B-GeneOrGeneProduct
were,276,O
genotyped,276,O
in,276,O
study,276,O
samples,276,O
using,276,O
the,276,O
TaqMan,276,O
Allelic,276,O
Discrimination,276,O
Assays,276,O
.,276,O
Three,277,O
SNPs,277,O
in,277,O
the,277,O
P2,277,O
promoter,277,O
region,277,O
(,277,O
rs4810424,277,B-SequenceVariant
",",277,O
rs1884614,277,B-SequenceVariant
",",277,O
and,277,O
rs2144908,277,B-SequenceVariant
),277,O
were,277,O
in,277,O
almost,277,O
complete,277,O
association,277,O
(,277,O
D,277,O
',277,O
>,277,O
0.97,277,O
",",277,O
r,277,O
(,277,O
2,277,O
),277,O
>,277,O
0.95,277,O
),277,O
and,277,O
",",277,O
therefore,277,O
",",277,O
only,277,O
rs4810424,277,B-SequenceVariant
was,277,O
included,277,O
in,277,O
further,277,O
analyses,277,O
.,277,O
Female,278,O
carriers,278,O
of,278,O
the,278,O
less,278,O
frequent,278,O
C,278,O
allele,278,O
of,278,O
rs4810424,278,B-SequenceVariant
had,278,O
a,278,O
1.7-fold,278,O
elevated,278,O
risk,278,O
[,278,O
95,278,O
%,278,O
confidence,278,O
interval,278,O
(,278,O
CI,278,O
),278,O
1.09-2.66,278,O
;,278,O
P=0.020,278,O
],278,O
for,278,O
the,278,O
conversion,278,O
to,278,O
diabetes,278,B-DiseaseOrPhenotypicFeature
compared,278,O
to,278,O
women,278,B-OrganismTaxon
with,278,O
the,278,O
common,278,O
genotype,278,O
after,278,O
the,278,O
adjustment,278,O
for,278,O
age,278,O
",",278,O
treatment,278,O
group,278,O
(,278,O
placebo,278,O
or,278,O
acarbose,278,B-ChemicalEntity
),278,O
",",278,O
smoking,278,O
",",278,O
weight,278,O
at,278,O
baseline,278,O
",",278,O
and,278,O
weight,278,O
change,278,O
.,278,O
No,279,O
association,279,O
was,279,O
found,279,O
in,279,O
men,279,B-OrganismTaxon
.,279,O
Haplotype,280,O
analysis,280,O
based,280,O
on,280,O
three,280,O
SNPs,280,O
(,280,O
rs4810424,280,B-SequenceVariant
",",280,O
rs2071197,280,B-SequenceVariant
",",280,O
and,280,O
rs3818247,280,B-SequenceVariant
),280,O
representing,280,O
the,280,O
linkage,280,O
disequilibrium,280,O
blocks,280,O
in,280,O
our,280,O
study,280,O
population,280,O
indicated,280,O
that,280,O
the,280,O
conversion,280,O
to,280,O
type,280,B-DiseaseOrPhenotypicFeature
2,280,I-DiseaseOrPhenotypicFeature
diabetes,280,I-DiseaseOrPhenotypicFeature
mellitus,280,I-DiseaseOrPhenotypicFeature
was,280,O
dependent,280,O
on,280,O
the,280,O
number,280,O
of,280,O
risk,280,O
alleles,280,O
in,280,O
different,280,O
haplotypes,280,O
in,280,O
women,280,B-OrganismTaxon
.,280,O
Our,281,O
results,281,O
suggest,281,O
that,281,O
SNPs,281,O
of,281,O
HNF4A,281,B-GeneOrGeneProduct
and,281,O
their,281,O
haplotypes,281,O
predispose,281,O
to,281,O
type,281,B-DiseaseOrPhenotypicFeature
2,281,I-DiseaseOrPhenotypicFeature
diabetes,281,I-DiseaseOrPhenotypicFeature
mellitus,281,I-DiseaseOrPhenotypicFeature
in,281,O
female,281,O
subjects,281,O
of,281,O
the,281,O
STOP-NIDDM,281,O
study,281,O
population,281,O
.,281,O
Antipsychotic-like,282,B-ChemicalEntity
profile,282,O
of,282,O
thioperamide,282,B-ChemicalEntity
",",282,O
a,282,O
selective,282,O
H3-receptor,282,B-GeneOrGeneProduct
antagonist,282,O
in,282,O
mice,282,B-OrganismTaxon
.,282,O
Experimental,283,O
and,283,O
clinical,283,O
evidence,283,O
points,283,O
to,283,O
a,283,O
role,283,O
of,283,O
central,283,O
histaminergic,283,O
system,283,O
in,283,O
the,283,O
pathogenesis,283,O
of,283,O
schizophrenia,283,B-DiseaseOrPhenotypicFeature
.,283,O
The,284,O
present,284,O
study,284,O
was,284,O
designed,284,O
to,284,O
study,284,O
the,284,O
effect,284,O
of,284,O
histamine,284,B-GeneOrGeneProduct
H,284,I-GeneOrGeneProduct
(,284,I-GeneOrGeneProduct
3,284,I-GeneOrGeneProduct
),284,I-GeneOrGeneProduct
-receptor,284,I-GeneOrGeneProduct
ligands,284,O
on,284,O
neuroleptic-induced,284,B-ChemicalEntity
catalepsy,284,B-DiseaseOrPhenotypicFeature
",",284,O
apomorphine-induced,284,B-ChemicalEntity
climbing,284,O
behavior,284,O
and,284,O
amphetamine-induced,284,B-ChemicalEntity
locomotor,284,O
activities,284,O
in,284,O
mice,284,B-OrganismTaxon
.,284,O
Catalepsy,285,B-DiseaseOrPhenotypicFeature
was,285,O
induced,285,O
by,285,O
haloperidol,285,B-ChemicalEntity
(,285,O
2,285,O
mg/kg,285,O
p.o,285,O
.,285,O
),286,O
",",286,O
while,286,O
apomorphine,286,O
(,286,O
1.5,286,O
mg/kg,286,O
s.c.,286,O
),286,O
and,286,O
amphetamine,286,O
(,286,O
2,286,O
mg/kg,286,O
s.c.,286,O
),286,O
were,286,O
used,286,O
for,286,O
studying,286,O
climbing,286,O
behavior,286,O
and,286,O
locomotor,286,O
activities,286,O
",",286,O
respectively,286,O
.,286,O
(,287,O
R,287,O
),287,O
-alpha-methylhistamine,287,O
(,287,B-ChemicalEntity
RAMH,287,O
),287,O
(,287,O
5,287,O
microg,287,O
i.c.v,287,O
.,287,O
),287,O
and,288,O
thioperamide,288,O
(,288,B-ChemicalEntity
THP,288,O
),288,O
(,288,O
15,288,O
mg/kg,288,O
i.p,288,O
.,288,O
),289,O
",",289,O
per,289,O
se,289,O
did,289,O
not,289,O
cause,289,O
catalepsy,289,O
.,289,O
Administration,290,O
of,290,O
THP,290,O
(,290,O
3.75,290,O
",",290,O
7.5,290,O
and,290,O
15,290,O
mg/kg,290,O
i.p,290,O
.,290,O
),290,O
1,291,O
h,291,O
prior,291,O
to,291,O
haloperidol,291,O
resulted,291,O
in,291,O
a,291,O
dose-dependent,291,O
increase,291,O
in,291,O
the,291,O
catalepsy,291,O
times,291,O
(,291,O
P,291,O
<,291,O
0.05,291,O
),291,O
.,291,O
However,292,O
",",292,O
pretreatment,292,O
with,292,O
RAMH,292,O
significantly,292,O
reversed,292,O
such,292,O
an,292,O
effect,292,O
of,292,O
THP,292,O
(,292,O
15,292,O
mg/kg,292,O
i.p,292,O
.,292,O
),292,O
.,292,O
RAMH,293,O
per,293,O
se,293,O
showed,293,O
significant,293,O
reduction,293,O
in,293,O
locomotor,293,O
time,293,O
",",293,O
distance,293,O
traveled,293,O
and,293,O
average,293,O
speed,293,O
but,293,O
THP,293,O
(,293,O
15,293,O
mg/kg,293,O
i.p,293,O
.,293,O
),293,O
per,294,O
se,294,O
had,294,O
no,294,O
effect,294,O
on,294,O
these,294,O
parameters,294,O
.,294,O
On,295,O
amphetamine-induced,295,O
hyperactivity,295,O
",",295,B-ChemicalEntity
THP,295,O
(,295,O
3.75,295,O
and,295,O
7.5,295,O
mg/kg,295,O
i.p,295,O
.,295,O
),295,O
reduced,296,O
locomotor,296,O
time,296,O
",",296,O
distance,296,O
traveled,296,O
and,296,O
average,296,O
speed,296,O
(,296,O
P,296,O
<,296,O
0.05,296,O
),296,O
.,296,O
Pretreatment,297,O
with,297,O
RAMH,297,O
(,297,O
5,297,O
microg,297,O
i.c.v,297,O
.,297,O
),297,O
could,298,O
partially,298,O
reverse,298,O
such,298,O
effects,298,O
of,298,O
THP,298,O
(,298,O
3.75,298,O
mg/kg,298,O
i.p,298,O
.,298,O
),298,O
.,298,O
Climbing,299,O
behavior,299,O
induced,299,O
by,299,O
apomorphine,299,O
was,299,O
reduced,299,O
in,299,O
animals,299,O
treated,299,O
with,299,O
THP,299,O
.,299,O
Such,300,O
an,300,O
effect,300,O
was,300,O
",",300,O
however,300,O
",",300,O
reversed,300,O
in,300,O
presence,300,O
of,300,O
RAMH,300,O
.,300,O
THP,301,O
exhibited,301,O
an,301,O
antipsychotic-like,301,O
profile,301,O
by,301,O
potentiating,301,O
haloperidol-induced,301,O
catalepsy,301,O
",",301,O
reducing,301,O
amphetamine-induced,301,O
hyperactivity,301,O
and,301,O
reducing,301,O
apomorphine-induced,301,O
climbing,301,O
in,301,O
mice,301,O
.,301,O
Such,302,O
effects,302,O
of,302,O
THP,302,O
were,302,O
reversed,302,O
by,302,O
RAMH,302,O
indicating,302,O
the,302,O
involvement,302,O
of,302,O
histamine,302,I-GeneOrGeneProduct
H,302,I-GeneOrGeneProduct
(,302,I-GeneOrGeneProduct
3,302,I-GeneOrGeneProduct
),302,I-GeneOrGeneProduct
-receptors,302,O
.,302,O
Findings,303,O
suggest,303,O
a,303,O
potential,303,O
for,303,O
H,303,I-ChemicalEntity
(,303,I-ChemicalEntity
3,303,I-ChemicalEntity
),303,I-ChemicalEntity
-receptor,303,I-ChemicalEntity
antagonists,303,O
in,303,O
improving,303,O
the,303,O
refractory,303,O
cases,303,O
of,303,O
schizophrenia,303,O
.,303,O
Association,304,O
of,304,O
DRD2,304,B-GeneOrGeneProduct
polymorphisms,304,O
and,304,O
chlorpromazine-induced,304,B-ChemicalEntity
extrapyramidal,304,B-DiseaseOrPhenotypicFeature
syndrome,304,I-DiseaseOrPhenotypicFeature
in,304,O
Chinese,304,O
schizophrenic,304,B-DiseaseOrPhenotypicFeature
patients,304,B-OrganismTaxon
.,304,O
AIM,305,O
:,305,O
Extrapyramidal,305,B-DiseaseOrPhenotypicFeature
syndrome,305,I-DiseaseOrPhenotypicFeature
(,305,O
EPS,305,B-DiseaseOrPhenotypicFeature
),305,O
is,305,O
most,305,O
commonly,305,O
affected,305,O
by,305,O
typical,305,O
antipsychotic,305,B-ChemicalEntity
drugs,305,I-ChemicalEntity
that,305,O
have,305,O
a,305,O
high,305,O
affinity,305,O
with,305,O
the,305,O
D2,305,B-GeneOrGeneProduct
receptor,305,I-GeneOrGeneProduct
.,305,O
Recently,306,O
",",306,O
many,306,O
research,306,O
groups,306,O
have,306,O
reported,306,O
on,306,O
the,306,O
positive,306,O
relationship,306,O
between,306,O
the,306,O
genetic,306,O
variations,306,O
in,306,O
the,306,O
DRD2,306,B-GeneOrGeneProduct
gene,306,O
and,306,O
the,306,O
therapeutic,306,O
response,306,O
in,306,O
schizophrenia,306,B-DiseaseOrPhenotypicFeature
patients,306,B-OrganismTaxon
as,306,O
a,306,O
result,306,O
of,306,O
the,306,O
role,306,O
of,306,O
variations,306,O
in,306,O
the,306,O
receptor,306,O
in,306,O
modulating,306,O
receptor,306,O
expression,306,O
.,306,O
In,307,O
this,307,O
study,307,O
",",307,O
we,307,O
evaluate,307,O
the,307,O
role,307,O
DRD2,307,B-GeneOrGeneProduct
plays,307,O
in,307,O
chlorpromazine-induced,307,B-ChemicalEntity
EPS,307,B-DiseaseOrPhenotypicFeature
in,307,O
schizophrenic,307,B-DiseaseOrPhenotypicFeature
patients,307,B-OrganismTaxon
.,307,O
METHODS,308,O
:,308,O
We,308,O
identified,308,O
seven,308,O
SNP,308,O
(,308,O
single,308,O
nucleotide,308,O
polymorphism,308,O
),308,O
(,308,O
-141Cins,308,B-SequenceVariant
>,308,I-SequenceVariant
del,308,I-SequenceVariant
",",308,O
TaqIB,308,O
",",308,O
TaqID,308,O
",",308,O
Ser311Cys,308,B-SequenceVariant
",",308,O
rs6275,308,B-SequenceVariant
",",308,O
rs6277,308,B-SequenceVariant
and,308,O
TaqIA,308,O
),308,O
in,308,O
the,308,O
DRD2,308,B-GeneOrGeneProduct
gene,308,O
in,308,O
146,308,O
schizophrenic,308,B-DiseaseOrPhenotypicFeature
inpatients,308,B-OrganismTaxon
(,308,O
59,308,O
with,308,O
EPS,308,B-DiseaseOrPhenotypicFeature
and,308,O
87,308,O
without,308,O
EPS,308,B-DiseaseOrPhenotypicFeature
according,308,O
to,308,O
the,308,O
Simpson-Angus,308,O
Scale,308,O
),308,O
treated,308,O
with,308,O
chlorpromazine,308,B-ChemicalEntity
after,308,O
8,308,O
weeks,308,O
.,308,O
The,309,O
alleles,309,O
of,309,O
all,309,O
loci,309,O
were,309,O
determined,309,O
by,309,O
PCR,309,O
(,309,O
polymerase,309,O
chain,309,O
reaction,309,O
),309,O
.,309,O
RESULTS,310,O
:,310,O
Polymorphisms,310,O
TaqID,310,O
",",310,O
Ser311Cys,310,B-SequenceVariant
and,310,O
rs6277,310,B-SequenceVariant
were,310,O
not,310,O
polymorphic,310,O
in,310,O
the,310,O
population,310,O
recruited,310,O
in,310,O
the,310,O
present,310,O
study,310,O
.,310,O
No,311,O
statistical,311,O
significance,311,O
was,311,O
found,311,O
in,311,O
the,311,O
allele,311,O
distribution,311,O
of,311,O
-141Cins,311,B-SequenceVariant
>,311,I-SequenceVariant
del,311,I-SequenceVariant
",",311,O
TaqIB,311,O
",",311,O
rs6275,311,B-SequenceVariant
and,311,O
TaqIA,311,O
or,311,O
in,311,O
the,311,O
estimated,311,O
haplotypes,311,O
(,311,O
constituted,311,O
by,311,O
TaqIB,311,O
",",311,O
rs6275,311,B-SequenceVariant
and,311,O
TaqIA,311,O
),311,O
in,311,O
linkage,311,O
disequilibrium,311,O
between,311,O
the,311,O
two,311,O
groups,311,O
.,311,O
CONCLUSION,312,O
:,312,O
Our,312,O
results,312,O
did,312,O
not,312,O
lend,312,O
strong,312,O
support,312,O
to,312,O
the,312,O
view,312,O
that,312,O
the,312,O
genetic,312,O
variation,312,O
of,312,O
the,312,O
DRD2,312,B-GeneOrGeneProduct
gene,312,O
plays,312,O
a,312,O
major,312,O
role,312,O
in,312,O
the,312,O
individually,312,O
variable,312,O
adverse,312,O
effect,312,O
induced,312,O
by,312,O
chlorpromazine,312,B-ChemicalEntity
",",312,O
at,312,O
least,312,O
in,312,O
Chinese,312,O
patients,312,B-OrganismTaxon
with,312,O
schizophrenia,312,B-DiseaseOrPhenotypicFeature
.,312,O
Our,313,O
results,313,O
confirmed,313,O
a,313,O
previous,313,O
study,313,O
on,313,O
the,313,O
relationship,313,O
between,313,O
DRD2,313,B-GeneOrGeneProduct
and,313,O
EPS,313,B-DiseaseOrPhenotypicFeature
in,313,O
Caucasians,313,O
.,313,O
Mutation,314,O
in,314,O
the,314,O
auxiliary,314,O
calcium-channel,314,B-ChemicalEntity
subunit,314,O
CACNA2D4,314,B-GeneOrGeneProduct
causes,314,O
autosomal,314,O
recessive,314,O
cone,314,B-DiseaseOrPhenotypicFeature
dystrophy,314,I-DiseaseOrPhenotypicFeature
.,314,O
Retinal,315,O
signal,315,O
transmission,315,O
depends,315,O
on,315,O
the,315,O
activity,315,O
of,315,O
high,315,O
voltage-gated,315,O
l-type,315,O
calcium,315,B-ChemicalEntity
channels,315,O
in,315,O
photoreceptor,315,O
ribbon,315,O
synapses,315,O
.,315,O
We,316,O
recently,316,O
identified,316,O
a,316,O
truncating,316,O
frameshift,316,O
mutation,316,O
in,316,O
the,316,O
Cacna2d4,316,B-GeneOrGeneProduct
gene,316,O
in,316,O
a,316,O
spontaneous,316,O
mouse,316,B-OrganismTaxon
mutant,316,O
with,316,O
profound,316,O
loss,316,O
of,316,O
retinal,316,O
signaling,316,O
and,316,O
an,316,O
abnormal,316,O
morphology,316,O
of,316,O
ribbon,316,O
synapses,316,O
in,316,O
rods,316,O
and,316,O
cones,316,O
.,316,O
The,317,O
Cacna2d4,317,B-GeneOrGeneProduct
gene,317,O
encodes,317,O
an,317,O
l-type,317,B-GeneOrGeneProduct
calcium-channel,317,I-GeneOrGeneProduct
auxiliary,317,I-GeneOrGeneProduct
subunit,317,I-GeneOrGeneProduct
of,317,I-GeneOrGeneProduct
the,317,I-GeneOrGeneProduct
alpha,317,I-GeneOrGeneProduct
(,317,I-GeneOrGeneProduct
2,317,I-GeneOrGeneProduct
),317,I-GeneOrGeneProduct
delta,317,I-GeneOrGeneProduct
type,317,I-GeneOrGeneProduct
.,317,O
Mutations,318,O
in,318,O
its,318,O
human,318,B-OrganismTaxon
orthologue,318,O
",",318,O
CACNA2D4,318,B-GeneOrGeneProduct
",",318,O
were,318,O
not,318,O
yet,318,O
known,318,O
to,318,O
be,318,O
associated,318,O
with,318,O
a,318,O
disease,318,O
.,318,O
We,319,O
performed,319,O
mutation,319,O
analyses,319,O
of,319,O
34,319,O
patients,319,B-OrganismTaxon
who,319,O
received,319,O
an,319,O
initial,319,O
diagnosis,319,O
of,319,O
night,319,B-DiseaseOrPhenotypicFeature
blindness,319,I-DiseaseOrPhenotypicFeature
",",319,O
and,319,O
",",319,O
in,319,O
two,319,O
affected,319,O
siblings,319,O
",",319,O
we,319,O
detected,319,O
a,319,O
homozygous,319,O
nucleotide,319,O
substitution,319,O
(,319,O
c.2406C,319,B-SequenceVariant
--,319,I-SequenceVariant
>,319,I-SequenceVariant
A,319,I-SequenceVariant
),319,O
in,319,O
CACNA2D4,319,B-GeneOrGeneProduct
.,319,O
The,320,O
mutation,320,O
introduces,320,O
a,320,O
premature,320,O
stop,320,O
codon,320,O
that,320,O
truncates,320,O
one-third,320,O
of,320,O
the,320,O
corresponding,320,O
open,320,O
reading,320,O
frame,320,O
.,320,O
Both,321,O
patients,321,B-OrganismTaxon
share,321,O
symptoms,321,O
of,321,O
slowly,321,O
progressing,321,O
cone,321,B-DiseaseOrPhenotypicFeature
dystrophy,321,I-DiseaseOrPhenotypicFeature
.,321,O
These,322,O
findings,322,O
represent,322,O
the,322,O
first,322,O
report,322,O
of,322,O
a,322,O
mutation,322,O
in,322,O
the,322,O
human,322,B-OrganismTaxon
CACNA2D4,322,B-GeneOrGeneProduct
gene,322,O
and,322,O
define,322,O
a,322,O
novel,322,O
gene,322,O
defect,322,O
that,322,O
causes,322,O
autosomal,322,O
recessive,322,O
cone,322,B-DiseaseOrPhenotypicFeature
dystrophy,322,I-DiseaseOrPhenotypicFeature
.,322,O
Placebo-level,323,O
incidence,323,O
of,323,O
extrapyramidal,323,B-DiseaseOrPhenotypicFeature
symptoms,323,I-DiseaseOrPhenotypicFeature
(,323,O
EPS,323,B-DiseaseOrPhenotypicFeature
),323,O
with,323,O
quetiapine,323,B-ChemicalEntity
in,323,O
controlled,323,O
studies,323,O
of,323,O
patients,323,B-OrganismTaxon
with,323,O
bipolar,323,B-DiseaseOrPhenotypicFeature
mania,323,I-DiseaseOrPhenotypicFeature
.,323,O
OBJECTIVES,324,O
:,324,O
To,324,O
evaluate,324,O
extrapyramidal,324,B-DiseaseOrPhenotypicFeature
symptoms,324,I-DiseaseOrPhenotypicFeature
(,324,O
EPS,324,B-DiseaseOrPhenotypicFeature
),324,O
",",324,O
including,324,O
akathisia,324,B-DiseaseOrPhenotypicFeature
",",324,O
with,324,O
quetiapine,324,B-ChemicalEntity
in,324,O
patients,324,B-OrganismTaxon
with,324,O
bipolar,324,B-DiseaseOrPhenotypicFeature
mania,324,I-DiseaseOrPhenotypicFeature
.,324,O
METHODS,325,O
:,325,O
Data,325,O
were,325,O
analyzed,325,O
from,325,O
four,325,O
similarly,325,O
designed,325,O
",",325,O
randomized,325,O
",",325,O
double-blind,325,O
",",325,O
3-,325,O
to,325,O
12-week,325,O
studies,325,O
.,325,O
Two,326,O
studies,326,O
evaluated,326,O
quetiapine,326,B-ChemicalEntity
monotherapy,326,O
(,326,O
up,326,O
to,326,O
800,326,O
mg/day,326,O
),326,O
(,326,O
n,326,O
=,326,O
209,326,O
),326,O
versus,326,O
placebo,326,O
(,326,O
n,326,O
=,326,O
198,326,O
),326,O
",",326,O
with,326,O
lithium,326,B-ChemicalEntity
or,326,O
haloperidol,326,B-ChemicalEntity
monotherapy,326,O
as,326,O
respective,326,O
active,326,O
controls,326,O
.,326,O
Two,327,O
studies,327,O
evaluated,327,O
quetiapine,327,B-ChemicalEntity
(,327,O
up,327,O
to,327,O
800,327,O
mg/day,327,O
),327,O
in,327,O
combination,327,O
with,327,O
a,327,O
mood,327,O
stabilizer,327,O
(,327,O
lithium,327,B-ChemicalEntity
or,327,O
divalproex,327,B-ChemicalEntity
",",327,O
QTP,327,B-ChemicalEntity
+,327,O
Li/DVP,327,B-ChemicalEntity
),327,O
(,327,O
n,327,O
=,327,O
196,327,O
),327,O
compared,327,O
to,327,O
placebo,327,O
and,327,O
mood,327,O
stabilizer,327,O
(,327,O
PBO,327,O
+,327,O
Li/DVP,327,B-ChemicalEntity
),327,O
(,327,O
n,327,O
=,327,O
203,327,O
),327,O
.,327,O
Extrapyramidal,328,B-DiseaseOrPhenotypicFeature
symptoms,328,I-DiseaseOrPhenotypicFeature
were,328,O
evaluated,328,O
using,328,O
the,328,O
Simpson-Angus,328,O
Scale,328,O
(,328,O
SAS,328,O
),328,O
",",328,O
the,328,O
Barnes,328,O
Akathisia,328,O
Rating,328,O
Scale,328,O
(,328,O
BARS,328,O
),328,O
",",328,O
adverse,328,O
event,328,O
reports,328,O
and,328,O
anticholinergic,328,B-ChemicalEntity
drug,328,I-ChemicalEntity
usage,328,O
.,328,O
RESULTS,329,O
:,329,O
The,329,O
incidence,329,O
of,329,O
EPS-related,329,B-DiseaseOrPhenotypicFeature
adverse,329,O
events,329,O
",",329,O
including,329,O
akathisia,329,B-DiseaseOrPhenotypicFeature
",",329,O
was,329,O
no,329,O
different,329,O
with,329,O
quetiapine,329,B-ChemicalEntity
monotherapy,329,O
(,329,O
12.9,329,O
%,329,O
),329,O
than,329,O
with,329,O
placebo,329,O
(,329,O
13.1,329,O
%,329,O
),329,O
.,329,O
Similarly,330,O
",",330,O
EPS-related,330,B-DiseaseOrPhenotypicFeature
adverse,330,O
events,330,O
with,330,O
QTP,330,B-ChemicalEntity
+,330,O
Li/DVP,330,B-ChemicalEntity
(,330,O
21.4,330,O
%,330,O
),330,O
were,330,O
no,330,O
different,330,O
than,330,O
with,330,O
PBO,330,O
+,330,O
Li/DVP,330,B-ChemicalEntity
(,330,O
19.2,330,O
%,330,O
),330,O
.,330,O
Adverse,331,O
events,331,O
related,331,O
to,331,O
EPS,331,B-DiseaseOrPhenotypicFeature
occurred,331,O
in,331,O
59.6,331,O
%,331,O
of,331,O
patients,331,B-OrganismTaxon
treated,331,O
with,331,O
haloperidol,331,B-ChemicalEntity
(,331,O
n,331,O
=,331,O
99,331,O
),331,O
monotherapy,331,O
",",331,O
whereas,331,O
26.5,331,O
%,331,O
of,331,O
patients,331,B-OrganismTaxon
treated,331,O
with,331,O
lithium,331,B-ChemicalEntity
(,331,O
n,331,O
=,331,O
98,331,O
),331,O
monotherapy,331,O
experienced,331,O
adverse,331,O
events,331,O
related,331,O
to,331,O
EPS,331,B-DiseaseOrPhenotypicFeature
.,331,O
The,332,O
incidence,332,O
of,332,O
akathisia,332,B-DiseaseOrPhenotypicFeature
was,332,O
low,332,O
and,332,O
similar,332,O
with,332,O
quetiapine,332,B-ChemicalEntity
monotherapy,332,O
(,332,O
3.3,332,O
%,332,O
),332,O
and,332,O
placebo,332,O
(,332,O
6.1,332,O
%,332,O
),332,O
",",332,O
and,332,O
with,332,O
QTP,332,B-ChemicalEntity
+,332,O
Li/DVP,332,B-ChemicalEntity
(,332,O
3.6,332,O
%,332,O
),332,O
and,332,O
PBO,332,O
+,332,O
Li/DVP,332,B-ChemicalEntity
(,332,O
4.9,332,O
%,332,O
),332,O
.,332,O
Lithium,333,B-ChemicalEntity
was,333,O
associated,333,O
with,333,O
a,333,O
significantly,333,O
higher,333,O
incidence,333,O
(,333,O
p,333,O
<,333,O
0.05,333,O
),333,O
of,333,O
tremor,333,B-DiseaseOrPhenotypicFeature
(,333,O
18.4,333,O
%,333,O
),333,O
than,333,O
quetiapine,333,B-ChemicalEntity
(,333,O
5.6,333,O
%,333,O
),333,O
;,333,O
cerebellar,333,O
tremor,333,B-DiseaseOrPhenotypicFeature
",",333,O
which,333,O
is,333,O
a,333,O
known,333,O
adverse,333,O
effect,333,O
of,333,O
lithium,333,B-ChemicalEntity
",",333,O
may,333,O
have,333,O
contributed,333,O
to,333,O
the,333,O
elevated,333,O
rate,333,O
of,333,O
tremor,333,B-DiseaseOrPhenotypicFeature
in,333,O
patients,333,B-OrganismTaxon
receiving,333,O
lithium,333,B-ChemicalEntity
therapy,333,O
.,333,O
Haloperidol,334,B-ChemicalEntity
induced,334,O
a,334,O
significantly,334,O
higher,334,O
incidence,334,O
(,334,O
p,334,O
<,334,O
0.001,334,O
),334,O
of,334,O
akathisia,334,B-DiseaseOrPhenotypicFeature
(,334,O
33.3,334,O
%,334,O
versus,334,O
5.9,334,O
%,334,O
),334,O
",",334,O
tremor,334,B-DiseaseOrPhenotypicFeature
(,334,O
30.3,334,O
%,334,O
versus,334,O
7.8,334,O
%,334,O
),334,O
",",334,O
and,334,O
extrapyramidal,334,B-DiseaseOrPhenotypicFeature
syndrome,334,I-DiseaseOrPhenotypicFeature
(,334,O
35.4,334,O
%,334,O
versus,334,O
5.9,334,O
%,334,O
),334,O
than,334,O
quetiapine,334,B-ChemicalEntity
.,334,O
No,335,O
significant,335,O
differences,335,O
were,335,O
observed,335,O
between,335,O
quetiapine,335,B-ChemicalEntity
and,335,O
placebo,335,O
on,335,O
SAS,335,O
and,335,O
BARS,335,O
scores,335,O
.,335,O
Anticholinergic,336,B-ChemicalEntity
use,336,O
was,336,O
low,336,O
and,336,O
similar,336,O
with,336,O
quetiapine,336,B-ChemicalEntity
or,336,O
placebo,336,O
.,336,O
CONCLUSIONS,337,O
:,337,O
In,337,O
bipolar,337,B-DiseaseOrPhenotypicFeature
mania,337,I-DiseaseOrPhenotypicFeature
",",337,O
the,337,O
incidence,337,O
of,337,O
EPS,337,B-DiseaseOrPhenotypicFeature
",",337,O
including,337,O
akathisia,337,B-DiseaseOrPhenotypicFeature
",",337,O
with,337,O
quetiapine,337,B-ChemicalEntity
therapy,337,O
is,337,O
similar,337,O
to,337,O
that,337,O
with,337,O
placebo,337,O
.,337,O
Randomized,338,O
comparison,338,O
of,338,O
olanzapine,338,B-ChemicalEntity
versus,338,O
risperidone,338,B-ChemicalEntity
for,338,O
the,338,O
treatment,338,O
of,338,O
first-episode,338,O
schizophrenia,338,B-DiseaseOrPhenotypicFeature
:,338,O
4-month,338,O
outcomes,338,O
.,338,O
OBJECTIVE,339,O
:,339,O
The,339,O
authors,339,O
compared,339,O
4-month,339,O
treatment,339,O
outcomes,339,O
for,339,O
olanzapine,339,B-ChemicalEntity
versus,339,O
risperidone,339,B-ChemicalEntity
in,339,O
patients,339,B-OrganismTaxon
with,339,O
first-episode,339,O
schizophrenia,339,B-DiseaseOrPhenotypicFeature
spectrum,339,O
disorders,339,O
.,339,O
METHOD,340,O
:,340,O
One,340,O
hundred,340,O
twelve,340,O
subjects,340,O
(,340,O
70,340,O
%,340,O
male,340,O
;,340,O
mean,340,O
age=23.3,340,O
years,340,O
[,340,O
SD,340,O
=,340,O
5.1,340,O
],340,O
),340,O
with,340,O
first-episode,340,O
schizophrenia,340,B-DiseaseOrPhenotypicFeature
(,340,O
75,340,O
%,340,O
),340,O
",",340,O
schizophreniform,340,B-DiseaseOrPhenotypicFeature
disorder,340,I-DiseaseOrPhenotypicFeature
(,340,O
17,340,O
%,340,O
),340,O
",",340,O
or,340,O
schizoaffective,340,B-DiseaseOrPhenotypicFeature
disorder,340,I-DiseaseOrPhenotypicFeature
(,340,O
8,340,O
%,340,O
),340,O
were,340,O
randomly,340,O
assigned,340,O
to,340,O
treatment,340,O
with,340,O
olanzapine,340,B-ChemicalEntity
(,340,O
2.5-20,340,O
mg/day,340,O
),340,O
or,340,O
risperidone,340,B-ChemicalEntity
(,340,O
1-6,340,O
mg/day,340,O
),340,O
.,340,O
RESULTS,341,O
:,341,O
Response,341,O
rates,341,O
did,341,O
not,341,O
significantly,341,O
differ,341,O
between,341,O
olanzapine,341,B-ChemicalEntity
(,341,O
43.7,341,O
%,341,O
",",341,O
95,341,O
%,341,O
CI=28.8,341,O
%,341,O
-58.6,341,O
%,341,O
),341,O
and,341,O
risperidone,341,B-ChemicalEntity
(,341,O
54.3,341,O
%,341,O
",",341,O
95,341,O
%,341,O
CI=39.9,341,O
%,341,O
-68.7,341,O
%,341,O
),341,O
.,341,O
Among,342,O
those,342,O
responding,342,O
to,342,O
treatment,342,O
",",342,O
more,342,O
subjects,342,O
in,342,O
the,342,O
olanzapine,342,B-ChemicalEntity
group,342,O
(,342,O
40.9,342,O
%,342,O
",",342,O
95,342,O
%,342,O
CI=16.8,342,O
%,342,O
-65.0,342,O
%,342,O
),342,O
than,342,O
in,342,O
the,342,O
risperidone,342,B-ChemicalEntity
group,342,O
(,342,O
18.9,342,O
%,342,O
",",342,O
95,342,O
%,342,O
CI=0,342,O
%,342,O
-39.2,342,O
%,342,O
),342,O
had,342,O
subsequent,342,O
ratings,342,O
not,342,O
meeting,342,O
response,342,O
criteria,342,O
.,342,O
Negative,343,O
symptom,343,O
outcomes,343,O
and,343,O
measures,343,O
of,343,O
parkinsonism,343,B-DiseaseOrPhenotypicFeature
and,343,O
akathisia,343,B-DiseaseOrPhenotypicFeature
did,343,O
not,343,O
differ,343,O
between,343,O
medications,343,O
.,343,O
Extrapyramidal,344,B-DiseaseOrPhenotypicFeature
symptom,344,I-DiseaseOrPhenotypicFeature
severity,344,O
scores,344,O
were,344,O
1.4,344,O
(,344,O
95,344,O
%,344,O
CI=1.2-1.6,344,O
),344,O
with,344,O
risperidone,344,B-ChemicalEntity
and,344,O
1.2,344,O
(,344,O
95,344,O
%,344,O
CI=1.0-1.4,344,O
),344,O
with,344,O
olanzapine,344,B-ChemicalEntity
.,344,O
Significantly,345,O
more,345,O
weight,345,B-DiseaseOrPhenotypicFeature
gain,345,I-DiseaseOrPhenotypicFeature
occurred,345,O
with,345,O
olanzapine,345,B-ChemicalEntity
than,345,O
with,345,O
risperidone,345,B-ChemicalEntity
:,345,O
the,345,O
increase,345,O
in,345,O
weight,345,O
at,345,O
4,345,O
months,345,O
relative,345,O
to,345,O
baseline,345,O
weight,345,O
was,345,O
17.3,345,O
%,345,O
(,345,O
95,345,O
%,345,O
CI=14.2,345,O
%,345,O
-20.5,345,O
%,345,O
),345,O
with,345,O
olanzapine,345,B-ChemicalEntity
and,345,O
11.3,345,O
%,345,O
(,345,O
95,345,O
%,345,O
CI=8.4,345,O
%,345,O
-14.3,345,O
%,345,O
),345,O
with,345,O
risperidone,345,B-ChemicalEntity
.,345,O
Body,346,O
mass,346,O
index,346,O
at,346,O
baseline,346,O
and,346,O
at,346,O
4,346,O
months,346,O
was,346,O
24.3,346,O
(,346,O
95,346,O
%,346,O
CI=22.8-25.7,346,O
),346,O
versus,346,O
28.2,346,O
(,346,O
95,346,O
%,346,O
CI=26.7-29.7,346,O
),346,O
with,346,O
olanzapine,346,B-ChemicalEntity
and,346,O
23.9,346,O
(,346,O
95,346,O
%,346,O
CI=22.5-25.3,346,O
),346,O
versus,346,O
26.7,346,O
(,346,O
95,346,O
%,346,O
CI=25.2-28.2,346,O
),346,O
with,346,O
risperidone,346,B-ChemicalEntity
.,346,O
CONCLUSIONS,347,O
:,347,O
Clinical,347,O
outcomes,347,O
with,347,O
risperidone,347,B-ChemicalEntity
were,347,O
equal,347,O
to,347,O
those,347,O
with,347,O
olanzapine,347,B-ChemicalEntity
",",347,O
and,347,O
response,347,O
may,347,O
be,347,O
more,347,O
stable,347,O
.,347,O
Olanzapine,348,B-ChemicalEntity
may,348,O
have,348,O
an,348,O
advantage,348,O
for,348,O
motor,348,O
side,348,O
effects,348,O
.,348,O
Both,349,O
medications,349,O
caused,349,O
substantial,349,O
rapid,349,O
weight,349,B-DiseaseOrPhenotypicFeature
gain,349,I-DiseaseOrPhenotypicFeature
",",349,O
but,349,O
weight,349,B-DiseaseOrPhenotypicFeature
gain,349,I-DiseaseOrPhenotypicFeature
was,349,O
greater,349,O
with,349,O
olanzapine,349,B-ChemicalEntity
.,349,O
Risks,350,O
and,350,O
benefits,350,O
of,350,O
COX-2,350,B-ChemicalEntity
inhibitors,350,I-ChemicalEntity
vs,350,O
non-selective,350,O
NSAIDs,350,B-ChemicalEntity
:,350,O
does,350,O
their,350,O
cardiovascular,350,O
risk,350,O
exceed,350,O
their,350,O
gastrointestinal,350,O
benefit,350,O
?,350,O
A,351,O
retrospective,351,O
cohort,351,O
study,351,O
.,351,O
OBJECTIVES,352,O
:,352,O
The,352,O
risk,352,O
of,352,O
acute,352,B-DiseaseOrPhenotypicFeature
myocardial,352,I-DiseaseOrPhenotypicFeature
infarction,352,I-DiseaseOrPhenotypicFeature
(,352,O
AMI,352,B-DiseaseOrPhenotypicFeature
),352,O
with,352,O
COX-2,352,B-ChemicalEntity
inhibitors,352,I-ChemicalEntity
may,352,O
offset,352,O
their,352,O
gastrointestinal,352,O
(,352,O
GI,352,O
),352,O
benefit,352,O
compared,352,O
with,352,O
non-selective,352,O
(,352,O
NS,352,O
),352,O
non-steroidal,352,B-ChemicalEntity
anti-inflammatory,352,I-ChemicalEntity
drugs,352,I-ChemicalEntity
(,352,O
NSAIDs,352,B-ChemicalEntity
),352,O
.,352,O
We,353,O
aimed,353,O
to,353,O
compare,353,O
the,353,O
risks,353,O
of,353,O
hospitalization,353,O
for,353,O
AMI,353,B-DiseaseOrPhenotypicFeature
and,353,O
GI,353,B-DiseaseOrPhenotypicFeature
bleeding,353,I-DiseaseOrPhenotypicFeature
among,353,O
elderly,353,O
patients,353,B-OrganismTaxon
using,353,O
COX-2,353,B-ChemicalEntity
inhibitors,353,I-ChemicalEntity
",",353,O
NS-NSAIDs,353,O
and,353,O
acetaminophen,353,B-ChemicalEntity
.,353,O
METHODS,354,O
:,354,O
We,354,O
conducted,354,O
a,354,O
retrospective,354,O
cohort,354,O
study,354,O
using,354,O
administrative,354,O
data,354,O
of,354,O
patients,354,B-OrganismTaxon
>,354,O
or,354,O
=65,354,O
years,354,O
of,354,O
age,354,O
who,354,O
filled,354,O
a,354,O
prescription,354,O
for,354,O
NSAID,354,B-ChemicalEntity
or,354,O
acetaminophen,354,B-ChemicalEntity
during,354,O
1999-2002,354,O
.,354,O
Outcomes,355,O
were,355,O
compared,355,O
using,355,O
Cox,355,O
regression,355,O
models,355,O
with,355,O
time-dependent,355,O
exposures,355,O
.,355,O
RESULTS,356,O
:,356,O
Person-years,356,O
of,356,O
exposure,356,O
among,356,O
non-users,356,O
of,356,O
aspirin,356,B-ChemicalEntity
were,356,O
:,356,O
"75,761",356,O
to,356,O
acetaminophen,356,B-ChemicalEntity
",",356,O
"42,671",356,O
to,356,O
rofecoxib,356,B-ChemicalEntity
"65,860",356,O
to,356,O
celecoxib,356,B-ChemicalEntity
",",356,O
and,356,O
"37,495",356,O
to,356,O
NS-NSAIDs,356,O
.,356,O
Among,357,O
users,357,O
of,357,O
aspirin,357,B-ChemicalEntity
",",357,O
they,357,O
were,357,O
:,357,O
"14,671",357,O
to,357,O
rofecoxib,357,B-ChemicalEntity
",",357,O
"22,875",357,O
to,357,O
celecoxib,357,B-ChemicalEntity
",",357,O
"9,832",357,O
to,357,O
NS-NSAIDs,357,O
and,357,O
"38,048",357,O
to,357,O
acetaminophen,357,B-ChemicalEntity
.,357,O
Among,358,O
non-users,358,O
of,358,O
aspirin,358,B-ChemicalEntity
",",358,O
the,358,O
adjusted,358,O
hazard,358,O
ratios,358,O
(,358,O
95,358,O
%,358,O
confidence,358,O
interval,358,O
),358,O
of,358,O
hospitalization,358,O
for,358,O
AMI/GI,358,B-DiseaseOrPhenotypicFeature
vs,358,O
the,358,O
acetaminophen,358,B-ChemicalEntity
(,358,O
with,358,O
no,358,O
aspirin,358,B-ChemicalEntity
),358,O
group,358,O
were,358,O
:,358,O
rofecoxib,358,B-ChemicalEntity
1.27,358,O
(,358,O
1.13,358,O
",",358,O
1.42,358,O
),358,O
",",358,O
celecoxib,358,B-ChemicalEntity
0.93,358,O
(,358,O
0.83,358,O
",",358,O
1.03,358,O
),358,O
",",358,O
naproxen,358,B-ChemicalEntity
1.59,358,O
(,358,O
1.31,358,O
",",358,O
1.93,358,O
),358,O
",",358,O
diclofenac,358,B-ChemicalEntity
1.17,358,O
(,358,O
0.99,358,O
",",358,O
1.38,358,O
),358,O
and,358,O
ibuprofen,358,B-ChemicalEntity
1.05,358,O
(,358,O
0.74,358,O
",",358,O
1.51,358,O
),358,O
.,358,O
Among,359,O
users,359,O
of,359,O
aspirin,359,B-ChemicalEntity
",",359,O
they,359,O
were,359,O
:,359,O
rofecoxib,359,B-ChemicalEntity
1.73,359,O
(,359,O
1.52,359,O
",",359,O
1.98,359,O
),359,O
",",359,O
celecoxib,359,B-ChemicalEntity
1.34,359,O
(,359,O
1.19,359,O
",",359,O
1.52,359,O
),359,O
",",359,O
ibuprofen,359,B-ChemicalEntity
1.51,359,O
(,359,O
0.95,359,O
",",359,O
2.41,359,O
),359,O
",",359,O
diclofenac,359,B-ChemicalEntity
1.69,359,O
(,359,O
1.35,359,O
",",359,O
2.10,359,O
),359,O
",",359,O
naproxen,359,B-ChemicalEntity
1.35,359,O
(,359,O
0.97,359,O
",",359,O
1.88,359,O
),359,O
and,359,O
acetaminophen,359,B-ChemicalEntity
1.29,359,O
(,359,O
1.17,359,O
",",359,O
1.42,359,O
),359,O
.,359,O
CONCLUSION,360,O
:,360,O
Among,360,O
non-users,360,O
of,360,O
aspirin,360,B-ChemicalEntity
",",360,O
naproxen,360,B-ChemicalEntity
seemed,360,O
to,360,O
carry,360,O
the,360,O
highest,360,O
risk,360,O
for,360,O
AMI/GI,360,B-DiseaseOrPhenotypicFeature
bleeding,360,I-DiseaseOrPhenotypicFeature
.,360,O
The,361,O
AMI/GI,361,B-DiseaseOrPhenotypicFeature
toxicity,361,I-DiseaseOrPhenotypicFeature
of,361,O
celecoxib,361,B-ChemicalEntity
was,361,O
similar,361,O
to,361,O
that,361,O
of,361,O
acetaminophen,361,B-ChemicalEntity
and,361,O
seemed,361,O
to,361,O
be,361,O
better,361,O
than,361,O
those,361,O
of,361,O
rofecoxib,361,B-ChemicalEntity
and,361,O
NS-NSAIDs,361,O
.,361,O
Among,362,O
users,362,O
of,362,O
aspirin,362,B-ChemicalEntity
",",362,O
both,362,O
celecoxib,362,B-ChemicalEntity
and,362,O
naproxen,362,B-ChemicalEntity
seemed,362,O
to,362,O
be,362,O
the,362,O
least,362,O
toxic,362,O
.,362,O
Quinine-induced,363,B-ChemicalEntity
arrhythmia,363,B-DiseaseOrPhenotypicFeature
in,363,O
a,363,O
patient,363,B-OrganismTaxon
with,363,O
severe,363,B-DiseaseOrPhenotypicFeature
malaria,363,I-DiseaseOrPhenotypicFeature
.,363,O
It,364,O
was,364,O
reported,364,O
that,364,O
there,364,O
was,364,O
a,364,O
case,364,O
of,364,O
severe,364,B-DiseaseOrPhenotypicFeature
malaria,364,I-DiseaseOrPhenotypicFeature
patient,364,B-OrganismTaxon
with,364,O
jaundice,364,B-DiseaseOrPhenotypicFeature
who,364,O
presented,364,O
with,364,O
arrhythmia,364,B-DiseaseOrPhenotypicFeature
(,364,O
premature,364,B-DiseaseOrPhenotypicFeature
ventricular,364,I-DiseaseOrPhenotypicFeature
contraction,364,I-DiseaseOrPhenotypicFeature
),364,O
while,364,O
getting,364,O
quinine,364,B-ChemicalEntity
infusion,364,O
was,364,O
reported,364,O
.,364,O
A,365,O
man,365,B-OrganismTaxon
",",365,O
25,365,O
years,365,O
old,365,O
",",365,O
was,365,O
admitted,365,O
to,365,O
hospital,365,O
with,365,O
high,365,O
fever,365,B-DiseaseOrPhenotypicFeature
",",365,O
chill,365,B-DiseaseOrPhenotypicFeature
",",365,O
vomiting,365,B-DiseaseOrPhenotypicFeature
",",365,O
jaundice,365,B-DiseaseOrPhenotypicFeature
.,365,O
The,366,O
patient,366,B-OrganismTaxon
was,366,O
fully,366,O
conscious,366,O
",",366,O
blood,366,O
pressure,366,O
120/80,366,O
mmHg,366,O
",",366,O
pulse,366,O
rate,366,O
100,366,O
x/minute,366,O
",",366,O
regular,366,O
.,366,O
On,367,O
admission,367,O
",",367,O
laboratory,367,O
examination,367,O
showed,367,O
Plasmodium,367,B-OrganismTaxon
falciparum,367,I-OrganismTaxon
(,367,O
++++,367,O
),367,O
",",367,O
total,367,O
bilirubin,367,B-ChemicalEntity
8.25,367,O
mg/dL,367,O
",",367,O
conjugated,367,O
bilirubin,367,B-ChemicalEntity
4.36,367,O
mg/dL,367,O
",",367,O
unconjugated,367,O
bilirubin,367,B-ChemicalEntity
3.89,367,O
mg/dL,367,O
",",367,O
potassium,367,B-ChemicalEntity
3.52,367,O
meq/L,367,O
Patient,367,B-OrganismTaxon
was,367,O
diagnosed,367,O
as,367,O
severe,367,B-DiseaseOrPhenotypicFeature
malaria,367,I-DiseaseOrPhenotypicFeature
with,367,O
jaundice,367,B-DiseaseOrPhenotypicFeature
and,367,O
got,367,O
quinine,367,B-ChemicalEntity
infusion,367,O
in,367,O
dextrose,367,B-ChemicalEntity
5,367,O
%,367,O
500,367,O
mg/8,367,O
hour,367,O
.,367,O
On,368,O
the,368,O
second,368,O
day,368,O
the,368,O
patient,368,B-OrganismTaxon
had,368,O
vomitus,368,B-DiseaseOrPhenotypicFeature
",",368,O
diarrhea,368,B-DiseaseOrPhenotypicFeature
",",368,O
tinnitus,368,B-DiseaseOrPhenotypicFeature
",",368,O
loss,368,B-DiseaseOrPhenotypicFeature
of,368,I-DiseaseOrPhenotypicFeature
hearing,368,I-DiseaseOrPhenotypicFeature
.,368,O
After,369,O
30,369,O
hours,369,O
of,369,O
quinine,369,B-ChemicalEntity
infusion,369,O
the,369,O
patient,369,B-OrganismTaxon
felt,369,O
palpitation,369,B-DiseaseOrPhenotypicFeature
and,369,O
electrocardiography,369,O
(,369,O
ECG,369,O
),369,O
recording,369,O
showed,369,O
premature,369,B-DiseaseOrPhenotypicFeature
ventricular,369,I-DiseaseOrPhenotypicFeature
contraction,369,I-DiseaseOrPhenotypicFeature
(,369,O
PVC,369,B-DiseaseOrPhenotypicFeature
),369,O
>,369,O
5,369,O
x/minute,369,O
",",369,O
trigemini,369,O
",",369,O
constant,369,O
type,369,O
--,369,O
sinoatrial,369,B-DiseaseOrPhenotypicFeature
block,369,I-DiseaseOrPhenotypicFeature
",",369,O
positive,369,O
U,369,O
wave,369,O
.,369,O
He,370,O
was,370,O
treated,370,O
with,370,O
lidocaine,370,B-ChemicalEntity
50,370,O
mg,370,O
intravenously,370,O
followed,370,O
by,370,O
infusion,370,O
1500,370,O
mg,370,O
in,370,O
dextrose,370,B-ChemicalEntity
5,370,O
%,370,O
/24,370,O
hour,370,O
and,370,O
potassium,370,B-ChemicalEntity
aspartate,370,I-ChemicalEntity
tablet,370,O
.,370,O
Quinine,371,B-ChemicalEntity
infusion,371,O
was,371,O
discontinued,371,O
and,371,O
changed,371,O
with,371,O
sulfate,371,O
quinine,371,B-ChemicalEntity
tablets,371,O
.,371,O
Three,372,O
hours,372,O
later,372,O
the,372,O
patient,372,B-OrganismTaxon
felt,372,O
better,372,O
",",372,O
the,372,O
frequency,372,O
of,372,O
PVC,372,B-DiseaseOrPhenotypicFeature
reduced,372,O
to,372,O
4,372,O
-,372,O
5,372,O
x/minute,372,O
and,372,O
on,372,O
the,372,O
third,372,O
day,372,O
ECG,372,O
was,372,O
normal,372,O
",",372,O
potassium,372,B-ChemicalEntity
level,372,O
was,372,O
3.34,372,O
meq/L,372,O
.,372,O
He,373,O
was,373,O
discharged,373,O
on,373,O
7th,373,O
day,373,O
in,373,O
good,373,O
condition,373,O
.,373,O
Quinine,374,B-ChemicalEntity
",",374,O
like,374,O
quinidine,374,B-ChemicalEntity
",",374,O
is,374,O
a,374,O
chincona,374,B-ChemicalEntity
alkaloid,374,I-ChemicalEntity
that,374,O
has,374,O
anti-arrhythmic,374,O
property,374,O
",",374,O
although,374,O
it,374,O
also,374,O
pro-arrhythmic,374,O
that,374,O
can,374,O
cause,374,O
various,374,O
arrhythmias,374,B-DiseaseOrPhenotypicFeature
",",374,O
including,374,O
severe,374,O
arrhythmia,374,B-DiseaseOrPhenotypicFeature
such,374,O
as,374,O
multiple,374,O
PVC,374,B-DiseaseOrPhenotypicFeature
.,374,O
Administration,375,O
of,375,O
parenteral,375,O
quinine,375,B-ChemicalEntity
must,375,O
be,375,O
done,375,O
carefully,375,O
and,375,O
with,375,O
good,375,O
observation,375,O
because,375,O
of,375,O
its,375,O
pro-arrhythmic,375,O
effect,375,O
",",375,O
especially,375,O
in,375,O
older,375,O
patients,375,B-OrganismTaxon
who,375,O
have,375,O
heart,375,B-DiseaseOrPhenotypicFeature
diseases,375,I-DiseaseOrPhenotypicFeature
or,375,O
patients,375,B-OrganismTaxon
with,375,O
electrolyte,375,B-DiseaseOrPhenotypicFeature
disorder,375,I-DiseaseOrPhenotypicFeature
(,375,O
hypokalemia,375,B-DiseaseOrPhenotypicFeature
),375,O
which,375,O
frequently,375,O
occurs,375,O
due,375,O
to,375,O
vomiting,375,B-DiseaseOrPhenotypicFeature
and,375,O
or,375,O
diarrhea,375,B-DiseaseOrPhenotypicFeature
in,375,O
malaria,375,B-DiseaseOrPhenotypicFeature
cases,375,O
.,375,O
Over-expression,376,O
of,376,O
BMP4,376,B-GeneOrGeneProduct
and,376,O
BMP5,376,B-GeneOrGeneProduct
in,376,O
a,376,O
child,376,O
with,376,O
axial,376,B-DiseaseOrPhenotypicFeature
skeletal,376,I-DiseaseOrPhenotypicFeature
malformations,376,I-DiseaseOrPhenotypicFeature
and,376,O
heterotopic,376,B-DiseaseOrPhenotypicFeature
ossification,376,I-DiseaseOrPhenotypicFeature
:,376,O
a,376,O
new,376,O
syndrome,376,O
.,376,O
Bone,377,B-GeneOrGeneProduct
morphogenetic,377,I-GeneOrGeneProduct
proteins,377,I-GeneOrGeneProduct
(,377,O
BMPs,377,B-GeneOrGeneProduct
),377,O
are,377,O
a,377,O
highly,377,O
conserved,377,O
class,377,O
of,377,O
signaling,377,O
molecules,377,O
that,377,O
induce,377,O
ectopic,377,B-DiseaseOrPhenotypicFeature
cartilage,377,I-DiseaseOrPhenotypicFeature
and,377,I-DiseaseOrPhenotypicFeature
bone,377,I-DiseaseOrPhenotypicFeature
formation,377,I-DiseaseOrPhenotypicFeature
in,377,O
vivo,377,O
.,377,O
Dysregulated,378,O
expression,378,O
of,378,O
bone,378,B-GeneOrGeneProduct
morphogenetic,378,I-GeneOrGeneProduct
protein,378,I-GeneOrGeneProduct
4,378,I-GeneOrGeneProduct
(,378,O
BMP4,378,B-GeneOrGeneProduct
),378,O
is,378,O
found,378,O
in,378,O
the,378,O
cells,378,O
of,378,O
patients,378,B-OrganismTaxon
who,378,O
have,378,O
fibrodysplasia,378,B-DiseaseOrPhenotypicFeature
ossificans,378,I-DiseaseOrPhenotypicFeature
progressiva,378,I-DiseaseOrPhenotypicFeature
(,378,O
FOP,378,B-DiseaseOrPhenotypicFeature
),378,O
",",378,O
a,378,O
genetic,378,O
disorder,378,O
of,378,O
axial,378,B-DiseaseOrPhenotypicFeature
and,378,I-DiseaseOrPhenotypicFeature
appendicular,378,I-DiseaseOrPhenotypicFeature
skeletal,378,I-DiseaseOrPhenotypicFeature
malformation,378,I-DiseaseOrPhenotypicFeature
and,378,O
progressive,378,O
heterotopic,378,B-DiseaseOrPhenotypicFeature
ossification,378,I-DiseaseOrPhenotypicFeature
.,378,O
Loss,379,O
of,379,O
function,379,O
mutations,379,O
in,379,O
the,379,O
bone,379,B-GeneOrGeneProduct
morphogenetic,379,I-GeneOrGeneProduct
protein,379,I-GeneOrGeneProduct
5,379,I-GeneOrGeneProduct
(,379,O
bmp5,379,B-GeneOrGeneProduct
),379,O
gene,379,O
leading,379,O
to,379,O
under-expression,379,O
of,379,O
BMP5,379,B-GeneOrGeneProduct
cause,379,O
the,379,O
murine,379,B-OrganismTaxon
short,379,B-DiseaseOrPhenotypicFeature
ear,379,I-DiseaseOrPhenotypicFeature
syndrome,379,I-DiseaseOrPhenotypicFeature
",",379,O
characterized,379,O
by,379,O
small,379,O
malformed,379,O
ears,379,O
and,379,O
a,379,O
broad,379,O
range,379,O
of,379,O
axial,379,B-DiseaseOrPhenotypicFeature
skeletal,379,I-DiseaseOrPhenotypicFeature
malformations,379,I-DiseaseOrPhenotypicFeature
.,379,O
We,380,O
found,380,O
features,380,O
reminiscent,380,O
of,380,O
both,380,O
the,380,O
short,380,O
ear,380,O
mouse,380,B-OrganismTaxon
and,380,O
FOP,380,B-DiseaseOrPhenotypicFeature
in,380,O
a,380,O
child,380,O
with,380,O
malformed,380,B-DiseaseOrPhenotypicFeature
external,380,I-DiseaseOrPhenotypicFeature
ears,380,I-DiseaseOrPhenotypicFeature
",",380,O
multiple,380,B-DiseaseOrPhenotypicFeature
malformations,380,I-DiseaseOrPhenotypicFeature
of,380,I-DiseaseOrPhenotypicFeature
the,380,I-DiseaseOrPhenotypicFeature
axial,380,I-DiseaseOrPhenotypicFeature
skeleton,380,I-DiseaseOrPhenotypicFeature
",",380,O
and,380,O
progressive,380,O
heterotopic,380,B-DiseaseOrPhenotypicFeature
ossification,380,I-DiseaseOrPhenotypicFeature
in,380,O
the,380,O
neck,380,O
and,380,O
back,380,O
.,380,O
We,381,O
examined,381,O
BMP,381,B-GeneOrGeneProduct
mRNA,381,O
expression,381,O
in,381,O
transformed,381,O
lymphocytes,381,O
by,381,O
semi-quantitative,381,O
RT-PCR,381,O
and,381,O
protein,381,O
expression,381,O
by,381,O
ELISA,381,O
assays,381,O
and,381,O
immunohistochemistry,381,O
.,381,O
Elevated,382,O
levels,382,O
of,382,O
BMP4,382,B-GeneOrGeneProduct
and,382,O
BMP5,382,B-GeneOrGeneProduct
mRNA,382,O
and,382,O
protein,382,O
were,382,O
detected,382,O
in,382,O
the,382,O
patient,382,B-OrganismTaxon
's,382,O
cells,382,O
while,382,O
levels,382,O
of,382,O
BMP2,382,B-GeneOrGeneProduct
mRNA,382,O
were,382,O
unchanged,382,O
.,382,O
Our,383,O
data,383,O
suggest,383,O
that,383,O
dysregulated,383,O
expression,383,O
of,383,O
BMP4,383,B-GeneOrGeneProduct
and,383,O
BMP5,383,B-GeneOrGeneProduct
genes,383,O
is,383,O
associated,383,O
with,383,O
an,383,O
array,383,O
of,383,O
human,383,B-OrganismTaxon
axial,383,B-DiseaseOrPhenotypicFeature
skeletal,383,I-DiseaseOrPhenotypicFeature
abnormalities,383,I-DiseaseOrPhenotypicFeature
similar,383,O
to,383,O
the,383,O
short,383,O
ear,383,O
mouse,383,B-OrganismTaxon
and,383,O
FOP,383,B-DiseaseOrPhenotypicFeature
.,383,O
Succimer,384,B-ChemicalEntity
chelation,384,O
improves,384,O
learning,384,O
",",384,O
attention,384,O
",",384,O
and,384,O
arousal,384,O
regulation,384,O
in,384,O
lead-exposed,384,B-ChemicalEntity
rats,384,B-OrganismTaxon
but,384,O
produces,384,O
lasting,384,O
cognitive,384,B-DiseaseOrPhenotypicFeature
impairment,384,I-DiseaseOrPhenotypicFeature
in,384,O
the,384,O
absence,384,O
of,384,O
lead,384,B-ChemicalEntity
exposure,384,O
.,384,O
BACKGROUND,385,O
:,385,O
There,385,O
is,385,O
growing,385,O
pressure,385,O
for,385,O
clinicians,385,O
to,385,O
prescribe,385,O
chelation,385,O
therapy,385,O
at,385,O
only,385,O
slightly,385,O
elevated,385,O
blood,385,O
lead,385,B-ChemicalEntity
levels,385,O
.,385,O
However,386,O
",",386,O
very,386,O
few,386,O
studies,386,O
have,386,O
evaluated,386,O
whether,386,O
chelation,386,O
improves,386,O
cognitive,386,O
outcomes,386,O
in,386,O
Pb-exposed,386,B-ChemicalEntity
children,386,O
",",386,O
or,386,O
whether,386,O
these,386,O
agents,386,O
have,386,O
adverse,386,O
effects,386,O
that,386,O
may,386,O
affect,386,O
brain,386,O
development,386,O
in,386,O
the,386,O
absence,386,O
of,386,O
Pb,386,B-ChemicalEntity
exposure,386,O
.,386,O
OBJECTIVES,387,O
:,387,O
The,387,O
present,387,O
study,387,O
was,387,O
designed,387,O
to,387,O
answer,387,O
these,387,O
questions,387,O
",",387,O
using,387,O
a,387,O
rodent,387,O
model,387,O
of,387,O
early,387,O
childhood,387,O
Pb,387,B-ChemicalEntity
exposure,387,O
and,387,O
treatment,387,O
with,387,O
succimer,387,B-ChemicalEntity
",",387,O
a,387,O
widely,387,O
used,387,O
chelating,387,O
agent,387,O
for,387,O
the,387,O
treatment,387,O
of,387,O
Pb,387,B-DiseaseOrPhenotypicFeature
poisoning,387,I-DiseaseOrPhenotypicFeature
.,387,O
RESULTS,388,O
:,388,O
Pb,388,B-ChemicalEntity
exposure,388,O
produced,388,O
lasting,388,O
impairments,388,B-DiseaseOrPhenotypicFeature
in,388,I-DiseaseOrPhenotypicFeature
learning,388,I-DiseaseOrPhenotypicFeature
",",388,I-DiseaseOrPhenotypicFeature
attention,388,I-DiseaseOrPhenotypicFeature
",",388,I-DiseaseOrPhenotypicFeature
inhibitory,388,I-DiseaseOrPhenotypicFeature
control,388,I-DiseaseOrPhenotypicFeature
",",388,I-DiseaseOrPhenotypicFeature
and,388,I-DiseaseOrPhenotypicFeature
arousal,388,I-DiseaseOrPhenotypicFeature
regulation,388,I-DiseaseOrPhenotypicFeature
",",388,O
paralleling,388,O
the,388,O
areas,388,O
of,388,O
dysfunction,388,O
seen,388,O
in,388,O
Pb-exposed,388,B-ChemicalEntity
children,388,O
.,388,O
Succimer,389,B-ChemicalEntity
treatment,389,O
of,389,O
the,389,O
Pb-exposed,389,B-ChemicalEntity
rats,389,B-OrganismTaxon
significantly,389,O
improved,389,O
learning,389,O
",",389,O
attention,389,O
",",389,O
and,389,O
arousal,389,O
regulation,389,O
",",389,O
although,389,O
the,389,O
efficacy,389,O
of,389,O
the,389,O
treatment,389,O
varied,389,O
as,389,O
a,389,O
function,389,O
of,389,O
the,389,O
Pb,389,B-ChemicalEntity
exposure,389,O
level,389,O
and,389,O
the,389,O
specific,389,O
functional,389,O
deficit,389,O
.,389,O
In,390,O
contrast,390,O
",",390,O
succimer,390,B-ChemicalEntity
treatment,390,O
of,390,O
rats,390,B-OrganismTaxon
not,390,O
previously,390,O
exposed,390,O
to,390,O
Pb,390,B-ChemicalEntity
produced,390,O
lasting,390,O
and,390,O
pervasive,390,O
cognitive,390,B-DiseaseOrPhenotypicFeature
and,390,I-DiseaseOrPhenotypicFeature
affective,390,I-DiseaseOrPhenotypicFeature
dysfunction,390,I-DiseaseOrPhenotypicFeature
comparable,390,O
in,390,O
magnitude,390,O
to,390,O
that,390,O
produced,390,O
by,390,O
the,390,O
higher,390,O
Pb,390,B-ChemicalEntity
exposure,390,O
regimen,390,O
.,390,O
CONCLUSIONS,391,O
:,391,O
These,391,O
are,391,O
the,391,O
first,391,O
data,391,O
",",391,O
to,391,O
our,391,O
knowledge,391,O
",",391,O
to,391,O
show,391,O
that,391,O
treatment,391,O
with,391,O
any,391,O
chelating,391,O
agent,391,O
can,391,O
alleviate,391,O
cognitive,391,B-DiseaseOrPhenotypicFeature
deficits,391,I-DiseaseOrPhenotypicFeature
due,391,O
to,391,O
Pb,391,B-ChemicalEntity
exposure,391,O
.,391,O
These,392,O
findings,392,O
suggest,392,O
that,392,O
it,392,O
may,392,O
be,392,O
possible,392,O
to,392,O
identify,392,O
a,392,O
succimer,392,B-ChemicalEntity
treatment,392,O
protocol,392,O
that,392,O
improves,392,O
cognitive,392,O
outcomes,392,O
in,392,O
Pb-exposed,392,B-ChemicalEntity
children,392,O
.,392,O
However,393,O
",",393,O
they,393,O
also,393,O
suggest,393,O
that,393,O
succimer,393,B-ChemicalEntity
treatment,393,O
should,393,O
be,393,O
strongly,393,O
discouraged,393,O
for,393,O
children,393,O
who,393,O
do,393,O
not,393,O
have,393,O
elevated,393,O
tissue,393,O
levels,393,O
of,393,O
Pb,393,B-ChemicalEntity
or,393,O
other,393,O
heavy,393,O
metals,393,O
.,393,O
Identification,394,O
of,394,O
PVT1,394,B-GeneOrGeneProduct
as,394,O
a,394,O
candidate,394,O
gene,394,O
for,394,O
end-stage,394,B-DiseaseOrPhenotypicFeature
renal,394,I-DiseaseOrPhenotypicFeature
disease,394,I-DiseaseOrPhenotypicFeature
in,394,O
type,394,B-DiseaseOrPhenotypicFeature
2,394,I-DiseaseOrPhenotypicFeature
diabetes,394,I-DiseaseOrPhenotypicFeature
using,394,O
a,394,O
pooling-based,394,O
genome-wide,394,O
single,394,O
nucleotide,394,O
polymorphism,394,O
association,394,O
study,394,O
.,394,O
To,395,O
identify,395,O
genetic,395,O
variants,395,O
contributing,395,O
to,395,O
end-stage,395,B-DiseaseOrPhenotypicFeature
renal,395,I-DiseaseOrPhenotypicFeature
disease,395,I-DiseaseOrPhenotypicFeature
(,395,O
ESRD,395,B-DiseaseOrPhenotypicFeature
),395,O
in,395,O
type,395,B-DiseaseOrPhenotypicFeature
2,395,I-DiseaseOrPhenotypicFeature
diabetes,395,I-DiseaseOrPhenotypicFeature
",",395,O
we,395,O
performed,395,O
a,395,O
genome-wide,395,O
analysis,395,O
of,395,O
"115,352",395,O
single,395,O
nucleotide,395,O
polymorphisms,395,O
(,395,O
SNPs,395,O
),395,O
in,395,O
pools,395,O
of,395,O
105,395,O
unrelated,395,O
case,395,O
subjects,395,O
with,395,O
ESRD,395,B-DiseaseOrPhenotypicFeature
and,395,O
102,395,O
unrelated,395,O
control,395,O
subjects,395,O
who,395,O
have,395,O
had,395,O
type,395,B-DiseaseOrPhenotypicFeature
2,395,I-DiseaseOrPhenotypicFeature
diabetes,395,I-DiseaseOrPhenotypicFeature
for,395,O
>,395,O
or,395,O
=10,395,O
years,395,O
without,395,O
macroalbuminuria,395,O
.,395,O
Using,396,O
a,396,O
sliding,396,O
window,396,O
statistic,396,O
of,396,O
ranked,396,O
SNPs,396,O
",",396,O
we,396,O
identified,396,O
a,396,O
200-kb,396,O
region,396,O
on,396,O
8q24,396,O
harboring,396,O
three,396,O
SNPs,396,O
showing,396,O
substantial,396,O
differences,396,O
in,396,O
allelic,396,O
frequency,396,O
between,396,O
case,396,O
and,396,O
control,396,O
pools,396,O
.,396,O
These,397,O
SNPs,397,O
were,397,O
genotyped,397,O
in,397,O
individuals,397,O
comprising,397,O
each,397,O
pool,397,O
",",397,O
and,397,O
strong,397,O
evidence,397,O
for,397,O
association,397,O
was,397,O
found,397,O
with,397,O
rs2720709,397,B-SequenceVariant
(,397,O
P,397,O
=,397,O
0.000021,397,O
;,397,O
odds,397,O
ratio,397,O
2.57,397,O
[,397,O
95,397,O
%,397,O
CI,397,O
1.66-3.96,397,O
],397,O
),397,O
",",397,O
which,397,O
is,397,O
located,397,O
in,397,O
the,397,O
plasmacytoma,397,O
variant,397,O
translocation,397,O
gene,397,O
PVT1,397,B-GeneOrGeneProduct
.,397,O
We,398,O
sequenced,398,O
all,398,O
exons,398,O
",",398,O
exon-intron,398,O
boundaries,398,O
",",398,O
and,398,O
the,398,O
promoter,398,O
of,398,O
PVT1,398,B-GeneOrGeneProduct
and,398,O
identified,398,O
47,398,O
variants,398,O
",",398,O
11,398,O
of,398,O
which,398,O
represented,398,O
nonredundant,398,O
markers,398,O
with,398,O
minor,398,O
allele,398,O
frequency,398,O
>,398,O
or,398,O
=0.05,398,O
.,398,O
We,399,O
subsequently,399,O
genotyped,399,O
these,399,O
11,399,O
variants,399,O
and,399,O
an,399,O
additional,399,O
87,399,O
SNPs,399,O
identified,399,O
through,399,O
public,399,O
databases,399,O
in,399,O
319-kb,399,O
flanking,399,O
rs2720709,399,B-SequenceVariant
(,399,O
approximately,399,O
1,399,O
SNP/3.5,399,O
kb,399,O
),399,O
;,399,O
23,399,O
markers,399,O
were,399,O
associated,399,O
with,399,O
ESRD,399,B-DiseaseOrPhenotypicFeature
at,399,O
P,399,O
<,399,O
0.01,399,O
.,399,O
The,400,O
strongest,400,O
evidence,400,O
for,400,O
association,400,O
was,400,O
found,400,O
for,400,O
rs2648875,400,B-SequenceVariant
(,400,O
P,400,O
=,400,O
0.0000018,400,O
;,400,O
2.97,400,O
[,400,O
1.90-4.65,400,O
],400,O
),400,O
",",400,O
which,400,O
maps,400,O
to,400,O
intron,400,O
8,400,O
of,400,O
PVT1,400,B-GeneOrGeneProduct
.,400,O
Together,401,O
",",401,O
these,401,O
results,401,O
suggest,401,O
that,401,O
PVT1,401,B-GeneOrGeneProduct
may,401,O
contribute,401,O
to,401,O
ESRD,401,B-DiseaseOrPhenotypicFeature
susceptibility,401,O
in,401,O
diabetes,401,B-DiseaseOrPhenotypicFeature
.,401,O
Regulatory,402,O
network,402,O
of,402,O
inflammation,402,B-DiseaseOrPhenotypicFeature
downstream,402,O
of,402,O
proteinase-activated,402,B-GeneOrGeneProduct
receptors,402,I-GeneOrGeneProduct
.,402,O
BACKGROUND,403,O
:,403,O
Protease-activated,403,B-GeneOrGeneProduct
receptors,403,I-GeneOrGeneProduct
(,403,O
PAR,403,B-GeneOrGeneProduct
),403,O
are,403,O
present,403,O
in,403,O
the,403,O
urinary,403,O
bladder,403,O
",",403,O
and,403,O
their,403,O
expression,403,O
is,403,O
altered,403,O
in,403,O
response,403,O
to,403,O
inflammation,403,B-DiseaseOrPhenotypicFeature
.,403,O
PARs,404,B-GeneOrGeneProduct
are,404,O
a,404,O
unique,404,O
class,404,O
of,404,O
G,404,O
protein-coupled,404,O
that,404,O
carry,404,O
their,404,O
own,404,O
ligands,404,O
",",404,O
which,404,O
remain,404,O
cryptic,404,O
until,404,O
unmasked,404,O
by,404,O
proteolytic,404,O
cleavage,404,O
.,404,O
Although,405,O
the,405,O
canonical,405,O
signal,405,O
transduction,405,O
pathway,405,O
downstream,405,O
of,405,O
PAR,405,B-GeneOrGeneProduct
activation,405,O
and,405,O
coupling,405,O
with,405,O
various,405,O
G,405,O
proteins,405,O
is,405,O
known,405,O
and,405,O
leads,405,O
to,405,O
the,405,O
rapid,405,O
transcription,405,O
of,405,O
genes,405,O
involved,405,O
in,405,O
inflammation,405,B-DiseaseOrPhenotypicFeature
",",405,O
the,405,O
effect,405,O
of,405,O
PAR,405,B-GeneOrGeneProduct
activation,405,O
on,405,O
the,405,O
downstream,405,O
transcriptome,405,O
is,405,O
unknown,405,O
.,405,O
We,406,O
have,406,O
shown,406,O
that,406,O
intravesical,406,O
administration,406,O
of,406,O
PAR-activating,406,B-GeneOrGeneProduct
peptides,406,O
leads,406,O
to,406,O
an,406,O
inflammatory,406,B-DiseaseOrPhenotypicFeature
reaction,406,O
characterized,406,O
by,406,O
edema,406,B-DiseaseOrPhenotypicFeature
and,406,O
granulocyte,406,O
infiltration,406,O
.,406,O
Moreover,407,O
",",407,O
the,407,O
inflammatory,407,B-DiseaseOrPhenotypicFeature
response,407,O
to,407,O
intravesical,407,O
instillation,407,O
of,407,O
known,407,O
pro-inflammatory,407,O
stimuli,407,O
such,407,O
as,407,O
E.,407,B-OrganismTaxon
coli,407,I-OrganismTaxon
lipopolysaccharide,407,B-ChemicalEntity
(,407,O
LPS,407,B-ChemicalEntity
),407,O
",",407,O
substance,407,B-ChemicalEntity
P,407,I-ChemicalEntity
(,407,O
SP,407,B-ChemicalEntity
),407,O
",",407,O
and,407,O
antigen,407,O
was,407,O
strongly,407,O
attenuated,407,O
by,407,O
PAR1-,407,B-GeneOrGeneProduct
and,407,O
to,407,O
a,407,O
lesser,407,O
extent,407,O
by,407,O
PAR2-deficiency,407,B-GeneOrGeneProduct
.,407,O
RESULTS,408,O
:,408,O
Here,408,O
",",408,O
cDNA,408,O
array,408,O
experiments,408,O
determined,408,O
inflammatory,408,B-DiseaseOrPhenotypicFeature
genes,408,O
whose,408,O
expression,408,O
is,408,O
dependent,408,O
on,408,O
PAR1,408,B-GeneOrGeneProduct
activation,408,O
.,408,O
For,409,O
this,409,O
purpose,409,O
",",409,O
we,409,O
compared,409,O
the,409,O
alteration,409,O
in,409,O
gene,409,O
expression,409,O
in,409,O
wild,409,O
type,409,O
and,409,O
PAR1-/-,409,B-GeneOrGeneProduct
mice,409,B-OrganismTaxon
induced,409,O
by,409,O
classical,409,O
pro-inflammatory,409,O
stimuli,409,O
(,409,O
LPS,409,B-ChemicalEntity
",",409,O
SP,409,B-ChemicalEntity
",",409,O
and,409,O
antigen,409,O
),409,O
.,409,O
75,410,O
transcripts,410,O
were,410,O
considered,410,O
to,410,O
be,410,O
dependent,410,O
on,410,O
PAR-1,410,B-GeneOrGeneProduct
activation,410,O
and,410,O
further,410,O
annotated,410,O
in,410,O
silico,410,O
by,410,O
Ingenuity,410,O
Pathways,410,O
Analysis,410,O
(,410,O
IPA,410,O
),410,O
and,410,O
gene,410,O
ontology,410,O
(,410,O
GO,410,O
),410,O
.,410,O
Selected,411,O
transcripts,411,O
were,411,O
target,411,O
validated,411,O
by,411,O
quantitative,411,O
PCR,411,O
(,411,O
Q-PCR,411,O
),411,O
.,411,O
Among,412,O
PAR1-dependent,412,B-GeneOrGeneProduct
transcripts,412,O
",",412,O
the,412,O
following,412,O
have,412,O
been,412,O
implicated,412,O
in,412,O
the,412,O
inflammatory,412,B-DiseaseOrPhenotypicFeature
process,412,O
:,412,O
b2m,412,B-GeneOrGeneProduct
",",412,O
ccl7,412,B-GeneOrGeneProduct
",",412,O
cd200,412,B-GeneOrGeneProduct
",",412,O
cd63,412,B-GeneOrGeneProduct
",",412,O
cdbpd,412,B-GeneOrGeneProduct
",",412,O
cfl1,412,B-GeneOrGeneProduct
",",412,O
dusp1,412,B-GeneOrGeneProduct
",",412,O
fkbp1a,412,B-GeneOrGeneProduct
",",412,O
fth1,412,B-GeneOrGeneProduct
",",412,O
hspb1,412,B-GeneOrGeneProduct
",",412,O
marcksl1,412,B-GeneOrGeneProduct
",",412,O
mmp2,412,B-GeneOrGeneProduct
",",412,O
myo5a,412,B-GeneOrGeneProduct
",",412,O
nfkbia,412,B-GeneOrGeneProduct
",",412,O
pax1,412,B-GeneOrGeneProduct
",",412,O
plaur,412,B-GeneOrGeneProduct
",",412,O
ppia,412,B-GeneOrGeneProduct
",",412,O
ptpn1,412,B-GeneOrGeneProduct
",",412,O
ptprcap,412,B-GeneOrGeneProduct
",",412,O
s100a10,412,B-GeneOrGeneProduct
",",412,O
sim2,412,B-GeneOrGeneProduct
",",412,O
and,412,O
tnfaip2,412,B-GeneOrGeneProduct
.,412,O
However,413,O
",",413,O
a,413,O
balanced,413,O
response,413,O
to,413,O
signals,413,O
of,413,O
injury,413,O
requires,413,O
a,413,O
transient,413,O
cellular,413,O
activation,413,O
of,413,O
a,413,O
panel,413,O
of,413,O
genes,413,O
together,413,O
with,413,O
inhibitory,413,O
systems,413,O
that,413,O
temper,413,O
the,413,O
overwhelming,413,O
inflammation,413,B-DiseaseOrPhenotypicFeature
.,413,O
In,414,O
this,414,O
context,414,O
",",414,O
the,414,O
activation,414,O
of,414,O
genes,414,O
such,414,O
as,414,O
dusp1,414,B-GeneOrGeneProduct
and,414,O
nfkbia,414,B-GeneOrGeneProduct
seems,414,O
to,414,O
counter-balance,414,O
the,414,O
inflammatory,414,B-DiseaseOrPhenotypicFeature
response,414,O
to,414,O
PAR,414,B-GeneOrGeneProduct
activation,414,O
by,414,O
limiting,414,O
prolonged,414,O
activation,414,O
of,414,O
p38,414,B-GeneOrGeneProduct
MAPK,414,I-GeneOrGeneProduct
and,414,O
increased,414,O
cytokine,414,O
production,414,O
.,414,O
In,415,O
contrast,415,O
",",415,O
transcripts,415,O
such,415,O
as,415,O
arf6,415,B-GeneOrGeneProduct
and,415,O
dcnt1,415,B-GeneOrGeneProduct
that,415,O
are,415,O
involved,415,O
in,415,O
the,415,O
mechanism,415,O
of,415,O
PAR,415,B-GeneOrGeneProduct
re-sensitization,415,O
would,415,O
tend,415,O
to,415,O
perpetuate,415,O
the,415,O
inflammatory,415,B-DiseaseOrPhenotypicFeature
reaction,415,O
in,415,O
response,415,O
to,415,O
common,415,O
pro-inflammatory,415,O
stimuli,415,O
.,415,O
CONCLUSION,416,O
:,416,O
The,416,O
combination,416,O
of,416,O
cDNA,416,O
array,416,O
results,416,O
and,416,O
genomic,416,O
networks,416,O
reveals,416,O
an,416,O
overriding,416,O
participation,416,O
of,416,O
PAR1,416,B-GeneOrGeneProduct
in,416,O
bladder,416,B-DiseaseOrPhenotypicFeature
inflammation,416,I-DiseaseOrPhenotypicFeature
",",416,O
provides,416,O
a,416,O
working,416,O
model,416,O
for,416,O
the,416,O
involvement,416,O
of,416,O
downstream,416,O
signaling,416,O
",",416,O
and,416,O
evokes,416,O
testable,416,O
hypotheses,416,O
regarding,416,O
the,416,O
transcriptome,416,O
downstream,416,O
of,416,O
PAR1,416,B-GeneOrGeneProduct
activation,416,O
.,416,O
It,417,O
remains,417,O
to,417,O
be,417,O
determined,417,O
whether,417,O
or,417,O
not,417,O
mechanisms,417,O
targeting,417,O
PAR1,417,B-GeneOrGeneProduct
gene,417,O
silencing,417,O
or,417,O
PAR1,417,B-GeneOrGeneProduct
blockade,417,O
will,417,O
ameliorate,417,O
the,417,O
clinical,417,O
manifestation,417,O
of,417,O
cystitis,417,B-DiseaseOrPhenotypicFeature
.,417,O
Caffeine,418,B-ChemicalEntity
challenge,418,O
test,418,O
in,418,O
panic,418,B-DiseaseOrPhenotypicFeature
disorder,418,I-DiseaseOrPhenotypicFeature
and,418,O
depression,418,B-DiseaseOrPhenotypicFeature
with,418,O
panic,418,B-DiseaseOrPhenotypicFeature
attacks,418,I-DiseaseOrPhenotypicFeature
.,418,O
Our,419,O
aim,419,O
was,419,O
to,419,O
observe,419,O
if,419,O
patients,419,B-OrganismTaxon
with,419,O
panic,419,B-DiseaseOrPhenotypicFeature
disorder,419,I-DiseaseOrPhenotypicFeature
(,419,O
PD,419,B-DiseaseOrPhenotypicFeature
),419,O
and,419,O
patients,419,B-OrganismTaxon
with,419,O
major,419,B-DiseaseOrPhenotypicFeature
depression,419,I-DiseaseOrPhenotypicFeature
with,419,O
panic,419,B-DiseaseOrPhenotypicFeature
attacks,419,I-DiseaseOrPhenotypicFeature
(,419,O
MDP,419,B-DiseaseOrPhenotypicFeature
),419,O
(,419,O
Diagnostic,419,O
and,419,O
Statistical,419,O
Manual,419,O
of,419,O
Mental,419,B-DiseaseOrPhenotypicFeature
Disorders,419,I-DiseaseOrPhenotypicFeature
",",419,O
Fourth,419,O
Edition,419,O
criteria,419,O
),419,O
respond,419,O
in,419,O
a,419,O
similar,419,O
way,419,O
to,419,O
the,419,O
induction,419,O
of,419,O
panic,419,B-DiseaseOrPhenotypicFeature
attacks,419,I-DiseaseOrPhenotypicFeature
by,419,O
an,419,O
oral,419,O
caffeine,419,B-ChemicalEntity
challenge,419,O
test,419,O
.,419,O
We,420,O
randomly,420,O
selected,420,O
29,420,O
patients,420,B-OrganismTaxon
with,420,O
PD,420,B-DiseaseOrPhenotypicFeature
",",420,O
27,420,O
with,420,O
MDP,420,B-DiseaseOrPhenotypicFeature
",",420,O
25,420,O
with,420,O
major,420,B-DiseaseOrPhenotypicFeature
depression,420,I-DiseaseOrPhenotypicFeature
without,420,O
panic,420,B-DiseaseOrPhenotypicFeature
attacks,420,I-DiseaseOrPhenotypicFeature
(,420,O
MD,420,B-DiseaseOrPhenotypicFeature
),420,O
",",420,O
and,420,O
28,420,O
healthy,420,O
volunteers,420,O
.,420,O
The,421,O
patients,421,B-OrganismTaxon
had,421,O
no,421,O
psychotropic,421,O
drug,421,O
for,421,O
at,421,O
least,421,O
a,421,O
4-week,421,O
period,421,O
.,421,O
In,422,O
a,422,O
randomized,422,O
double-blind,422,O
experiment,422,O
performed,422,O
in,422,O
2,422,O
occasions,422,O
7,422,O
days,422,O
apart,422,O
",",422,O
480,422,O
mg,422,O
caffeine,422,B-ChemicalEntity
and,422,O
a,422,O
caffeine-free,422,B-ChemicalEntity
(,422,O
placebo,422,O
),422,O
solution,422,O
were,422,O
administered,422,O
in,422,O
a,422,O
coffee,422,O
form,422,O
and,422,O
anxiety,422,B-DiseaseOrPhenotypicFeature
scales,422,O
were,422,O
applied,422,O
before,422,O
and,422,O
after,422,O
each,422,O
test,422,O
.,422,O
A,423,O
total,423,O
of,423,O
58.6,423,O
%,423,O
(,423,O
n,423,O
=,423,O
17,423,O
),423,O
of,423,O
patients,423,B-OrganismTaxon
with,423,O
PD,423,B-DiseaseOrPhenotypicFeature
",",423,O
44.4,423,O
%,423,O
(,423,O
n,423,O
=,423,O
12,423,O
),423,O
of,423,O
patients,423,B-OrganismTaxon
with,423,O
MDP,423,B-DiseaseOrPhenotypicFeature
",",423,O
12.0,423,O
%,423,O
(,423,O
n,423,O
=,423,O
3,423,O
),423,O
of,423,O
patients,423,B-OrganismTaxon
with,423,O
MD,423,B-DiseaseOrPhenotypicFeature
",",423,O
and,423,O
7.1,423,O
%,423,O
(,423,O
n=,423,O
2,423,O
),423,O
of,423,O
control,423,O
subjects,423,O
had,423,O
a,423,O
panic,423,B-DiseaseOrPhenotypicFeature
attack,423,I-DiseaseOrPhenotypicFeature
after,423,O
the,423,O
480-mg,423,O
caffeine,423,B-ChemicalEntity
challenge,423,O
test,423,O
(,423,O
chi,423,O
(,423,O
2,423,O
),423,O
(,423,O
3,423,O
),423,O
=,423,O
16.22,423,O
",",423,O
P,423,O
=,423,O
.001,423,O
),423,O
.,423,O
The,424,O
patients,424,B-OrganismTaxon
with,424,O
PD,424,B-DiseaseOrPhenotypicFeature
and,424,O
MDP,424,B-DiseaseOrPhenotypicFeature
were,424,O
more,424,O
sensitive,424,O
to,424,O
caffeine,424,B-ChemicalEntity
than,424,O
were,424,O
patients,424,B-OrganismTaxon
with,424,O
MD,424,B-DiseaseOrPhenotypicFeature
and,424,O
healthy,424,O
volunteers,424,O
.,424,O
No,425,O
panic,425,B-DiseaseOrPhenotypicFeature
attack,425,I-DiseaseOrPhenotypicFeature
was,425,O
observed,425,O
after,425,O
the,425,O
caffeine-free,425,B-ChemicalEntity
solution,425,O
intake,425,O
.,425,O
The,426,O
patients,426,B-OrganismTaxon
with,426,O
MD,426,B-DiseaseOrPhenotypicFeature
had,426,O
a,426,O
lower,426,O
heart,426,O
rate,426,O
response,426,O
to,426,O
the,426,O
test,426,O
than,426,O
all,426,O
the,426,O
other,426,O
groups,426,O
(,426,O
2-way,426,O
analysis,426,O
of,426,O
variance,426,O
",",426,O
group,426,O
by,426,O
time,426,O
interaction,426,O
with,426,O
Greenhouse-Geisser,426,O
correction,426,O
:,426,O
F,426,O
(,426,O
"3,762",426,O
),426,O
=,426,O
2.85,426,O
",",426,O
P,426,O
=,426,O
.026,426,O
),426,O
.,426,O
Our,427,O
data,427,O
suggest,427,O
that,427,O
there,427,O
is,427,O
an,427,O
association,427,O
between,427,O
panic,427,B-DiseaseOrPhenotypicFeature
attacks,427,I-DiseaseOrPhenotypicFeature
",",427,O
no,427,O
matter,427,O
if,427,O
associated,427,O
with,427,O
PD,427,B-DiseaseOrPhenotypicFeature
or,427,O
MDP,427,B-DiseaseOrPhenotypicFeature
",",427,O
and,427,O
hyperreactivity,427,O
to,427,O
an,427,O
oral,427,O
caffeine,427,B-ChemicalEntity
challenge,427,O
test,427,O
.,427,O
A,428,O
novel,428,O
IRF6,428,B-GeneOrGeneProduct
nonsense,428,O
mutation,428,O
(,428,O
Y67X,428,B-SequenceVariant
),428,O
in,428,O
a,428,O
German,428,O
family,428,O
with,428,O
Van,428,B-DiseaseOrPhenotypicFeature
der,428,I-DiseaseOrPhenotypicFeature
Woude,428,I-DiseaseOrPhenotypicFeature
syndrome,428,I-DiseaseOrPhenotypicFeature
.,428,O
Van,429,B-DiseaseOrPhenotypicFeature
der,429,I-DiseaseOrPhenotypicFeature
Woude,429,I-DiseaseOrPhenotypicFeature
syndrome,429,I-DiseaseOrPhenotypicFeature
(,429,O
VWS,429,B-DiseaseOrPhenotypicFeature
),429,O
is,429,O
the,429,O
most,429,O
common,429,O
type,429,O
of,429,O
syndromic,429,B-DiseaseOrPhenotypicFeature
orofacial,429,I-DiseaseOrPhenotypicFeature
cleft,429,I-DiseaseOrPhenotypicFeature
",",429,O
which,429,O
accounts,429,O
for,429,O
approximately,429,O
2,429,O
%,429,O
of,429,O
all,429,O
cleft,429,B-DiseaseOrPhenotypicFeature
lip,429,I-DiseaseOrPhenotypicFeature
and,429,I-DiseaseOrPhenotypicFeature
palate,429,I-DiseaseOrPhenotypicFeature
cases,429,O
.,429,O
It,430,O
is,430,O
characterised,430,O
by,430,O
variable,430,O
association,430,O
of,430,O
lower,430,O
lip,430,B-DiseaseOrPhenotypicFeature
pits,430,I-DiseaseOrPhenotypicFeature
",",430,O
cleft,430,B-DiseaseOrPhenotypicFeature
lip,430,I-DiseaseOrPhenotypicFeature
and,430,O
cleft,430,B-DiseaseOrPhenotypicFeature
palate,430,I-DiseaseOrPhenotypicFeature
",",430,O
and,430,O
hypodontia,430,B-DiseaseOrPhenotypicFeature
.,430,O
VWS,431,B-DiseaseOrPhenotypicFeature
arises,431,O
as,431,O
the,431,O
result,431,O
of,431,O
mutations,431,O
in,431,O
the,431,O
gene,431,O
encoding,431,O
interferon,431,B-GeneOrGeneProduct
regulatory,431,I-GeneOrGeneProduct
factor,431,I-GeneOrGeneProduct
6,431,I-GeneOrGeneProduct
(,431,O
IRF6,431,B-GeneOrGeneProduct
),431,O
.,431,O
The,432,O
disorder,432,O
is,432,O
transmitted,432,O
in,432,O
an,432,O
autosomal,432,O
dominant,432,O
manner,432,O
",",432,O
with,432,O
high,432,O
penetrance,432,O
and,432,O
variable,432,O
expressivity,432,O
.,432,O
Very,433,O
recently,433,O
",",433,O
mutations,433,O
of,433,O
the,433,O
IRF6,433,B-GeneOrGeneProduct
gene,433,O
in,433,O
exons,433,O
2-9,433,O
have,433,O
been,433,O
found,433,O
in,433,O
VWS,433,B-DiseaseOrPhenotypicFeature
patients,433,B-OrganismTaxon
",",433,O
suggesting,433,O
that,433,O
this,433,O
gene,433,O
plays,433,O
an,433,O
important,433,O
role,433,O
in,433,O
orofacial,433,O
development,433,O
.,433,O
We,434,O
report,434,O
a,434,O
novel,434,O
mutation,434,O
of,434,O
the,434,O
IRF6,434,B-GeneOrGeneProduct
gene,434,O
in,434,O
a,434,O
German,434,O
family,434,O
.,434,O
Five,435,O
out,435,O
of,435,O
the,435,O
12,435,O
persons,435,O
affected,435,O
were,435,O
able,435,O
to,435,O
be,435,O
investigated,435,O
.,435,O
The,436,O
mutation,436,O
produced,436,O
a,436,O
stop,436,O
codon,436,O
within,436,O
exon,436,O
4,436,O
of,436,O
the,436,O
IRF6,436,B-GeneOrGeneProduct
gene,436,O
.,436,O
All,437,O
5,437,O
patients,437,B-OrganismTaxon
were,437,O
heterozygous,437,O
for,437,O
a,437,O
base,437,O
substitution,437,O
c.201C,437,B-SequenceVariant
>,437,I-SequenceVariant
A,437,I-SequenceVariant
changing,437,O
the,437,O
tyrosine,437,B-SequenceVariant
codon,437,I-SequenceVariant
at,437,I-SequenceVariant
amino,437,I-SequenceVariant
acid,437,I-SequenceVariant
position,437,I-SequenceVariant
67,437,I-SequenceVariant
into,437,I-SequenceVariant
a,437,I-SequenceVariant
stop,437,I-SequenceVariant
codon,437,O
(,437,O
p.Y67X,437,B-SequenceVariant
),437,O
in,437,O
exon,437,O
4,437,O
.,437,O
The,438,O
premature,438,O
stop,438,O
codon,438,O
was,438,O
responsible,438,O
for,438,O
a,438,O
truncated,438,O
protein,438,O
lacking,438,O
parts,438,O
of,438,O
the,438,O
DNA-,438,O
binding,438,O
domain,438,O
and,438,O
the,438,O
complete,438,O
Smad-interferon,438,B-GeneOrGeneProduct
regulatory,438,I-GeneOrGeneProduct
factor-binding,438,O
domain,438,O
probably,438,O
essential,438,O
for,438,O
interactions,438,O
with,438,O
the,438,O
Smad,438,B-GeneOrGeneProduct
transcription,438,O
factors,438,O
.,438,O
A,439,O
novel,439,O
compound,439,O
",",439,O
maltolyl,439,B-ChemicalEntity
p-coumarate,439,I-ChemicalEntity
",",439,O
attenuates,439,O
cognitive,439,B-DiseaseOrPhenotypicFeature
deficits,439,I-DiseaseOrPhenotypicFeature
and,439,O
shows,439,O
neuroprotective,439,O
effects,439,O
in,439,O
vitro,439,O
and,439,O
in,439,O
vivo,439,O
dementia,439,B-DiseaseOrPhenotypicFeature
models,439,O
.,439,O
To,440,O
develop,440,O
a,440,O
novel,440,O
and,440,O
effective,440,O
drug,440,O
that,440,O
could,440,O
enhance,440,O
cognitive,440,O
function,440,O
and,440,O
neuroprotection,440,O
",",440,O
we,440,O
newly,440,O
synthesized,440,O
maltolyl,440,B-ChemicalEntity
p-coumarate,440,I-ChemicalEntity
by,440,O
the,440,O
esterification,440,O
of,440,O
maltol,440,B-ChemicalEntity
and,440,O
p-coumaric,440,B-ChemicalEntity
acid,440,I-ChemicalEntity
.,440,O
In,441,O
the,441,O
present,441,O
study,441,O
",",441,O
we,441,O
investigated,441,O
whether,441,O
maltolyl,441,B-ChemicalEntity
p-coumarate,441,I-ChemicalEntity
could,441,O
improve,441,O
cognitive,441,B-DiseaseOrPhenotypicFeature
decline,441,I-DiseaseOrPhenotypicFeature
in,441,O
scopolamine-injected,441,B-ChemicalEntity
rats,441,B-OrganismTaxon
and,441,O
in,441,O
amyloid,441,B-ChemicalEntity
beta,441,I-ChemicalEntity
peptide,441,I-ChemicalEntity
(,441,I-ChemicalEntity
1-42,441,I-ChemicalEntity
),441,I-ChemicalEntity
-infused,441,O
rats,441,B-OrganismTaxon
.,441,O
Maltolyl,442,B-ChemicalEntity
p-coumarate,442,I-ChemicalEntity
was,442,O
found,442,O
to,442,O
attenuate,442,O
cognitive,442,B-DiseaseOrPhenotypicFeature
deficits,442,I-DiseaseOrPhenotypicFeature
in,442,O
both,442,O
rat,442,B-OrganismTaxon
models,442,O
using,442,O
passive,442,O
avoidance,442,O
test,442,O
and,442,O
to,442,O
reduce,442,O
apoptotic,442,O
cell,442,O
death,442,O
observed,442,O
in,442,O
the,442,O
hippocampus,442,O
of,442,O
the,442,O
amyloid,442,B-ChemicalEntity
beta,442,I-ChemicalEntity
peptide,442,I-ChemicalEntity
(,442,I-ChemicalEntity
1-42,442,I-ChemicalEntity
),442,I-ChemicalEntity
-infused,442,O
rats,442,B-OrganismTaxon
.,442,O
We,443,O
also,443,O
examined,443,O
the,443,O
neuroprotective,443,O
effects,443,O
of,443,O
maltolyl,443,B-ChemicalEntity
p-coumarate,443,I-ChemicalEntity
in,443,O
vitro,443,O
using,443,O
SH-SY5Y,443,B-CellLine
cells,443,O
.,443,O
Cells,444,O
were,444,O
pretreated,444,O
with,444,O
maltolyl,444,B-ChemicalEntity
p-coumarate,444,I-ChemicalEntity
",",444,O
before,444,O
exposed,444,O
to,444,O
amyloid,444,B-ChemicalEntity
beta,444,I-ChemicalEntity
peptide,444,I-ChemicalEntity
(,444,I-ChemicalEntity
1-42,444,I-ChemicalEntity
),444,I-ChemicalEntity
",",444,O
glutamate,444,B-ChemicalEntity
or,444,O
H2O2,444,B-ChemicalEntity
.,444,O
We,445,O
found,445,O
that,445,O
maltolyl,445,B-ChemicalEntity
p-coumarate,445,I-ChemicalEntity
significantly,445,O
decreased,445,O
apoptotic,445,O
cell,445,O
death,445,O
and,445,O
reduced,445,O
reactive,445,B-ChemicalEntity
oxygen,445,I-ChemicalEntity
species,445,I-ChemicalEntity
",",445,O
cytochrome,445,B-ChemicalEntity
c,445,I-ChemicalEntity
release,445,O
",",445,O
and,445,O
caspase,445,B-GeneOrGeneProduct
3,445,I-GeneOrGeneProduct
activation,445,O
.,445,O
Taking,446,O
these,446,O
in,446,O
vitro,446,O
and,446,O
in,446,O
vivo,446,O
results,446,O
together,446,O
",",446,O
our,446,O
study,446,O
suggests,446,O
that,446,O
maltolyl,446,B-ChemicalEntity
p-coumarate,446,I-ChemicalEntity
is,446,O
a,446,O
potentially,446,O
effective,446,O
candidate,446,O
against,446,O
Alzheimer,446,B-DiseaseOrPhenotypicFeature
's,446,I-DiseaseOrPhenotypicFeature
disease,446,I-DiseaseOrPhenotypicFeature
that,446,O
is,446,O
characterized,446,O
by,446,O
wide,446,O
spread,446,O
neuronal,446,B-DiseaseOrPhenotypicFeature
death,446,I-DiseaseOrPhenotypicFeature
and,446,O
progressive,446,O
decline,446,B-DiseaseOrPhenotypicFeature
of,446,I-DiseaseOrPhenotypicFeature
cognitive,446,I-DiseaseOrPhenotypicFeature
function,446,I-DiseaseOrPhenotypicFeature
.,446,O
Attenuation,447,O
of,447,O
methamphetamine-induced,447,B-ChemicalEntity
nigrostriatal,447,O
dopaminergic,447,B-ChemicalEntity
neurotoxicity,447,B-DiseaseOrPhenotypicFeature
in,447,O
mice,447,B-OrganismTaxon
by,447,O
lipopolysaccharide,447,B-ChemicalEntity
pretreatment,447,O
.,447,O
Immunological,448,O
activation,448,O
has,448,O
been,448,O
proposed,448,O
to,448,O
play,448,O
a,448,O
role,448,O
in,448,O
methamphetamine-induced,448,B-ChemicalEntity
dopaminergic,448,B-DiseaseOrPhenotypicFeature
terminal,448,I-DiseaseOrPhenotypicFeature
damage,448,I-DiseaseOrPhenotypicFeature
.,448,O
In,449,O
this,449,O
study,449,O
",",449,O
we,449,O
examined,449,O
the,449,O
roles,449,O
of,449,O
lipopolysaccharide,449,B-ChemicalEntity
",",449,O
a,449,O
pro-inflammatory,449,O
and,449,O
inflammatory,449,B-DiseaseOrPhenotypicFeature
factor,449,O
",",449,O
treatment,449,O
in,449,O
modulating,449,O
the,449,O
methamphetamine-induced,449,B-ChemicalEntity
nigrostriatal,449,O
dopamine,449,B-ChemicalEntity
neurotoxicity,449,B-DiseaseOrPhenotypicFeature
.,449,O
Lipopolysaccharide,450,B-ChemicalEntity
pretreatment,450,O
did,450,O
not,450,O
affect,450,O
the,450,O
basal,450,O
body,450,O
temperature,450,O
or,450,O
methamphetamine-elicited,450,B-ChemicalEntity
hyperthermia,450,B-DiseaseOrPhenotypicFeature
three,450,O
days,450,O
later,450,O
.,450,O
Such,451,O
systemic,451,O
lipopolysaccharide,451,B-ChemicalEntity
treatment,451,O
mitigated,451,O
methamphetamine-induced,451,B-ChemicalEntity
striatal,451,O
dopamine,451,B-ChemicalEntity
and,451,O
"3,4-dihydroxyphenylacetic",451,B-ChemicalEntity
acid,451,I-ChemicalEntity
depletions,451,O
in,451,O
a,451,O
dose-dependent,451,O
manner,451,O
.,451,O
As,452,O
the,452,O
most,452,O
potent,452,O
dose,452,O
(,452,O
1,452,O
mg/kg,452,O
),452,O
of,452,O
lipopolysaccharide,452,B-ChemicalEntity
was,452,O
administered,452,O
two,452,O
weeks,452,O
",",452,O
one,452,O
day,452,O
before,452,O
or,452,O
after,452,O
the,452,O
methamphetamine,452,B-ChemicalEntity
dosing,452,O
regimen,452,O
",",452,O
methamphetamine-induced,452,B-ChemicalEntity
striatal,452,O
dopamine,452,B-ChemicalEntity
and,452,O
"3,4-dihydroxyphenylacetic",452,B-ChemicalEntity
acid,452,I-ChemicalEntity
depletions,452,O
remained,452,O
unaltered,452,O
.,452,O
Moreover,453,O
",",453,O
systemic,453,O
lipopolysaccharide,453,B-ChemicalEntity
pretreatment,453,O
(,453,O
1,453,O
mg/kg,453,O
),453,O
attenuated,453,O
local,453,O
methamphetamine,453,B-ChemicalEntity
infusion-produced,453,O
dopamine,453,B-ChemicalEntity
and,453,O
"3,4-dihydroxyphenylacetic",453,B-ChemicalEntity
acid,453,I-ChemicalEntity
depletions,453,O
in,453,O
the,453,O
striatum,453,O
",",453,O
indicating,453,O
that,453,O
the,453,O
protective,453,O
effect,453,O
of,453,O
lipopolysaccharide,453,B-ChemicalEntity
is,453,O
less,453,O
likely,453,O
due,453,O
to,453,O
interrupted,453,O
peripheral,453,O
distribution,453,O
or,453,O
metabolism,453,O
of,453,O
methamphetamine,453,B-ChemicalEntity
.,453,O
We,454,O
concluded,454,O
a,454,O
critical,454,O
time,454,O
window,454,O
for,454,O
systemic,454,O
lipopolysaccharide,454,B-ChemicalEntity
pretreatment,454,O
in,454,O
exerting,454,O
effective,454,O
protection,454,O
against,454,O
methamphetamine-induced,454,B-ChemicalEntity
nigrostriatal,454,O
dopamine,454,B-ChemicalEntity
neurotoxicity,454,B-DiseaseOrPhenotypicFeature
.,454,O
Coincidence,455,O
of,455,O
mutations,455,O
in,455,O
different,455,O
connexin,455,O
genes,455,O
in,455,O
Hungarian,455,O
patients,455,B-OrganismTaxon
.,455,O
Mutations,456,O
in,456,O
the,456,O
GJB2,456,B-GeneOrGeneProduct
gene,456,O
are,456,O
the,456,O
most,456,O
common,456,O
cause,456,O
of,456,O
hereditary,456,O
prelingual,456,O
sensorineural,456,B-DiseaseOrPhenotypicFeature
hearing,456,I-DiseaseOrPhenotypicFeature
impairment,456,I-DiseaseOrPhenotypicFeature
in,456,O
Europe,456,O
.,456,O
Several,457,O
studies,457,O
indicate,457,O
that,457,O
different,457,O
members,457,O
of,457,O
the,457,O
connexin,457,O
protein,457,O
family,457,O
interact,457,O
to,457,O
form,457,O
gap,457,O
junctions,457,O
in,457,O
the,457,O
inner,457,O
ear,457,O
.,457,O
Mutations,458,O
in,458,O
different,458,O
connexin,458,O
genes,458,O
may,458,O
accumulate,458,O
and,458,O
",",458,O
consequently,458,O
lead,458,O
to,458,O
hearing,458,B-DiseaseOrPhenotypicFeature
impairment,458,I-DiseaseOrPhenotypicFeature
.,458,O
Therefore,459,O
",",459,O
we,459,O
screened,459,O
47,459,O
Hungarian,459,O
GJB2-,459,B-GeneOrGeneProduct
heterozygous,459,O
(,459,O
one,459,O
mutation,459,O
in,459,O
coding,459,O
exon,459,O
of,459,O
the,459,O
GJB2,459,B-GeneOrGeneProduct
gene,459,O
),459,O
patients,459,B-OrganismTaxon
with,459,O
hearing,459,B-DiseaseOrPhenotypicFeature
impairment,459,I-DiseaseOrPhenotypicFeature
for,459,O
DNA,459,O
changes,459,O
in,459,O
two,459,O
further,459,O
connexin,459,O
genes,459,O
(,459,O
GJB6,459,B-GeneOrGeneProduct
and,459,O
GJB3,459,B-GeneOrGeneProduct
),459,O
and,459,O
in,459,O
the,459,O
5,459,O
',459,O
non-coding,459,O
region,459,O
of,459,O
GJB2,459,B-GeneOrGeneProduct
including,459,O
the,459,O
splice,459,O
sites,459,O
.,459,O
Eleven,460,O
out,460,O
of,460,O
47,460,O
GJB2-heterozygous,460,B-GeneOrGeneProduct
patients,460,B-OrganismTaxon
analyzed,460,O
carried,460,O
the,460,O
splice,460,O
site,460,O
mutation,460,O
-3170G,460,B-SequenceVariant
>,460,I-SequenceVariant
A,460,I-SequenceVariant
in,460,O
the,460,O
5'UTR,460,O
region,460,O
of,460,O
GJB2,460,B-GeneOrGeneProduct
.,460,O
One,461,O
out,461,O
of,461,O
these,461,O
11,461,O
patients,461,B-OrganismTaxon
showed,461,O
homozygous,461,O
-3170G,461,B-SequenceVariant
>,461,I-SequenceVariant
A,461,I-SequenceVariant
genotype,461,O
in,461,O
combination,461,O
with,461,O
p.R127H,461,B-SequenceVariant
.,461,O
Next,462,O
to,462,O
the,462,O
GJB2,462,B-GeneOrGeneProduct
mutations,462,O
we,462,O
noted,462,O
2,462,O
cases,462,O
of,462,O
deletion,462,O
in,462,O
GJB6,462,B-GeneOrGeneProduct
[,462,O
Delta,462,O
(,462,O
GJB6-D13S1830,462,B-GeneOrGeneProduct
),462,O
],462,O
and,462,O
3,462,O
(,462,O
2,462,O
new,462,O
and,462,O
1,462,O
described,462,O
),462,O
base,462,O
substitutions,462,O
in,462,O
GJB3,462,B-GeneOrGeneProduct
[,462,O
c.357C,462,B-SequenceVariant
>,462,I-SequenceVariant
T,462,I-SequenceVariant
",",462,O
c.798C,462,B-SequenceVariant
>,462,I-SequenceVariant
T,462,I-SequenceVariant
and,462,O
c.94C,462,B-SequenceVariant
>,462,I-SequenceVariant
T,462,I-SequenceVariant
(,462,O
p.R32W,462,B-SequenceVariant
),462,O
],462,O
which,462,O
are,462,O
unlikely,462,O
disease-causing,462,O
.,462,O
Our,463,O
results,463,O
suggest,463,O
the,463,O
importance,463,O
of,463,O
routine,463,O
screening,463,O
for,463,O
the,463,O
rather,463,O
frequent,463,O
-3170G,463,B-SequenceVariant
>,463,I-SequenceVariant
A,463,I-SequenceVariant
mutation,463,O
(,463,O
in,463,O
addition,463,O
to,463,O
c.35delG,463,B-SequenceVariant
),463,O
in,463,O
patients,463,B-OrganismTaxon
with,463,O
hearing,463,B-DiseaseOrPhenotypicFeature
impairment,463,I-DiseaseOrPhenotypicFeature
.,463,O
Myocardial,464,O
Fas,464,B-GeneOrGeneProduct
ligand,464,I-GeneOrGeneProduct
expression,464,O
increases,464,O
susceptibility,464,O
to,464,O
AZT-induced,464,B-ChemicalEntity
cardiomyopathy,464,B-DiseaseOrPhenotypicFeature
.,464,O
BACKGROUND,465,O
:,465,O
Dilated,465,B-DiseaseOrPhenotypicFeature
cardiomyopathy,465,I-DiseaseOrPhenotypicFeature
(,465,O
DCM,465,B-DiseaseOrPhenotypicFeature
),465,O
and,465,O
myocarditis,465,B-DiseaseOrPhenotypicFeature
occur,465,O
in,465,O
many,465,O
HIV-infected,465,B-DiseaseOrPhenotypicFeature
individuals,465,O
",",465,O
resulting,465,O
in,465,O
symptomatic,465,O
heart,465,B-DiseaseOrPhenotypicFeature
failure,465,I-DiseaseOrPhenotypicFeature
in,465,O
up,465,O
to,465,O
5,465,O
%,465,O
of,465,O
patients,465,B-OrganismTaxon
.,465,O
Highly,466,O
active,466,O
antiretroviral,466,O
therapy,466,O
(,466,O
HAART,466,O
),466,O
has,466,O
significantly,466,O
reduced,466,O
morbidity,466,O
and,466,O
mortality,466,O
of,466,O
acquired,466,B-DiseaseOrPhenotypicFeature
immunodeficiency,466,I-DiseaseOrPhenotypicFeature
syndrome,466,I-DiseaseOrPhenotypicFeature
(,466,O
AIDS,466,B-DiseaseOrPhenotypicFeature
),466,O
",",466,O
but,466,O
has,466,O
resulted,466,O
in,466,O
an,466,O
increase,466,O
in,466,O
cardiac,466,B-DiseaseOrPhenotypicFeature
and,466,I-DiseaseOrPhenotypicFeature
skeletal,466,I-DiseaseOrPhenotypicFeature
myopathies,466,I-DiseaseOrPhenotypicFeature
.,466,O
METHODS,467,O
AND,467,O
RESULTS,467,O
:,467,O
In,467,O
order,467,O
to,467,O
investigate,467,O
whether,467,O
the,467,O
HAART,467,O
component,467,O
zidovudine,467,B-ChemicalEntity
(,467,O
"3'-azido-2',3'-deoxythymidine",467,B-ChemicalEntity
;,467,O
AZT,467,B-ChemicalEntity
),467,O
triggers,467,O
the,467,O
Fas-dependent,467,B-GeneOrGeneProduct
cell-death,467,O
pathway,467,O
and,467,O
cause,467,O
cytoskeletal,467,O
disruption,467,O
in,467,O
a,467,O
murine,467,B-OrganismTaxon
model,467,O
of,467,O
DCM,467,B-DiseaseOrPhenotypicFeature
",",467,O
8-week-old,467,O
transgenic,467,O
(,467,O
expressing,467,O
Fas,467,B-GeneOrGeneProduct
ligand,467,I-GeneOrGeneProduct
in,467,O
the,467,O
myocardium,467,O
:,467,O
FasL,467,B-GeneOrGeneProduct
Tg,467,O
),467,O
and,467,O
non-transgenic,467,O
(,467,O
NTg,467,O
),467,O
mice,467,B-OrganismTaxon
received,467,O
water,467,O
ad,467,O
libitum,467,O
containing,467,O
different,467,O
concentrations,467,O
of,467,O
AZT,467,B-ChemicalEntity
(,467,O
0,467,O
",",467,O
0.07,467,O
",",467,O
0.2,467,O
",",467,O
and,467,O
0.7,467,O
mg/ml,467,O
),467,O
.,467,O
After,468,O
6,468,O
weeks,468,O
",",468,O
cardiac,468,O
function,468,O
was,468,O
assessed,468,O
by,468,O
echocardiography,468,O
and,468,O
morphology,468,O
was,468,O
assessed,468,O
by,468,O
histopathologic,468,O
and,468,O
immunohistochemical,468,O
methods,468,O
.,468,O
NTg,469,O
and,469,O
untreated,469,O
FasL,469,B-GeneOrGeneProduct
Tg,469,O
mice,469,B-OrganismTaxon
showed,469,O
little,469,O
or,469,O
no,469,O
change,469,O
in,469,O
cardiac,469,O
structure,469,O
or,469,O
function,469,O
.,469,O
In,470,O
contrast,470,O
",",470,O
AZT-treated,470,B-ChemicalEntity
FasL,470,B-GeneOrGeneProduct
Tg,470,O
mice,470,B-OrganismTaxon
developed,470,O
cardiac,470,B-DiseaseOrPhenotypicFeature
dilation,470,I-DiseaseOrPhenotypicFeature
and,470,O
depressed,470,B-DiseaseOrPhenotypicFeature
cardiac,470,I-DiseaseOrPhenotypicFeature
function,470,I-DiseaseOrPhenotypicFeature
in,470,O
a,470,O
dose-dependent,470,O
manner,470,O
",",470,O
with,470,O
concomitant,470,O
inflammatory,470,B-DiseaseOrPhenotypicFeature
infiltration,470,O
of,470,O
both,470,O
ventricles,470,O
.,470,O
These,471,O
changes,471,O
were,471,O
associated,471,O
with,471,O
an,471,O
increased,471,O
sarcolemmal,471,O
expression,471,O
of,471,O
Fas,471,B-GeneOrGeneProduct
and,471,O
FasL,471,B-GeneOrGeneProduct
",",471,O
as,471,O
well,471,O
as,471,O
increased,471,O
activation,471,O
of,471,O
caspase,471,B-GeneOrGeneProduct
3,471,I-GeneOrGeneProduct
",",471,O
translocation,471,O
of,471,O
calpain,471,B-GeneOrGeneProduct
1,471,I-GeneOrGeneProduct
to,471,O
the,471,O
sarcolemma,471,O
and,471,O
sarcomere,471,O
",",471,O
and,471,O
increased,471,O
numbers,471,O
of,471,O
cells,471,O
undergoing,471,O
apoptosis,471,O
.,471,O
These,472,O
were,472,O
associated,472,O
with,472,O
changes,472,O
in,472,O
dystrophin,472,B-GeneOrGeneProduct
and,472,O
cardiac,472,B-GeneOrGeneProduct
troponin,472,I-GeneOrGeneProduct
I,472,I-GeneOrGeneProduct
localization,472,O
",",472,O
as,472,O
well,472,O
as,472,O
loss,472,O
of,472,O
sarcolemmal,472,O
integrity,472,O
.,472,O
CONCLUSIONS,473,O
:,473,O
The,473,O
expression,473,O
of,473,O
Fas,473,B-GeneOrGeneProduct
ligand,473,I-GeneOrGeneProduct
in,473,O
the,473,O
myocardium,473,O
",",473,O
as,473,O
identified,473,O
in,473,O
HIV-positive,473,B-OrganismTaxon
patients,473,B-OrganismTaxon
",",473,O
might,473,O
increase,473,O
the,473,O
susceptibility,473,O
to,473,O
HAART-induced,473,O
cardiomyopathy,473,B-DiseaseOrPhenotypicFeature
due,473,O
to,473,O
activation,473,O
of,473,O
apoptotic,473,O
pathways,473,O
",",473,O
resulting,473,O
in,473,O
cardiac,473,B-DiseaseOrPhenotypicFeature
dilation,473,I-DiseaseOrPhenotypicFeature
and,473,I-DiseaseOrPhenotypicFeature
dysfunction,473,I-DiseaseOrPhenotypicFeature
.,473,O
Skewed,474,O
X,474,O
inactivation,474,O
in,474,O
an,474,O
X,474,B-DiseaseOrPhenotypicFeature
linked,474,I-DiseaseOrPhenotypicFeature
nystagmus,474,I-DiseaseOrPhenotypicFeature
family,474,O
resulted,474,O
from,474,O
a,474,O
novel,474,O
",",474,O
p.R229G,474,B-SequenceVariant
",",474,O
missense,474,O
mutation,474,O
in,474,O
the,474,O
FRMD7,474,B-GeneOrGeneProduct
gene,474,O
.,474,O
AIMS,475,O
:,475,O
This,475,O
study,475,O
aimed,475,O
to,475,O
identify,475,O
the,475,O
underlying,475,O
genetic,475,B-DiseaseOrPhenotypicFeature
defect,475,I-DiseaseOrPhenotypicFeature
of,475,O
a,475,O
large,475,O
Turkish,475,O
X,475,B-DiseaseOrPhenotypicFeature
linked,475,I-DiseaseOrPhenotypicFeature
nystagmus,475,I-DiseaseOrPhenotypicFeature
(,475,O
NYS,475,B-DiseaseOrPhenotypicFeature
),475,O
family,475,O
.,475,O
METHODS,476,O
:,476,O
Both,476,O
Xp11,476,O
and,476,O
Xq26,476,O
loci,476,O
were,476,O
tested,476,O
by,476,O
linkage,476,O
analysis,476,O
.,476,O
The,477,O
12,477,O
exons,477,O
and,477,O
intron-exon,477,O
junctions,477,O
of,477,O
the,477,O
FRMD7,477,B-GeneOrGeneProduct
gene,477,O
were,477,O
screened,477,O
by,477,O
direct,477,O
sequencing,477,O
.,477,O
X,478,O
chromosome,478,O
inactivation,478,O
analysis,478,O
was,478,O
performed,478,O
by,478,O
enzymatic,478,O
predigestion,478,O
of,478,O
DNA,478,O
with,478,O
a,478,O
methylation-sensitive,478,O
enzyme,478,O
",",478,O
followed,478,O
by,478,O
PCR,478,O
of,478,O
the,478,O
polymorphic,478,O
CAG,478,B-SequenceVariant
repeat,478,I-SequenceVariant
of,478,O
the,478,O
androgen,478,B-GeneOrGeneProduct
receptor,478,I-GeneOrGeneProduct
gene,478,O
.,478,O
RESULTS,479,O
:,479,O
The,479,O
family,479,O
contained,479,O
162,479,O
individuals,479,O
",",479,O
among,479,O
whom,479,O
28,479,O
had,479,O
NYS,479,B-DiseaseOrPhenotypicFeature
.,479,O
Linkage,480,O
analysis,480,O
confirmed,480,O
the,480,O
Xq26,480,O
locus,480,O
.,480,O
A,481,O
novel,481,O
missense,481,O
c.686C,481,B-SequenceVariant
>,481,I-SequenceVariant
G,481,I-SequenceVariant
mutation,481,O
",",481,O
which,481,O
causes,481,O
the,481,O
substitution,481,O
of,481,O
a,481,O
conserved,481,O
arginine,481,B-SequenceVariant
at,481,I-SequenceVariant
amino,481,I-SequenceVariant
acid,481,I-SequenceVariant
position,481,I-SequenceVariant
229,481,I-SequenceVariant
by,481,I-SequenceVariant
glycine,481,I-SequenceVariant
(,481,O
p.R229G,481,B-SequenceVariant
),481,O
in,481,O
exon,481,O
8,481,O
of,481,O
the,481,O
FRMD7,481,B-GeneOrGeneProduct
gene,481,O
",",481,O
was,481,O
observed,481,O
.,481,O
This,482,O
change,482,O
was,482,O
not,482,O
documented,482,O
in,482,O
120,482,O
control,482,O
individuals,482,O
.,482,O
The,483,O
clinical,483,O
findings,483,O
in,483,O
a,483,O
female,483,O
who,483,O
was,483,O
homozygous,483,O
for,483,O
the,483,O
mutation,483,O
were,483,O
not,483,O
different,483,O
from,483,O
those,483,O
of,483,O
affected,483,O
heterozygous,483,O
females,483,O
.,483,O
Skewed,484,O
X,484,O
inactivation,484,O
was,484,O
remarkable,484,O
in,484,O
the,484,O
affected,484,O
females,484,O
of,484,O
the,484,O
family,484,O
.,484,O
CONCLUSIONS,485,O
:,485,O
A,485,O
novel,485,O
p.R229G,485,B-SequenceVariant
mutation,485,O
in,485,O
the,485,O
FRMD7,485,B-GeneOrGeneProduct
gene,485,O
causes,485,O
the,485,O
NYS,485,B-DiseaseOrPhenotypicFeature
phenotype,485,O
",",485,O
and,485,O
skewed,485,O
X,485,O
inactivation,485,O
influences,485,O
the,485,O
manifestation,485,O
of,485,O
the,485,O
disease,485,O
in,485,O
X,485,B-DiseaseOrPhenotypicFeature
linked,485,I-DiseaseOrPhenotypicFeature
NYS,485,I-DiseaseOrPhenotypicFeature
females,485,O
.,485,O
Analysis,486,O
of,486,O
-1082,486,O
IL-10,486,B-GeneOrGeneProduct
gene,486,O
polymorphism,486,O
in,486,O
Iranian,486,O
patients,486,B-OrganismTaxon
with,486,O
generalized,486,O
aggressive,486,B-DiseaseOrPhenotypicFeature
periodontitis,486,I-DiseaseOrPhenotypicFeature
.,486,O
BACKGROUND,487,O
:,487,O
Periodontitis,487,B-DiseaseOrPhenotypicFeature
is,487,O
a,487,O
multifactorial,487,O
disease,487,O
and,487,O
its,487,O
severe,487,O
forms,487,O
",",487,O
such,487,O
as,487,O
aggressive,487,B-DiseaseOrPhenotypicFeature
periodontitis,487,I-DiseaseOrPhenotypicFeature
",",487,O
are,487,O
suggested,487,O
to,487,O
have,487,O
a,487,O
genetic,487,O
basis,487,O
.,487,O
Among,488,O
the,488,O
genetic,488,O
factors,488,O
",",488,O
polymorphisms,488,O
in,488,O
cytokine,488,O
genes,488,O
have,488,O
recently,488,O
been,488,O
described,488,O
in,488,O
susceptibility,488,O
to,488,O
periodontitis,488,B-DiseaseOrPhenotypicFeature
.,488,O
IL-10,489,B-GeneOrGeneProduct
is,489,O
a,489,O
multi-functional,489,O
cytokine,489,O
thought,489,O
to,489,O
play,489,O
a,489,O
role,489,O
in,489,O
the,489,O
pathogenesis,489,O
of,489,O
periodontitis,489,B-DiseaseOrPhenotypicFeature
.,489,O
A,490,O
substitution,490,O
G/A,490,B-SequenceVariant
polymorphism,490,O
in,490,O
the,490,O
promoter,490,O
region,490,O
of,490,O
the,490,O
IL-10,490,B-GeneOrGeneProduct
gene,490,O
at,490,O
position,490,O
-1082,490,O
has,490,O
been,490,O
associated,490,O
with,490,O
different,490,O
amounts,490,O
of,490,O
IL-10,490,B-GeneOrGeneProduct
production,490,O
.,490,O
The,491,O
aim,491,O
of,491,O
the,491,O
present,491,O
study,491,O
was,491,O
to,491,O
investigate,491,O
the,491,O
possible,491,O
links,491,O
between,491,O
-1082,491,B-SequenceVariant
(,491,I-SequenceVariant
G/A,491,I-SequenceVariant
),491,I-SequenceVariant
polymorphism,491,O
of,491,O
the,491,O
IL-10,491,B-GeneOrGeneProduct
gene,491,O
and,491,O
the,491,O
generalized,491,O
form,491,O
of,491,O
aggressive,491,B-DiseaseOrPhenotypicFeature
periodontitis,491,I-DiseaseOrPhenotypicFeature
.,491,O
MATERIAL/METHODS,492,O
:,492,O
This,492,O
study,492,O
included,492,O
52,492,O
Iranian,492,O
Khorasanian,492,O
(,492,O
north-east,492,O
province,492,O
of,492,O
Iran,492,O
),492,O
subjects,492,O
suffering,492,O
from,492,O
generalized,492,O
aggressive,492,B-DiseaseOrPhenotypicFeature
periodontitis,492,I-DiseaseOrPhenotypicFeature
referred,492,O
to,492,O
the,492,O
Periodontology,492,O
Department,492,O
of,492,O
Mashhad,492,O
Dental,492,O
School,492,O
.,492,O
They,493,O
were,493,O
compared,493,O
to,493,O
61,493,O
age,493,O
and,493,O
sex-matched,493,O
healthy,493,O
controls,493,O
of,493,O
the,493,O
same,493,O
race,493,O
.,493,O
DNA,494,O
was,494,O
isolated,494,O
from,494,O
peripheral,494,O
blood,494,O
cells,494,O
and,494,O
genotyping,494,O
was,494,O
performed,494,O
by,494,O
means,494,O
of,494,O
the,494,O
amplification,494,O
refractory,494,O
mutation,494,O
system,494,O
polymerase,494,O
chain,494,O
reaction,494,O
(,494,O
ARMS-PCR,494,O
),494,O
method,494,O
.,494,O
Data,495,O
were,495,O
analyzed,495,O
using,495,O
the,495,O
chi-squared,495,O
test,495,O
.,495,O
RESULTS,496,O
:,496,O
There,496,O
was,496,O
no,496,O
marked,496,O
difference,496,O
in,496,O
genotype,496,O
frequencies,496,O
between,496,O
the,496,O
controls,496,O
and,496,O
generalized,496,O
aggressive,496,B-DiseaseOrPhenotypicFeature
periodontitis,496,I-DiseaseOrPhenotypicFeature
patients,496,B-OrganismTaxon
(,496,O
p=0.585,496,O
),496,O
.,496,O
Moreover,497,O
",",497,O
no,497,O
association,497,O
between,497,O
patients,497,B-OrganismTaxon
and,497,O
normal,497,O
subjects,497,O
was,497,O
found,497,O
in,497,O
their,497,O
allele,497,O
frequency,497,O
(,497,O
p=0.329,497,O
),497,O
.,497,O
CONCLUSIONS,498,O
:,498,O
We,498,O
conclude,498,O
that,498,O
the,498,O
polymorphic,498,O
nucleotide,498,O
A,498,B-SequenceVariant
at,498,I-SequenceVariant
position,498,I-SequenceVariant
-1082,498,I-SequenceVariant
of,498,O
the,498,O
IL-10,498,B-GeneOrGeneProduct
gene,498,O
is,498,O
not,498,O
associated,498,O
with,498,O
generalized,498,O
aggressive,498,B-DiseaseOrPhenotypicFeature
periodontitis,498,I-DiseaseOrPhenotypicFeature
in,498,O
the,498,O
Iranian,498,O
population,498,O
.,498,O
Identification,499,O
of,499,O
apolipoprotein,499,B-GeneOrGeneProduct
E,499,I-GeneOrGeneProduct
Guangzhou,499,O
(,499,O
arginine,499,B-SequenceVariant
150,499,I-SequenceVariant
proline,499,I-SequenceVariant
),499,O
",",499,O
a,499,O
new,499,O
variant,499,O
associated,499,O
with,499,O
lipoprotein,499,B-DiseaseOrPhenotypicFeature
glomerulopathy,499,I-DiseaseOrPhenotypicFeature
.,499,O
BACKGROUND/AIMS,500,O
:,500,O
Lipoprotein,500,B-DiseaseOrPhenotypicFeature
glomerulopathy,500,I-DiseaseOrPhenotypicFeature
(,500,O
LPG,500,B-DiseaseOrPhenotypicFeature
),500,O
is,500,O
a,500,O
rare,500,O
disease,500,O
characterized,500,O
by,500,O
thrombus-like,500,B-DiseaseOrPhenotypicFeature
substances,500,O
in,500,O
markedly,500,O
dilated,500,B-DiseaseOrPhenotypicFeature
glomerular,500,I-DiseaseOrPhenotypicFeature
capillaries,500,I-DiseaseOrPhenotypicFeature
and,500,O
elevated,500,O
plasma,500,O
levels,500,O
of,500,O
apolipoprotein,500,B-GeneOrGeneProduct
E,500,I-GeneOrGeneProduct
(,500,O
apoE,500,B-GeneOrGeneProduct
),500,O
.,500,O
Previous,501,O
studies,501,O
have,501,O
shown,501,O
that,501,O
genetic,501,O
disorders,501,O
of,501,O
apoE,501,B-GeneOrGeneProduct
may,501,O
contribute,501,O
to,501,O
the,501,O
pathogenesis,501,O
of,501,O
LPG,501,B-DiseaseOrPhenotypicFeature
",",501,O
but,501,O
LPG,501,B-DiseaseOrPhenotypicFeature
may,501,O
not,501,O
be,501,O
caused,501,O
by,501,O
apoE,501,B-GeneOrGeneProduct
gene,501,O
mutations,501,O
in,501,O
Chinese,501,O
patients,501,B-OrganismTaxon
.,501,O
This,502,O
study,502,O
investigated,502,O
the,502,O
association,502,O
of,502,O
a,502,O
new,502,O
variant,502,O
of,502,O
apoE,502,B-GeneOrGeneProduct
with,502,O
LPG,502,B-DiseaseOrPhenotypicFeature
in,502,O
a,502,O
Chinese,502,O
family,502,O
.,502,O
METHODS,503,O
:,503,O
The,503,O
apoE,503,B-GeneOrGeneProduct
gene,503,O
in,503,O
a,503,O
family,503,O
with,503,O
4,503,O
LPG,503,B-DiseaseOrPhenotypicFeature
patients,503,B-OrganismTaxon
was,503,O
sequenced,503,O
.,503,O
The,504,O
polymerase,504,O
chain,504,O
reaction,504,O
product,504,O
of,504,O
coding,504,O
region,504,O
of,504,O
apoE,504,B-GeneOrGeneProduct
exon,504,O
4,504,O
was,504,O
cloned,504,O
into,504,O
pMD,504,O
18-T,504,O
vector,504,O
and,504,O
then,504,O
sequenced,504,O
.,504,O
RESULTS,505,O
:,505,O
A,505,O
novel,505,O
point,505,O
mutation,505,O
in,505,O
exon,505,O
4,505,O
of,505,O
the,505,O
apoE,505,B-GeneOrGeneProduct
gene,505,O
was,505,O
identified,505,O
in,505,O
all,505,O
4,505,O
LPG,505,B-DiseaseOrPhenotypicFeature
patients,505,B-OrganismTaxon
and,505,O
1,505,O
asymptomatic,505,O
family,505,O
member,505,O
.,505,O
Sequence,506,O
analysis,506,O
confirmed,506,O
a,506,O
nucleotide,506,O
G,506,B-SequenceVariant
to,506,I-SequenceVariant
C,506,I-SequenceVariant
point,506,I-SequenceVariant
mutation,506,I-SequenceVariant
in,506,I-SequenceVariant
exon,506,I-SequenceVariant
4,506,I-SequenceVariant
(,506,I-SequenceVariant
base,506,I-SequenceVariant
308,506,I-SequenceVariant
),506,I-SequenceVariant
of,506,O
the,506,O
apoE,506,B-GeneOrGeneProduct
gene,506,O
in,506,O
all,506,O
patients,506,B-OrganismTaxon
and,506,O
the,506,O
asymptomatic,506,O
family,506,O
member,506,O
.,506,O
This,507,O
missense,507,O
mutation,507,O
denotes,507,O
amino,507,O
acid,507,O
substitution,507,O
of,507,O
the,507,O
proline,507,B-SequenceVariant
residue,507,I-SequenceVariant
for,507,I-SequenceVariant
arginine,507,I-SequenceVariant
residue,507,I-SequenceVariant
at,507,I-SequenceVariant
position,507,I-SequenceVariant
150,507,I-SequenceVariant
of,507,O
apoE,507,B-GeneOrGeneProduct
.,507,O
Those,508,O
patients,508,B-OrganismTaxon
were,508,O
all,508,O
heterozygotes,508,O
with,508,O
apoE,508,B-GeneOrGeneProduct
Guangzhou,508,O
.,508,O
One,509,O
of,509,O
2,509,O
grandsons,509,O
was,509,O
a,509,O
heterozygous,509,O
carrier,509,O
of,509,O
apoE,509,B-GeneOrGeneProduct
Guangzhou,509,O
",",509,O
although,509,O
he,509,O
did,509,O
not,509,O
have,509,O
proteinuria,509,B-DiseaseOrPhenotypicFeature
.,509,O
CONCLUSION,510,O
:,510,O
The,510,O
results,510,O
of,510,O
this,510,O
study,510,O
suggest,510,O
that,510,O
apoE,510,B-GeneOrGeneProduct
(,510,O
arginine,510,B-SequenceVariant
150,510,I-SequenceVariant
proline,510,I-SequenceVariant
),510,O
is,510,O
a,510,O
novel,510,O
apoE,510,B-GeneOrGeneProduct
variant,510,O
that,510,O
etiologically,510,O
related,510,O
to,510,O
LPG,510,B-DiseaseOrPhenotypicFeature
.,510,O
This,511,O
variant,511,O
(,511,O
apoE,511,B-GeneOrGeneProduct
Guangzhou,511,O
),511,O
may,511,O
cause,511,O
a,511,O
marked,511,O
molecular,511,O
conformational,511,O
change,511,O
of,511,O
the,511,O
apoE,511,B-GeneOrGeneProduct
and,511,O
thus,511,O
impair,511,O
its,511,O
binding,511,O
ability,511,O
to,511,O
lipids,511,B-ChemicalEntity
.,511,O
Hypothalamic,512,O
prolactin,512,B-GeneOrGeneProduct
receptor,512,I-GeneOrGeneProduct
messenger,512,O
ribonucleic,512,B-ChemicalEntity
acid,512,I-ChemicalEntity
levels,512,O
",",512,O
prolactin,512,B-GeneOrGeneProduct
signaling,512,O
",",512,O
and,512,O
hyperprolactinemic,512,B-DiseaseOrPhenotypicFeature
inhibition,512,O
of,512,O
pulsatile,512,O
luteinizing,512,B-ChemicalEntity
hormone,512,I-ChemicalEntity
secretion,512,O
are,512,O
dependent,512,O
on,512,O
estradiol,512,B-ChemicalEntity
.,512,O
Hyperprolactinemia,513,B-DiseaseOrPhenotypicFeature
can,513,O
reduce,513,O
fertility,513,O
and,513,O
libido,513,O
.,513,O
Although,514,O
central,514,O
prolactin,514,B-GeneOrGeneProduct
actions,514,O
are,514,O
thought,514,O
to,514,O
contribute,514,O
to,514,O
this,514,O
",",514,O
the,514,O
mechanisms,514,O
are,514,O
poorly,514,O
understood,514,O
.,514,O
We,515,O
first,515,O
tested,515,O
whether,515,O
chronic,515,O
hyperprolactinemia,515,B-DiseaseOrPhenotypicFeature
inhibited,515,O
two,515,O
neuroendocrine,515,O
parameters,515,O
necessary,515,O
for,515,O
female,515,O
fertility,515,O
:,515,O
pulsatile,515,O
LH,515,B-ChemicalEntity
secretion,515,O
and,515,O
the,515,O
estrogen-induced,515,B-ChemicalEntity
LH,515,B-ChemicalEntity
surge,515,O
.,515,O
Chronic,516,O
hyperprolactinemia,516,B-DiseaseOrPhenotypicFeature
induced,516,O
by,516,O
the,516,O
dopamine,516,B-ChemicalEntity
antagonist,516,O
sulpiride,516,B-ChemicalEntity
caused,516,O
a,516,O
40,516,O
%,516,O
reduction,516,O
LH,516,B-ChemicalEntity
pulse,516,O
frequency,516,O
in,516,O
ovariectomized,516,O
rats,516,B-OrganismTaxon
",",516,O
but,516,O
only,516,O
in,516,O
the,516,O
presence,516,O
of,516,O
chronic,516,O
low,516,O
levels,516,O
of,516,O
estradiol,516,B-ChemicalEntity
.,516,O
Sulpiride,517,B-ChemicalEntity
did,517,O
not,517,O
affect,517,O
the,517,O
magnitude,517,O
of,517,O
a,517,O
steroid-induced,517,B-ChemicalEntity
LH,517,B-ChemicalEntity
surge,517,O
or,517,O
the,517,O
percentage,517,O
of,517,O
GnRH,517,O
neurons,517,O
activated,517,O
during,517,O
the,517,O
surge,517,O
.,517,O
Estradiol,518,B-ChemicalEntity
is,518,O
known,518,O
to,518,O
influence,518,O
expression,518,O
of,518,O
the,518,O
long,518,O
form,518,O
of,518,O
prolactin,518,B-GeneOrGeneProduct
receptors,518,I-GeneOrGeneProduct
(,518,O
PRL-R,518,B-GeneOrGeneProduct
),518,O
and,518,O
components,518,O
of,518,O
prolactin,518,B-GeneOrGeneProduct
's,518,O
signaling,518,O
pathway,518,O
.,518,O
To,519,O
test,519,O
the,519,O
hypothesis,519,O
that,519,O
estrogen,519,B-ChemicalEntity
increases,519,O
PRL-R,519,B-GeneOrGeneProduct
expression,519,O
and,519,O
sensitivity,519,O
to,519,O
prolactin,519,B-GeneOrGeneProduct
",",519,O
we,519,O
next,519,O
demonstrated,519,O
that,519,O
estradiol,519,B-ChemicalEntity
greatly,519,O
augments,519,O
prolactin-induced,519,B-GeneOrGeneProduct
STAT5,519,B-GeneOrGeneProduct
activation,519,O
.,519,O
Lastly,520,O
",",520,O
we,520,O
measured,520,O
PRL-R,520,B-GeneOrGeneProduct
and,520,O
suppressor,520,B-GeneOrGeneProduct
of,520,I-GeneOrGeneProduct
cytokine,520,I-GeneOrGeneProduct
signaling,520,I-GeneOrGeneProduct
(,520,O
SOCS-1,520,B-GeneOrGeneProduct
and,520,I-GeneOrGeneProduct
-3,520,I-GeneOrGeneProduct
and,520,O
CIS,520,B-GeneOrGeneProduct
",",520,O
which,520,O
reflect,520,O
the,520,O
level,520,O
of,520,O
prolactin,520,B-GeneOrGeneProduct
signaling,520,O
),520,O
mRNAs,520,O
in,520,O
response,520,O
to,520,O
sulpiride,520,B-ChemicalEntity
and,520,O
estradiol,520,B-ChemicalEntity
.,520,O
Sulpiride,521,B-ChemicalEntity
induced,521,O
only,521,O
SOCS-1,521,B-GeneOrGeneProduct
in,521,O
the,521,O
medial,521,O
preoptic,521,O
area,521,O
",",521,O
where,521,O
GnRH,521,O
neurons,521,O
are,521,O
regulated,521,O
",",521,O
but,521,O
in,521,O
the,521,O
arcuate,521,O
nucleus,521,O
and,521,O
choroid,521,O
plexus,521,O
",",521,O
PRL-R,521,B-GeneOrGeneProduct
",",521,O
SOCS-3,521,B-GeneOrGeneProduct
",",521,O
and,521,O
CIS,521,B-GeneOrGeneProduct
mRNA,521,O
levels,521,O
were,521,O
also,521,O
induced,521,O
.,521,O
Estradiol,522,B-ChemicalEntity
enhanced,522,O
these,522,O
effects,522,O
on,522,O
SOCS-3,522,B-GeneOrGeneProduct
and,522,O
CIS,522,B-GeneOrGeneProduct
.,522,O
Interestingly,523,O
",",523,O
estradiol,523,B-ChemicalEntity
also,523,O
induced,523,O
PRL-R,523,B-GeneOrGeneProduct
",",523,O
SOCS-3,523,B-GeneOrGeneProduct
",",523,O
and,523,O
CIS,523,B-GeneOrGeneProduct
mRNA,523,O
levels,523,O
independently,523,O
.,523,O
These,524,O
data,524,O
show,524,O
that,524,O
GnRH,524,O
pulse,524,O
frequency,524,O
is,524,O
inhibited,524,O
by,524,O
chronic,524,O
hyperprolactinemia,524,B-DiseaseOrPhenotypicFeature
in,524,O
a,524,O
steroid-dependent,524,B-ChemicalEntity
manner,524,O
.,524,O
They,525,O
also,525,O
provide,525,O
evidence,525,O
for,525,O
estradiol-dependent,525,B-ChemicalEntity
and,525,O
brain,525,O
region-specific,525,O
regulation,525,O
of,525,O
PRL-R,525,B-GeneOrGeneProduct
expression,525,O
and,525,O
signaling,525,O
responses,525,O
by,525,O
prolactin,525,B-GeneOrGeneProduct
.,525,O
Ginsenoside,526,B-ChemicalEntity
Rg1,526,I-ChemicalEntity
restores,526,O
the,526,O
impairment,526,B-DiseaseOrPhenotypicFeature
of,526,I-DiseaseOrPhenotypicFeature
learning,526,I-DiseaseOrPhenotypicFeature
induced,526,O
by,526,O
chronic,526,O
morphine,526,B-ChemicalEntity
administration,526,O
in,526,O
rats,526,B-OrganismTaxon
.,526,O
Rg1,527,B-ChemicalEntity
",",527,O
as,527,O
a,527,O
ginsenoside,527,B-ChemicalEntity
extracted,527,O
from,527,O
Panax,527,B-OrganismTaxon
ginseng,527,I-OrganismTaxon
",",527,O
could,527,O
ameliorate,527,O
spatial,527,O
learning,527,B-DiseaseOrPhenotypicFeature
impairment,527,I-DiseaseOrPhenotypicFeature
.,527,O
Previous,528,O
studies,528,O
have,528,O
demonstrated,528,O
that,528,O
Rg1,528,B-ChemicalEntity
might,528,O
be,528,O
a,528,O
useful,528,O
agent,528,O
for,528,O
the,528,O
prevention,528,O
and,528,O
treatment,528,O
of,528,O
the,528,O
adverse,528,O
effects,528,O
of,528,O
morphine,528,B-ChemicalEntity
.,528,O
The,529,O
aim,529,O
of,529,O
this,529,O
study,529,O
was,529,O
to,529,O
investigate,529,O
the,529,O
effect,529,O
of,529,O
Rg1,529,B-ChemicalEntity
on,529,O
learning,529,B-DiseaseOrPhenotypicFeature
impairment,529,I-DiseaseOrPhenotypicFeature
by,529,O
chronic,529,O
morphine,529,B-ChemicalEntity
administration,529,O
and,529,O
the,529,O
mechanism,529,O
responsible,529,O
for,529,O
this,529,O
effect,529,O
.,529,O
Male,530,O
rats,530,B-OrganismTaxon
were,530,O
subcutaneously,530,O
injected,530,O
with,530,O
morphine,530,B-ChemicalEntity
(,530,O
10,530,O
mg/kg,530,O
),530,O
twice,530,O
a,530,O
day,530,O
at,530,O
12,530,O
hour,530,O
intervals,530,O
for,530,O
10,530,O
days,530,O
",",530,O
and,530,O
Rg1,530,B-ChemicalEntity
(,530,O
30,530,O
mg/kg,530,O
),530,O
was,530,O
intraperitoneally,530,O
injected,530,O
2,530,O
hours,530,O
after,530,O
the,530,O
second,530,O
injection,530,O
of,530,O
morphine,530,B-ChemicalEntity
once,530,O
a,530,O
day,530,O
for,530,O
10,530,O
days,530,O
.,530,O
Spatial,531,O
learning,531,O
capacity,531,O
was,531,O
assessed,531,O
in,531,O
the,531,O
Morris,531,O
water,531,O
maze,531,O
.,531,O
The,532,O
results,532,O
showed,532,O
that,532,O
rats,532,B-OrganismTaxon
treated,532,O
with,532,O
Morphine/Rg1,532,B-ChemicalEntity
decreased,532,O
escape,532,O
latency,532,O
and,532,O
increased,532,O
the,532,O
time,532,O
spent,532,O
in,532,O
platform,532,O
quadrant,532,O
and,532,O
entering,532,O
frequency,532,O
.,532,O
By,533,O
implantation,533,O
of,533,O
electrodes,533,O
and,533,O
electrophysiological,533,O
recording,533,O
in,533,O
vivo,533,O
",",533,O
the,533,O
results,533,O
showed,533,O
that,533,O
Rg1,533,B-ChemicalEntity
restored,533,O
the,533,O
long-term,533,O
potentiation,533,O
(,533,O
LTP,533,O
),533,O
impaired,533,O
by,533,O
morphine,533,B-ChemicalEntity
in,533,O
both,533,O
freely,533,O
moving,533,O
and,533,O
anaesthetised,533,O
rats,533,B-OrganismTaxon
.,533,O
The,534,O
electrophysiological,534,O
recording,534,O
in,534,O
vitro,534,O
showed,534,O
that,534,O
Rg1,534,B-ChemicalEntity
restored,534,O
the,534,O
LTP,534,O
in,534,O
slices,534,O
from,534,O
the,534,O
rats,534,B-OrganismTaxon
treated,534,O
with,534,O
morphine,534,B-ChemicalEntity
",",534,O
but,534,O
not,534,O
changed,534,O
LTP,534,O
in,534,O
the,534,O
slices,534,O
from,534,O
normal,534,O
saline-,534,O
or,534,O
morphine/Rg1-treated,534,B-ChemicalEntity
rats,534,B-OrganismTaxon
;,534,O
this,534,O
restoration,534,O
could,534,O
be,534,O
inhibited,534,O
by,534,O
N-methyl-D-aspartate,534,B-GeneOrGeneProduct
(,534,I-GeneOrGeneProduct
NMDA,534,I-GeneOrGeneProduct
),534,I-GeneOrGeneProduct
receptor,534,I-GeneOrGeneProduct
antagonist,534,O
MK801,534,B-ChemicalEntity
.,534,O
We,535,O
conclude,535,O
that,535,O
Rg1,535,B-ChemicalEntity
may,535,O
significantly,535,O
improve,535,O
the,535,O
spatial,535,O
learning,535,O
capacity,535,O
impaired,535,O
by,535,O
chonic,535,O
morphine,535,B-ChemicalEntity
administration,535,O
and,535,O
restore,535,O
the,535,O
morphine-inhibited,535,B-ChemicalEntity
LTP,535,O
.,535,O
This,536,O
effect,536,O
is,536,O
NMDA,536,B-GeneOrGeneProduct
receptor,536,I-GeneOrGeneProduct
dependent,536,O
.,536,O
Identification,537,O
of,537,O
novel,537,O
mutations,537,O
and,537,O
sequence,537,O
variants,537,O
in,537,O
the,537,O
SOX2,537,B-GeneOrGeneProduct
and,537,O
CHX10,537,B-GeneOrGeneProduct
genes,537,O
in,537,O
patients,537,B-OrganismTaxon
with,537,O
anophthalmia/microphthalmia,537,B-DiseaseOrPhenotypicFeature
.,537,O
PURPOSE,538,O
:,538,O
Mutations,538,O
in,538,O
the,538,O
SOX2,538,B-GeneOrGeneProduct
and,538,O
CHX10,538,B-GeneOrGeneProduct
genes,538,O
have,538,O
been,538,O
reported,538,O
in,538,O
patients,538,B-OrganismTaxon
with,538,O
anophthalmia,538,B-DiseaseOrPhenotypicFeature
and/or,538,O
microphthalmia,538,B-DiseaseOrPhenotypicFeature
.,538,O
In,539,O
this,539,O
study,539,O
",",539,O
we,539,O
evaluated,539,O
34,539,O
anophthalmic/microphthalmic,539,B-DiseaseOrPhenotypicFeature
patient,539,B-OrganismTaxon
DNA,539,O
samples,539,O
(,539,O
two,539,O
sets,539,O
of,539,O
siblings,539,O
included,539,O
),539,O
for,539,O
mutations,539,O
and,539,O
sequence,539,O
variants,539,O
in,539,O
SOX2,539,B-GeneOrGeneProduct
and,539,O
CHX10,539,B-GeneOrGeneProduct
.,539,O
METHODS,540,O
:,540,O
Conformational,540,O
sensitive,540,O
gel,540,O
electrophoresis,540,O
(,540,O
CSGE,540,O
),540,O
was,540,O
used,540,O
for,540,O
the,540,O
initial,540,O
SOX2,540,B-GeneOrGeneProduct
and,540,O
CHX10,540,B-GeneOrGeneProduct
screening,540,O
of,540,O
34,540,O
affected,540,O
individuals,540,O
(,540,O
two,540,O
sets,540,O
of,540,O
siblings,540,O
),540,O
",",540,O
five,540,O
unaffected,540,O
family,540,O
members,540,O
",",540,O
and,540,O
80,540,O
healthy,540,O
controls,540,O
.,540,O
Patient,541,B-OrganismTaxon
samples,541,O
containing,541,O
heteroduplexes,541,O
were,541,O
selected,541,O
for,541,O
sequence,541,O
analysis,541,O
.,541,O
Base,542,O
pair,542,O
changes,542,O
in,542,O
SOX2,542,B-GeneOrGeneProduct
and,542,O
CHX10,542,B-GeneOrGeneProduct
were,542,O
confirmed,542,O
by,542,O
sequencing,542,O
bidirectionally,542,O
in,542,O
patient,542,B-OrganismTaxon
samples,542,O
.,542,O
RESULTS,543,O
:,543,O
Two,543,O
novel,543,O
heterozygous,543,O
mutations,543,O
and,543,O
two,543,O
sequence,543,O
variants,543,O
(,543,O
one,543,O
known,543,O
),543,O
in,543,O
SOX2,543,B-GeneOrGeneProduct
were,543,O
identified,543,O
in,543,O
this,543,O
cohort,543,O
.,543,O
Mutation,544,O
c.310,544,B-SequenceVariant
G,544,I-SequenceVariant
>,544,I-SequenceVariant
T,544,I-SequenceVariant
(,544,O
p.,544,B-SequenceVariant
Glu104X,544,I-SequenceVariant
),544,O
",",544,O
found,544,O
in,544,O
one,544,O
patient,544,B-OrganismTaxon
",",544,O
was,544,O
in,544,O
the,544,O
region,544,O
encoding,544,O
the,544,O
high,544,O
mobility,544,O
group,544,O
(,544,O
HMG,544,O
),544,O
DNA-binding,544,O
domain,544,O
and,544,O
resulted,544,O
in,544,O
a,544,O
change,544,O
from,544,O
glutamic,544,B-SequenceVariant
acid,544,I-SequenceVariant
to,544,I-SequenceVariant
a,544,I-SequenceVariant
stop,544,I-SequenceVariant
codon,544,I-SequenceVariant
.,544,O
The,545,O
second,545,O
mutation,545,O
",",545,O
noted,545,O
in,545,O
two,545,O
affected,545,O
siblings,545,O
",",545,O
was,545,O
a,545,O
single,545,O
nucleotide,545,O
deletion,545,O
c.549delC,545,B-SequenceVariant
(,545,O
p.,545,B-SequenceVariant
Pro184ArgfsX19,545,I-SequenceVariant
),545,O
in,545,O
the,545,O
region,545,O
encoding,545,O
the,545,O
activation,545,O
domain,545,O
",",545,O
resulting,545,O
in,545,O
a,545,O
frameshift,545,O
and,545,O
premature,545,O
termination,545,O
of,545,O
the,545,O
coding,545,O
sequence,545,O
.,545,O
The,546,O
shortened,546,O
protein,546,O
products,546,O
may,546,O
result,546,O
in,546,O
the,546,O
loss,546,O
of,546,O
function,546,O
.,546,O
In,547,O
addition,547,O
",",547,O
a,547,O
novel,547,O
nucleotide,547,O
substitution,547,O
c.,547,B-SequenceVariant
*,547,I-SequenceVariant
557G,547,I-SequenceVariant
>,547,I-SequenceVariant
A,547,I-SequenceVariant
was,547,O
identified,547,O
in,547,O
the,547,O
3'-untranslated,547,O
region,547,O
in,547,O
one,547,O
patient,547,B-OrganismTaxon
.,547,O
The,548,O
relationship,548,O
between,548,O
the,548,O
nucleotide,548,O
change,548,O
and,548,O
the,548,O
protein,548,O
function,548,O
is,548,O
indeterminate,548,O
.,548,O
A,549,O
known,549,O
single,549,O
nucleotide,549,O
polymorphism,549,O
(,549,O
c.,549,B-SequenceVariant
*,549,I-SequenceVariant
469,549,I-SequenceVariant
C,549,I-SequenceVariant
>,549,I-SequenceVariant
A,549,I-SequenceVariant
",",549,O
SNP,549,O
rs11915160,549,B-SequenceVariant
),549,O
was,549,O
also,549,O
detected,549,O
in,549,O
2,549,O
of,549,O
the,549,O
34,549,O
patients,549,B-OrganismTaxon
.,549,O
Screening,550,O
of,550,O
CHX10,550,B-GeneOrGeneProduct
identified,550,O
two,550,O
synonymous,550,O
sequence,550,O
variants,550,O
",",550,O
c.471,550,B-SequenceVariant
C,550,I-SequenceVariant
>,550,I-SequenceVariant
T,550,I-SequenceVariant
(,550,O
p.Ser157Ser,550,B-SequenceVariant
",",550,O
rs35435463,550,B-SequenceVariant
),550,O
and,550,O
c.579,550,B-SequenceVariant
G,550,I-SequenceVariant
>,550,I-SequenceVariant
A,550,I-SequenceVariant
(,550,O
p.,550,B-SequenceVariant
Gln193Gln,550,I-SequenceVariant
",",550,O
novel,550,O
SNP,550,O
),550,O
",",550,O
and,550,O
one,550,O
non-synonymous,550,O
sequence,550,O
variant,550,O
",",550,O
c.871,550,B-SequenceVariant
G,550,I-SequenceVariant
>,550,I-SequenceVariant
A,550,I-SequenceVariant
(,550,O
p.,550,B-SequenceVariant
Asp291Asn,550,I-SequenceVariant
",",550,O
novel,550,O
SNP,550,O
),550,O
.,550,O
The,551,O
non-synonymous,551,O
polymorphism,551,O
was,551,O
also,551,O
present,551,O
in,551,O
healthy,551,O
controls,551,O
",",551,O
suggesting,551,O
non-causality,551,O
.,551,O
CONCLUSIONS,552,O
:,552,O
These,552,O
results,552,O
support,552,O
the,552,O
role,552,O
of,552,O
SOX2,552,B-GeneOrGeneProduct
in,552,O
ocular,552,O
development,552,O
.,552,O
Loss,553,O
of,553,O
SOX2,553,B-GeneOrGeneProduct
function,553,O
results,553,O
in,553,O
severe,553,O
eye,553,B-DiseaseOrPhenotypicFeature
malformation,553,I-DiseaseOrPhenotypicFeature
.,553,O
CHX10,554,B-GeneOrGeneProduct
was,554,O
not,554,O
implicated,554,O
with,554,O
microphthalmia/anophthalmia,554,B-DiseaseOrPhenotypicFeature
in,554,O
our,554,O
patient,554,B-OrganismTaxon
cohort,554,O
.,554,O
Repetitive,555,O
transcranial,555,O
magnetic,555,O
stimulation,555,O
for,555,O
levodopa-induced,555,B-ChemicalEntity
dyskinesias,555,B-DiseaseOrPhenotypicFeature
in,555,O
Parkinson,555,B-DiseaseOrPhenotypicFeature
's,555,I-DiseaseOrPhenotypicFeature
disease,555,I-DiseaseOrPhenotypicFeature
.,555,O
In,556,O
a,556,O
placebo-controlled,556,O
",",556,O
single-blinded,556,O
",",556,O
crossover,556,O
study,556,O
",",556,O
we,556,O
assessed,556,O
the,556,O
effect,556,O
of,556,O
``,556,O
real,556,O
'',556,O
repetitive,556,O
transcranial,556,O
magnetic,556,O
stimulation,556,O
(,556,O
rTMS,556,O
),556,O
versus,556,O
``,556,O
sham,556,O
'',556,O
rTMS,556,O
(,556,O
placebo,556,O
),556,O
on,556,O
peak,556,O
dose,556,O
dyskinesias,556,B-DiseaseOrPhenotypicFeature
in,556,O
patients,556,B-OrganismTaxon
with,556,O
Parkinson,556,B-DiseaseOrPhenotypicFeature
's,556,I-DiseaseOrPhenotypicFeature
disease,556,I-DiseaseOrPhenotypicFeature
(,556,O
PD,556,B-DiseaseOrPhenotypicFeature
),556,O
.,556,O
Ten,557,O
patients,557,B-OrganismTaxon
with,557,O
PD,557,B-DiseaseOrPhenotypicFeature
and,557,O
prominent,557,O
dyskinesias,557,B-DiseaseOrPhenotypicFeature
had,557,O
rTMS,557,O
(,557,O
"1,800",557,O
pulses,557,O
;,557,O
1,557,O
Hz,557,O
rate,557,O
),557,O
delivered,557,O
over,557,O
the,557,O
motor,557,O
cortex,557,O
for,557,O
4,557,O
consecutive,557,O
days,557,O
twice,557,O
",",557,O
once,557,O
real,557,O
stimuli,557,O
and,557,O
once,557,O
sham,557,O
stimulation,557,O
were,557,O
used,557,O
;,557,O
evaluations,557,O
were,557,O
done,557,O
at,557,O
the,557,O
baseline,557,O
and,557,O
1,557,O
day,557,O
after,557,O
the,557,O
end,557,O
of,557,O
each,557,O
of,557,O
the,557,O
treatment,557,O
series,557,O
.,557,O
Direct,558,O
comparison,558,O
between,558,O
sham,558,O
and,558,O
real,558,O
rTMS,558,O
effects,558,O
showed,558,O
no,558,O
significant,558,O
difference,558,O
in,558,O
clinician-assessed,558,O
dyskinesia,558,B-DiseaseOrPhenotypicFeature
severity,558,O
.,558,O
However,559,O
",",559,O
comparison,559,O
with,559,O
the,559,O
baseline,559,O
showed,559,O
small,559,O
but,559,O
significant,559,O
reduction,559,O
in,559,O
dyskinesia,559,B-DiseaseOrPhenotypicFeature
severity,559,O
following,559,O
real,559,O
rTMS,559,O
but,559,O
not,559,O
placebo,559,O
.,559,O
The,560,O
major,560,O
effect,560,O
was,560,O
on,560,O
dystonia,560,B-DiseaseOrPhenotypicFeature
subscore,560,O
.,560,O
Similarly,561,O
",",561,O
in,561,O
patient,561,B-OrganismTaxon
diaries,561,O
",",561,O
although,561,O
both,561,O
treatments,561,O
caused,561,O
reduction,561,O
in,561,O
subjective,561,O
dyskinesia,561,B-DiseaseOrPhenotypicFeature
scores,561,O
during,561,O
the,561,O
days,561,O
of,561,O
intervention,561,O
",",561,O
the,561,O
effect,561,O
was,561,O
sustained,561,O
for,561,O
3,561,O
days,561,O
after,561,O
the,561,O
intervention,561,O
for,561,O
the,561,O
real,561,O
rTMS,561,O
only,561,O
.,561,O
Following,562,O
rTMS,562,O
",",562,O
no,562,O
side,562,O
effects,562,O
and,562,O
no,562,O
adverse,562,O
effects,562,O
on,562,O
motor,562,O
function,562,O
and,562,O
PD,562,B-DiseaseOrPhenotypicFeature
symptoms,562,O
were,562,O
noted,562,O
.,562,O
The,563,O
results,563,O
suggest,563,O
the,563,O
existence,563,O
of,563,O
residual,563,O
beneficial,563,O
clinical,563,O
aftereffects,563,O
of,563,O
consecutive,563,O
daily,563,O
applications,563,O
of,563,O
low-frequency,563,O
rTMS,563,O
on,563,O
dyskinesias,563,B-DiseaseOrPhenotypicFeature
in,563,O
PD,563,B-DiseaseOrPhenotypicFeature
.,563,O
The,564,O
effects,564,O
may,564,O
be,564,O
further,564,O
exploited,564,O
for,564,O
potential,564,O
therapeutic,564,O
uses,564,O
.,564,O
Bradykinin,565,B-ChemicalEntity
receptors,565,I-ChemicalEntity
antagonists,565,I-ChemicalEntity
and,565,O
nitric,565,B-ChemicalEntity
oxide,565,I-ChemicalEntity
synthase,565,I-ChemicalEntity
inhibitors,565,I-ChemicalEntity
in,565,O
vincristine,565,B-ChemicalEntity
and,565,O
streptozotocin,565,B-ChemicalEntity
induced,565,O
hyperalgesia,565,B-DiseaseOrPhenotypicFeature
in,565,O
chemotherapy,565,O
and,565,O
diabetic,565,B-DiseaseOrPhenotypicFeature
neuropathy,565,I-DiseaseOrPhenotypicFeature
rat,565,B-OrganismTaxon
model,565,O
.,565,O
PURPOSE,566,O
:,566,O
The,566,O
influence,566,O
of,566,O
an,566,O
irreversible,566,O
inhibitor,566,O
of,566,O
constitutive,566,B-GeneOrGeneProduct
NO,566,I-GeneOrGeneProduct
synthase,566,I-GeneOrGeneProduct
(,566,O
L-NOArg,566,B-ChemicalEntity
;,566,O
1.0,566,O
mg/kg,566,O
ip,566,O
),566,O
",",566,O
a,566,O
relatively,566,O
selective,566,O
inhibitor,566,O
of,566,O
inducible,566,B-GeneOrGeneProduct
NO,566,I-GeneOrGeneProduct
synthase,566,I-GeneOrGeneProduct
(,566,O
L-NIL,566,B-ChemicalEntity
;,566,O
1.0,566,O
mg/kg,566,O
ip,566,O
),566,O
and,566,O
a,566,O
relatively,566,O
specific,566,O
inhibitor,566,O
of,566,O
neuronal,566,B-GeneOrGeneProduct
NO,566,I-GeneOrGeneProduct
synthase,566,I-GeneOrGeneProduct
(,566,O
7-NI,566,B-ChemicalEntity
;,566,O
0.1,566,O
mg/kg,566,O
ip,566,O
),566,O
",",566,O
on,566,O
antihyperalgesic,566,O
action,566,O
of,566,O
selective,566,O
antagonists,566,O
of,566,O
B2,566,B-GeneOrGeneProduct
and,566,I-GeneOrGeneProduct
B1,566,I-GeneOrGeneProduct
receptors,566,I-GeneOrGeneProduct
:,566,O
D-Arg-,566,B-ChemicalEntity
[,566,I-ChemicalEntity
Hyp3,566,I-ChemicalEntity
",",566,I-ChemicalEntity
Thi5,566,I-ChemicalEntity
",",566,I-ChemicalEntity
D-Tic7,566,I-ChemicalEntity
",",566,I-ChemicalEntity
Oic8,566,I-ChemicalEntity
],566,I-ChemicalEntity
bradykinin,566,I-ChemicalEntity
(,566,O
HOE,566,B-ChemicalEntity
140,566,I-ChemicalEntity
;,566,O
70,566,O
nmol/kg,566,O
ip,566,O
),566,O
or,566,O
des,566,B-ChemicalEntity
Arg10,566,I-ChemicalEntity
HOE,566,I-ChemicalEntity
140,566,I-ChemicalEntity
(,566,O
70,566,O
nmol/kg,566,O
ip,566,O
),566,O
respectively,566,O
",",566,O
in,566,O
model,566,O
of,566,O
diabetic,566,B-DiseaseOrPhenotypicFeature
(,566,I-DiseaseOrPhenotypicFeature
streptozotocin-induced,566,I-DiseaseOrPhenotypicFeature
),566,I-DiseaseOrPhenotypicFeature
and,566,I-DiseaseOrPhenotypicFeature
toxic,566,I-DiseaseOrPhenotypicFeature
(,566,I-DiseaseOrPhenotypicFeature
vincristine-induced,566,I-DiseaseOrPhenotypicFeature
),566,I-DiseaseOrPhenotypicFeature
neuropathy,566,I-DiseaseOrPhenotypicFeature
was,566,O
investigated,566,O
.,566,O
METHODS,567,O
:,567,O
The,567,O
changes,567,O
in,567,O
pain,567,B-DiseaseOrPhenotypicFeature
thresholds,567,O
were,567,O
determined,567,O
using,567,O
mechanical,567,O
stimuli,567,O
--,567,O
the,567,O
modification,567,O
of,567,O
the,567,O
classic,567,O
paw,567,O
withdrawal,567,O
test,567,O
described,567,O
by,567,O
Randall-Selitto,567,O
.,567,O
RESULTS,568,O
:,568,O
The,568,O
results,568,O
of,568,O
this,568,O
paper,568,O
confirm,568,O
that,568,O
inhibition,568,O
of,568,O
bradykinin,568,B-GeneOrGeneProduct
receptors,568,I-GeneOrGeneProduct
and,568,O
inducible,568,B-GeneOrGeneProduct
NO,568,I-GeneOrGeneProduct
synthase,568,I-GeneOrGeneProduct
but,568,O
not,568,O
neuronal,568,B-GeneOrGeneProduct
NO,568,I-GeneOrGeneProduct
synthase,568,I-GeneOrGeneProduct
activity,568,O
reduces,568,O
diabetic,568,B-DiseaseOrPhenotypicFeature
hyperalgesia,568,I-DiseaseOrPhenotypicFeature
.,568,O
Pretreatment,569,O
with,569,O
L-NOArg,569,B-ChemicalEntity
and,569,O
L-NIL,569,B-ChemicalEntity
but,569,O
not,569,O
7-NI,569,B-ChemicalEntity
",",569,O
significantly,569,O
increases,569,O
antihyperalgesic,569,O
activity,569,O
both,569,O
HOE,569,B-ChemicalEntity
140,569,I-ChemicalEntity
and,569,O
des,569,B-ChemicalEntity
Arg10,569,I-ChemicalEntity
HOE,569,I-ChemicalEntity
140,569,I-ChemicalEntity
.,569,O
It,570,O
was,570,O
also,570,O
shown,570,O
that,570,O
both,570,O
products,570,O
of,570,O
inducible,570,B-GeneOrGeneProduct
NO,570,I-GeneOrGeneProduct
synthase,570,I-GeneOrGeneProduct
and,570,O
neuronal,570,B-GeneOrGeneProduct
NO,570,I-GeneOrGeneProduct
synthase,570,I-GeneOrGeneProduct
activation,570,O
as,570,O
well,570,O
as,570,O
bradykinin,570,B-GeneOrGeneProduct
are,570,O
involved,570,O
in,570,O
hyperalgesia,570,B-DiseaseOrPhenotypicFeature
produced,570,O
by,570,O
vincristine,570,B-ChemicalEntity
.,570,O
Moreover,571,O
",",571,O
L-NOArg,571,B-ChemicalEntity
and,571,O
7-NI,571,B-ChemicalEntity
but,571,O
not,571,O
L-NIL,571,B-ChemicalEntity
intensify,571,O
antihyperalgesic,571,O
activity,571,O
of,571,O
HOE,571,B-ChemicalEntity
140,571,I-ChemicalEntity
or,571,O
des-Arg10HOE,571,B-ChemicalEntity
140,571,I-ChemicalEntity
in,571,O
toxic,571,B-DiseaseOrPhenotypicFeature
neuropathy,571,I-DiseaseOrPhenotypicFeature
.,571,O
CONCLUSIONS,572,O
:,572,O
Results,572,O
of,572,O
these,572,O
studies,572,O
suggest,572,O
that,572,O
B1,572,B-GeneOrGeneProduct
and,572,I-GeneOrGeneProduct
B2,572,I-GeneOrGeneProduct
receptors,572,I-GeneOrGeneProduct
are,572,O
engaged,572,O
in,572,O
transmission,572,O
of,572,O
nociceptive,572,O
stimuli,572,O
in,572,O
both,572,O
diabetic,572,B-DiseaseOrPhenotypicFeature
and,572,I-DiseaseOrPhenotypicFeature
toxic,572,I-DiseaseOrPhenotypicFeature
neuropathy,572,I-DiseaseOrPhenotypicFeature
.,572,O
In,573,O
streptozotocin-induced,573,B-ChemicalEntity
hyperalgesia,573,B-DiseaseOrPhenotypicFeature
",",573,O
inducible,573,B-GeneOrGeneProduct
NO,573,I-GeneOrGeneProduct
synthase,573,I-GeneOrGeneProduct
participates,573,O
in,573,O
pronociceptive,573,O
activity,573,O
of,573,O
bradykinin,573,B-GeneOrGeneProduct
",",573,O
whereas,573,O
in,573,O
vincristine-induced,573,B-ChemicalEntity
hyperalgesia,573,B-DiseaseOrPhenotypicFeature
bradykinin,573,B-GeneOrGeneProduct
seemed,573,O
to,573,O
activate,573,O
neuronal,573,B-GeneOrGeneProduct
NO,573,I-GeneOrGeneProduct
synthase,573,I-GeneOrGeneProduct
pathway,573,O
.,573,O
Therefore,574,O
",",574,O
concomitant,574,O
administration,574,O
of,574,O
small,574,O
doses,574,O
of,574,O
bradykinin,574,B-ChemicalEntity
receptor,574,I-ChemicalEntity
antagonists,574,I-ChemicalEntity
and,574,O
NO,574,B-ChemicalEntity
synthase,574,I-ChemicalEntity
inhibitors,574,I-ChemicalEntity
can,574,O
be,574,O
effective,574,O
in,574,O
alleviation,574,O
of,574,O
neuropathic,574,B-DiseaseOrPhenotypicFeature
pain,574,I-DiseaseOrPhenotypicFeature
",",574,O
even,574,O
in,574,O
hospital,574,O
care,574,O
.,574,O
Clusters,575,O
of,575,O
multidrug-resistant,575,O
Mycobacterium,575,B-OrganismTaxon
tuberculosis,575,I-OrganismTaxon
cases,575,O
",",575,O
Europe,575,O
.,575,O
Molecular,576,O
surveillance,576,O
of,576,O
multidrug-resistant,576,B-DiseaseOrPhenotypicFeature
tuberculosis,576,I-DiseaseOrPhenotypicFeature
(,576,O
MDR,576,B-DiseaseOrPhenotypicFeature
TB,576,I-DiseaseOrPhenotypicFeature
),576,O
was,576,O
implemented,576,O
in,576,O
Europe,576,O
as,576,O
case,576,O
reporting,576,O
in,576,O
2005,576,O
.,576,O
For,577,O
all,577,O
new,577,O
MDR,577,B-DiseaseOrPhenotypicFeature
TB,577,I-DiseaseOrPhenotypicFeature
cases,577,O
detected,577,O
from,577,O
January,577,O
2003,577,O
through,577,O
June,577,O
2007,577,O
",",577,O
countries,577,O
reported,577,O
case-based,577,O
epidemiologic,577,O
data,577,O
and,577,O
DNA,577,O
fingerprint,577,O
patterns,577,O
of,577,O
MDR,577,B-DiseaseOrPhenotypicFeature
TB,577,I-DiseaseOrPhenotypicFeature
strains,577,O
when,577,O
available,577,O
.,577,O
International,578,O
clusters,578,O
were,578,O
detected,578,O
and,578,O
analyzed,578,O
.,578,O
From,579,O
2003,579,O
through,579,O
mid-2007,579,O
in,579,O
Europe,579,O
",",579,O
"2,494",579,O
cases,579,O
of,579,O
MDR,579,B-DiseaseOrPhenotypicFeature
TB,579,I-DiseaseOrPhenotypicFeature
were,579,O
reported,579,O
from,579,O
24,579,O
European,579,O
countries,579,O
.,579,O
Epidemiologic,580,O
and,580,O
molecular,580,O
data,580,O
were,580,O
linked,580,O
for,580,O
593,580,O
(,580,O
39,580,O
%,580,O
),580,O
cases,580,O
",",580,O
and,580,O
672,580,O
insertion,580,O
sequence,580,O
6110,580,O
DNA,580,O
fingerprint,580,O
patterns,580,O
were,580,O
reported,580,O
from,580,O
19,580,O
countries,580,O
.,580,O
Of,581,O
these,581,O
patterns,581,O
",",581,O
288,581,O
(,581,O
43,581,O
%,581,O
),581,O
belonged,581,O
to,581,O
18,581,O
European,581,O
clusters,581,O
;,581,O
7,581,O
clusters,581,O
(,581,O
242/288,581,O
cases,581,O
",",581,O
84,581,O
%,581,O
),581,O
were,581,O
characterized,581,O
by,581,O
strains,581,O
of,581,O
the,581,O
Beijing,581,O
genotype,581,O
family,581,O
",",581,O
including,581,O
the,581,O
largest,581,O
cluster,581,O
(,581,O
175/288,581,O
cases,581,O
",",581,O
61,581,O
%,581,O
),581,O
.,581,O
Both,582,O
clustering,582,O
and,582,O
the,582,O
Beijing,582,O
genotype,582,O
were,582,O
associated,582,O
with,582,O
strains,582,O
originating,582,O
in,582,O
eastern,582,O
European,582,O
countries,582,O
.,582,O
Molecular,583,O
cluster,583,O
detection,583,O
contributes,583,O
to,583,O
identification,583,O
of,583,O
transmission,583,O
profile,583,O
",",583,O
risk,583,O
factors,583,O
",",583,O
and,583,O
control,583,O
measures,583,O
.,583,O
The,584,O
glycine,584,B-GeneOrGeneProduct
transporter-1,584,I-GeneOrGeneProduct
inhibitor,584,O
SSR103800,584,B-ChemicalEntity
displays,584,O
a,584,O
selective,584,O
and,584,O
specific,584,O
antipsychotic-like,584,O
profile,584,O
in,584,O
normal,584,O
and,584,O
transgenic,584,O
mice,584,B-OrganismTaxon
.,584,O
Schizophrenia,585,B-DiseaseOrPhenotypicFeature
has,585,O
been,585,O
initially,585,O
associated,585,O
with,585,O
dysfunction,585,O
in,585,O
dopamine,585,B-ChemicalEntity
neurotransmission,585,O
.,585,O
However,586,O
",",586,O
the,586,O
observation,586,O
that,586,O
antagonists,586,O
of,586,O
the,586,O
glutamate,586,B-GeneOrGeneProduct
N-methyl-D-aspartate,586,I-GeneOrGeneProduct
(,586,I-GeneOrGeneProduct
NMDA,586,I-GeneOrGeneProduct
),586,I-GeneOrGeneProduct
receptor,586,I-GeneOrGeneProduct
produce,586,O
schizophrenic-like,586,B-DiseaseOrPhenotypicFeature
symptoms,586,O
in,586,O
humans,586,B-OrganismTaxon
has,586,O
led,586,O
to,586,O
the,586,O
idea,586,O
of,586,O
a,586,O
dysfunctioning,586,O
of,586,O
the,586,O
glutamatergic,586,O
system,586,O
via,586,O
its,586,O
NMDA,586,B-GeneOrGeneProduct
receptor,586,I-GeneOrGeneProduct
.,586,O
As,587,O
a,587,O
result,587,O
",",587,O
there,587,O
is,587,O
a,587,O
growing,587,O
interest,587,O
in,587,O
the,587,O
development,587,O
of,587,O
pharmacological,587,O
agents,587,O
with,587,O
potential,587,O
antipsychotic,587,O
properties,587,O
that,587,O
enhance,587,O
the,587,O
activity,587,O
of,587,O
the,587,O
glutamatergic,587,O
system,587,O
via,587,O
a,587,O
modulation,587,O
of,587,O
the,587,O
NMDA,587,B-GeneOrGeneProduct
receptor,587,I-GeneOrGeneProduct
.,587,O
Among,588,O
them,588,O
are,588,O
glycine,588,B-GeneOrGeneProduct
transporter-1,588,I-GeneOrGeneProduct
(,588,O
GlyT1,588,B-GeneOrGeneProduct
),588,O
inhibitors,588,O
such,588,O
as,588,O
SSR103800,588,B-ChemicalEntity
",",588,O
which,588,O
indirectly,588,O
enhance,588,O
NMDA,588,B-GeneOrGeneProduct
receptor,588,I-GeneOrGeneProduct
function,588,O
by,588,O
increasing,588,O
the,588,O
glycine,588,B-ChemicalEntity
(,588,O
a,588,O
co-agonist,588,O
for,588,O
the,588,O
NMDA,588,B-GeneOrGeneProduct
receptor,588,I-GeneOrGeneProduct
),588,O
levels,588,O
in,588,O
the,588,O
synapse,588,O
.,588,O
This,589,O
study,589,O
aimed,589,O
at,589,O
investigating,589,O
the,589,O
potential,589,O
antipsychotic-like,589,O
properties,589,O
of,589,O
SSR103800,589,B-ChemicalEntity
",",589,O
with,589,O
a,589,O
particular,589,O
focus,589,O
on,589,O
models,589,O
of,589,O
hyperactivity,589,B-DiseaseOrPhenotypicFeature
",",589,O
involving,589,O
either,589,O
drug,589,O
challenge,589,O
(,589,O
ie,589,O
",",589,O
amphetamine,589,B-ChemicalEntity
and,589,O
MK-801,589,B-ChemicalEntity
),589,O
or,589,O
transgenic,589,O
mice,589,B-OrganismTaxon
(,589,O
ie,589,O
",",589,O
NMDA,589,B-GeneOrGeneProduct
Nr1,589,I-GeneOrGeneProduct
(,589,O
neo-/-,589,O
),589,O
and,589,O
DAT,589,B-GeneOrGeneProduct
(,589,O
-/-,589,O
),589,O
),589,O
.,589,O
Results,590,O
showed,590,O
that,590,O
SSR103800,590,B-ChemicalEntity
(,590,O
10-30,590,O
mg/kg,590,O
p.o,590,O
.,590,O
),590,O
blocked,591,O
hyperactivity,591,B-DiseaseOrPhenotypicFeature
induced,591,O
by,591,O
the,591,O
non-competitive,591,O
NMDA,591,B-GeneOrGeneProduct
receptor,591,I-GeneOrGeneProduct
antagonist,591,O
",",591,O
MK-801,591,B-ChemicalEntity
and,591,O
partially,591,O
reversed,591,O
spontaneous,591,O
hyperactivity,591,B-DiseaseOrPhenotypicFeature
of,591,O
NMDA,591,B-GeneOrGeneProduct
Nr1,591,I-GeneOrGeneProduct
(,591,O
neo-/-,591,O
),591,O
mice,591,B-OrganismTaxon
.,591,O
In,592,O
contrast,592,O
",",592,O
SSR103800,592,B-ChemicalEntity
failed,592,O
to,592,O
affect,592,O
hyperactivity,592,B-DiseaseOrPhenotypicFeature
induced,592,O
by,592,O
amphetamine,592,B-ChemicalEntity
or,592,O
naturally,592,O
observed,592,O
in,592,O
dopamine,592,B-GeneOrGeneProduct
transporter,592,I-GeneOrGeneProduct
(,592,O
DAT,592,B-GeneOrGeneProduct
(,592,O
-/-,592,O
),592,O
),592,O
knockout,592,O
mice,592,B-OrganismTaxon
(,592,O
10-30,592,O
mg/kg,592,O
p.o,592,O
.,592,O
),592,O
.,592,O
Importantly,593,O
",",593,O
both,593,O
classical,593,O
(,593,O
haloperidol,593,B-ChemicalEntity
),593,O
and,593,O
atypical,593,O
(,593,O
olanzapine,593,B-ChemicalEntity
",",593,O
clozapine,593,B-ChemicalEntity
and,593,O
aripiprazole,593,B-ChemicalEntity
),593,O
antipsychotics,593,O
were,593,O
effective,593,O
in,593,O
all,593,O
these,593,O
models,593,O
of,593,O
hyperactivity,593,B-DiseaseOrPhenotypicFeature
.,593,O
However,594,O
",",594,O
unlike,594,O
these,594,O
latter,594,O
",",594,O
SSR103800,594,B-ChemicalEntity
did,594,O
not,594,O
produce,594,O
catalepsy,594,B-DiseaseOrPhenotypicFeature
(,594,O
retention,594,O
on,594,O
the,594,O
bar,594,O
test,594,O
),594,O
up,594,O
to,594,O
30,594,O
mg/kg,594,O
p.o,594,O
.,594,O
Together,595,O
these,595,O
findings,595,O
show,595,O
that,595,O
the,595,O
GlyT1,595,B-GeneOrGeneProduct
inhibitor,595,O
",",595,O
SSR103800,595,B-ChemicalEntity
",",595,O
produces,595,O
antipsychotic-like,595,O
effects,595,O
",",595,O
which,595,O
differ,595,O
from,595,O
those,595,O
observed,595,O
with,595,O
compounds,595,O
primarily,595,O
targeting,595,O
the,595,O
dopaminergic,595,B-ChemicalEntity
system,595,O
",",595,O
and,595,O
has,595,O
a,595,O
reduced,595,O
side-effect,595,O
potential,595,O
as,595,O
compared,595,O
with,595,O
these,595,O
latter,595,O
drugs,595,O
.,595,O
Polymorphisms,596,O
in,596,O
the,596,O
FOXP3,596,B-GeneOrGeneProduct
gene,596,O
in,596,O
Han,596,O
Chinese,596,O
psoriasis,596,B-DiseaseOrPhenotypicFeature
patients,596,B-OrganismTaxon
.,596,O
BACKGROUND,597,O
:,597,O
Psoriasis,597,B-DiseaseOrPhenotypicFeature
is,597,O
a,597,O
common,597,O
dermatological,597,B-DiseaseOrPhenotypicFeature
disorder,597,I-DiseaseOrPhenotypicFeature
",",597,O
in,597,O
which,597,O
autoimmunity,597,O
plays,597,O
an,597,O
important,597,O
role,597,O
.,597,O
CD4,598,B-GeneOrGeneProduct
(,598,O
+,598,O
),598,O
CD25,598,B-GeneOrGeneProduct
(,598,O
+,598,O
),598,O
regulatory,598,O
T,598,O
cells,598,O
(,598,O
T-regs,598,O
),598,O
have,598,O
been,598,O
suggested,598,O
to,598,O
be,598,O
involved,598,O
in,598,O
the,598,O
pathogenesis,598,O
of,598,O
some,598,O
autoimmune,598,B-DiseaseOrPhenotypicFeature
diseases,598,I-DiseaseOrPhenotypicFeature
.,598,O
T-regs,599,O
express,599,O
the,599,O
fork,599,O
head/winged,599,O
helix,599,O
transcription,599,O
factor,599,O
",",599,O
FOXP3,599,B-GeneOrGeneProduct
",",599,O
which,599,O
appears,599,O
to,599,O
be,599,O
of,599,O
key,599,O
importance,599,O
in,599,O
the,599,O
development,599,O
and,599,O
function,599,O
of,599,O
T-regs,599,O
.,599,O
Studies,600,O
have,600,O
found,600,O
that,600,O
single-nucleotide,600,O
polymorphisms,600,O
(,600,O
SNPs,600,O
),600,O
in,600,O
the,600,O
FOXP3,600,B-GeneOrGeneProduct
gene,600,O
contribute,600,O
to,600,O
susceptibility,600,O
to,600,O
some,600,O
autoimmune,600,B-DiseaseOrPhenotypicFeature
disorders,600,I-DiseaseOrPhenotypicFeature
.,600,O
However,601,O
",",601,O
information,601,O
about,601,O
FOXP3,601,B-GeneOrGeneProduct
gene,601,O
in,601,O
psoriasis,601,B-DiseaseOrPhenotypicFeature
is,601,O
limited,601,O
.,601,O
OBJECTIVE,602,O
:,602,O
This,602,O
study,602,O
evaluated,602,O
the,602,O
association,602,O
between,602,O
FOXP3,602,B-GeneOrGeneProduct
gene,602,O
SNPs,602,O
and,602,O
susceptibility,602,O
to,602,O
psoriasis,602,B-DiseaseOrPhenotypicFeature
in,602,O
a,602,O
Han,602,O
Chinese,602,O
population,602,O
.,602,O
METHODS,603,O
:,603,O
In,603,O
a,603,O
hospital-based,603,O
case-control,603,O
study,603,O
",",603,O
524,603,O
patients,603,B-OrganismTaxon
with,603,O
psoriasis,603,B-DiseaseOrPhenotypicFeature
and,603,O
549,603,O
psoriasis-free,603,B-DiseaseOrPhenotypicFeature
controls,603,O
were,603,O
recruited,603,O
according,603,O
to,603,O
age,603,O
and,603,O
gender,603,O
.,603,O
We,604,O
investigated,604,O
four,604,O
SNPs,604,O
in,604,O
the,604,O
FOXP3,604,B-GeneOrGeneProduct
gene,604,O
(,604,O
-6054,604,B-SequenceVariant
",",604,I-SequenceVariant
deletion/ATT,604,I-SequenceVariant
;,604,O
-3279,604,B-SequenceVariant
",",604,I-SequenceVariant
A/C,604,I-SequenceVariant
;,604,O
-924,604,B-SequenceVariant
",",604,I-SequenceVariant
A/G,604,I-SequenceVariant
;,604,O
IVS9+459,604,B-SequenceVariant
",",604,I-SequenceVariant
A/G,604,I-SequenceVariant
),604,O
in,604,O
psoriatic,604,B-DiseaseOrPhenotypicFeature
patients,604,B-OrganismTaxon
",",604,O
and,604,O
assessed,604,O
allele,604,O
and,604,O
genotype,604,O
frequencies,604,O
in,604,O
psoriatic,604,B-DiseaseOrPhenotypicFeature
patients,604,B-OrganismTaxon
(,604,O
237,604,O
females,604,O
",",604,O
287,604,O
males,604,O
),604,O
and,604,O
normal,604,O
controls,604,O
(,604,O
272,604,O
females,604,O
",",604,O
277,604,O
males,604,O
),604,O
.,604,O
The,605,O
polymorphisms,605,O
were,605,O
genotyped,605,O
using,605,O
the,605,O
PCR,605,O
sequence-specific,605,O
primer,605,O
(,605,O
PCR-SSP,605,O
),605,O
technique,605,O
and,605,O
PCR-restriction,605,O
fragment,605,O
length,605,O
polymorphism,605,O
(,605,O
RFLP,605,O
),605,O
analysis,605,O
.,605,O
RESULTS,606,O
:,606,O
We,606,O
found,606,O
that,606,O
increased,606,O
risk,606,O
of,606,O
psoriasis,606,B-DiseaseOrPhenotypicFeature
was,606,O
associated,606,O
with,606,O
the,606,O
FOXP3,606,B-GeneOrGeneProduct
-3279,606,B-SequenceVariant
AC,606,I-SequenceVariant
genotype,606,O
(,606,O
adjusted,606,O
OR,606,O
",",606,O
1.32,606,O
;,606,O
95,606,O
%,606,O
CI,606,O
",",606,O
1.01-1.74,606,O
),606,O
and,606,O
the,606,O
combined,606,O
AC+AA,606,O
genotype,606,O
(,606,O
adjusted,606,O
OR,606,O
",",606,O
1.38,606,O
;,606,O
95,606,O
%,606,O
CI,606,O
",",606,O
1.07-1.78,606,O
),606,O
",",606,O
compared,606,O
with,606,O
the,606,O
-3279,606,B-SequenceVariant
CC,606,I-SequenceVariant
genotype,606,O
.,606,O
We,607,O
also,607,O
found,607,O
that,607,O
an,607,O
increased,607,O
risk,607,O
of,607,O
psoriasis,607,B-DiseaseOrPhenotypicFeature
was,607,O
associated,607,O
with,607,O
the,607,O
FOXP3,607,B-GeneOrGeneProduct
IVS9+459,607,B-SequenceVariant
GG,607,I-SequenceVariant
genotype,607,O
(,607,O
adjusted,607,O
OR,607,O
",",607,O
2.24,607,O
;,607,O
95,607,O
%,607,O
CI,607,O
",",607,O
1.41-3.58,607,O
),607,O
.,607,O
However,608,O
",",608,O
the,608,O
combined,608,O
GA+GG,608,O
genotype,608,O
showed,608,O
no,608,O
such,608,O
tendency,608,O
(,608,O
adjusted,608,O
OR=1.28,608,O
;,608,O
95,608,O
%,608,O
CI,608,O
",",608,O
1.00-1.64,608,O
),608,O
",",608,O
compared,608,O
with,608,O
the,608,O
IVS9+459,608,B-SequenceVariant
AA,608,I-SequenceVariant
genotype,608,O
.,608,O
There,609,O
was,609,O
no,609,O
evidence,609,O
of,609,O
an,609,O
increased,609,O
risk,609,O
associated,609,O
with,609,O
the,609,O
FOXP3-6054,609,B-GeneOrGeneProduct
deletion/ATT,609,I-SequenceVariant
or,609,O
FOXP3-924,609,B-GeneOrGeneProduct
A/G,609,I-SequenceVariant
genotype,609,O
.,609,O
In,610,O
combined,610,O
genotype,610,O
analyses,610,O
",",610,O
the,610,O
FOXP3-3279,610,B-GeneOrGeneProduct
AC+AA,610,I-SequenceVariant
genotype,610,O
was,610,O
more,610,O
obviously,610,O
associated,610,O
in,610,O
males,610,O
(,610,O
adjusted,610,O
OR=1.60,610,O
",",610,O
95,610,O
%,610,O
CI=1.11-2.31,610,O
),610,O
and,610,O
severe,610,O
psoriasis,610,B-DiseaseOrPhenotypicFeature
patients,610,B-OrganismTaxon
(,610,O
PASI,610,O
score,610,O
>,610,O
20,610,O
;,610,O
adjusted,610,O
OR=1.97,610,O
",",610,O
95,610,O
%,610,O
CI=1.41-2.75,610,O
),610,O
.,610,O
Meanwhile,611,O
",",611,O
the,611,O
FOXP3,611,B-GeneOrGeneProduct
IVS9+459,611,B-SequenceVariant
GA+GG,611,I-SequenceVariant
genotype,611,O
was,611,O
also,611,O
associated,611,O
with,611,O
severe,611,O
psoriasis,611,B-DiseaseOrPhenotypicFeature
patients,611,B-OrganismTaxon
(,611,O
adjusted,611,O
OR=1.69,611,O
",",611,O
95,611,O
%,611,O
CI=1.21-2.36,611,O
),611,O
.,611,O
CONCLUSIONS,612,O
:,612,O
FOXP3,612,B-GeneOrGeneProduct
polymorphisms,612,O
appear,612,O
to,612,O
contribute,612,O
to,612,O
the,612,O
risk,612,O
of,612,O
psoriasis,612,B-DiseaseOrPhenotypicFeature
in,612,O
a,612,O
Han,612,O
Chinese,612,O
population,612,O
.,612,O
Larger,613,O
studies,613,O
are,613,O
needed,613,O
to,613,O
confirm,613,O
these,613,O
findings,613,O
.,613,O
Fluoxetine,614,B-ChemicalEntity
improves,614,O
the,614,O
memory,614,B-DiseaseOrPhenotypicFeature
deficits,614,I-DiseaseOrPhenotypicFeature
caused,614,O
by,614,O
the,614,O
chemotherapy,614,O
agent,614,O
5-fluorouracil,614,B-ChemicalEntity
.,614,O
Cancer,615,B-DiseaseOrPhenotypicFeature
patients,615,B-OrganismTaxon
who,615,O
have,615,O
been,615,O
treated,615,O
with,615,O
systemic,615,O
adjuvant,615,O
chemotherapy,615,O
have,615,O
described,615,O
experiencing,615,O
deteriorations,615,O
in,615,O
cognition,615,O
.,615,O
A,616,O
widely,616,O
used,616,O
chemotherapeutic,616,O
agent,616,O
",",616,O
5-fluorouracil,616,B-ChemicalEntity
(,616,O
5-FU,616,B-ChemicalEntity
),616,O
",",616,O
readily,616,O
crosses,616,O
the,616,O
blood-brain,616,O
barrier,616,O
and,616,O
so,616,O
could,616,O
have,616,O
a,616,O
direct,616,O
effect,616,O
on,616,O
brain,616,O
function,616,O
.,616,O
In,617,O
particular,617,O
this,617,O
anti,617,O
mitotic,617,O
drug,617,O
could,617,O
reduce,617,O
cell,617,O
proliferation,617,O
in,617,O
the,617,O
neurogenic,617,O
regions,617,O
of,617,O
the,617,O
adult,617,O
brain,617,O
.,617,O
In,618,O
contrast,618,O
reports,618,O
indicate,618,O
that,618,O
hippocampal,618,O
dependent,618,O
neurogenesis,618,O
and,618,O
cognition,618,O
are,618,O
enhanced,618,O
by,618,O
the,618,O
SSRI,618,B-ChemicalEntity
antidepressant,618,O
Fluoxetine,618,B-ChemicalEntity
.,618,O
In,619,O
this,619,O
investigation,619,O
the,619,O
behavioural,619,O
effects,619,O
of,619,O
chronic,619,O
(,619,O
two,619,O
week,619,O
),619,O
treatment,619,O
with,619,O
5-FU,619,B-ChemicalEntity
and,619,O
(,619,O
three,619,O
weeks,619,O
),619,O
with,619,O
Fluoxetine,619,B-ChemicalEntity
either,619,O
separately,619,O
or,619,O
in,619,O
combination,619,O
with,619,O
5-FU,619,B-ChemicalEntity
were,619,O
tested,619,O
on,619,O
adult,619,O
Lister,619,O
hooded,619,O
rats,619,B-OrganismTaxon
.,619,O
Behavioural,620,O
effects,620,O
were,620,O
tested,620,O
using,620,O
a,620,O
context,620,O
dependent,620,O
conditioned,620,O
emotional,620,O
response,620,O
test,620,O
(,620,O
CER,620,O
),620,O
which,620,O
showed,620,O
that,620,O
animals,620,O
treated,620,O
with,620,O
5-FU,620,B-ChemicalEntity
had,620,O
a,620,O
significant,620,O
reduction,620,O
in,620,O
freezing,620,O
time,620,O
compared,620,O
to,620,O
controls,620,O
.,620,O
A,621,O
separate,621,O
group,621,O
of,621,O
animals,621,O
was,621,O
tested,621,O
using,621,O
a,621,O
hippocampal,621,O
dependent,621,O
spatial,621,O
working,621,O
memory,621,O
test,621,O
",",621,O
the,621,O
object,621,O
location,621,O
recognition,621,O
test,621,O
(,621,O
OLR,621,O
),621,O
.,621,O
Animals,622,O
treated,622,O
only,622,O
with,622,O
5-FU,622,B-ChemicalEntity
showed,622,O
significant,622,O
deficits,622,O
in,622,O
their,622,O
ability,622,O
to,622,O
carry,622,O
out,622,O
the,622,O
OLR,622,O
task,622,O
but,622,O
co,622,O
administration,622,O
of,622,O
Fluoxetine,622,B-ChemicalEntity
improved,622,O
their,622,O
performance,622,O
.,622,O
5-FU,623,B-ChemicalEntity
chemotherapy,623,O
caused,623,O
a,623,O
significant,623,O
reduction,623,O
in,623,O
the,623,O
number,623,O
of,623,O
proliferating,623,O
cells,623,O
in,623,O
the,623,O
sub,623,O
granular,623,O
zone,623,O
of,623,O
the,623,O
dentate,623,O
gyrus,623,O
compared,623,O
to,623,O
controls,623,O
.,623,O
This,624,O
reduction,624,O
was,624,O
eliminated,624,O
when,624,O
Fluoxetine,624,B-ChemicalEntity
was,624,O
co,624,O
administered,624,O
with,624,O
5-FU,624,B-ChemicalEntity
.,624,O
Fluoxetine,625,B-ChemicalEntity
on,625,O
its,625,O
own,625,O
had,625,O
no,625,O
effect,625,O
on,625,O
proliferating,625,O
cell,625,O
number,625,O
or,625,O
behaviour,625,O
.,625,O
These,626,O
findings,626,O
suggest,626,O
that,626,O
5-FU,626,B-ChemicalEntity
can,626,O
negatively,626,O
affect,626,O
both,626,O
cell,626,O
proliferation,626,O
and,626,O
hippocampal,626,O
dependent,626,O
working,626,O
memory,626,O
and,626,O
that,626,O
these,626,O
deficits,626,O
can,626,O
be,626,O
reversed,626,O
by,626,O
the,626,O
simultaneous,626,O
administration,626,O
of,626,O
the,626,O
antidepressant,626,O
Fluoxetine,626,B-ChemicalEntity
.,626,O
U87MG,627,B-CellLine
decoded,627,O
:,627,O
the,627,O
genomic,627,O
sequence,627,O
of,627,O
a,627,O
cytogenetically,627,O
aberrant,627,O
human,627,B-OrganismTaxon
cancer,627,B-DiseaseOrPhenotypicFeature
cell,627,O
line,627,O
.,627,O
U87MG,628,B-CellLine
is,628,O
a,628,O
commonly,628,O
studied,628,O
grade,628,B-DiseaseOrPhenotypicFeature
IV,628,I-DiseaseOrPhenotypicFeature
glioma,628,I-DiseaseOrPhenotypicFeature
cell,628,O
line,628,O
that,628,O
has,628,O
been,628,O
analyzed,628,O
in,628,O
at,628,O
least,628,O
"1,700",628,O
publications,628,O
over,628,O
four,628,O
decades,628,O
.,628,O
In,629,O
order,629,O
to,629,O
comprehensively,629,O
characterize,629,O
the,629,O
genome,629,O
of,629,O
this,629,O
cell,629,O
line,629,O
and,629,O
to,629,O
serve,629,O
as,629,O
a,629,O
model,629,O
of,629,O
broad,629,O
cancer,629,B-DiseaseOrPhenotypicFeature
genome,629,O
sequencing,629,O
",",629,O
we,629,O
have,629,O
generated,629,O
greater,629,O
than,629,O
30x,629,O
genomic,629,O
sequence,629,O
coverage,629,O
using,629,O
a,629,O
novel,629,O
50-base,629,O
mate,629,O
paired,629,O
strategy,629,O
with,629,O
a,629,O
1.4kb,629,O
mean,629,O
insert,629,O
library,629,O
.,629,O
A,630,O
total,630,O
of,630,O
"1,014,984,286",630,O
mate-end,630,O
and,630,O
"120,691,623",630,O
single-end,630,O
two-base,630,O
encoded,630,O
reads,630,O
were,630,O
generated,630,O
from,630,O
five,630,O
slides,630,O
.,630,O
All,631,O
data,631,O
were,631,O
aligned,631,O
using,631,O
a,631,O
custom,631,O
designed,631,O
tool,631,O
called,631,O
BFAST,631,O
",",631,O
allowing,631,O
optimal,631,O
color,631,O
space,631,O
read,631,O
alignment,631,O
and,631,O
accurate,631,O
identification,631,O
of,631,O
DNA,631,O
variants,631,O
.,631,O
The,632,O
aligned,632,O
sequence,632,O
reads,632,O
and,632,O
mate-pair,632,O
information,632,O
identified,632,O
35,632,O
interchromosomal,632,O
translocation,632,O
events,632,O
",",632,O
"1,315",632,O
structural,632,O
variations,632,O
(,632,O
>,632,O
100,632,O
bp,632,O
),632,O
",",632,O
"191,743",632,O
small,632,O
(,632,O
<,632,O
21,632,O
bp,632,O
),632,O
insertions,632,O
and,632,O
deletions,632,O
(,632,O
indels,632,O
),632,O
",",632,O
and,632,O
"2,384,470",632,O
single,632,O
nucleotide,632,O
variations,632,O
(,632,O
SNVs,632,O
),632,O
.,632,O
Among,633,O
these,633,O
observations,633,O
",",633,O
the,633,O
known,633,O
homozygous,633,O
mutation,633,O
in,633,O
PTEN,633,B-GeneOrGeneProduct
was,633,O
robustly,633,O
identified,633,O
",",633,O
and,633,O
genes,633,O
involved,633,O
in,633,O
cell,633,O
adhesion,633,O
were,633,O
overrepresented,633,O
in,633,O
the,633,O
mutated,633,O
gene,633,O
list,633,O
.,633,O
Data,634,O
were,634,O
compared,634,O
to,634,O
"219,187",634,O
heterozygous,634,O
single,634,O
nucleotide,634,O
polymorphisms,634,O
assayed,634,O
by,634,O
Illumina,634,O
1M,634,O
Duo,634,O
genotyping,634,O
array,634,O
to,634,O
assess,634,O
accuracy,634,O
:,634,O
93.83,634,O
%,634,O
of,634,O
all,634,O
SNPs,634,O
were,634,O
reliably,634,O
detected,634,O
at,634,O
filtering,634,O
thresholds,634,O
that,634,O
yield,634,O
greater,634,O
than,634,O
99.99,634,O
%,634,O
sequence,634,O
accuracy,634,O
.,634,O
Protein,635,O
coding,635,O
sequences,635,O
were,635,O
disrupted,635,O
predominantly,635,O
in,635,O
this,635,O
cancer,635,B-DiseaseOrPhenotypicFeature
cell,635,O
line,635,O
due,635,O
to,635,O
small,635,O
indels,635,O
",",635,O
large,635,O
deletions,635,O
",",635,O
and,635,O
translocations,635,O
.,635,O
In,636,O
total,636,O
",",636,O
512,636,O
genes,636,O
were,636,O
homozygously,636,O
mutated,636,O
",",636,O
including,636,O
154,636,O
by,636,O
SNVs,636,O
",",636,O
178,636,O
by,636,O
small,636,O
indels,636,O
",",636,O
145,636,O
by,636,O
large,636,O
microdeletions,636,O
",",636,O
and,636,O
35,636,O
by,636,O
interchromosomal,636,O
translocations,636,O
to,636,O
reveal,636,O
a,636,O
highly,636,O
mutated,636,O
cell,636,O
line,636,O
genome,636,O
.,636,O
Of,637,O
the,637,O
small,637,O
homozygously,637,O
mutated,637,O
variants,637,O
",",637,O
8,637,O
SNVs,637,O
and,637,O
99,637,O
indels,637,O
were,637,O
novel,637,O
events,637,O
not,637,O
present,637,O
in,637,O
dbSNP,637,O
.,637,O
These,638,O
data,638,O
demonstrate,638,O
that,638,O
routine,638,O
generation,638,O
of,638,O
broad,638,O
cancer,638,B-DiseaseOrPhenotypicFeature
genome,638,O
sequence,638,O
is,638,O
possible,638,O
outside,638,O
of,638,O
genome,638,O
centers,638,O
.,638,O
The,639,O
sequence,639,O
analysis,639,O
of,639,O
U87MG,639,B-CellLine
provides,639,O
an,639,O
unparalleled,639,O
level,639,O
of,639,O
mutational,639,O
resolution,639,O
compared,639,O
to,639,O
any,639,O
cell,639,O
line,639,O
to,639,O
date,639,O
.,639,O
Large,640,O
deletion,640,O
involving,640,O
exon,640,O
5,640,O
of,640,O
the,640,O
arylsulfatase,640,B-GeneOrGeneProduct
B,640,I-GeneOrGeneProduct
gene,640,O
caused,640,O
apparent,640,O
homozygosity,640,O
in,640,O
a,640,O
mucopolysaccharidosis,640,B-DiseaseOrPhenotypicFeature
type,640,I-DiseaseOrPhenotypicFeature
VI,640,I-DiseaseOrPhenotypicFeature
patient,640,B-OrganismTaxon
.,640,O
Apparent,641,O
homozygosity,641,O
for,641,O
the,641,O
mutation,641,O
p.R315X,641,B-SequenceVariant
present,641,O
on,641,O
exon,641,O
5,641,O
of,641,O
the,641,O
arylsulfatase,641,B-GeneOrGeneProduct
B,641,I-GeneOrGeneProduct
(,641,O
ARSB,641,B-GeneOrGeneProduct
),641,O
gene,641,O
in,641,O
a,641,O
mucopolysaccharidosis,641,B-DiseaseOrPhenotypicFeature
type,641,I-DiseaseOrPhenotypicFeature
VI,641,I-DiseaseOrPhenotypicFeature
patient,641,B-OrganismTaxon
was,641,O
solved,641,O
in,641,O
this,641,O
study,641,O
by,641,O
further,641,O
testing,641,O
for,641,O
a,641,O
second,641,O
mutation,641,O
.,641,O
Patient,642,B-OrganismTaxon
cDNA,642,O
analysis,642,O
revealed,642,O
that,642,O
the,642,O
entire,642,O
exon,642,O
5,642,O
of,642,O
the,642,O
ARSB,642,B-GeneOrGeneProduct
gene,642,O
was,642,O
lacking,642,O
;,642,O
this,642,O
new,642,O
mutation,642,O
was,642,O
identified,642,O
as,642,O
c.899-1142del,642,B-SequenceVariant
.,642,O
As,643,O
the,643,O
genomic,643,O
DNA,643,O
sequencing,643,O
excluded,643,O
the,643,O
presence,643,O
of,643,O
splicing,643,O
mutations,643,O
",",643,O
polymerase,643,O
chain,643,O
reaction,643,O
analysis,643,O
was,643,O
performed,643,O
for,643,O
polymorphisms,643,O
listed,643,O
in,643,O
the,643,O
NCBI,643,O
SNP,643,O
database,643,O
for,643,O
the,643,O
ARSB,643,B-GeneOrGeneProduct
gene,643,O
.,643,O
This,644,O
allowed,644,O
the,644,O
mutation,644,O
at,644,O
the,644,O
genomic,644,O
DNA,644,O
level,644,O
to,644,O
be,644,O
identified,644,O
as,644,O
g.99367-102002del,644,B-SequenceVariant
;,644,O
this,644,O
gross,644,O
deletion,644,O
",",644,O
involving,644,O
the,644,O
entire,644,O
exon,644,O
5,644,O
of,644,O
the,644,O
gene,644,O
and,644,O
parts,644,O
of,644,O
introns,644,O
4,644,O
and,644,O
5,644,O
led,644,O
to,644,O
a,644,O
frameshift,644,O
starting,644,O
at,644,O
amino,644,O
acid,644,O
300,644,O
and,644,O
resulting,644,O
in,644,O
a,644,O
protein,644,O
with,644,O
39,644,O
%,644,O
amino,644,O
acids,644,O
different,644,O
from,644,O
the,644,O
normal,644,O
enzyme,644,O
.,644,O
We,645,O
stress,645,O
that,645,O
extensive,645,O
DNA,645,O
analysis,645,O
needs,645,O
to,645,O
be,645,O
performed,645,O
in,645,O
case,645,O
of,645,O
apparent,645,O
homozygosity,645,O
to,645,O
avoid,645,O
potential,645,O
errors,645,O
in,645,O
genetic,645,O
counseling,645,O
.,645,O
Risk,646,O
of,646,O
nephropathy,646,B-DiseaseOrPhenotypicFeature
after,646,O
consumption,646,O
of,646,O
nonionic,646,O
contrast,646,B-ChemicalEntity
media,646,I-ChemicalEntity
by,646,O
children,646,O
undergoing,646,O
cardiac,646,O
angiography,646,O
:,646,O
a,646,O
prospective,646,O
study,646,O
.,646,O
Despite,647,O
increasing,647,O
reports,647,O
on,647,O
nonionic,647,O
contrast,647,B-ChemicalEntity
media-induced,647,O
nephropathy,647,B-DiseaseOrPhenotypicFeature
(,647,O
CIN,647,B-DiseaseOrPhenotypicFeature
),647,O
in,647,O
hospitalized,647,O
adult,647,O
patients,647,B-OrganismTaxon
during,647,O
cardiac,647,O
procedures,647,O
",",647,O
the,647,O
studies,647,O
in,647,O
pediatrics,647,O
are,647,O
limited,647,O
",",647,O
with,647,O
even,647,O
less,647,O
focus,647,O
on,647,O
possible,647,O
predisposing,647,O
factors,647,O
and,647,O
preventive,647,O
measures,647,O
for,647,O
patients,647,B-OrganismTaxon
undergoing,647,O
cardiac,647,O
angiography,647,O
.,647,O
This,648,O
prospective,648,O
study,648,O
determined,648,O
the,648,O
incidence,648,O
of,648,O
CIN,648,B-DiseaseOrPhenotypicFeature
for,648,O
two,648,O
nonionic,648,O
contrast,648,B-ChemicalEntity
media,648,I-ChemicalEntity
(,648,O
CM,648,B-ChemicalEntity
),648,O
",",648,O
iopromide,648,B-ChemicalEntity
and,648,O
iohexol,648,B-ChemicalEntity
",",648,O
among,648,O
80,648,O
patients,648,B-OrganismTaxon
younger,648,O
than,648,O
18,648,O
years,648,O
and,648,O
compared,648,O
the,648,O
rates,648,O
for,648,O
this,648,O
complication,648,O
in,648,O
relation,648,O
to,648,O
the,648,O
type,648,O
and,648,O
dosage,648,O
of,648,O
CM,648,B-ChemicalEntity
and,648,O
the,648,O
presence,648,O
of,648,O
cyanosis,648,B-DiseaseOrPhenotypicFeature
.,648,O
The,649,O
80,649,O
patients,649,B-OrganismTaxon
in,649,O
the,649,O
study,649,O
consecutively,649,O
received,649,O
either,649,O
iopromide,649,B-ChemicalEntity
(,649,O
group,649,O
A,649,O
",",649,O
n,649,O
=,649,O
40,649,O
),649,O
or,649,O
iohexol,649,B-ChemicalEntity
(,649,O
group,649,O
B,649,O
",",649,O
n,649,O
=,649,O
40,649,O
),649,O
.,649,O
Serum,650,O
sodium,650,B-ChemicalEntity
(,650,O
Na,650,B-ChemicalEntity
),650,O
",",650,O
potassium,650,B-ChemicalEntity
(,650,O
K,650,B-ChemicalEntity
),650,O
",",650,O
and,650,O
creatinine,650,B-ChemicalEntity
(,650,O
Cr,650,B-ChemicalEntity
),650,O
were,650,O
measured,650,O
24,650,O
h,650,O
before,650,O
angiography,650,O
as,650,O
baseline,650,O
values,650,O
",",650,O
then,650,O
measured,650,O
again,650,O
at,650,O
12-,650,O
",",650,O
24-,650,O
",",650,O
and,650,O
48-h,650,O
intervals,650,O
after,650,O
CM,650,B-ChemicalEntity
use,650,O
.,650,O
Urine,651,O
samples,651,O
for,651,O
Na,651,B-ChemicalEntity
and,651,O
Cr,651,B-ChemicalEntity
also,651,O
were,651,O
checked,651,O
at,651,O
the,651,O
same,651,O
intervals,651,O
.,651,O
Risk,652,O
of,652,O
renal,652,B-DiseaseOrPhenotypicFeature
failure,652,I-DiseaseOrPhenotypicFeature
",",652,O
Injury,652,B-DiseaseOrPhenotypicFeature
to,652,I-DiseaseOrPhenotypicFeature
the,652,I-DiseaseOrPhenotypicFeature
kidney,652,I-DiseaseOrPhenotypicFeature
",",652,O
Failure,652,B-DiseaseOrPhenotypicFeature
of,652,I-DiseaseOrPhenotypicFeature
kidney,652,I-DiseaseOrPhenotypicFeature
function,652,I-DiseaseOrPhenotypicFeature
",",652,O
Loss,652,B-DiseaseOrPhenotypicFeature
of,652,I-DiseaseOrPhenotypicFeature
kidney,652,I-DiseaseOrPhenotypicFeature
function,652,I-DiseaseOrPhenotypicFeature
",",652,O
and,652,O
End-stage,652,O
renal,652,B-DiseaseOrPhenotypicFeature
damage,652,I-DiseaseOrPhenotypicFeature
(,652,O
RIFLE,652,O
criteria,652,O
),652,O
were,652,O
used,652,O
to,652,O
define,652,O
CIN,652,B-DiseaseOrPhenotypicFeature
and,652,O
its,652,O
incidence,652,O
in,652,O
the,652,O
study,652,O
population,652,O
.,652,O
Accordingly,653,O
",",653,O
among,653,O
the,653,O
15,653,O
CIN,653,B-DiseaseOrPhenotypicFeature
patients,653,B-OrganismTaxon
(,653,O
18.75,653,O
%,653,O
),653,O
",",653,O
7.5,653,O
%,653,O
of,653,O
the,653,O
patients,653,B-OrganismTaxon
in,653,O
group,653,O
A,653,O
had,653,O
increased,653,O
risk,653,O
and,653,O
3.75,653,O
%,653,O
had,653,O
renal,653,B-DiseaseOrPhenotypicFeature
injury,653,I-DiseaseOrPhenotypicFeature
",",653,O
whereas,653,O
5,653,O
%,653,O
of,653,O
group,653,O
B,653,O
had,653,O
increased,653,O
risk,653,O
and,653,O
2.5,653,O
%,653,O
had,653,O
renal,653,B-DiseaseOrPhenotypicFeature
injury,653,I-DiseaseOrPhenotypicFeature
.,653,O
Whereas,654,O
33.3,654,O
%,654,O
of,654,O
the,654,O
patients,654,B-OrganismTaxon
with,654,O
CIN,654,B-DiseaseOrPhenotypicFeature
were,654,O
among,654,O
those,654,O
who,654,O
received,654,O
the,654,O
proper,654,O
dosage,654,O
of,654,O
CM,654,B-ChemicalEntity
",",654,O
the,654,O
percentage,654,O
increased,654,O
to,654,O
66.6,654,O
%,654,O
among,654,O
those,654,O
who,654,O
received,654,O
larger,654,O
doses,654,O
",",654,O
with,654,O
a,654,O
significant,654,O
difference,654,O
in,654,O
the,654,O
incidence,654,O
of,654,O
CIN,654,B-DiseaseOrPhenotypicFeature
related,654,O
to,654,O
the,654,O
different,654,O
dosages,654,O
of,654,O
CM,654,B-ChemicalEntity
(,654,O
p,654,O
=,654,O
0.014,654,O
),654,O
.,654,O
Among,655,O
the,655,O
15,655,O
patients,655,B-OrganismTaxon
with,655,O
CIN,655,B-DiseaseOrPhenotypicFeature
",",655,O
6,655,O
had,655,O
cyanotic,655,O
congenital,655,B-DiseaseOrPhenotypicFeature
heart,655,I-DiseaseOrPhenotypicFeature
diseases,655,I-DiseaseOrPhenotypicFeature
",",655,O
but,655,O
the,655,O
incidence,655,O
did,655,O
not,655,O
differ,655,O
significantly,655,O
from,655,O
that,655,O
for,655,O
the,655,O
noncyanotic,655,O
patients,655,B-OrganismTaxon
(,655,O
p,655,O
=,655,O
0.243,655,O
),655,O
.,655,O
Although,656,O
clinically,656,O
silent,656,O
",",656,O
CIN,656,B-DiseaseOrPhenotypicFeature
is,656,O
not,656,O
rare,656,O
in,656,O
pediatrics,656,O
.,656,O
The,657,O
incidence,657,O
depends,657,O
on,657,O
dosage,657,O
but,657,O
not,657,O
on,657,O
the,657,O
type,657,O
of,657,O
consumed,657,O
nonionic,657,O
CM,657,B-ChemicalEntity
",",657,O
nor,657,O
on,657,O
the,657,O
presence,657,O
of,657,O
cyanosis,657,B-DiseaseOrPhenotypicFeature
",",657,O
and,657,O
although,657,O
CIN,657,B-DiseaseOrPhenotypicFeature
usually,657,O
is,657,O
reversible,657,O
",",657,O
more,657,O
concern,657,O
is,657,O
needed,657,O
for,657,O
the,657,O
prevention,657,O
of,657,O
such,657,O
a,657,O
complication,657,O
in,657,O
children,657,O
.,657,O
Sex-differential,658,O
genetic,658,O
effect,658,O
of,658,O
phosphodiesterase,658,B-GeneOrGeneProduct
4D,658,I-GeneOrGeneProduct
(,658,O
PDE4D,658,B-GeneOrGeneProduct
),658,O
on,658,O
carotid,658,B-DiseaseOrPhenotypicFeature
atherosclerosis,658,I-DiseaseOrPhenotypicFeature
.,658,O
BACKGROUND,659,O
:,659,O
The,659,O
phosphodiesterase,659,B-GeneOrGeneProduct
4D,659,I-GeneOrGeneProduct
(,659,O
PDE4D,659,B-GeneOrGeneProduct
),659,O
gene,659,O
was,659,O
reported,659,O
as,659,O
a,659,O
susceptibility,659,O
gene,659,O
to,659,O
stroke,659,B-DiseaseOrPhenotypicFeature
.,659,O
The,660,O
genetic,660,O
effect,660,O
might,660,O
be,660,O
attributed,660,O
to,660,O
its,660,O
role,660,O
in,660,O
modulating,660,O
the,660,O
atherogenic,660,B-DiseaseOrPhenotypicFeature
process,660,O
in,660,O
the,660,O
carotid,660,O
arteries,660,O
.,660,O
Using,661,O
carotid,661,O
intima-media,661,O
thickness,661,O
(,661,O
IMT,661,O
),661,O
and,661,O
plaque,661,O
index,661,O
as,661,O
phenotypes,661,O
",",661,O
the,661,O
present,661,O
study,661,O
sought,661,O
to,661,O
determine,661,O
the,661,O
influence,661,O
of,661,O
this,661,O
gene,661,O
on,661,O
subclinical,661,O
atherosclerosis,661,B-DiseaseOrPhenotypicFeature
.,661,O
METHODS,662,O
:,662,O
Carotid,662,O
ultrasonography,662,O
was,662,O
performed,662,O
on,662,O
1013,662,O
stroke-free,662,B-DiseaseOrPhenotypicFeature
subjects,662,O
who,662,O
participated,662,O
in,662,O
the,662,O
health,662,O
screening,662,O
programs,662,O
(,662,O
age,662,O
52.6,662,O
+/-,662,O
12.2,662,O
;,662,O
47.6,662,O
%,662,O
men,662,B-OrganismTaxon
),662,O
.,662,O
Genotype,663,O
distribution,663,O
was,663,O
compared,663,O
among,663,O
the,663,O
high-risk,663,O
(,663,O
plaque,663,O
index,663,O
>,663,O
or,663,O
=,663,O
4,663,O
),663,O
",",663,O
low-risk,663,O
(,663,O
index,663,O
=,663,O
1-3,663,O
),663,O
",",663,O
and,663,O
reference,663,O
(,663,O
index,663,O
=,663,O
0,663,O
),663,O
groups,663,O
.,663,O
We,664,O
analyzed,664,O
continuous,664,O
IMT,664,O
data,664,O
and,664,O
further,664,O
dichotomized,664,O
IMT,664,O
data,664,O
using,664,O
mean,664,O
plus,664,O
one,664,O
standard,664,O
deviation,664,O
as,664,O
the,664,O
cutoff,664,O
level,664,O
.,664,O
Because,665,O
the,665,O
plaque,665,O
prevalence,665,O
and,665,O
IMT,665,O
values,665,O
displayed,665,O
a,665,O
notable,665,O
difference,665,O
between,665,O
men,665,B-OrganismTaxon
and,665,O
women,665,B-OrganismTaxon
",",665,O
we,665,O
carried,665,O
out,665,O
sex-specific,665,O
analyses,665,O
in,665,O
addition,665,O
to,665,O
analyzing,665,O
the,665,O
overall,665,O
data,665,O
.,665,O
Rs702553,666,B-SequenceVariant
at,666,O
the,666,O
PDE4D,666,B-GeneOrGeneProduct
gene,666,O
was,666,O
selected,666,O
because,666,O
it,666,O
conferred,666,O
a,666,O
risk,666,O
for,666,O
young,666,O
stroke,666,B-DiseaseOrPhenotypicFeature
in,666,O
our,666,O
previous,666,O
report,666,O
.,666,O
Previous,667,O
young,667,O
stroke,667,B-DiseaseOrPhenotypicFeature
data,667,O
(,667,O
190,667,O
cases,667,O
and,667,O
211,667,O
controls,667,O
),667,O
with,667,O
an,667,O
additional,667,O
532,667,O
control,667,O
subjects,667,O
without,667,O
ultrasonic,667,O
data,667,O
were,667,O
shown,667,O
as,667,O
a,667,O
cross-validation,667,O
for,667,O
the,667,O
genetic,667,O
effect,667,O
.,667,O
RESULTS,668,O
:,668,O
In,668,O
the,668,O
overall,668,O
analyses,668,O
",",668,O
the,668,O
rare,668,O
homozygote,668,O
of,668,O
rs702553,668,B-SequenceVariant
led,668,O
to,668,O
an,668,O
OR,668,O
of,668,O
3.1,668,O
(,668,O
p,668,O
=,668,O
0.034,668,O
),668,O
for,668,O
a,668,O
plaque,668,O
index,668,O
>,668,O
or,668,O
=,668,O
4,668,O
.,668,O
When,669,O
subjects,669,O
were,669,O
stratified,669,O
by,669,O
sex,669,O
",",669,O
the,669,O
genetic,669,O
effect,669,O
was,669,O
only,669,O
evident,669,O
in,669,O
men,669,B-OrganismTaxon
but,669,O
not,669,O
in,669,O
women,669,B-OrganismTaxon
.,669,O
Comparing,670,O
male,670,O
subjects,670,O
with,670,O
plaque,670,O
index,670,O
>,670,O
or,670,O
=,670,O
4,670,O
and,670,O
those,670,O
with,670,O
plaque,670,O
index,670,O
=,670,O
0,670,O
",",670,O
the,670,O
TT,670,O
genotype,670,O
was,670,O
over-represented,670,O
(,670,O
27.6,670,O
%,670,O
vs.,670,O
13.4,670,O
%,670,O
",",670,O
p,670,O
=,670,O
0.008,670,O
),670,O
.,670,O
For,671,O
dichotomized,671,O
IMT,671,O
data,671,O
in,671,O
men,671,B-OrganismTaxon
",",671,O
the,671,O
TT,671,O
genotype,671,O
had,671,O
an,671,O
OR,671,O
of,671,O
2.1,671,O
(,671,O
p,671,O
=,671,O
0.032,671,O
),671,O
for,671,O
a,671,O
thicker,671,O
IMT,671,O
at,671,O
the,671,O
common,671,O
carotid,671,O
artery,671,O
compared,671,O
with,671,O
the,671,O
(,671,O
AA,671,O
+,671,O
AT,671,O
),671,O
genotypes,671,O
.,671,O
In,672,O
women,672,B-OrganismTaxon
",",672,O
neither,672,O
IMT,672,O
nor,672,O
plaque,672,O
index,672,O
was,672,O
associated,672,O
with,672,O
rs702553,672,B-SequenceVariant
.,672,O
Similarly,673,O
",",673,O
SNP,673,O
rs702553,673,B-SequenceVariant
was,673,O
only,673,O
significant,673,O
in,673,O
young,673,O
stroke,673,B-DiseaseOrPhenotypicFeature
men,673,B-OrganismTaxon
(,673,O
OR,673,O
=,673,O
1.8,673,O
",",673,O
p,673,O
=,673,O
0.025,673,O
),673,O
but,673,O
not,673,O
in,673,O
women,673,B-OrganismTaxon
(,673,O
p,673,O
=,673,O
0.27,673,O
),673,O
.,673,O
CONCLUSIONS,674,O
:,674,O
The,674,O
present,674,O
study,674,O
demonstrates,674,O
a,674,O
sex-differential,674,O
effect,674,O
of,674,O
PDE4D,674,B-GeneOrGeneProduct
on,674,O
IMT,674,O
",",674,O
plaque,674,O
index,674,O
and,674,O
stroke,674,B-DiseaseOrPhenotypicFeature
",",674,O
which,674,O
highlights,674,O
its,674,O
influence,674,O
on,674,O
various,674,O
aspects,674,O
of,674,O
atherogenesis,674,B-DiseaseOrPhenotypicFeature
.,674,O
Elevation,675,O
of,675,O
ADAM10,675,B-GeneOrGeneProduct
",",675,O
ADAM17,675,B-GeneOrGeneProduct
",",675,O
MMP-2,675,B-GeneOrGeneProduct
and,675,O
MMP-9,675,B-GeneOrGeneProduct
expression,675,O
with,675,O
media,675,O
degeneration,675,O
features,675,O
CaCl2-induced,675,B-ChemicalEntity
thoracic,675,B-DiseaseOrPhenotypicFeature
aortic,675,I-DiseaseOrPhenotypicFeature
aneurysm,675,I-DiseaseOrPhenotypicFeature
in,675,O
a,675,O
rat,675,B-OrganismTaxon
model,675,O
.,675,O
PURPOSE,676,O
:,676,O
This,676,O
study,676,O
was,676,O
designed,676,O
to,676,O
establish,676,O
a,676,O
rat,676,B-OrganismTaxon
model,676,O
of,676,O
thoracic,676,B-DiseaseOrPhenotypicFeature
aortic,676,I-DiseaseOrPhenotypicFeature
aneurysm,676,I-DiseaseOrPhenotypicFeature
(,676,O
TAA,676,B-DiseaseOrPhenotypicFeature
),676,O
by,676,O
calcium,676,B-ChemicalEntity
chloride,676,I-ChemicalEntity
(,676,O
CaCl,676,B-ChemicalEntity
(,676,I-ChemicalEntity
2,676,I-ChemicalEntity
),676,I-ChemicalEntity
),676,O
-induced,676,O
arterial,676,B-DiseaseOrPhenotypicFeature
injury,676,I-DiseaseOrPhenotypicFeature
and,676,O
to,676,O
explore,676,O
the,676,O
potential,676,O
role,676,O
of,676,O
a,676,B-GeneOrGeneProduct
disintegrin,676,I-GeneOrGeneProduct
and,676,I-GeneOrGeneProduct
metalloproteinase,676,I-GeneOrGeneProduct
(,676,O
ADAM,676,B-GeneOrGeneProduct
),676,O
",",676,O
matrix,676,B-GeneOrGeneProduct
metalloproteinases,676,I-GeneOrGeneProduct
(,676,O
MMPs,676,B-GeneOrGeneProduct
),676,O
and,676,O
their,676,O
endogenous,676,O
inhibitors,676,O
(,676,O
TIMPs,676,O
),676,O
in,676,O
TAA,676,B-DiseaseOrPhenotypicFeature
formation,676,O
.,676,O
METHODS,677,O
:,677,O
Thoracic,677,O
aorta,677,O
of,677,O
male,677,O
Sprague-Dawley,677,O
rats,677,B-OrganismTaxon
was,677,O
exposed,677,O
to,677,O
0.5M,677,O
CaCl,677,B-ChemicalEntity
(,677,I-ChemicalEntity
2,677,I-ChemicalEntity
),677,I-ChemicalEntity
or,677,O
normal,677,O
saline,677,O
(,677,O
NaCl,677,B-ChemicalEntity
),677,O
.,677,O
After,678,O
12weeks,678,O
",",678,O
animals,678,O
were,678,O
euthanized,678,O
",",678,O
and,678,O
CaCl,678,B-ChemicalEntity
(,678,I-ChemicalEntity
2,678,I-ChemicalEntity
),678,I-ChemicalEntity
-treated,678,O
",",678,O
CaCl,678,B-ChemicalEntity
(,678,I-ChemicalEntity
2,678,I-ChemicalEntity
),678,I-ChemicalEntity
-untreated,678,O
(,678,O
n=12,678,O
),678,O
and,678,O
NaCl-treated,678,B-ChemicalEntity
aortic,678,O
segments,678,O
(,678,O
n=12,678,O
),678,O
were,678,O
collected,678,O
for,678,O
histological,678,O
and,678,O
molecular,678,O
assessments,678,O
.,678,O
MMP-TIMP,679,B-GeneOrGeneProduct
and,679,O
ADAM,679,B-GeneOrGeneProduct
mRNAs,679,O
were,679,O
semi-quantitatively,679,O
analyzed,679,O
and,679,O
protein,679,O
expressions,679,O
were,679,O
determined,679,O
by,679,O
immunohistochemistry,679,O
.,679,O
RESULTS,680,O
:,680,O
Despite,680,O
similar,680,O
external,680,O
diameters,680,O
among,680,O
CaCl,680,B-ChemicalEntity
(,680,I-ChemicalEntity
2,680,I-ChemicalEntity
),680,I-ChemicalEntity
-treated,680,O
",",680,O
non-CaCl,680,O
(,680,I-ChemicalEntity
2,680,I-ChemicalEntity
),680,I-ChemicalEntity
-treated,680,O
and,680,O
NaCl-treated,680,B-ChemicalEntity
segments,680,O
",",680,O
aneurymal,680,O
alteration,680,O
(,680,O
n=6,680,O
",",680,O
50,680,O
%,680,O
),680,O
",",680,O
media,680,O
degeneration,680,O
with,680,O
regional,680,O
disruption,680,O
",",680,O
fragmentation,680,O
of,680,O
elastic,680,O
fiber,680,O
",",680,O
and,680,O
increased,680,O
collagen,680,O
deposition,680,O
(,680,O
n=12,680,O
",",680,O
100,680,O
%,680,O
),680,O
were,680,O
demonstrated,680,O
in,680,O
CaCl,680,B-ChemicalEntity
(,680,I-ChemicalEntity
2,680,I-ChemicalEntity
),680,I-ChemicalEntity
-treated,680,O
segments,680,O
.,680,O
MMP-2,681,B-GeneOrGeneProduct
",",681,O
MMP-9,681,B-GeneOrGeneProduct
",",681,O
ADAM-10,681,B-GeneOrGeneProduct
and,681,O
ADAM-17,681,B-GeneOrGeneProduct
mRNA,681,O
levels,681,O
were,681,O
increased,681,O
in,681,O
CaCl,681,B-ChemicalEntity
(,681,I-ChemicalEntity
2,681,I-ChemicalEntity
),681,I-ChemicalEntity
-treated,681,O
segments,681,O
(,681,O
all,681,O
p,681,O
<,681,O
0.01,681,O
),681,O
",",681,O
with,681,O
trends,681,O
of,681,O
elevation,681,O
in,681,O
CaCl,681,B-ChemicalEntity
(,681,I-ChemicalEntity
2,681,I-ChemicalEntity
),681,I-ChemicalEntity
-untreated,681,O
segments,681,O
",",681,O
as,681,O
compared,681,O
with,681,O
NaCl-treated,681,B-ChemicalEntity
segments,681,O
.,681,O
Immunohistochemistry,682,O
displayed,682,O
significantly,682,O
increased,682,O
expressions,682,O
of,682,O
MMP-2,682,B-GeneOrGeneProduct
",",682,O
MMP-9,682,B-GeneOrGeneProduct
",",682,O
ADAM-10,682,B-GeneOrGeneProduct
and,682,O
ADAM-17,682,B-GeneOrGeneProduct
(,682,O
all,682,O
p,682,O
<,682,O
0.01,682,O
),682,O
in,682,O
intima,682,O
and,682,O
media,682,O
for,682,O
CaCl,682,B-ChemicalEntity
(,682,I-ChemicalEntity
2,682,I-ChemicalEntity
),682,I-ChemicalEntity
-treated,682,O
segments,682,O
.,682,O
TIMP,683,B-GeneOrGeneProduct
mRNA,683,O
and,683,O
tissue,683,O
levels,683,O
did,683,O
not,683,O
differ,683,O
obviously,683,O
among,683,O
the,683,O
three,683,O
aortic,683,O
segments,683,O
.,683,O
CONCLUSION,684,O
:,684,O
This,684,O
study,684,O
establishes,684,O
a,684,O
TAA,684,B-DiseaseOrPhenotypicFeature
model,684,O
by,684,O
periarterial,684,O
CaCl,684,B-ChemicalEntity
(,684,I-ChemicalEntity
2,684,I-ChemicalEntity
),684,I-ChemicalEntity
exposure,684,O
in,684,O
rats,684,B-OrganismTaxon
",",684,O
and,684,O
demonstrates,684,O
a,684,O
significant,684,O
elevation,684,O
of,684,O
expression,684,O
of,684,O
MMP-2,684,B-GeneOrGeneProduct
",",684,O
MMP-9,684,B-GeneOrGeneProduct
",",684,O
ADAM10,684,B-GeneOrGeneProduct
and,684,O
ADAM17,684,B-GeneOrGeneProduct
in,684,O
the,684,O
pathogenesis,684,O
of,684,O
vascular,684,O
remodeling,684,O
.,684,O
Lack,685,O
of,685,O
association,685,O
of,685,O
C-C,685,B-GeneOrGeneProduct
chemokine,685,I-GeneOrGeneProduct
receptor,685,I-GeneOrGeneProduct
5,685,I-GeneOrGeneProduct
DD32,685,B-SequenceVariant
deletion,685,I-SequenceVariant
status,685,O
with,685,O
rheumatoid,685,B-DiseaseOrPhenotypicFeature
arthritis,685,I-DiseaseOrPhenotypicFeature
",",685,O
systemic,685,B-DiseaseOrPhenotypicFeature
lupus,685,I-DiseaseOrPhenotypicFeature
erythematosus,685,I-DiseaseOrPhenotypicFeature
",",685,O
lupus,685,B-DiseaseOrPhenotypicFeature
nephritis,685,I-DiseaseOrPhenotypicFeature
",",685,O
and,685,O
disease,685,O
severity,685,O
.,685,O
OBJECTIVE,686,O
:,686,O
C-C,686,B-GeneOrGeneProduct
chemokine,686,I-GeneOrGeneProduct
receptor,686,I-GeneOrGeneProduct
5,686,I-GeneOrGeneProduct
(,686,O
CCR5,686,B-GeneOrGeneProduct
),686,O
plays,686,O
an,686,O
important,686,O
role,686,O
in,686,O
inflammation,686,B-DiseaseOrPhenotypicFeature
.,686,O
A,687,O
32,687,B-SequenceVariant
base-pair,687,I-SequenceVariant
(,687,I-SequenceVariant
DD32,687,I-SequenceVariant
),687,I-SequenceVariant
deletion,687,I-SequenceVariant
in,687,O
the,687,O
CCR5,687,B-GeneOrGeneProduct
gene,687,O
leads,687,O
to,687,O
a,687,O
nonfunctional,687,O
receptor,687,O
.,687,O
This,688,O
deletion,688,O
has,688,O
been,688,O
reported,688,O
to,688,O
have,688,O
a,688,O
protective,688,O
effect,688,O
on,688,O
the,688,O
development,688,O
and,688,O
progression,688,O
of,688,O
several,688,O
autoimmune,688,B-DiseaseOrPhenotypicFeature
diseases,688,I-DiseaseOrPhenotypicFeature
.,688,O
We,689,O
investigated,689,O
whether,689,O
the,689,O
DD32,689,B-SequenceVariant
deletion,689,I-SequenceVariant
is,689,O
associated,689,O
with,689,O
disease,689,O
susceptibility,689,O
in,689,O
a,689,O
population,689,O
of,689,O
patients,689,B-OrganismTaxon
with,689,O
rheumatoid,689,B-DiseaseOrPhenotypicFeature
arthritis,689,I-DiseaseOrPhenotypicFeature
(,689,O
RA,689,B-DiseaseOrPhenotypicFeature
),689,O
",",689,O
systemic,689,B-DiseaseOrPhenotypicFeature
lupus,689,I-DiseaseOrPhenotypicFeature
erythematosus,689,I-DiseaseOrPhenotypicFeature
(,689,O
SLE,689,B-DiseaseOrPhenotypicFeature
),689,O
",",689,O
and,689,O
lupus,689,B-DiseaseOrPhenotypicFeature
nephritis,689,I-DiseaseOrPhenotypicFeature
(,689,O
LN,689,B-DiseaseOrPhenotypicFeature
),689,O
;,689,O
and,689,O
whether,689,O
it,689,O
is,689,O
associated,689,O
with,689,O
disease,689,O
severity,689,O
.,689,O
METHODS,690,O
:,690,O
DNA,690,O
samples,690,O
from,690,O
405,690,O
RA,690,B-DiseaseOrPhenotypicFeature
patients,690,B-OrganismTaxon
",",690,O
97,690,O
SLE,690,B-DiseaseOrPhenotypicFeature
patients,690,B-OrganismTaxon
",",690,O
113,690,O
LN,690,B-DiseaseOrPhenotypicFeature
patients,690,B-OrganismTaxon
",",690,O
and,690,O
431,690,O
healthy,690,O
controls,690,O
were,690,O
genotyped,690,O
for,690,O
the,690,O
CCR5,690,B-GeneOrGeneProduct
DD32,690,B-SequenceVariant
deletion,690,I-SequenceVariant
.,690,O
Differences,691,O
in,691,O
genotype,691,O
frequencies,691,O
were,691,O
tested,691,O
between,691,O
patients,691,B-OrganismTaxon
and,691,O
controls,691,O
.,691,O
Association,692,O
of,692,O
genotypes,692,O
with,692,O
disease,692,O
severity,692,O
was,692,O
analyzed,692,O
.,692,O
RESULTS,693,O
:,693,O
Genotype,693,O
frequencies,693,O
of,693,O
each,693,O
group,693,O
were,693,O
in,693,O
Hardy-Weinberg,693,O
equilibrium,693,O
.,693,O
The,694,O
genotype,694,O
frequencies,694,O
of,694,O
patients,694,B-OrganismTaxon
did,694,O
not,694,O
differ,694,O
significantly,694,O
from,694,O
controls,694,O
(,694,O
CCR5/DD32,694,B-GeneOrGeneProduct
",",694,O
DD32/DD32,694,B-SequenceVariant
:,694,O
RA,694,B-DiseaseOrPhenotypicFeature
18.3,694,O
%,694,O
and,694,O
1.2,694,O
%,694,O
",",694,O
respectively,694,O
;,694,O
SLE,694,B-DiseaseOrPhenotypicFeature
17.5,694,O
%,694,O
and,694,O
2.1,694,O
%,694,O
;,694,O
LN,694,B-DiseaseOrPhenotypicFeature
13.3,694,O
%,694,O
and,694,O
1.8,694,O
%,694,O
;,694,O
controls,694,O
20.0,694,O
%,694,O
and,694,O
2.8,694,O
%,694,O
),694,O
.,694,O
However,695,O
",",695,O
there,695,O
was,695,O
a,695,O
trend,695,O
for,695,O
lower,695,O
DD32,695,B-SequenceVariant
deletion,695,I-SequenceVariant
allele,695,O
frequency,695,O
in,695,O
LN,695,B-DiseaseOrPhenotypicFeature
patients,695,B-OrganismTaxon
compared,695,O
to,695,O
controls,695,O
(,695,O
p,695,O
=,695,O
0.08,695,O
),695,O
.,695,O
There,696,O
was,696,O
no,696,O
significant,696,O
association,696,O
between,696,O
the,696,O
CCR5,696,B-GeneOrGeneProduct
status,696,O
and,696,O
disease,696,O
severity,696,O
in,696,O
RA,696,B-DiseaseOrPhenotypicFeature
",",696,O
SLE,696,B-DiseaseOrPhenotypicFeature
",",696,O
or,696,O
LN,696,B-DiseaseOrPhenotypicFeature
.,696,O
CONCLUSION,697,O
:,697,O
Although,697,O
an,697,O
association,697,O
with,697,O
LN,697,B-DiseaseOrPhenotypicFeature
can,697,O
not,697,O
be,697,O
excluded,697,O
",",697,O
the,697,O
CCR5,697,B-GeneOrGeneProduct
DD32,697,B-SequenceVariant
deletion,697,I-SequenceVariant
does,697,O
not,697,O
seem,697,O
to,697,O
be,697,O
a,697,O
disease,697,O
susceptibility,697,O
genotype,697,O
for,697,O
RA,697,B-DiseaseOrPhenotypicFeature
",",697,O
SLE,697,B-DiseaseOrPhenotypicFeature
",",697,O
or,697,O
LN,697,B-DiseaseOrPhenotypicFeature
.,697,O
No,698,O
significant,698,O
effect,698,O
of,698,O
the,698,O
DD32,698,B-SequenceVariant
deletion,698,I-SequenceVariant
on,698,O
disease,698,O
severity,698,O
was,698,O
demonstrated,698,O
.,698,O
Hepatic,699,O
but,699,O
not,699,O
brain,699,O
iron,699,B-ChemicalEntity
is,699,O
rapidly,699,O
chelated,699,O
by,699,O
deferasirox,699,B-ChemicalEntity
in,699,O
aceruloplasminemia,699,B-DiseaseOrPhenotypicFeature
due,699,O
to,699,O
a,699,O
novel,699,O
gene,699,O
mutation,699,O
.,699,O
BACKGROUND,700,O
_,700,O
#,700,O
38,700,O
;,700,O
AIMS,700,O
:,700,O
Aceruloplasminemia,700,B-DiseaseOrPhenotypicFeature
is,700,O
a,700,O
rare,700,O
autosomal,700,B-DiseaseOrPhenotypicFeature
recessive,700,I-DiseaseOrPhenotypicFeature
neurodegenerative,700,I-DiseaseOrPhenotypicFeature
disease,700,I-DiseaseOrPhenotypicFeature
associated,700,O
with,700,O
brain,700,O
and,700,O
liver,700,O
iron,700,B-ChemicalEntity
accumulation,700,O
which,700,O
typically,700,O
presents,700,O
with,700,O
movement,700,B-DiseaseOrPhenotypicFeature
disorders,700,I-DiseaseOrPhenotypicFeature
",",700,O
retinal,700,B-DiseaseOrPhenotypicFeature
degeneration,700,I-DiseaseOrPhenotypicFeature
",",700,O
and,700,O
diabetes,700,B-DiseaseOrPhenotypicFeature
mellitus,700,I-DiseaseOrPhenotypicFeature
.,700,O
Ceruloplasmin,701,B-GeneOrGeneProduct
is,701,O
a,701,O
multi-copper,701,O
ferroxidase,701,B-ChemicalEntity
that,701,O
is,701,O
secreted,701,O
into,701,O
plasma,701,O
and,701,O
facilitates,701,O
cellular,701,O
iron,701,B-ChemicalEntity
export,701,O
and,701,O
iron,701,B-ChemicalEntity
binding,701,O
to,701,O
transferrin,701,B-GeneOrGeneProduct
.,701,O
RESULTS,702,O
:,702,O
A,702,O
novel,702,O
homozygous,702,O
ceruloplasmin,702,B-GeneOrGeneProduct
gene,702,O
mutation,702,O
",",702,O
c.2554+1G,702,B-SequenceVariant
>,702,I-SequenceVariant
T,702,I-SequenceVariant
",",702,O
was,702,O
identified,702,O
as,702,O
the,702,O
cause,702,O
of,702,O
aceruloplasminemia,702,B-DiseaseOrPhenotypicFeature
in,702,O
three,702,O
affected,702,O
siblings,702,O
.,702,O
Two,703,O
siblings,703,O
presented,703,O
with,703,O
movement,703,B-DiseaseOrPhenotypicFeature
disorders,703,I-DiseaseOrPhenotypicFeature
and,703,O
diabetes,703,B-DiseaseOrPhenotypicFeature
.,703,O
Complementary,704,O
DNA,704,O
sequencing,704,O
showed,704,O
that,704,O
this,704,O
mutation,704,O
causes,704,O
skipping,704,O
of,704,O
exon,704,O
14,704,O
and,704,O
deletion,704,B-SequenceVariant
of,704,I-SequenceVariant
amino,704,I-SequenceVariant
acids,704,I-SequenceVariant
809-852,704,I-SequenceVariant
while,704,O
preserving,704,O
the,704,O
open,704,O
reading,704,O
frame,704,O
.,704,O
Western,705,O
blotting,705,O
of,705,O
liver,705,O
extracts,705,O
and,705,O
sera,705,O
of,705,O
affected,705,O
patients,705,B-OrganismTaxon
showed,705,O
retention,705,O
of,705,O
the,705,O
abnormal,705,O
protein,705,O
in,705,O
the,705,O
liver,705,O
.,705,O
Aceruloplasminemia,706,B-DiseaseOrPhenotypicFeature
was,706,O
associated,706,O
with,706,O
severe,706,O
brain,706,O
and,706,O
liver,706,O
iron,706,B-DiseaseOrPhenotypicFeature
overload,706,I-DiseaseOrPhenotypicFeature
",",706,O
where,706,O
hepatic,706,O
mRNA,706,O
expression,706,O
of,706,O
the,706,O
iron,706,B-ChemicalEntity
hormone,706,O
hepcidin,706,B-GeneOrGeneProduct
was,706,O
increased,706,O
",",706,O
corresponding,706,O
to,706,O
the,706,O
degree,706,O
of,706,O
iron,706,B-DiseaseOrPhenotypicFeature
overload,706,I-DiseaseOrPhenotypicFeature
.,706,O
Hepatic,707,O
iron,707,B-ChemicalEntity
concentration,707,O
normalized,707,O
after,707,O
3,707,O
and,707,O
5months,707,O
of,707,O
iron,707,B-ChemicalEntity
chelation,707,O
therapy,707,O
with,707,O
deferasirox,707,B-ChemicalEntity
",",707,O
which,707,O
was,707,O
also,707,O
associated,707,O
with,707,O
reduced,707,O
insulin,707,B-GeneOrGeneProduct
demands,707,O
.,707,O
During,708,O
short,708,O
term,708,O
treatment,708,O
there,708,O
was,708,O
no,708,O
clinical,708,O
or,708,O
imaging,708,O
evidence,708,O
for,708,O
significant,708,O
effects,708,O
on,708,O
brain,708,O
iron,708,B-DiseaseOrPhenotypicFeature
overload,708,I-DiseaseOrPhenotypicFeature
.,708,O
CONCLUSIONS,709,O
:,709,O
Aceruloplasminemia,709,B-DiseaseOrPhenotypicFeature
can,709,O
show,709,O
an,709,O
incomplete,709,O
clinical,709,O
penetrance,709,O
but,709,O
is,709,O
invariably,709,O
associated,709,O
with,709,O
iron,709,B-ChemicalEntity
accumulation,709,O
in,709,O
the,709,O
liver,709,O
and,709,O
in,709,O
the,709,O
brain,709,O
.,709,O
Iron,710,B-ChemicalEntity
accumulation,710,O
in,710,O
aceruloplasminemia,710,B-DiseaseOrPhenotypicFeature
is,710,O
a,710,O
result,710,O
of,710,O
defective,710,O
cellular,710,O
iron,710,B-ChemicalEntity
export,710,O
",",710,O
where,710,O
hepcidin,710,B-GeneOrGeneProduct
regulation,710,O
is,710,O
appropriate,710,O
for,710,O
the,710,O
degree,710,O
of,710,O
iron,710,B-DiseaseOrPhenotypicFeature
overload,710,I-DiseaseOrPhenotypicFeature
.,710,O
Iron,711,B-ChemicalEntity
chelation,711,O
with,711,O
deferasirox,711,B-ChemicalEntity
was,711,O
effective,711,O
in,711,O
mobilizing,711,O
hepatic,711,O
iron,711,B-ChemicalEntity
but,711,O
has,711,O
no,711,O
effect,711,O
on,711,O
brain,711,O
iron,711,B-ChemicalEntity
.,711,O
Syncope,712,B-DiseaseOrPhenotypicFeature
caused,712,O
by,712,O
hyperkalemia,712,B-DiseaseOrPhenotypicFeature
during,712,O
use,712,O
of,712,O
a,712,O
combined,712,O
therapy,712,O
with,712,O
the,712,O
angiotensin-converting,712,B-ChemicalEntity
enzyme,712,I-ChemicalEntity
inhibitor,712,I-ChemicalEntity
and,712,O
spironolactone,712,B-ChemicalEntity
.,712,O
A,713,O
76,713,O
year-old,713,O
woman,713,B-OrganismTaxon
with,713,O
a,713,O
history,713,O
of,713,O
coronary,713,O
artery,713,O
bypass,713,O
grafting,713,O
and,713,O
prior,713,O
myocardial,713,B-DiseaseOrPhenotypicFeature
infarction,713,I-DiseaseOrPhenotypicFeature
was,713,O
transferred,713,O
to,713,O
the,713,O
emergency,713,O
room,713,O
with,713,O
loss,713,B-DiseaseOrPhenotypicFeature
of,713,I-DiseaseOrPhenotypicFeature
consciousness,713,I-DiseaseOrPhenotypicFeature
due,713,O
to,713,O
marked,713,O
bradycardia,713,B-DiseaseOrPhenotypicFeature
caused,713,O
by,713,O
hyperkalemia,713,B-DiseaseOrPhenotypicFeature
.,713,O
The,714,O
concentration,714,O
of,714,O
serum,714,O
potassium,714,B-ChemicalEntity
was,714,O
high,714,O
",",714,O
and,714,O
normal,714,O
sinus,714,O
rhythm,714,O
was,714,O
restored,714,O
after,714,O
correction,714,O
of,714,O
the,714,O
serum,714,O
potassium,714,B-ChemicalEntity
level,714,O
.,714,O
The,715,O
cause,715,O
of,715,O
hyperkalemia,715,B-DiseaseOrPhenotypicFeature
was,715,O
considered,715,O
to,715,O
be,715,O
several,715,O
doses,715,O
of,715,O
spiranolactone,715,B-ChemicalEntity
",",715,O
an,715,O
aldosterone,715,B-ChemicalEntity
antagonist,715,O
",",715,O
in,715,O
addition,715,O
to,715,O
the,715,O
long-term,715,O
intake,715,O
of,715,O
ramipril,715,B-ChemicalEntity
",",715,O
an,715,O
ACE,715,B-GeneOrGeneProduct
inhibitor,715,O
.,715,O
This,716,O
case,716,O
is,716,O
a,716,O
good,716,O
example,716,O
of,716,O
electrolyte,716,O
imbalance,716,O
causing,716,O
acute,716,O
life-threatening,716,O
cardiac,716,O
events,716,O
.,716,O
Clinicians,717,O
should,717,O
be,717,O
alert,717,O
to,717,O
the,717,O
possibility,717,O
of,717,O
hyperkalemia,717,B-DiseaseOrPhenotypicFeature
",",717,O
especially,717,O
in,717,O
elderly,717,O
patients,717,B-OrganismTaxon
using,717,O
ACE/ARB,717,B-GeneOrGeneProduct
in,717,O
combination,717,O
with,717,O
potassium,717,B-ChemicalEntity
sparing,717,O
agents,717,O
and,717,O
who,717,O
have,717,O
mild,717,O
renal,717,B-DiseaseOrPhenotypicFeature
disturbance,717,I-DiseaseOrPhenotypicFeature
.,717,O
Cerebrospinal,718,O
fluid,718,O
penetration,718,O
of,718,O
high-dose,718,O
daptomycin,718,B-ChemicalEntity
in,718,O
suspected,718,O
Staphylococcus,718,B-OrganismTaxon
aureus,718,I-OrganismTaxon
meningitis,718,B-DiseaseOrPhenotypicFeature
.,718,O
OBJECTIVE,719,O
:,719,O
To,719,O
report,719,O
a,719,O
case,719,O
of,719,O
methicillin-sensitive,719,B-ChemicalEntity
Staphylococcus,719,B-OrganismTaxon
aureus,719,I-OrganismTaxon
(,719,O
MSSA,719,O
),719,O
bacteremia,719,B-DiseaseOrPhenotypicFeature
with,719,O
suspected,719,O
MSSA,719,O
meningitis,719,B-DiseaseOrPhenotypicFeature
treated,719,O
with,719,O
high-dose,719,O
daptomycin,719,B-ChemicalEntity
assessed,719,O
with,719,O
concurrent,719,O
serum,719,O
and,719,O
cerebrospinal,719,O
fluid,719,O
(,719,O
CSF,719,O
),719,O
concentrations,719,O
.,719,O
CASE,720,O
SUMMARY,720,O
:,720,O
A,720,O
54-year-old,720,O
male,720,O
presented,720,O
to,720,O
the,720,O
emergency,720,O
department,720,O
with,720,O
generalized,720,O
weakness,720,B-DiseaseOrPhenotypicFeature
and,720,O
presumed,720,O
health-care-associated,720,O
pneumonia,720,B-DiseaseOrPhenotypicFeature
shown,720,O
on,720,O
chest,720,O
radiograph,720,O
.,720,O
Treatment,721,O
was,721,O
empirically,721,O
initiated,721,O
with,721,O
vancomycin,721,B-ChemicalEntity
",",721,O
levofloxacin,721,B-ChemicalEntity
",",721,O
and,721,O
piperacillin/tazobactam,721,B-ChemicalEntity
.,721,O
Blood,722,O
cultures,722,O
revealed,722,O
S.,722,B-OrganismTaxon
aureus,722,I-OrganismTaxon
susceptible,722,O
to,722,O
oxacillin,722,B-ChemicalEntity
.,722,O
Empiric,723,O
antibiotic,723,B-ChemicalEntity
treatment,723,O
was,723,O
narrowed,723,O
to,723,O
nafcillin,723,B-ChemicalEntity
on,723,O
day,723,O
4,723,O
.,723,O
On,724,O
day,724,O
8,724,O
",",724,O
the,724,O
patient,724,B-OrganismTaxon
developed,724,O
acute,724,B-DiseaseOrPhenotypicFeature
renal,724,I-DiseaseOrPhenotypicFeature
failure,724,I-DiseaseOrPhenotypicFeature
(,724,O
serum,724,O
creatinine,724,B-ChemicalEntity
1.9,724,O
mg/dL,724,O
",",724,O
increased,724,O
from,724,O
1.2,724,O
mg/dL,724,O
the,724,O
previous,724,O
day,724,O
and,724,O
0.8,724,O
mg/dL,724,O
on,724,O
admission,724,O
),724,O
.,724,O
The,725,O
patient,725,B-OrganismTaxon
's,725,O
Glasgow,725,O
Coma,725,B-DiseaseOrPhenotypicFeature
Score,725,O
was,725,O
3,725,O
",",725,O
with,725,O
normal,725,O
findings,725,O
shown,725,O
on,725,O
computed,725,O
tomography,725,O
scan,725,O
of,725,O
the,725,O
head,725,O
72,725,O
hours,725,O
following,725,O
an,725,O
episode,725,O
of,725,O
cardiac,725,B-DiseaseOrPhenotypicFeature
arrest,725,I-DiseaseOrPhenotypicFeature
on,725,O
day,725,O
10,725,O
.,725,O
The,726,O
patient,726,B-OrganismTaxon
experienced,726,O
relapsing,726,O
MSSA,726,O
bacteremia,726,B-DiseaseOrPhenotypicFeature
on,726,O
day,726,O
9,726,O
",",726,O
increasing,726,O
the,726,O
suspicion,726,O
for,726,O
a,726,O
central,726,B-DiseaseOrPhenotypicFeature
nervous,726,I-DiseaseOrPhenotypicFeature
system,726,I-DiseaseOrPhenotypicFeature
(,726,I-DiseaseOrPhenotypicFeature
CNS,726,I-DiseaseOrPhenotypicFeature
),726,I-DiseaseOrPhenotypicFeature
infection,726,I-DiseaseOrPhenotypicFeature
.,726,O
Nafcillin,727,B-ChemicalEntity
was,727,O
discontinued,727,O
and,727,O
daptomycin,727,B-ChemicalEntity
9,727,O
mg/kg,727,O
daily,727,O
was,727,O
initiated,727,O
for,727,O
suspected,727,O
meningitis,727,B-DiseaseOrPhenotypicFeature
and,727,O
was,727,O
continued,727,O
until,727,O
the,727,O
patient,727,B-OrganismTaxon
's,727,O
death,727,B-DiseaseOrPhenotypicFeature
on,727,O
day,727,O
16,727,O
.,727,O
Daptomycin,728,B-ChemicalEntity
serum,728,O
and,728,O
CSF,728,O
trough,728,O
concentrations,728,O
were,728,O
11.21,728,O
ug/mL,728,O
and,728,O
0.52,728,O
ug/mL,728,O
",",728,O
respectively,728,O
",",728,O
prior,728,O
to,728,O
the,728,O
third,728,O
dose,728,O
.,728,O
Lumbar,729,O
puncture,729,O
results,729,O
were,729,O
inconclusive,729,O
and,729,O
no,729,O
further,729,O
blood,729,O
cultures,729,O
were,729,O
positive,729,O
for,729,O
MSSA,729,O
.,729,O
Creatine,730,B-GeneOrGeneProduct
kinase,730,I-GeneOrGeneProduct
levels,730,O
were,730,O
normal,730,O
prior,730,O
to,730,O
daptomycin,730,B-ChemicalEntity
therapy,730,O
and,730,O
were,730,O
not,730,O
reassessed,730,O
.,730,O
DISCUSSION,731,O
:,731,O
Daptomycin,731,B-ChemicalEntity
was,731,O
initiated,731,O
in,731,O
our,731,O
patient,731,B-OrganismTaxon
secondary,731,O
to,731,O
possible,731,O
nafcillin-induced,731,B-ChemicalEntity
acute,731,O
interstitial,731,B-DiseaseOrPhenotypicFeature
nephritis,731,I-DiseaseOrPhenotypicFeature
and,731,O
relapsing,731,O
bacteremia,731,B-DiseaseOrPhenotypicFeature
.,731,O
At,732,O
a,732,O
dose,732,O
of,732,O
9,732,O
mg/kg,732,O
",",732,O
resultant,732,O
penetration,732,O
of,732,O
5,732,O
%,732,O
was,732,O
higher,732,O
than,732,O
in,732,O
previous,732,O
reports,732,O
",",732,O
more,732,O
consistent,732,O
with,732,O
inflamed,732,O
meninges,732,O
.,732,O
CONCLUSIONS,733,O
:,733,O
High-dose,733,O
daptomycin,733,B-ChemicalEntity
may,733,O
be,733,O
an,733,O
alternative,733,O
option,733,O
for,733,O
MSSA,733,O
bacteremia,733,B-DiseaseOrPhenotypicFeature
with,733,O
or,733,O
without,733,O
a,733,O
CNS,733,O
source,733,O
in,733,O
patients,733,B-OrganismTaxon
who,733,O
have,733,O
failed,733,O
or,733,O
can,733,O
not,733,O
tolerate,733,O
standard,733,O
therapy,733,O
.,733,O
Further,734,O
clinical,734,O
evaluation,734,O
in,734,O
patients,734,B-OrganismTaxon
with,734,O
confirmed,734,O
meningitis,734,B-DiseaseOrPhenotypicFeature
is,734,O
warranted,734,O
.,734,O
Familial,735,O
glucocorticoid,735,B-GeneOrGeneProduct
receptor,735,I-GeneOrGeneProduct
haploinsufficiency,735,O
by,735,O
non-sense,735,O
mediated,735,O
mRNA,735,O
decay,735,O
",",735,O
adrenal,735,B-DiseaseOrPhenotypicFeature
hyperplasia,735,I-DiseaseOrPhenotypicFeature
and,735,O
apparent,735,B-DiseaseOrPhenotypicFeature
mineralocorticoid,735,I-DiseaseOrPhenotypicFeature
excess,735,I-DiseaseOrPhenotypicFeature
.,735,O
Primary,736,O
glucocorticoid,736,B-DiseaseOrPhenotypicFeature
resistance,736,I-DiseaseOrPhenotypicFeature
(,736,O
OMIM,736,B-DiseaseOrPhenotypicFeature
138040,736,I-DiseaseOrPhenotypicFeature
),736,O
is,736,O
a,736,O
rare,736,O
hereditary,736,B-DiseaseOrPhenotypicFeature
disease,736,I-DiseaseOrPhenotypicFeature
that,736,O
causes,736,O
a,736,O
generalized,736,O
partial,736,O
insensitivity,736,O
to,736,O
glucocorticoid,736,B-ChemicalEntity
action,736,O
",",736,O
due,736,O
to,736,O
genetic,736,O
alterations,736,O
of,736,O
the,736,O
glucocorticoid,736,B-GeneOrGeneProduct
receptor,736,I-GeneOrGeneProduct
(,736,O
GR,736,B-GeneOrGeneProduct
),736,O
.,736,O
Investigation,737,O
of,737,O
adrenal,737,B-DiseaseOrPhenotypicFeature
incidentalomas,737,I-DiseaseOrPhenotypicFeature
led,737,O
to,737,O
the,737,O
discovery,737,O
of,737,O
a,737,O
family,737,O
(,737,O
eight,737,O
affected,737,O
individuals,737,O
spanning,737,O
three,737,O
generations,737,O
),737,O
",",737,O
prone,737,O
to,737,O
cortisol,737,B-DiseaseOrPhenotypicFeature
resistance,737,I-DiseaseOrPhenotypicFeature
",",737,O
bilateral,737,B-DiseaseOrPhenotypicFeature
adrenal,737,I-DiseaseOrPhenotypicFeature
hyperplasia,737,I-DiseaseOrPhenotypicFeature
",",737,O
arterial,737,O
hypertension,737,B-DiseaseOrPhenotypicFeature
and,737,O
hypokalemia,737,B-DiseaseOrPhenotypicFeature
.,737,O
This,738,O
phenotype,738,O
exacerbated,738,O
over,738,O
time,738,O
",",738,O
cosegregates,738,O
with,738,O
the,738,O
first,738,O
heterozygous,738,O
nonsense,738,O
mutation,738,O
p.R469,738,B-SequenceVariant
[,738,I-SequenceVariant
R,738,I-SequenceVariant
",",738,I-SequenceVariant
X,738,I-SequenceVariant
],738,I-SequenceVariant
reported,738,O
to,738,O
date,738,O
for,738,O
the,738,O
GR,738,B-GeneOrGeneProduct
",",738,O
replacing,738,O
an,738,O
arginine,738,B-SequenceVariant
(,738,I-SequenceVariant
CGA,738,I-SequenceVariant
),738,I-SequenceVariant
by,738,I-SequenceVariant
a,738,I-SequenceVariant
stop,738,I-SequenceVariant
(,738,I-SequenceVariant
TGA,738,I-SequenceVariant
),738,I-SequenceVariant
at,738,I-SequenceVariant
amino-acid,738,I-SequenceVariant
469,738,I-SequenceVariant
in,738,O
the,738,O
second,738,O
zinc,738,O
finger,738,O
of,738,O
the,738,O
DNA-binding,738,O
domain,738,O
of,738,O
the,738,O
receptor,738,O
.,738,O
In,739,O
vitro,739,O
",",739,O
this,739,O
mutation,739,O
leads,739,O
to,739,O
a,739,O
truncated,739,O
50-kDa,739,O
GR,739,B-GeneOrGeneProduct
lacking,739,O
hormone,739,O
and,739,O
DNA,739,O
binding,739,O
capacity,739,O
",",739,O
devoid,739,O
of,739,O
hormone-dependent,739,O
nuclear,739,O
translocation,739,O
and,739,O
transactivation,739,O
properties,739,O
.,739,O
In,740,O
the,740,O
proband,740,O
's,740,O
fibroblasts,740,O
",",740,O
we,740,O
provided,740,O
evidence,740,O
for,740,O
the,740,O
lack,740,O
of,740,O
expression,740,O
of,740,O
the,740,O
defective,740,O
allele,740,O
in,740,O
vivo,740,O
.,740,O
The,741,O
absence,741,O
of,741,O
detectable,741,O
mutated,741,O
GR,741,B-GeneOrGeneProduct
mRNA,741,O
was,741,O
accompanied,741,O
by,741,O
a,741,O
50,741,O
%,741,O
reduction,741,O
in,741,O
wild,741,O
type,741,O
GR,741,B-GeneOrGeneProduct
transcript,741,O
and,741,O
protein,741,O
.,741,O
This,742,O
reduced,742,O
GR,742,B-GeneOrGeneProduct
expression,742,O
leads,742,O
to,742,O
a,742,O
significantly,742,O
below-normal,742,O
induction,742,O
of,742,O
glucocorticoid-induced,742,B-ChemicalEntity
target,742,O
genes,742,O
",",742,O
FKBP5,742,B-GeneOrGeneProduct
in,742,O
fibroblasts,742,O
.,742,O
We,743,O
demonstrated,743,O
that,743,O
the,743,O
molecular,743,O
mechanisms,743,O
of,743,O
glucocorticoid,743,B-ChemicalEntity
signaling,743,O
dysfunction,743,O
involved,743,O
GR,743,B-GeneOrGeneProduct
haploinsufficiency,743,O
due,743,O
to,743,O
the,743,O
selective,743,O
degradation,743,O
of,743,O
the,743,O
mutated,743,O
GR,743,B-GeneOrGeneProduct
transcript,743,O
through,743,O
a,743,O
nonsense-mediated,743,O
mRNA,743,O
Decay,743,O
that,743,O
was,743,O
experimentally,743,O
validated,743,O
on,743,O
emetine-treated,743,B-ChemicalEntity
propositus,743,O
',743,O
fibroblasts,743,O
.,743,O
GR,744,B-GeneOrGeneProduct
haploinsufficiency,744,O
leads,744,O
to,744,O
hypertension,744,B-DiseaseOrPhenotypicFeature
due,744,O
to,744,O
illicit,744,O
occupation,744,O
of,744,O
renal,744,O
mineralocorticoid,744,B-GeneOrGeneProduct
receptor,744,I-GeneOrGeneProduct
by,744,O
elevated,744,O
cortisol,744,B-ChemicalEntity
rather,744,O
than,744,O
to,744,O
increased,744,O
mineralocorticoid,744,B-ChemicalEntity
production,744,O
reported,744,O
in,744,O
primary,744,O
glucocorticoid,744,B-DiseaseOrPhenotypicFeature
resistance,744,I-DiseaseOrPhenotypicFeature
.,744,O
Indeed,745,O
",",745,O
apparent,745,B-DiseaseOrPhenotypicFeature
mineralocorticoid,745,I-DiseaseOrPhenotypicFeature
excess,745,I-DiseaseOrPhenotypicFeature
was,745,O
demonstrated,745,O
by,745,O
a,745,O
decrease,745,O
in,745,O
urinary,745,O
tetrahydrocortisone-tetrahydrocortisol,745,B-ChemicalEntity
ratio,745,O
in,745,O
affected,745,O
patients,745,B-OrganismTaxon
",",745,O
revealing,745,O
reduced,745,O
glucocorticoid,745,B-ChemicalEntity
degradation,745,O
by,745,O
renal,745,O
activity,745,O
of,745,O
the,745,O
11b-hydroxysteroid,745,B-GeneOrGeneProduct
dehydrogenase,745,I-GeneOrGeneProduct
type,745,I-GeneOrGeneProduct
2,745,I-GeneOrGeneProduct
",",745,O
a,745,O
GR,745,B-GeneOrGeneProduct
regulated,745,O
gene,745,O
.,745,O
We,746,O
propose,746,O
thus,746,O
that,746,O
GR,746,B-GeneOrGeneProduct
haploinsufficiency,746,O
compromises,746,O
glucocorticoid,746,B-ChemicalEntity
sensitivity,746,O
and,746,O
may,746,O
represent,746,O
a,746,O
novel,746,O
genetic,746,O
cause,746,O
of,746,O
subclinical,746,O
hypercortisolism,746,B-DiseaseOrPhenotypicFeature
",",746,O
incidentally,746,O
revealed,746,O
bilateral,746,B-DiseaseOrPhenotypicFeature
adrenal,746,I-DiseaseOrPhenotypicFeature
hyperplasia,746,I-DiseaseOrPhenotypicFeature
and,746,O
mineralocorticoid-independent,746,B-ChemicalEntity
hypertension,746,B-DiseaseOrPhenotypicFeature
.,746,O
Mutational,747,O
analysis,747,O
of,747,O
CYP2C8,747,B-GeneOrGeneProduct
in,747,O
hypertensive,747,B-DiseaseOrPhenotypicFeature
patients,747,B-OrganismTaxon
using,747,O
denaturing,747,O
high,747,O
performance,747,O
liquid,747,O
chromatography,747,O
.,747,O
WHAT,748,O
IS,748,O
KNOWN,748,O
AND,748,O
OBJECTIVE,748,O
:,748,O
CYP2C8,748,B-GeneOrGeneProduct
is,748,O
involved,748,O
in,748,O
the,748,O
cytochrome,748,B-GeneOrGeneProduct
P450,748,I-GeneOrGeneProduct
(,748,I-GeneOrGeneProduct
CYP,748,I-GeneOrGeneProduct
),748,I-GeneOrGeneProduct
epoxygenase,748,I-GeneOrGeneProduct
pathway,748,O
.,748,O
Arachidonic,749,B-ChemicalEntity
acid,749,I-ChemicalEntity
metabolites,749,O
such,749,O
as,749,O
epoxyeicosatrienenoic,749,B-ChemicalEntity
acids,749,I-ChemicalEntity
and,749,O
hydroxyeicosatetrenoic,749,B-ChemicalEntity
acids,749,I-ChemicalEntity
",",749,O
produced,749,O
may,749,O
have,749,O
a,749,O
role,749,O
in,749,O
hypertension,749,B-DiseaseOrPhenotypicFeature
.,749,O
We,750,O
aimed,750,O
to,750,O
develop,750,O
a,750,O
medium,750,O
through-put,750,O
method,750,O
for,750,O
screening,750,O
samples,750,O
of,750,O
known,750,O
and,750,O
new,750,O
mutations,750,O
of,750,O
CYP2C8,750,B-GeneOrGeneProduct
using,750,O
denaturing,750,O
high,750,O
performance,750,O
liquid,750,O
chromatography,750,O
(,750,O
DHPLC,750,O
),750,O
.,750,O
METHODS,751,O
:,751,O
DNA,751,O
samples,751,O
from,751,O
200,751,O
subjects,751,O
(,751,O
hypertensive,751,B-DiseaseOrPhenotypicFeature
patients,751,B-OrganismTaxon
and,751,O
healthy,751,O
controls,751,O
),751,O
were,751,O
screened,751,O
for,751,O
SNPs,751,O
in,751,O
CYP2C8,751,B-GeneOrGeneProduct
using,751,O
DHPLC,751,O
.,751,O
Genotypes,752,O
and,752,O
allelic,752,O
frequencies,752,O
of,752,O
CYP2C8,752,B-GeneOrGeneProduct
between,752,O
the,752,O
healthy,752,O
controls,752,O
and,752,O
patients,752,B-OrganismTaxon
with,752,O
hypertension,752,B-DiseaseOrPhenotypicFeature
were,752,O
compared,752,O
.,752,O
RESULTS,753,O
AND,753,O
DISCUSSIONS,753,O
:,753,O
Six,753,O
variants,753,O
were,753,O
detected,753,O
and,753,O
two,753,O
were,753,O
new,753,O
;,753,O
T,753,B-SequenceVariant
deletion,753,I-SequenceVariant
at,753,I-SequenceVariant
5063,753,I-SequenceVariant
and,753,O
substitution,753,O
of,753,O
C,753,B-SequenceVariant
to,753,I-SequenceVariant
T,753,I-SequenceVariant
at,753,I-SequenceVariant
33468,753,I-SequenceVariant
in,753,O
exon,753,O
8,753,O
.,753,O
Differences,754,O
in,754,O
variant,754,O
frequencies,754,O
were,754,O
detected,754,O
between,754,O
the,754,O
controls,754,O
and,754,O
hypertensive,754,B-DiseaseOrPhenotypicFeature
patients,754,B-OrganismTaxon
.,754,O
The,755,O
controls,755,O
have,755,O
significantly,755,O
higher,755,O
prevalence,755,O
of,755,O
C35322C,755,B-SequenceVariant
compared,755,O
to,755,O
the,755,O
patients,755,B-OrganismTaxon
.,755,O
The,756,O
functional,756,O
significance,756,O
of,756,O
the,756,O
SNP,756,O
at,756,O
35322,756,O
requires,756,O
further,756,O
study,756,O
.,756,O
Having,757,O
homozygous,757,O
C35322C,757,B-SequenceVariant
could,757,O
be,757,O
a,757,O
protective,757,O
factor,757,O
for,757,O
hypertension,757,B-DiseaseOrPhenotypicFeature
.,757,O
WHAT,758,O
IS,758,O
NEW,758,O
AND,758,O
CONCLUSION,758,O
:,758,O
Denaturing,758,O
high,758,O
performance,758,O
liquid,758,O
chromatography,758,O
is,758,O
useful,758,O
for,758,O
population,758,O
screening,758,O
to,758,O
identify,758,O
new,758,O
and,758,O
existing,758,O
SNPs,758,O
.,758,O
A,759,O
higher,759,O
frequency,759,O
of,759,O
the,759,O
C35322T,759,B-SequenceVariant
SNP,759,O
was,759,O
observed,759,O
among,759,O
hypertensive,759,B-DiseaseOrPhenotypicFeature
patients,759,B-OrganismTaxon
than,759,O
control,759,O
subjects,759,O
.,759,O
This,760,O
potentially,760,O
important,760,O
observation,760,O
requires,760,O
confirmation,760,O
and,760,O
the,760,O
clinical,760,O
significance,760,O
assessed,760,O
.,760,O
Detection,761,O
of,761,O
EGFR,761,B-GeneOrGeneProduct
mutations,761,O
in,761,O
plasma,761,O
DNA,761,O
from,761,O
lung,761,B-DiseaseOrPhenotypicFeature
cancer,761,I-DiseaseOrPhenotypicFeature
patients,761,B-OrganismTaxon
by,761,O
mass,761,O
spectrometry,761,O
genotyping,761,O
is,761,O
predictive,761,O
of,761,O
tumor,761,B-DiseaseOrPhenotypicFeature
EGFR,761,B-GeneOrGeneProduct
status,761,O
and,761,O
response,761,O
to,761,O
EGFR,761,B-GeneOrGeneProduct
inhibitors,761,O
.,761,O
AIMS,762,O
:,762,O
EGFR,762,B-GeneOrGeneProduct
mutations,762,O
now,762,O
guide,762,O
the,762,O
clinical,762,O
use,762,O
of,762,O
EGFR-targeted,762,B-GeneOrGeneProduct
therapy,762,O
in,762,O
lung,762,B-DiseaseOrPhenotypicFeature
cancer,762,I-DiseaseOrPhenotypicFeature
.,762,O
However,763,O
",",763,O
standard,763,O
EGFR,763,B-GeneOrGeneProduct
mutation,763,O
analysis,763,O
requires,763,O
a,763,O
minimum,763,O
amount,763,O
of,763,O
tumor,763,B-DiseaseOrPhenotypicFeature
tissue,763,O
",",763,O
which,763,O
may,763,O
not,763,O
be,763,O
available,763,O
in,763,O
certain,763,O
situations,763,O
.,763,O
In,764,O
this,764,O
study,764,O
",",764,O
we,764,O
combined,764,O
a,764,O
mass,764,O
spectrometry,764,O
genotyping,764,O
assay,764,O
(,764,O
Sequenom,764,O
),764,O
with,764,O
a,764,O
mutant-enriched,764,O
PCR,764,O
(,764,O
ME-PCR,764,O
),764,O
to,764,O
detect,764,O
EGFR,764,B-GeneOrGeneProduct
mutations,764,O
in,764,O
free,764,O
plasma,764,O
DNA,764,O
from,764,O
patients,764,B-OrganismTaxon
with,764,O
lung,764,B-DiseaseOrPhenotypicFeature
cancer,764,I-DiseaseOrPhenotypicFeature
.,764,O
METHOD,765,O
:,765,O
DNAs,765,O
were,765,O
extracted,765,O
from,765,O
31,765,O
plasma,765,O
samples,765,O
from,765,O
31,765,O
patients,765,B-OrganismTaxon
and,765,O
analyzed,765,O
by,765,O
both,765,O
methods,765,O
for,765,O
EGFR,765,B-GeneOrGeneProduct
Exon,765,O
19,765,O
deletion,765,O
and,765,O
EGFR,765,B-GeneOrGeneProduct
L858R,765,B-SequenceVariant
mutation,765,O
.,765,O
Results,766,O
in,766,O
plasma,766,O
DNA,766,O
samples,766,O
were,766,O
compared,766,O
with,766,O
EGFR,766,B-GeneOrGeneProduct
mutation,766,O
status,766,O
obtained,766,O
in,766,O
tumor,766,B-DiseaseOrPhenotypicFeature
DNA,766,O
(,766,O
18/31,766,O
EGFR,766,B-GeneOrGeneProduct
mutant,766,O
),766,O
.,766,O
The,767,O
relationship,767,O
of,767,O
EGFR,767,B-GeneOrGeneProduct
mutation,767,O
status,767,O
in,767,O
tumor,767,B-DiseaseOrPhenotypicFeature
and/or,767,O
plasma,767,O
samples,767,O
to,767,O
overall,767,O
survival,767,O
was,767,O
assessed,767,O
.,767,O
RESULTS,768,O
:,768,O
The,768,O
EGFR,768,B-GeneOrGeneProduct
mutation,768,O
status,768,O
in,768,O
plasma,768,O
DNA,768,O
was,768,O
identical,768,O
to,768,O
the,768,O
primary,768,O
tumor,768,B-DiseaseOrPhenotypicFeature
in,768,O
61,768,O
%,768,O
of,768,O
patients,768,B-OrganismTaxon
(,768,O
19/31,768,O
),768,O
.,768,O
By,769,O
mass,769,O
spectrometry,769,O
genotyping,769,O
",",769,O
the,769,O
plasma,769,O
samples,769,O
contained,769,O
mutant,769,O
DNA,769,O
corresponding,769,O
to,769,O
5/14,769,O
EGFR,769,B-GeneOrGeneProduct
Exon,769,O
19,769,O
deletions,769,O
and,769,O
3/4,769,O
EGFR,769,B-GeneOrGeneProduct
L858R,769,B-SequenceVariant
mutations,769,O
previously,769,O
diagnosed,769,O
in,769,O
the,769,O
matched,769,O
tumors,769,B-DiseaseOrPhenotypicFeature
.,769,O
Two,770,O
samples,770,O
were,770,O
positive,770,O
in,770,O
plasma,770,O
DNA,770,O
but,770,O
negative,770,O
in,770,O
primary,770,O
tumor,770,B-DiseaseOrPhenotypicFeature
tissue,770,O
.,770,O
Results,771,O
were,771,O
similar,771,O
for,771,O
samples,771,O
studied,771,O
by,771,O
ME-PCR,771,O
.,771,O
For,772,O
patients,772,B-OrganismTaxon
treated,772,O
with,772,O
erlotinib,772,B-ChemicalEntity
",",772,O
overall,772,O
survival,772,O
was,772,O
correlated,772,O
with,772,O
the,772,O
presence,772,O
of,772,O
EGFR,772,B-GeneOrGeneProduct
mutation,772,O
in,772,O
plasma,772,O
and/or,772,O
tumor,772,B-DiseaseOrPhenotypicFeature
tissue,772,O
(,772,O
p=0.002,772,O
),772,O
",",772,O
with,772,O
the,772,O
two,772,O
patients,772,B-OrganismTaxon
positive,772,O
only,772,O
in,772,O
plasma,772,O
DNA,772,O
showing,772,O
responses,772,O
and,772,O
favorable,772,O
outcomes,772,O
.,772,O
CONCLUSION,773,O
:,773,O
The,773,O
detection,773,O
of,773,O
EGFR,773,B-GeneOrGeneProduct
mutations,773,O
in,773,O
plasma,773,O
DNA,773,O
samples,773,O
by,773,O
mass,773,O
spectrometry,773,O
genotyping,773,O
and,773,O
ME-PCR,773,O
is,773,O
feasible,773,O
.,773,O
A,774,O
positive,774,O
EGFR,774,B-GeneOrGeneProduct
result,774,O
in,774,O
plasma,774,O
DNA,774,O
has,774,O
a,774,O
high,774,O
predictive,774,O
value,774,O
for,774,O
tumor,774,B-DiseaseOrPhenotypicFeature
EGFR,774,B-GeneOrGeneProduct
status,774,O
and,774,O
for,774,O
favorable,774,O
clinical,774,O
course,774,O
on,774,O
EGFR-targeted,774,B-GeneOrGeneProduct
therapy,774,O
and,774,O
could,774,O
therefore,774,O
be,774,O
useful,774,O
in,774,O
guiding,774,O
clinical,774,O
decisions,774,O
in,774,O
patients,774,B-OrganismTaxon
with,774,O
insufficient,774,O
or,774,O
unavailable,774,O
tumor,774,B-DiseaseOrPhenotypicFeature
specimens,774,O
.,774,O
Strong,775,O
association,775,O
of,775,O
677,775,B-SequenceVariant
C,775,I-SequenceVariant
>,775,I-SequenceVariant
T,775,I-SequenceVariant
substitution,775,O
in,775,O
the,775,O
MTHFR,775,B-GeneOrGeneProduct
gene,775,O
with,775,O
male,775,B-DiseaseOrPhenotypicFeature
infertility,775,I-DiseaseOrPhenotypicFeature
--,775,O
a,775,O
study,775,O
on,775,O
an,775,O
indian,775,O
population,775,O
and,775,O
a,775,O
meta-analysis,775,O
.,775,O
BACKGROUND,776,O
:,776,O
Methylenetetrahydrofolate,776,B-GeneOrGeneProduct
reductase,776,I-GeneOrGeneProduct
(,776,O
MTHFR,776,B-GeneOrGeneProduct
),776,O
is,776,O
an,776,O
important,776,O
enzyme,776,O
of,776,O
folate,776,B-ChemicalEntity
and,776,O
methionine,776,B-ChemicalEntity
metabolism,776,O
",",776,O
making,776,O
it,776,O
crucial,776,O
for,776,O
DNA,776,O
synthesis,776,O
and,776,O
methylation,776,O
.,776,O
The,777,O
objective,777,O
of,777,O
this,777,O
study,777,O
was,777,O
to,777,O
analyze,777,O
MTHFR,777,B-GeneOrGeneProduct
gene,777,O
677C,777,B-SequenceVariant
>,777,I-SequenceVariant
T,777,I-SequenceVariant
polymorphism,777,O
in,777,O
infertile,777,O
male,777,O
individuals,777,O
from,777,O
North,777,O
India,777,O
",",777,O
followed,777,O
by,777,O
a,777,O
meta-analysis,777,O
on,777,O
our,777,O
data,777,O
and,777,O
published,777,O
studies,777,O
.,777,O
METHODOLOGY/PRINCIPAL,778,O
FINDINGS,778,O
:,778,O
We,778,O
undertook,778,O
genotyping,778,O
on,778,O
a,778,O
total,778,O
of,778,O
837,778,O
individuals,778,O
including,778,O
well,778,O
characterized,778,O
infertile,778,O
(,778,O
N=522,778,O
),778,O
and,778,O
confirmed,778,O
fertile,778,O
(,778,O
N=315,778,O
),778,O
individuals,778,O
.,778,O
The,779,O
SNP,779,O
was,779,O
typed,779,O
by,779,O
direct,779,O
DNA,779,O
sequencing,779,O
.,779,O
Chi,780,O
square,780,O
test,780,O
was,780,O
done,780,O
for,780,O
statistical,780,O
analysis,780,O
.,780,O
Published,781,O
studies,781,O
were,781,O
searched,781,O
using,781,O
appropriate,781,O
keywords,781,O
.,781,O
Source,782,O
of,782,O
data,782,O
collection,782,O
for,782,O
meta-analysis,782,O
included,782,O
'Pubmed,782,O
',782,O
",",782,O
'Ovid,782,O
',782,O
and,782,O
'Google,782,O
Scholar,782,O
',782,O
.,782,O
Those,783,O
studies,783,O
analyzing,783,O
677C,783,B-SequenceVariant
>,783,I-SequenceVariant
T,783,I-SequenceVariant
polymorphism,783,O
in,783,O
male,783,B-DiseaseOrPhenotypicFeature
infertility,783,I-DiseaseOrPhenotypicFeature
and,783,O
presenting,783,O
all,783,O
relevant,783,O
data,783,O
were,783,O
included,783,O
in,783,O
meta-analysis,783,O
.,783,O
The,784,O
genotype,784,O
data,784,O
for,784,O
infertile,784,O
subjects,784,O
and,784,O
fertile,784,O
controls,784,O
was,784,O
extracted,784,O
from,784,O
each,784,O
study,784,O
.,784,O
Chi,785,O
square,785,O
test,785,O
was,785,O
done,785,O
to,785,O
obtain,785,O
odds,785,O
ratio,785,O
(,785,O
OR,785,O
),785,O
and,785,O
p-value,785,O
.,785,O
Meta-analysis,786,O
was,786,O
performed,786,O
using,786,O
Comprehensive,786,O
Meta-analysis,786,O
software,786,O
(,786,O
Version,786,O
2,786,O
),786,O
.,786,O
The,787,O
frequency,787,O
of,787,O
mutant,787,O
(,787,O
T,787,O
),787,O
allele,787,O
(,787,O
p=0.0025,787,O
),787,O
and,787,O
genotypes,787,O
(,787,O
CT+TT,787,O
),787,O
(,787,O
p=0.0187,787,O
),787,O
was,787,O
significantly,787,O
higher,787,O
in,787,O
infertile,787,O
individuals,787,O
in,787,O
comparison,787,O
to,787,O
fertile,787,O
controls,787,O
in,787,O
our,787,O
case-control,787,O
study,787,O
.,787,O
The,788,O
overall,788,O
summary,788,O
estimate,788,O
(,788,O
OR,788,O
),788,O
for,788,O
allele,788,O
and,788,O
genotype,788,O
meta-analysis,788,O
were,788,O
1.304,788,O
(,788,O
p=0.000,788,O
),788,O
",",788,O
1.310,788,O
(,788,O
p=0.000,788,O
),788,O
",",788,O
respectively,788,O
",",788,O
establishing,788,O
significant,788,O
association,788,O
of,788,O
677C,788,B-SequenceVariant
>,788,I-SequenceVariant
T,788,I-SequenceVariant
polymorphism,788,O
with,788,O
male,788,B-DiseaseOrPhenotypicFeature
infertility,788,I-DiseaseOrPhenotypicFeature
.,788,O
CONCLUSIONS/SIGNIFICANCE,789,O
:,789,O
677C,789,B-SequenceVariant
>,789,I-SequenceVariant
T,789,I-SequenceVariant
substitution,789,O
associated,789,O
strongly,789,O
with,789,O
male,789,B-DiseaseOrPhenotypicFeature
infertility,789,I-DiseaseOrPhenotypicFeature
in,789,O
Indian,789,O
population,789,O
.,789,O
Allele,790,O
and,790,O
genotype,790,O
meta-analysis,790,O
also,790,O
supported,790,O
its,790,O
strong,790,O
correlation,790,O
with,790,O
male,790,B-DiseaseOrPhenotypicFeature
infertility,790,I-DiseaseOrPhenotypicFeature
",",790,O
thus,790,O
establishing,790,O
it,790,O
as,790,O
a,790,O
risk,790,O
factor,790,O
.,790,O
Autosomal,791,O
dominant,791,O
mutation,791,O
in,791,O
the,791,O
signal,791,O
peptide,791,O
of,791,O
renin,791,B-GeneOrGeneProduct
in,791,O
a,791,O
kindred,791,O
with,791,O
anemia,791,B-DiseaseOrPhenotypicFeature
",",791,O
hyperuricemia,791,B-DiseaseOrPhenotypicFeature
",",791,O
and,791,O
CKD,791,B-DiseaseOrPhenotypicFeature
.,791,O
Homozygous,792,O
or,792,O
compound,792,O
heterozygous,792,O
mutations,792,O
in,792,O
renin,792,B-GeneOrGeneProduct
(,792,O
REN,792,B-GeneOrGeneProduct
),792,O
cause,792,O
renal,792,B-DiseaseOrPhenotypicFeature
tubular,792,I-DiseaseOrPhenotypicFeature
dysgenesis,792,I-DiseaseOrPhenotypicFeature
",",792,O
which,792,O
is,792,O
characterized,792,O
by,792,O
death,792,B-DiseaseOrPhenotypicFeature
in,792,O
utero,792,O
due,792,O
to,792,O
kidney,792,B-DiseaseOrPhenotypicFeature
failure,792,I-DiseaseOrPhenotypicFeature
and,792,O
pulmonary,792,B-DiseaseOrPhenotypicFeature
hypoplasia,792,I-DiseaseOrPhenotypicFeature
.,792,O
The,793,O
phenotype,793,O
resembles,793,O
the,793,O
fetopathy,793,B-DiseaseOrPhenotypicFeature
caused,793,O
by,793,O
angiotensin-converting,793,B-ChemicalEntity
enzyme,793,I-ChemicalEntity
inhibitor,793,I-ChemicalEntity
or,793,O
angiotensin,793,B-ChemicalEntity
receptor,793,I-ChemicalEntity
blocker,793,I-ChemicalEntity
intake,793,O
during,793,O
pregnancy,793,O
.,793,O
Recently,794,O
",",794,O
heterozygous,794,O
REN,794,B-GeneOrGeneProduct
mutations,794,O
were,794,O
shown,794,O
to,794,O
result,794,O
in,794,O
early-onset,794,O
hyperuricemia,794,B-DiseaseOrPhenotypicFeature
",",794,O
anemia,794,B-DiseaseOrPhenotypicFeature
",",794,O
and,794,O
chronic,794,B-DiseaseOrPhenotypicFeature
kidney,794,I-DiseaseOrPhenotypicFeature
disease,794,I-DiseaseOrPhenotypicFeature
(,794,O
CKD,794,B-DiseaseOrPhenotypicFeature
),794,O
.,794,O
To,795,O
date,795,O
",",795,O
only,795,O
3,795,O
different,795,O
heterozygous,795,O
REN,795,B-GeneOrGeneProduct
mutations,795,O
have,795,O
been,795,O
published,795,O
.,795,O
We,796,O
report,796,O
mutation,796,O
analysis,796,O
of,796,O
the,796,O
REN,796,B-GeneOrGeneProduct
gene,796,O
in,796,O
39,796,O
kindreds,796,O
with,796,O
hyperuricemia,796,B-DiseaseOrPhenotypicFeature
and,796,O
CKD,796,B-DiseaseOrPhenotypicFeature
who,796,O
previously,796,O
tested,796,O
negative,796,O
for,796,O
mutations,796,O
in,796,O
the,796,O
UMOD,796,B-GeneOrGeneProduct
(,796,O
uromodulin,796,B-GeneOrGeneProduct
),796,O
and,796,O
HNF1B,796,B-GeneOrGeneProduct
(,796,O
hepatocyte,796,B-GeneOrGeneProduct
nuclear,796,I-GeneOrGeneProduct
factor,796,I-GeneOrGeneProduct
1b,796,I-GeneOrGeneProduct
),796,O
genes,796,O
.,796,O
We,797,O
identified,797,O
one,797,O
kindred,797,O
with,797,O
a,797,O
novel,797,O
thymidine,797,B-SequenceVariant
to,797,I-SequenceVariant
cytosine,797,I-SequenceVariant
mutation,797,I-SequenceVariant
at,797,I-SequenceVariant
position,797,I-SequenceVariant
28,797,I-SequenceVariant
in,797,O
the,797,O
REN,797,B-GeneOrGeneProduct
complementary,797,O
DNA,797,O
",",797,O
corresponding,797,O
to,797,O
a,797,O
tryptophan,797,B-SequenceVariant
to,797,I-SequenceVariant
arginine,797,I-SequenceVariant
substitution,797,I-SequenceVariant
at,797,I-SequenceVariant
amino,797,I-SequenceVariant
acid,797,I-SequenceVariant
10,797,I-SequenceVariant
",",797,O
which,797,O
is,797,O
found,797,O
within,797,O
the,797,O
signal,797,O
sequence,797,O
(,797,O
c.28T,797,B-SequenceVariant
>,797,I-SequenceVariant
C,797,I-SequenceVariant
;,797,O
p.W10R,797,B-SequenceVariant
),797,O
.,797,O
On,798,O
this,798,O
basis,798,O
",",798,O
we,798,O
conclude,798,O
that,798,O
REN,798,B-GeneOrGeneProduct
mutations,798,O
are,798,O
rare,798,O
events,798,O
in,798,O
patients,798,B-OrganismTaxon
with,798,O
CKD,798,B-DiseaseOrPhenotypicFeature
.,798,O
Within,799,O
the,799,O
kindred,799,O
",",799,O
we,799,O
found,799,O
affected,799,O
individuals,799,O
over,799,O
4,799,O
generations,799,O
who,799,O
carried,799,O
the,799,O
novel,799,O
REN,799,B-GeneOrGeneProduct
mutation,799,O
and,799,O
were,799,O
characterized,799,O
by,799,O
significant,799,O
anemia,799,B-DiseaseOrPhenotypicFeature
",",799,O
hyperuricemia,799,B-DiseaseOrPhenotypicFeature
",",799,O
and,799,O
CKD,799,B-DiseaseOrPhenotypicFeature
.,799,O
Anemia,800,B-DiseaseOrPhenotypicFeature
was,800,O
severe,800,O
and,800,O
disproportional,800,O
to,800,O
the,800,O
degree,800,O
of,800,O
decreased,800,O
kidney,800,O
function,800,O
.,800,O
Because,801,O
all,801,O
heterozygous,801,O
REN,801,B-GeneOrGeneProduct
mutations,801,O
that,801,O
have,801,O
been,801,O
described,801,O
are,801,O
localized,801,O
in,801,O
the,801,O
signal,801,O
sequence,801,O
",",801,O
screening,801,O
of,801,O
the,801,O
REN,801,B-GeneOrGeneProduct
gene,801,O
for,801,O
patients,801,B-OrganismTaxon
with,801,O
CKD,801,B-DiseaseOrPhenotypicFeature
with,801,O
hyperuricemia,801,B-DiseaseOrPhenotypicFeature
and,801,O
anemia,801,B-DiseaseOrPhenotypicFeature
may,801,O
best,801,O
be,801,O
focused,801,O
on,801,O
sequencing,801,O
of,801,O
exon,801,O
1,801,O
",",801,O
which,801,O
encodes,801,O
the,801,O
signal,801,O
peptide,801,O
.,801,O
TNFR-associated,802,B-GeneOrGeneProduct
factor,802,I-GeneOrGeneProduct
2,802,I-GeneOrGeneProduct
deficiency,802,O
in,802,O
B,802,O
lymphocytes,802,O
predisposes,802,O
to,802,O
chronic,802,B-DiseaseOrPhenotypicFeature
lymphocytic,802,I-DiseaseOrPhenotypicFeature
leukemia/small,802,O
lymphocytic,802,I-DiseaseOrPhenotypicFeature
lymphoma,802,I-DiseaseOrPhenotypicFeature
in,802,O
mice,802,B-OrganismTaxon
.,802,O
We,803,O
have,803,O
previously,803,O
shown,803,O
that,803,O
transgenic,803,O
(,803,O
tg,803,O
),803,O
mice,803,B-OrganismTaxon
expressing,803,O
in,803,O
B,803,O
lymphocytes,803,O
both,803,O
BCL-2,803,B-GeneOrGeneProduct
and,803,O
a,803,O
TNFR-associated,803,B-GeneOrGeneProduct
factor,803,I-GeneOrGeneProduct
2,803,I-GeneOrGeneProduct
(,803,O
TRAF2,803,B-GeneOrGeneProduct
),803,O
mutant,803,O
lacking,803,O
the,803,O
really,803,O
interesting,803,O
new,803,O
gene,803,O
and,803,O
zinc,803,O
finger,803,O
domains,803,O
(,803,O
TRAF2DN,803,O
),803,O
develop,803,O
small,803,B-DiseaseOrPhenotypicFeature
lymphocytic,803,I-DiseaseOrPhenotypicFeature
lymphoma,803,I-DiseaseOrPhenotypicFeature
and,803,O
chronic,803,B-DiseaseOrPhenotypicFeature
lymphocytic,803,I-DiseaseOrPhenotypicFeature
leukemia,803,I-DiseaseOrPhenotypicFeature
with,803,O
high,803,O
incidence,803,O
(,803,O
Zapata,803,O
et,803,O
al,803,O
.,803,O
2004,804,O
.,804,O
Proc,805,O
.,805,O
Nat,806,O
.,806,O
Acad,807,O
.,807,O
Sci,808,O
.,808,O
USA,809,O
101,809,O
:,809,O
16600-16605,809,O
),809,O
.,809,O
Further,810,O
analysis,810,O
of,810,O
the,810,O
expression,810,O
of,810,O
TRAF2,810,B-GeneOrGeneProduct
and,810,O
TRAF2DN,810,O
in,810,O
purified,810,O
B,810,O
cells,810,O
demonstrated,810,O
that,810,O
expression,810,O
of,810,O
both,810,O
endogenous,810,O
TRAF2,810,B-GeneOrGeneProduct
and,810,O
tg,810,O
TRAF2DN,810,O
was,810,O
negligible,810,O
in,810,O
Traf2DN-tg,810,B-CellLine
B,810,I-CellLine
cells,810,O
compared,810,O
with,810,O
wild-type,810,O
mice,810,B-OrganismTaxon
.,810,O
This,811,O
was,811,O
the,811,O
result,811,O
of,811,O
proteasome-dependent,811,B-GeneOrGeneProduct
degradation,811,O
",",811,O
and,811,O
rendered,811,O
TRAF2DN,811,O
B,811,O
cells,811,O
as,811,O
bona,811,O
fide,811,O
TRAF2-deficient,811,B-GeneOrGeneProduct
B,811,O
cells,811,O
.,811,O
Similar,812,O
to,812,O
B,812,O
cells,812,O
with,812,O
targeted,812,O
Traf2,812,B-GeneOrGeneProduct
deletion,812,O
",",812,O
Traf2DN-tg,812,B-CellLine
mice,812,B-OrganismTaxon
show,812,O
expanded,812,O
marginal,812,O
zone,812,O
B,812,O
cell,812,O
population,812,O
and,812,O
have,812,O
constitutive,812,O
p100,812,B-GeneOrGeneProduct
NF-kappaB2,812,I-GeneOrGeneProduct
processing,812,O
.,812,O
Also,813,O
",",813,O
TRAF3,813,B-GeneOrGeneProduct
",",813,O
X-linked,813,B-GeneOrGeneProduct
inhibitor,813,I-GeneOrGeneProduct
of,813,I-GeneOrGeneProduct
apoptosis,813,I-GeneOrGeneProduct
",",813,O
and,813,O
Bcl-X,813,B-GeneOrGeneProduct
(,813,I-GeneOrGeneProduct
L,813,I-GeneOrGeneProduct
),813,I-GeneOrGeneProduct
expression,813,O
levels,813,O
were,813,O
increased,813,O
",",813,O
whereas,813,O
cellular,813,B-GeneOrGeneProduct
inhibitors,813,I-GeneOrGeneProduct
of,813,I-GeneOrGeneProduct
apoptosis,813,I-GeneOrGeneProduct
1,813,I-GeneOrGeneProduct
and,813,I-GeneOrGeneProduct
2,813,I-GeneOrGeneProduct
levels,813,O
were,813,O
drastically,813,O
reduced,813,O
compared,813,O
with,813,O
those,813,O
found,813,O
in,813,O
wild-type,813,O
B,813,O
cells,813,O
.,813,O
Moreover,814,O
",",814,O
consistent,814,O
with,814,O
previous,814,O
results,814,O
",",814,O
we,814,O
also,814,O
show,814,O
that,814,O
TRAF2,814,B-GeneOrGeneProduct
was,814,O
required,814,O
for,814,O
efficient,814,O
JNK,814,B-GeneOrGeneProduct
and,814,O
ERK,814,B-GeneOrGeneProduct
activation,814,O
in,814,O
response,814,O
to,814,O
CD40,814,B-GeneOrGeneProduct
engagement,814,O
.,814,O
However,815,O
",",815,O
TRAF2,815,B-GeneOrGeneProduct
was,815,O
deleterious,815,O
for,815,O
BCR-mediated,815,B-GeneOrGeneProduct
activation,815,O
of,815,O
these,815,O
kinases,815,O
.,815,O
In,816,O
contrast,816,O
",",816,O
TRAF2,816,B-GeneOrGeneProduct
deficiency,816,O
had,816,O
no,816,O
effect,816,O
on,816,O
CD40-mediated,816,B-GeneOrGeneProduct
p38,816,B-GeneOrGeneProduct
MAPK,816,I-GeneOrGeneProduct
activation,816,O
but,816,O
significantly,816,O
reduced,816,O
BCR-mediated,816,B-GeneOrGeneProduct
p38,816,B-GeneOrGeneProduct
activation,816,O
.,816,O
Finally,817,O
",",817,O
we,817,O
further,817,O
confirm,817,O
that,817,O
TRAF2,817,B-GeneOrGeneProduct
was,817,O
required,817,O
for,817,O
CD40-mediated,817,B-GeneOrGeneProduct
proliferation,817,O
",",817,O
but,817,O
its,817,O
absence,817,O
relieved,817,O
B,817,O
cells,817,O
of,817,O
the,817,O
need,817,O
for,817,O
B,817,B-GeneOrGeneProduct
cell,817,I-GeneOrGeneProduct
activating,817,I-GeneOrGeneProduct
factor,817,I-GeneOrGeneProduct
for,817,O
survival,817,O
.,817,O
Altogether,818,O
",",818,O
our,818,O
results,818,O
suggest,818,O
that,818,O
TRAF2,818,B-GeneOrGeneProduct
deficiency,818,O
cooperates,818,O
with,818,O
BCL-2,818,B-GeneOrGeneProduct
in,818,O
promoting,818,O
chronic,818,B-DiseaseOrPhenotypicFeature
lymphocytic,818,I-DiseaseOrPhenotypicFeature
leukemia/small,818,O
lymphocytic,818,I-DiseaseOrPhenotypicFeature
lymphoma,818,I-DiseaseOrPhenotypicFeature
in,818,O
mice,818,B-OrganismTaxon
",",818,O
possibly,818,O
by,818,O
specifically,818,O
enforcing,818,O
marginal,818,O
zone,818,O
B,818,O
cell,818,O
accumulation,818,O
",",818,O
increasing,818,O
X-linked,818,B-GeneOrGeneProduct
inhibitor,818,I-GeneOrGeneProduct
of,818,I-GeneOrGeneProduct
apoptosis,818,I-GeneOrGeneProduct
expression,818,O
",",818,O
and,818,O
rendering,818,O
B,818,O
cells,818,O
independent,818,O
of,818,O
B,818,B-GeneOrGeneProduct
cell,818,I-GeneOrGeneProduct
activating,818,I-GeneOrGeneProduct
factor,818,I-GeneOrGeneProduct
for,818,O
survival,818,O
.,818,O
Context-,819,O
and,819,O
cell-dependent,819,O
effects,819,O
of,819,O
Delta-like,819,B-GeneOrGeneProduct
4,819,I-GeneOrGeneProduct
targeting,819,O
in,819,O
the,819,O
bone,819,O
marrow,819,O
microenvironment,819,O
.,819,O
Delta-like,820,B-GeneOrGeneProduct
4,820,I-GeneOrGeneProduct
(,820,O
Dll4,820,B-GeneOrGeneProduct
),820,O
is,820,O
a,820,O
ligand,820,O
of,820,O
the,820,O
Notch,820,B-GeneOrGeneProduct
pathway,820,O
family,820,O
which,820,O
has,820,O
been,820,O
widely,820,O
studied,820,O
in,820,O
the,820,O
context,820,O
of,820,O
tumor,820,B-DiseaseOrPhenotypicFeature
angiogenesis,820,O
",",820,O
its,820,O
blockade,820,O
shown,820,O
to,820,O
result,820,O
in,820,O
non-productive,820,O
angiogenesis,820,O
and,820,O
halted,820,O
tumor,820,B-DiseaseOrPhenotypicFeature
growth,820,O
.,820,O
As,821,O
Dll4,821,B-GeneOrGeneProduct
inhibitors,821,O
enter,821,O
the,821,O
clinic,821,O
",",821,O
there,821,O
is,821,O
an,821,O
emerging,821,O
need,821,O
to,821,O
understand,821,O
their,821,O
side,821,O
effects,821,O
",",821,O
namely,821,O
the,821,O
systemic,821,O
consequences,821,O
of,821,O
Dll4,821,B-GeneOrGeneProduct
:,821,O
Notch,821,B-GeneOrGeneProduct
blockade,821,O
in,821,O
tissues,821,O
other,821,O
than,821,O
tumors,821,B-DiseaseOrPhenotypicFeature
.,821,O
The,822,O
present,822,O
study,822,O
focused,822,O
on,822,O
the,822,O
effects,822,O
of,822,O
systemic,822,O
anti-Dll4,822,O
targeting,822,O
in,822,O
the,822,O
bone,822,O
marrow,822,O
(,822,O
BM,822,O
),822,O
microenvironment,822,O
.,822,O
Here,823,O
we,823,O
show,823,O
that,823,O
Dll4,823,B-GeneOrGeneProduct
blockade,823,O
with,823,O
monoclonal,823,O
antibodies,823,O
perturbs,823,O
the,823,O
BM,823,O
vascular,823,O
niche,823,O
of,823,O
sub-lethally,823,O
irradiated,823,O
mice,823,B-OrganismTaxon
",",823,O
resulting,823,O
in,823,O
increased,823,O
CD31,823,B-GeneOrGeneProduct
(,823,O
+,823,O
),823,O
",",823,O
VE-Cadherin,823,B-GeneOrGeneProduct
(,823,O
+,823,O
),823,O
and,823,O
c-kit,823,B-GeneOrGeneProduct
(,823,O
+,823,O
),823,O
vessel,823,O
density,823,O
",",823,O
and,823,O
also,823,O
increased,823,O
megakaryocytes,823,O
",",823,O
whereas,823,O
CD105,823,B-GeneOrGeneProduct
(,823,O
+,823,O
),823,O
",",823,O
VEGFR3,823,B-GeneOrGeneProduct
(,823,O
+,823,O
),823,O
",",823,O
SMA,823,B-GeneOrGeneProduct
(,823,O
+,823,O
),823,O
and,823,O
lectin,823,B-GeneOrGeneProduct
(,823,O
+,823,O
),823,O
vessel,823,O
density,823,O
remained,823,O
unaltered,823,O
.,823,O
We,824,O
investigated,824,O
also,824,O
the,824,O
expression,824,O
of,824,O
angiocrine,824,O
genes,824,O
upon,824,O
Dll4,824,B-GeneOrGeneProduct
treatment,824,O
in,824,O
vivo,824,O
",",824,O
and,824,O
demonstrate,824,O
that,824,O
IGFbp2,824,B-GeneOrGeneProduct
",",824,O
IGFbp3,824,B-GeneOrGeneProduct
",",824,O
Angpt2,824,B-GeneOrGeneProduct
",",824,O
Dll4,824,B-GeneOrGeneProduct
",",824,O
DHH,824,B-GeneOrGeneProduct
and,824,O
VEGF-A,824,B-GeneOrGeneProduct
are,824,O
upregulated,824,O
",",824,O
while,824,O
FGF1,824,B-GeneOrGeneProduct
and,824,O
CSF2,824,B-GeneOrGeneProduct
are,824,O
reduced,824,O
.,824,O
In,825,O
vitro,825,O
treatment,825,O
of,825,O
endothelial,825,O
cells,825,O
with,825,O
anti-Dll4,825,O
reduced,825,O
Akt,825,B-GeneOrGeneProduct
phosphorylation,825,O
while,825,O
maintaining,825,O
similar,825,O
levels,825,O
of,825,O
Erk,825,B-GeneOrGeneProduct
1/2,825,I-GeneOrGeneProduct
phosphorylation,825,O
.,825,O
Besides,826,O
its,826,O
effects,826,O
in,826,O
the,826,O
BM,826,O
vascular,826,O
niche,826,O
",",826,O
anti-Dll4,826,O
treatment,826,O
perturbed,826,O
hematopoiesis,826,O
",",826,O
as,826,O
evidenced,826,O
by,826,O
increased,826,O
myeloid,826,O
(,826,O
CD11b,826,B-GeneOrGeneProduct
(,826,O
+,826,O
),826,O
),826,O
",",826,O
decreased,826,O
B,826,O
(,826,O
B220,826,B-GeneOrGeneProduct
(,826,O
+,826,O
),826,O
),826,O
and,826,O
T,826,O
(,826,O
CD3,826,B-GeneOrGeneProduct
(,826,O
+,826,O
),826,O
),826,O
lymphoid,826,O
BM,826,O
content,826,O
of,826,O
treated,826,O
mice,826,B-OrganismTaxon
",",826,O
with,826,O
a,826,O
corresponding,826,O
increase,826,O
in,826,O
myeloid,826,O
circulating,826,O
cells,826,O
.,826,O
Moreover,827,O
",",827,O
anti-Dll4,827,O
treatment,827,O
also,827,O
increased,827,O
the,827,O
number,827,O
of,827,O
CFU-M,827,O
and,827,O
-G,827,O
colonies,827,O
in,827,O
methylcellulose,827,O
assays,827,O
",",827,O
independently,827,O
of,827,O
Notch1,827,B-GeneOrGeneProduct
.,827,O
Finally,828,O
",",828,O
anti-Dll4,828,O
treatment,828,O
of,828,O
donor,828,O
BM,828,O
improved,828,O
the,828,O
hematopoietic,828,O
recovery,828,O
of,828,O
lethally,828,O
irradiated,828,O
recipients,828,O
in,828,O
a,828,O
transplant,828,O
setting,828,O
.,828,O
Together,829,O
",",829,O
our,829,O
data,829,O
reveals,829,O
the,829,O
hematopoietic,829,O
(,829,O
BM,829,O
),829,O
effects,829,O
of,829,O
systemic,829,O
anti-Dll4,829,O
treatment,829,O
result,829,O
from,829,O
qualitative,829,O
vascular,829,O
changes,829,O
and,829,O
also,829,O
direct,829,O
hematopoietic,829,O
cell,829,O
modulation,829,O
",",829,O
which,829,O
may,829,O
be,829,O
favorable,829,O
in,829,O
a,829,O
transplant,829,O
setting,829,O
.,829,O
Upregulation,830,O
of,830,O
T-cell,830,B-GeneOrGeneProduct
factor-4,830,I-GeneOrGeneProduct
isoform-responsive,830,O
target,830,O
genes,830,O
in,830,O
hepatocellular,830,B-DiseaseOrPhenotypicFeature
carcinoma,830,I-DiseaseOrPhenotypicFeature
.,830,O
BACKGROUND,831,O
:,831,O
The,831,O
Wnt/beta-catenin,831,B-GeneOrGeneProduct
signalling,831,O
pathway,831,O
regulates,831,O
genes,831,O
involved,831,O
in,831,O
cell,831,O
proliferation,831,O
",",831,O
survival,831,O
",",831,O
migration,831,O
and,831,O
invasion,831,O
through,831,O
regulation,831,O
by,831,O
T-cell,831,B-GeneOrGeneProduct
factor,831,I-GeneOrGeneProduct
(,831,I-GeneOrGeneProduct
TCF,831,I-GeneOrGeneProduct
),831,I-GeneOrGeneProduct
-4,831,I-GeneOrGeneProduct
transcription,831,I-GeneOrGeneProduct
factor,831,I-GeneOrGeneProduct
proteins,831,O
.,831,O
However,832,O
",",832,O
the,832,O
role,832,O
of,832,O
TCF-4,832,B-GeneOrGeneProduct
isoforms,832,O
generated,832,O
by,832,O
alternative,832,O
splicing,832,O
events,832,O
in,832,O
hepatocellular,832,B-DiseaseOrPhenotypicFeature
carcinoma,832,I-DiseaseOrPhenotypicFeature
(,832,O
HCC,832,B-DiseaseOrPhenotypicFeature
),832,O
is,832,O
unknown,832,O
.,832,O
AIM,833,O
:,833,O
Here,833,O
",",833,O
we,833,O
investigated,833,O
TCF-4,833,B-GeneOrGeneProduct
isoforms,833,O
(,833,O
TCF-4J,833,B-GeneOrGeneProduct
and,833,I-GeneOrGeneProduct
K,833,I-GeneOrGeneProduct
),833,O
-responsive,833,O
target,833,O
genes,833,O
that,833,O
are,833,O
important,833,O
in,833,O
hepatic,833,B-DiseaseOrPhenotypicFeature
oncogenesis,833,I-DiseaseOrPhenotypicFeature
and,833,O
tumour,833,B-DiseaseOrPhenotypicFeature
development,833,O
.,833,O
METHODS,834,O
:,834,O
Gene,834,O
expression,834,O
microarray,834,O
was,834,O
performed,834,O
on,834,O
HCC,834,B-DiseaseOrPhenotypicFeature
cells,834,O
overexpressing,834,O
TCF-4J,834,B-GeneOrGeneProduct
and,834,I-GeneOrGeneProduct
K,834,I-GeneOrGeneProduct
isoforms,834,O
.,834,O
Expression,835,O
level,835,O
of,835,O
selected,835,O
target,835,O
genes,835,O
was,835,O
evaluated,835,O
and,835,O
correlations,835,O
were,835,O
made,835,O
between,835,O
their,835,O
expression,835,O
level,835,O
and,835,O
that,835,O
of,835,O
TCF-4,835,B-GeneOrGeneProduct
isoform,835,O
in,835,O
47,835,O
pairs,835,O
of,835,O
human,835,B-OrganismTaxon
HCC,835,B-DiseaseOrPhenotypicFeature
tumours,835,I-DiseaseOrPhenotypicFeature
.,835,O
RESULTS,836,O
:,836,O
Comparison,836,O
by,836,O
gene,836,O
expression,836,O
microarray,836,O
revealed,836,O
that,836,O
447,836,O
genes,836,O
were,836,O
upregulated,836,O
and,836,O
343,836,O
downregulated,836,O
more,836,O
than,836,O
2.0-fold,836,O
in,836,O
TCF-4J,836,B-GeneOrGeneProduct
compared,836,O
with,836,O
TCF-4K,836,B-GeneOrGeneProduct
expressing,836,O
cells,836,O
.,836,O
We,837,O
validated,837,O
expression,837,O
of,837,O
18,837,O
selected,837,O
target,837,O
genes,837,O
involved,837,O
in,837,O
Wnt/beta-catenin,837,B-GeneOrGeneProduct
",",837,O
insulin/IGF-1/IRS1,837,B-GeneOrGeneProduct
and,837,O
Notch,837,B-GeneOrGeneProduct
signalling,837,O
pathways,837,O
in,837,O
47,837,O
pairs,837,O
of,837,O
human,837,B-OrganismTaxon
HCCs,837,B-DiseaseOrPhenotypicFeature
and,837,O
adjacent,837,O
uninvolved,837,O
liver,837,O
tissues,837,O
.,837,O
It,838,O
was,838,O
observed,838,O
that,838,O
13,838,O
genes,838,O
(,838,O
CLDN2,838,B-GeneOrGeneProduct
",",838,O
STK17B,838,B-GeneOrGeneProduct
",",838,O
SPP1,838,B-GeneOrGeneProduct
",",838,O
AXIN2,838,B-GeneOrGeneProduct
",",838,O
WISP2,838,B-GeneOrGeneProduct
",",838,O
MMP7,838,B-GeneOrGeneProduct
",",838,O
IRS1,838,B-GeneOrGeneProduct
",",838,O
ANXA1,838,B-GeneOrGeneProduct
",",838,O
CAMK2N1,838,B-GeneOrGeneProduct
",",838,O
ASPH,838,B-GeneOrGeneProduct
",",838,O
GPR56,838,B-GeneOrGeneProduct
",",838,O
CD24,838,B-GeneOrGeneProduct
and,838,O
JAG1,838,B-GeneOrGeneProduct
),838,O
activated,838,O
by,838,O
TCF-4J,838,B-GeneOrGeneProduct
isoform,838,O
in,838,O
HCC,838,B-DiseaseOrPhenotypicFeature
cells,838,O
",",838,O
were,838,O
also,838,O
upregulated,838,O
in,838,O
HCC,838,B-DiseaseOrPhenotypicFeature
tumours,838,I-DiseaseOrPhenotypicFeature
compared,838,O
with,838,O
adjacent,838,O
peritumour,838,O
tissue,838,O
;,838,O
more,838,O
importantly,838,O
",",838,O
10,838,O
genes,838,O
exhibited,838,O
a,838,O
significant,838,O
correlation,838,O
with,838,O
the,838,O
TCF-4J,838,B-GeneOrGeneProduct
expression,838,O
level,838,O
in,838,O
tumour,838,B-DiseaseOrPhenotypicFeature
.,838,O
CONCLUSION,839,O
:,839,O
TCF-4,839,B-GeneOrGeneProduct
isoforms,839,O
(,839,O
TCF-4J,839,B-GeneOrGeneProduct
and,839,I-GeneOrGeneProduct
K,839,I-GeneOrGeneProduct
),839,O
activated,839,O
different,839,O
downstream,839,O
target,839,O
genes,839,O
in,839,O
HCC,839,B-DiseaseOrPhenotypicFeature
.,839,O
The,840,O
biological,840,O
consequence,840,O
of,840,O
TCF-4J,840,B-GeneOrGeneProduct
isoform,840,O
expression,840,O
was,840,O
upregulation,840,O
of,840,O
genes,840,O
associated,840,O
with,840,O
tripartite,840,O
Wnt/beta-catenin,840,B-GeneOrGeneProduct
",",840,O
insulin/IGF-1/IRS1,840,B-GeneOrGeneProduct
and,840,O
Notch,840,B-GeneOrGeneProduct
signal,840,O
transduction,840,O
pathway,840,O
activation,840,O
",",840,O
which,840,O
contribute,840,O
to,840,O
the,840,O
pathogenesis,840,O
of,840,O
HCC,840,B-DiseaseOrPhenotypicFeature
.,840,O
Biochemical,841,O
effects,841,O
of,841,O
Solidago,841,B-ChemicalEntity
virgaurea,841,I-ChemicalEntity
extract,841,I-ChemicalEntity
on,841,O
experimental,841,O
cardiotoxicity,841,B-DiseaseOrPhenotypicFeature
.,841,O
Cardiovascular,842,B-DiseaseOrPhenotypicFeature
diseases,842,I-DiseaseOrPhenotypicFeature
(,842,O
CVDs,842,B-DiseaseOrPhenotypicFeature
),842,O
are,842,O
the,842,O
major,842,O
health,842,O
problem,842,O
of,842,O
advanced,842,O
as,842,O
well,842,O
as,842,O
developing,842,O
countries,842,O
of,842,O
the,842,O
world,842,O
.,842,O
The,843,O
aim,843,O
of,843,O
the,843,O
present,843,O
study,843,O
was,843,O
to,843,O
investigate,843,O
the,843,O
protective,843,O
effect,843,O
of,843,O
the,843,O
Solidago,843,B-ChemicalEntity
virgaurea,843,I-ChemicalEntity
extract,843,I-ChemicalEntity
on,843,O
isoproterenol-induced,843,B-ChemicalEntity
cardiotoxicity,843,B-DiseaseOrPhenotypicFeature
in,843,O
rats,843,B-OrganismTaxon
.,843,O
The,844,O
subcutaneous,844,O
injection,844,O
of,844,O
isoproterenol,844,B-ChemicalEntity
(,844,O
30,844,O
mg/kg,844,O
),844,O
into,844,O
rats,844,B-OrganismTaxon
twice,844,O
at,844,O
an,844,O
interval,844,O
of,844,O
24,844,O
h,844,O
",",844,O
for,844,O
two,844,O
consecutive,844,O
days,844,O
",",844,O
led,844,O
to,844,O
a,844,O
significant,844,O
increase,844,O
in,844,O
serum,844,O
lactate,844,B-GeneOrGeneProduct
dehydrogenase,844,I-GeneOrGeneProduct
",",844,O
creatine,844,B-GeneOrGeneProduct
phosphokinase,844,I-GeneOrGeneProduct
",",844,O
alanine,844,B-GeneOrGeneProduct
transaminase,844,I-GeneOrGeneProduct
",",844,O
aspartate,844,B-GeneOrGeneProduct
transaminase,844,I-GeneOrGeneProduct
",",844,O
and,844,O
angiotensin-converting,844,B-GeneOrGeneProduct
enzyme,844,I-GeneOrGeneProduct
activities,844,O
",",844,O
total,844,O
cholesterol,844,B-ChemicalEntity
",",844,O
triglycerides,844,B-ChemicalEntity
",",844,O
free,844,O
serum,844,O
fatty,844,B-ChemicalEntity
acid,844,I-ChemicalEntity
",",844,O
cardiac,844,O
tissue,844,O
malondialdehyde,844,B-ChemicalEntity
(,844,O
MDA,844,B-ChemicalEntity
),844,O
",",844,O
and,844,O
nitric,844,B-ChemicalEntity
oxide,844,I-ChemicalEntity
levels,844,O
and,844,O
a,844,O
significant,844,O
decrease,844,O
in,844,O
levels,844,O
of,844,O
glutathione,844,B-ChemicalEntity
and,844,O
superoxide,844,B-GeneOrGeneProduct
dismutase,844,I-GeneOrGeneProduct
in,844,O
cardiac,844,O
tissue,844,O
as,844,O
compared,844,O
to,844,O
the,844,O
normal,844,O
control,844,O
group,844,O
(,844,O
P,844,O
<,844,O
0.05,844,O
),844,O
.,844,O
Pretreatment,845,O
with,845,O
S.,845,B-ChemicalEntity
virgaurea,845,I-ChemicalEntity
extract,845,I-ChemicalEntity
for,845,O
5,845,O
weeks,845,O
at,845,O
a,845,O
dose,845,O
of,845,O
250,845,O
mg/kg,845,O
followed,845,O
by,845,O
isoproterenol,845,B-ChemicalEntity
injection,845,O
significantly,845,O
prevented,845,O
the,845,O
observed,845,O
alterations,845,O
.,845,O
Captopril,846,B-ChemicalEntity
(,846,O
50,846,O
mg/kg/day,846,O
",",846,O
given,846,O
orally,846,O
),846,O
",",846,O
an,846,O
inhibitor,846,O
of,846,O
angiotensin-converting,846,B-GeneOrGeneProduct
enzyme,846,I-GeneOrGeneProduct
used,846,O
as,846,O
a,846,O
standard,846,O
cardioprotective,846,B-ChemicalEntity
drug,846,I-ChemicalEntity
",",846,O
was,846,O
used,846,O
as,846,O
a,846,O
positive,846,O
control,846,O
in,846,O
this,846,O
study,846,O
.,846,O
The,847,O
data,847,O
of,847,O
the,847,O
present,847,O
study,847,O
suggest,847,O
that,847,O
S.,847,B-ChemicalEntity
virgaurea,847,I-ChemicalEntity
extract,847,I-ChemicalEntity
exerts,847,O
its,847,O
protective,847,O
effect,847,O
by,847,O
decreasing,847,O
MDA,847,B-ChemicalEntity
level,847,O
and,847,O
increasing,847,O
the,847,O
antioxidant,847,O
status,847,O
in,847,O
isoproterenol-treated,847,B-ChemicalEntity
rats,847,B-OrganismTaxon
.,847,O
The,848,O
study,848,O
emphasizes,848,O
the,848,O
beneficial,848,O
action,848,O
of,848,O
S.,848,B-ChemicalEntity
virgaurea,848,I-ChemicalEntity
extract,848,I-ChemicalEntity
as,848,O
a,848,O
cardioprotective,848,B-ChemicalEntity
agent,848,I-ChemicalEntity
.,848,O
A,849,O
homozygous,849,O
mutation,849,O
in,849,O
LYRM7/MZM1L,849,B-GeneOrGeneProduct
associated,849,O
with,849,O
early,849,O
onset,849,O
encephalopathy,849,B-DiseaseOrPhenotypicFeature
",",849,O
lactic,849,B-DiseaseOrPhenotypicFeature
acidosis,849,I-DiseaseOrPhenotypicFeature
",",849,O
and,849,O
severe,849,O
reduction,849,B-DiseaseOrPhenotypicFeature
of,849,I-DiseaseOrPhenotypicFeature
mitochondrial,849,I-DiseaseOrPhenotypicFeature
complex,849,I-DiseaseOrPhenotypicFeature
III,849,I-DiseaseOrPhenotypicFeature
activity,849,O
.,849,O
Mutations,850,O
in,850,O
nuclear,850,O
genes,850,O
associated,850,O
with,850,O
defective,850,B-DiseaseOrPhenotypicFeature
complex,850,I-DiseaseOrPhenotypicFeature
III,850,I-DiseaseOrPhenotypicFeature
(,850,I-DiseaseOrPhenotypicFeature
cIII,850,I-DiseaseOrPhenotypicFeature
),850,I-DiseaseOrPhenotypicFeature
of,850,I-DiseaseOrPhenotypicFeature
the,850,I-DiseaseOrPhenotypicFeature
mitochondrial,850,I-DiseaseOrPhenotypicFeature
respiratory,850,O
chain,850,O
are,850,O
rare,850,O
",",850,O
having,850,O
been,850,O
found,850,O
in,850,O
only,850,O
two,850,O
cIII,850,B-GeneOrGeneProduct
assembly,850,O
factors,850,O
and,850,O
",",850,O
as,850,O
private,850,O
changes,850,O
in,850,O
single,850,O
families,850,O
",",850,O
three,850,O
cIII,850,B-GeneOrGeneProduct
structural,850,O
subunits,850,O
.,850,O
Recently,851,O
",",851,O
human,851,B-OrganismTaxon
LYRM7/MZM1L,851,B-GeneOrGeneProduct
",",851,O
the,851,O
ortholog,851,O
of,851,O
yeast,851,B-OrganismTaxon
MZM1,851,B-GeneOrGeneProduct
",",851,O
has,851,O
been,851,O
identified,851,O
as,851,O
a,851,O
new,851,O
assembly,851,O
factor,851,O
for,851,O
cIII,851,B-GeneOrGeneProduct
.,851,O
In,852,O
a,852,O
baby,852,O
patient,852,B-OrganismTaxon
with,852,O
early,852,O
onset,852,O
",",852,O
severe,852,O
encephalopathy,852,B-DiseaseOrPhenotypicFeature
",",852,O
lactic,852,B-DiseaseOrPhenotypicFeature
acidosis,852,I-DiseaseOrPhenotypicFeature
and,852,O
profound,852,O
",",852,O
isolated,852,O
cIII,852,B-DiseaseOrPhenotypicFeature
deficiency,852,I-DiseaseOrPhenotypicFeature
in,852,O
skeletal,852,O
muscle,852,O
",",852,O
we,852,O
identified,852,O
a,852,O
disease-segregating,852,O
homozygous,852,O
mutation,852,O
(,852,O
c.73G,852,B-SequenceVariant
>,852,I-SequenceVariant
A,852,I-SequenceVariant
),852,O
in,852,O
LYRM7/MZM1L,852,B-GeneOrGeneProduct
",",852,O
predicting,852,O
a,852,O
drastic,852,O
change,852,O
in,852,O
a,852,O
highly,852,O
conserved,852,O
amino-acid,852,O
residue,852,O
(,852,O
p.Asp25Asn,852,B-SequenceVariant
),852,O
.,852,O
In,853,O
a,853,O
mzm1D,853,B-GeneOrGeneProduct
yeast,853,B-OrganismTaxon
strain,853,O
",",853,O
the,853,O
expression,853,O
of,853,O
a,853,O
mzm1,853,B-GeneOrGeneProduct
(,853,O
D25N,853,B-SequenceVariant
),853,O
mutant,853,O
allele,853,O
caused,853,O
temperature-sensitive,853,O
respiratory,853,B-DiseaseOrPhenotypicFeature
growth,853,I-DiseaseOrPhenotypicFeature
defect,853,I-DiseaseOrPhenotypicFeature
",",853,O
decreased,853,O
oxygen,853,B-ChemicalEntity
consumption,853,O
",",853,O
impaired,853,O
maturation/stabilization,853,O
of,853,O
the,853,O
Rieske,853,B-GeneOrGeneProduct
Fe-S,853,I-GeneOrGeneProduct
protein,853,I-GeneOrGeneProduct
",",853,O
and,853,O
reduced,853,O
complex,853,B-GeneOrGeneProduct
III,853,I-GeneOrGeneProduct
activity,853,O
and,853,O
amount,853,O
.,853,O
LYRM7/MZM1L,854,B-GeneOrGeneProduct
is,854,O
a,854,O
novel,854,O
disease,854,O
gene,854,O
",",854,O
causing,854,O
cIII-defective,854,B-DiseaseOrPhenotypicFeature
",",854,O
early,854,O
onset,854,O
",",854,O
severe,854,O
mitochondrial,854,B-DiseaseOrPhenotypicFeature
encephalopathy,854,I-DiseaseOrPhenotypicFeature
.,854,O
CTR9/PAF1c,855,B-GeneOrGeneProduct
regulates,855,O
molecular,855,O
lineage,855,O
identity,855,O
",",855,O
histone,855,B-GeneOrGeneProduct
H3K36,855,O
trimethylation,855,O
and,855,O
genomic,855,O
imprinting,855,O
during,855,O
preimplantation,855,O
development,855,O
.,855,O
Genome-wide,856,O
epigenetic,856,O
reprogramming,856,O
is,856,O
required,856,O
for,856,O
successful,856,O
preimplantation,856,O
development,856,O
.,856,O
Inappropriate,857,O
or,857,O
deficient,857,O
chromatin,857,O
regulation,857,O
can,857,O
result,857,O
in,857,O
defective,857,O
lineage,857,O
specification,857,O
and,857,O
loss,857,O
of,857,O
genomic,857,O
imprinting,857,O
",",857,O
compromising,857,O
normal,857,O
development,857,O
.,857,O
Here,858,O
we,858,O
report,858,O
that,858,O
two,858,O
members,858,O
of,858,O
the,858,O
RNA,858,B-GeneOrGeneProduct
polymerase,858,I-GeneOrGeneProduct
II,858,I-GeneOrGeneProduct
associated,858,I-GeneOrGeneProduct
factor,858,I-GeneOrGeneProduct
",",858,I-GeneOrGeneProduct
homolog,858,I-GeneOrGeneProduct
(,858,I-GeneOrGeneProduct
Saccharomyces,858,I-GeneOrGeneProduct
cerevisiae,858,I-GeneOrGeneProduct
),858,I-GeneOrGeneProduct
complex,858,I-GeneOrGeneProduct
(,858,O
PAF1,858,B-GeneOrGeneProduct
complex,858,I-GeneOrGeneProduct
),858,O
components,858,O
",",858,O
Ctr9,858,B-GeneOrGeneProduct
and,858,O
Rtf1,858,B-GeneOrGeneProduct
",",858,O
are,858,O
required,858,O
during,858,O
mammalian,858,O
preimplantation,858,O
development,858,O
.,858,O
We,859,O
demonstrate,859,O
that,859,O
Ctr9-deficient,859,B-GeneOrGeneProduct
embryos,859,O
fail,859,O
to,859,O
correctly,859,O
specify,859,O
lineages,859,O
at,859,O
the,859,O
blastocyst,859,O
stage,859,O
.,859,O
Expression,860,O
of,860,O
some,860,O
lineage,860,O
specific,860,O
factors,860,O
is,860,O
markedly,860,O
reduced,860,O
in,860,O
Ctr9,860,B-GeneOrGeneProduct
knockdown,860,O
embryos,860,O
",",860,O
including,860,O
Eomes,860,B-GeneOrGeneProduct
",",860,O
Elf5,860,B-GeneOrGeneProduct
and,860,O
Sox2,860,B-GeneOrGeneProduct
",",860,O
while,860,O
others,860,O
are,860,O
inappropriately,860,O
expressed,860,O
(,860,O
Oct4,860,B-GeneOrGeneProduct
",",860,O
Nanog,860,B-GeneOrGeneProduct
",",860,O
Gata6,860,B-GeneOrGeneProduct
",",860,O
Fgf4,860,B-GeneOrGeneProduct
and,860,O
Sox17,860,B-GeneOrGeneProduct
),860,O
.,860,O
We,861,O
also,861,O
show,861,O
that,861,O
several,861,O
imprinted,861,O
genes,861,O
(,861,O
Mest,861,B-GeneOrGeneProduct
",",861,O
Peg3,861,B-GeneOrGeneProduct
",",861,O
Snrpn,861,B-GeneOrGeneProduct
and,861,O
Meg3,861,B-GeneOrGeneProduct
),861,O
are,861,O
aberrantly,861,O
expressed,861,O
although,861,O
allele,861,O
specific,861,O
DNA,861,O
methylation,861,O
is,861,O
not,861,O
altered,861,O
.,861,O
We,862,O
document,862,O
a,862,O
loss,862,O
of,862,O
histone,862,B-GeneOrGeneProduct
H3,862,I-GeneOrGeneProduct
lysine,862,O
36,862,O
trimethylation,862,O
(,862,O
H3K36me3,862,B-GeneOrGeneProduct
),862,O
in,862,O
Ctr9-deficient,862,B-GeneOrGeneProduct
embryos,862,O
and,862,O
confirm,862,O
that,862,O
knockdown,862,O
of,862,O
either,862,O
Setd2,862,B-GeneOrGeneProduct
or,862,O
Rtf1,862,B-GeneOrGeneProduct
results,862,O
in,862,O
similar,862,O
phenotypes,862,O
.,862,O
These,863,O
findings,863,O
show,863,O
that,863,O
the,863,O
PAF1,863,B-GeneOrGeneProduct
complex,863,I-GeneOrGeneProduct
is,863,O
required,863,O
for,863,O
mammalian,863,O
development,863,O
",",863,O
likely,863,O
through,863,O
regulation,863,O
of,863,O
H3K36me3,863,B-GeneOrGeneProduct
",",863,O
and,863,O
indicate,863,O
functional,863,O
conservation,863,O
of,863,O
the,863,O
PAF1,863,B-GeneOrGeneProduct
complex,863,I-GeneOrGeneProduct
from,863,O
yeast,863,B-OrganismTaxon
to,863,O
mammals,863,O
in,863,O
vivo,863,O
.,863,O
Association,864,O
of,864,O
a,864,O
FGFR-4,864,B-GeneOrGeneProduct
gene,864,O
polymorphism,864,O
with,864,O
bronchopulmonary,864,B-DiseaseOrPhenotypicFeature
dysplasia,864,I-DiseaseOrPhenotypicFeature
and,864,O
neonatal,864,B-DiseaseOrPhenotypicFeature
respiratory,864,I-DiseaseOrPhenotypicFeature
distress,864,I-DiseaseOrPhenotypicFeature
.,864,O
BACKGROUND,865,O
:,865,O
Bronchopulmonary,865,B-DiseaseOrPhenotypicFeature
dysplasia,865,I-DiseaseOrPhenotypicFeature
(,865,O
BPD,865,B-DiseaseOrPhenotypicFeature
),865,O
is,865,O
the,865,O
most,865,O
common,865,O
chronic,865,O
lung,865,B-DiseaseOrPhenotypicFeature
disease,865,I-DiseaseOrPhenotypicFeature
of,865,O
premature,865,B-DiseaseOrPhenotypicFeature
birth,865,I-DiseaseOrPhenotypicFeature
",",865,O
characterized,865,O
by,865,O
impaired,865,B-DiseaseOrPhenotypicFeature
alveolar,865,I-DiseaseOrPhenotypicFeature
development,865,I-DiseaseOrPhenotypicFeature
and,865,O
inflammation,865,B-DiseaseOrPhenotypicFeature
.,865,O
Pathomechanisms,866,O
contributing,866,O
to,866,O
BPD,866,B-DiseaseOrPhenotypicFeature
are,866,O
poorly,866,O
understood,866,O
.,866,O
However,867,O
",",867,O
it,867,O
is,867,O
assumed,867,O
that,867,O
genetic,867,O
factors,867,O
predispose,867,O
to,867,O
BPD,867,B-DiseaseOrPhenotypicFeature
and,867,O
other,867,O
pulmonary,867,B-DiseaseOrPhenotypicFeature
diseases,867,I-DiseaseOrPhenotypicFeature
of,867,O
preterm,867,O
neonates,867,O
",",867,O
such,867,O
as,867,O
neonatal,867,B-DiseaseOrPhenotypicFeature
respiratory,867,I-DiseaseOrPhenotypicFeature
distress,867,I-DiseaseOrPhenotypicFeature
syndrome,867,I-DiseaseOrPhenotypicFeature
(,867,O
RDS,867,B-DiseaseOrPhenotypicFeature
),867,O
.,867,O
For,868,O
association,868,O
studies,868,O
",",868,O
genes,868,O
upregulated,868,O
during,868,O
alveolarization,868,O
are,868,O
major,868,O
candidates,868,O
for,868,O
genetic,868,O
analysis,868,O
",",868,O
for,868,O
example,868,O
",",868,O
matrix,868,B-GeneOrGeneProduct
metalloproteinases,868,I-GeneOrGeneProduct
(,868,O
MMPs,868,B-GeneOrGeneProduct
),868,O
and,868,O
fibroblast,868,B-GeneOrGeneProduct
growth,868,I-GeneOrGeneProduct
factors,868,I-GeneOrGeneProduct
(,868,O
FGFs,868,B-GeneOrGeneProduct
),868,O
and,868,O
their,868,O
receptors,868,O
(,868,O
FGFR,868,B-GeneOrGeneProduct
),868,O
.,868,O
OBJECTIVE,869,O
:,869,O
Determining,869,O
genetic,869,O
risk,869,O
variants,869,O
in,869,O
a,869,O
Caucasian,869,O
population,869,O
of,869,O
premature,869,O
neonates,869,O
with,869,O
BPD,869,B-DiseaseOrPhenotypicFeature
and,869,O
RDS,869,B-DiseaseOrPhenotypicFeature
.,869,O
Methods,870,O
.,870,O
We,871,O
genotyped,871,O
27,871,O
polymorphisms,871,O
within,871,O
14,871,O
candidate,871,O
genes,871,O
via,871,O
restriction,871,O
fragment,871,O
length,871,O
polymorphism,871,O
(,871,O
RFLP,871,O
),871,O
:,871,O
MMP-1,871,B-GeneOrGeneProduct
",",871,I-GeneOrGeneProduct
-2,871,I-GeneOrGeneProduct
",",871,I-GeneOrGeneProduct
-9,871,I-GeneOrGeneProduct
",",871,I-GeneOrGeneProduct
and,871,I-GeneOrGeneProduct
-12,871,I-GeneOrGeneProduct
",",871,I-GeneOrGeneProduct
-16,871,I-GeneOrGeneProduct
",",871,O
FGF,871,B-GeneOrGeneProduct
receptors,871,I-GeneOrGeneProduct
2,871,I-GeneOrGeneProduct
and,871,I-GeneOrGeneProduct
4,871,I-GeneOrGeneProduct
",",871,O
FGF-2,871,B-GeneOrGeneProduct
",",871,I-GeneOrGeneProduct
-3,871,I-GeneOrGeneProduct
",",871,I-GeneOrGeneProduct
-4,871,I-GeneOrGeneProduct
",",871,I-GeneOrGeneProduct
-7,871,I-GeneOrGeneProduct
",",871,I-GeneOrGeneProduct
and,871,I-GeneOrGeneProduct
-18,871,I-GeneOrGeneProduct
",",871,O
Signal-Regulatory,871,B-GeneOrGeneProduct
Protein,871,I-GeneOrGeneProduct
a,871,I-GeneOrGeneProduct
(,871,O
SIRPA,871,B-GeneOrGeneProduct
),871,O
and,871,O
Thyroid,871,B-GeneOrGeneProduct
Transcription,871,I-GeneOrGeneProduct
Factor-1,871,I-GeneOrGeneProduct
(,871,O
TTF-1,871,B-GeneOrGeneProduct
),871,O
.,871,O
RESULTS,872,O
:,872,O
Five,872,O
single,872,O
nucleotide,872,O
polymorphisms,872,O
(,872,O
SNPs,872,O
),872,O
in,872,O
MMP-9,872,B-GeneOrGeneProduct
",",872,O
MMP-12,872,B-GeneOrGeneProduct
",",872,O
FGFR-4,872,B-GeneOrGeneProduct
",",872,O
FGF-3,872,B-GeneOrGeneProduct
",",872,O
and,872,O
FGF-7,872,B-GeneOrGeneProduct
are,872,O
associated,872,O
(,872,O
P,872,O
<,872,O
0.05,872,O
),872,O
with,872,O
RDS,872,B-DiseaseOrPhenotypicFeature
",",872,O
defined,872,O
as,872,O
surfactant,872,O
application,872,O
within,872,O
the,872,O
first,872,O
24,872,O
hours,872,O
after,872,O
birth,872,O
.,872,O
One,873,O
of,873,O
them,873,O
",",873,O
in,873,O
FGFR-4,873,B-GeneOrGeneProduct
(,873,O
rs1966265,873,B-SequenceVariant
),873,O
",",873,O
is,873,O
associated,873,O
with,873,O
both,873,O
RDS,873,B-DiseaseOrPhenotypicFeature
(,873,O
P,873,O
=,873,O
0.003,873,O
),873,O
and,873,O
BPD,873,B-DiseaseOrPhenotypicFeature
(,873,O
P,873,O
=,873,O
0.023,873,O
),873,O
.,873,O
CONCLUSION,874,O
:,874,O
rs1966265,874,B-SequenceVariant
in,874,O
FGF,874,B-GeneOrGeneProduct
receptor,874,I-GeneOrGeneProduct
4,874,I-GeneOrGeneProduct
is,874,O
a,874,O
possible,874,O
genetic,874,O
key,874,O
variant,874,O
in,874,O
alveolar,874,B-DiseaseOrPhenotypicFeature
diseases,874,I-DiseaseOrPhenotypicFeature
of,874,O
preterm,874,O
newborns,874,O
.,874,O
Glial,875,O
activation,875,O
and,875,O
post-synaptic,875,O
neurotoxicity,875,B-DiseaseOrPhenotypicFeature
:,875,O
the,875,O
key,875,O
events,875,O
in,875,O
Streptozotocin,875,B-ChemicalEntity
(,875,O
ICV,875,O
),875,O
induced,875,O
memory,875,B-DiseaseOrPhenotypicFeature
impairment,875,I-DiseaseOrPhenotypicFeature
in,875,O
rats,875,B-OrganismTaxon
.,875,O
In,876,O
the,876,O
present,876,O
study,876,O
the,876,O
role,876,O
of,876,O
glial,876,O
activation,876,O
and,876,O
post,876,O
synaptic,876,O
toxicity,876,B-DiseaseOrPhenotypicFeature
in,876,O
ICV,876,O
Streptozotocin,876,B-ChemicalEntity
(,876,O
STZ,876,B-ChemicalEntity
),876,O
induced,876,O
memory,876,B-DiseaseOrPhenotypicFeature
impaired,876,I-DiseaseOrPhenotypicFeature
rats,876,B-OrganismTaxon
was,876,O
explored,876,O
.,876,O
In,877,O
experiment,877,O
set,877,O
up,877,O
1,877,O
:,877,O
Memory,877,B-DiseaseOrPhenotypicFeature
deficit,877,I-DiseaseOrPhenotypicFeature
was,877,O
found,877,O
in,877,O
Morris,877,O
water,877,O
maze,877,O
test,877,O
on,877,O
14-16,877,O
days,877,O
after,877,O
STZ,877,B-ChemicalEntity
(,877,O
ICV,877,O
;,877,O
3mg/Kg,877,O
),877,O
administration,877,O
.,877,O
STZ,878,B-ChemicalEntity
causes,878,O
increased,878,O
expression,878,O
of,878,O
GFAP,878,B-GeneOrGeneProduct
",",878,O
CD11b,878,B-GeneOrGeneProduct
and,878,O
TNF-a,878,B-GeneOrGeneProduct
indicating,878,O
glial,878,O
activation,878,O
and,878,O
neuroinflammation,878,B-DiseaseOrPhenotypicFeature
.,878,O
STZ,879,B-ChemicalEntity
also,879,O
significantly,879,O
increased,879,O
the,879,O
level,879,O
of,879,O
ROS,879,B-ChemicalEntity
",",879,O
nitrite,879,B-ChemicalEntity
",",879,O
Ca,879,B-ChemicalEntity
(,879,I-ChemicalEntity
2+,879,I-ChemicalEntity
),879,I-ChemicalEntity
and,879,O
reduced,879,O
the,879,O
mitochondrial,879,O
activity,879,O
in,879,O
synaptosomal,879,O
preparation,879,O
illustrating,879,O
free,879,O
radical,879,O
generation,879,O
and,879,O
excitotoxicity,879,B-DiseaseOrPhenotypicFeature
.,879,O
Increased,880,O
expression,880,O
and,880,O
activity,880,O
of,880,O
Caspase-3,880,B-GeneOrGeneProduct
was,880,O
also,880,O
observed,880,O
in,880,O
STZ,880,B-ChemicalEntity
treated,880,O
rat,880,B-OrganismTaxon
which,880,O
specify,880,O
apoptotic,880,O
cell,880,O
death,880,O
in,880,O
hippocampus,880,O
and,880,O
cortex,880,O
.,880,O
STZ,881,B-ChemicalEntity
treatment,881,O
showed,881,O
decrease,881,O
expression,881,O
of,881,O
post,881,O
synaptic,881,O
markers,881,O
CaMKIIa,881,B-GeneOrGeneProduct
and,881,O
PSD-95,881,B-GeneOrGeneProduct
",",881,O
while,881,O
",",881,O
expression,881,O
of,881,O
pre,881,O
synaptic,881,O
markers,881,O
(,881,O
synaptophysin,881,B-GeneOrGeneProduct
and,881,O
SNAP-25,881,B-GeneOrGeneProduct
),881,O
remains,881,O
unaltered,881,O
indicating,881,O
selective,881,O
post,881,O
synaptic,881,O
neurotoxicity,881,B-DiseaseOrPhenotypicFeature
.,881,O
Oral,882,O
treatment,882,O
with,882,O
Memantine,882,B-ChemicalEntity
(,882,O
10mg/kg,882,O
),882,O
and,882,O
Ibuprofen,882,B-ChemicalEntity
(,882,O
50,882,O
mg/kg,882,O
),882,O
daily,882,O
for,882,O
13,882,O
days,882,O
attenuated,882,O
STZ,882,B-ChemicalEntity
induced,882,O
glial,882,O
activation,882,O
",",882,O
apoptotic,882,O
cell,882,O
death,882,O
and,882,O
post,882,O
synaptic,882,O
neurotoxicity,882,B-DiseaseOrPhenotypicFeature
in,882,O
rat,882,B-OrganismTaxon
brain,882,O
.,882,O
Further,883,O
",",883,O
in,883,O
experiment,883,O
set,883,O
up,883,O
2,883,O
:,883,O
where,883,O
memory,883,O
function,883,O
was,883,O
not,883,O
affected,883,O
i.e,883,O
.,883,O
7-9,884,O
days,884,O
after,884,O
STZ,884,B-ChemicalEntity
treatment,884,O
.,884,O
The,885,O
level,885,O
of,885,O
GFAP,885,B-GeneOrGeneProduct
",",885,O
CD11b,885,B-GeneOrGeneProduct
",",885,O
TNF-a,885,B-GeneOrGeneProduct
",",885,O
ROS,885,B-ChemicalEntity
and,885,O
nitrite,885,B-ChemicalEntity
levels,885,O
were,885,O
increased,885,O
.,885,O
On,886,O
the,886,O
other,886,O
hand,886,O
",",886,O
apoptotic,886,O
marker,886,O
",",886,O
synaptic,886,O
markers,886,O
",",886,O
mitochondrial,886,O
activity,886,O
and,886,O
Ca,886,B-ChemicalEntity
(,886,I-ChemicalEntity
2+,886,I-ChemicalEntity
),886,I-ChemicalEntity
levels,886,O
remained,886,O
unaffected,886,O
.,886,O
Collective,887,O
data,887,O
indicates,887,O
that,887,O
neuroinflammatory,887,B-DiseaseOrPhenotypicFeature
process,887,O
and,887,O
oxidative,887,O
stress,887,O
occurs,887,O
earlier,887,O
to,887,O
apoptosis,887,O
and,887,O
does,887,O
not,887,O
affect,887,O
memory,887,O
function,887,O
.,887,O
Present,888,O
study,888,O
clearly,888,O
suggests,888,O
that,888,O
glial,888,O
activation,888,O
and,888,O
post,888,O
synaptic,888,O
neurotoxicity,888,B-DiseaseOrPhenotypicFeature
are,888,O
the,888,O
key,888,O
factors,888,O
in,888,O
STZ,888,B-ChemicalEntity
induced,888,O
memory,888,B-DiseaseOrPhenotypicFeature
impairment,888,I-DiseaseOrPhenotypicFeature
and,888,O
neuronal,888,O
cell,888,O
death,888,O
.,888,O
Pre-treatment,889,O
of,889,O
bupivacaine-induced,889,B-ChemicalEntity
cardiovascular,889,B-DiseaseOrPhenotypicFeature
depression,889,I-DiseaseOrPhenotypicFeature
using,889,O
different,889,O
lipid,889,B-ChemicalEntity
formulations,889,O
of,889,O
propofol,889,B-ChemicalEntity
.,889,O
BACKGROUND,890,O
:,890,O
Pre-treatment,890,O
with,890,O
lipid,890,B-ChemicalEntity
emulsions,890,I-ChemicalEntity
has,890,O
been,890,O
shown,890,O
to,890,O
increase,890,O
lethal,890,O
doses,890,O
of,890,O
bupivacaine,890,B-ChemicalEntity
",",890,O
and,890,O
the,890,O
lipid,890,B-ChemicalEntity
content,890,O
of,890,O
propofol,890,B-ChemicalEntity
may,890,O
alleviate,890,O
bupivacaine-induced,890,B-ChemicalEntity
cardiotoxicity,890,B-DiseaseOrPhenotypicFeature
.,890,O
The,891,O
aim,891,O
of,891,O
this,891,O
study,891,O
is,891,O
to,891,O
investigate,891,O
the,891,O
effects,891,O
of,891,O
propofol,891,B-ChemicalEntity
in,891,O
intralipid,891,B-ChemicalEntity
or,891,O
medialipid,891,B-ChemicalEntity
emulsions,891,O
on,891,O
bupivacaine-induced,891,B-ChemicalEntity
cardiotoxicity,891,B-DiseaseOrPhenotypicFeature
.,891,O
METHODS,892,O
:,892,O
Rats,892,B-OrganismTaxon
were,892,O
anaesthetised,892,O
with,892,O
ketamine,892,B-ChemicalEntity
and,892,O
were,892,O
given,892,O
0.5,892,O
mg/kg/min,892,O
propofol,892,B-ChemicalEntity
in,892,O
intralipid,892,B-ChemicalEntity
(,892,O
Group,892,O
P,892,O
),892,O
",",892,O
propofol,892,B-ChemicalEntity
in,892,O
medialipid,892,B-ChemicalEntity
(,892,O
Group,892,O
L,892,O
),892,O
",",892,O
or,892,O
saline,892,O
(,892,O
Group,892,O
C,892,O
),892,O
over,892,O
20,892,O
min,892,O
.,892,O
Thereafter,893,O
",",893,O
2,893,O
mg/kg/min,893,O
bupivacaine,893,B-ChemicalEntity
0.5,893,O
%,893,O
was,893,O
infused,893,O
.,893,O
We,894,O
recorded,894,O
time,894,O
to,894,O
first,894,O
dysrhythmia,894,B-DiseaseOrPhenotypicFeature
occurrence,894,O
",",894,O
respective,894,O
times,894,O
to,894,O
25,894,O
%,894,O
and,894,O
50,894,O
%,894,O
reduction,894,O
of,894,O
the,894,O
heart,894,O
rate,894,O
(,894,O
HR,894,O
),894,O
and,894,O
mean,894,O
arterial,894,O
pressure,894,O
",",894,O
and,894,O
time,894,O
to,894,O
asystole,894,B-DiseaseOrPhenotypicFeature
and,894,O
total,894,O
amount,894,O
of,894,O
bupivacaine,894,B-ChemicalEntity
consumption,894,O
.,894,O
Blood,895,O
and,895,O
tissue,895,O
samples,895,O
were,895,O
collected,895,O
following,895,O
asystole,895,B-DiseaseOrPhenotypicFeature
.,895,O
RESULTS,896,O
:,896,O
The,896,O
time,896,O
to,896,O
first,896,O
dysrhythmia,896,B-DiseaseOrPhenotypicFeature
occurrence,896,O
",",896,O
time,896,O
to,896,O
25,896,O
%,896,O
and,896,O
50,896,O
%,896,O
reductions,896,O
in,896,O
HR,896,O
",",896,O
and,896,O
time,896,O
to,896,O
asystole,896,B-DiseaseOrPhenotypicFeature
were,896,O
longer,896,O
in,896,O
Group,896,O
P,896,O
than,896,O
the,896,O
other,896,O
groups,896,O
.,896,O
The,897,O
cumulative,897,O
bupivacaine,897,B-ChemicalEntity
dose,897,O
given,897,O
at,897,O
those,897,O
time,897,O
points,897,O
was,897,O
higher,897,O
in,897,O
Group,897,O
P.,897,O
Plasma,897,O
bupivacaine,897,B-ChemicalEntity
levels,897,O
were,897,O
significantly,897,O
lower,897,O
in,897,O
Group,897,O
P,897,O
than,897,O
in,897,O
Group,897,O
C.,897,O
Bupivacaine,897,B-ChemicalEntity
levels,897,O
in,897,O
the,897,O
brain,897,O
and,897,O
heart,897,O
were,897,O
significantly,897,O
lower,897,O
in,897,O
Group,897,O
P,897,O
and,897,O
Group,897,O
L,897,O
than,897,O
in,897,O
Group,897,O
C.,897,O
CONCLUSION,897,O
:,897,O
We,897,O
conclude,897,O
that,897,O
pre-treatment,897,O
with,897,O
propofol,897,B-ChemicalEntity
in,897,O
intralipid,897,B-ChemicalEntity
",",897,O
compared,897,O
with,897,O
propofol,897,B-ChemicalEntity
in,897,O
medialipid,897,B-ChemicalEntity
or,897,O
saline,897,O
",",897,O
delayed,897,O
the,897,O
onset,897,O
of,897,O
bupivacaine-induced,897,B-ChemicalEntity
cardiotoxic,897,B-DiseaseOrPhenotypicFeature
effects,897,O
as,897,O
well,897,O
as,897,O
reduced,897,O
plasma,897,O
bupivacaine,897,B-ChemicalEntity
levels,897,O
.,897,O
Further,898,O
studies,898,O
are,898,O
needed,898,O
to,898,O
explore,898,O
tissue,898,O
bupivacaine,898,B-ChemicalEntity
levels,898,O
of,898,O
propofol,898,B-ChemicalEntity
in,898,O
medialipid,898,B-ChemicalEntity
and,898,O
adapt,898,O
these,898,O
results,898,O
to,898,O
clinical,898,O
practice,898,O
.,898,O
Regulation,899,O
of,899,O
signal,899,B-GeneOrGeneProduct
transducer,899,I-GeneOrGeneProduct
and,899,I-GeneOrGeneProduct
activator,899,I-GeneOrGeneProduct
of,899,I-GeneOrGeneProduct
transcription,899,I-GeneOrGeneProduct
3,899,I-GeneOrGeneProduct
and,899,O
apoptotic,899,O
pathways,899,O
by,899,O
betaine,899,B-ChemicalEntity
attenuates,899,O
isoproterenol-induced,899,B-ChemicalEntity
acute,899,O
myocardial,899,B-DiseaseOrPhenotypicFeature
injury,899,I-DiseaseOrPhenotypicFeature
in,899,O
rats,899,B-OrganismTaxon
.,899,O
The,900,O
present,900,O
study,900,O
was,900,O
designed,900,O
to,900,O
investigate,900,O
the,900,O
cardioprotective,900,O
effects,900,O
of,900,O
betaine,900,B-ChemicalEntity
on,900,O
acute,900,O
myocardial,900,B-DiseaseOrPhenotypicFeature
ischemia,900,I-DiseaseOrPhenotypicFeature
induced,900,O
experimentally,900,O
in,900,O
rats,900,B-OrganismTaxon
focusing,900,O
on,900,O
regulation,900,O
of,900,O
signal,900,B-GeneOrGeneProduct
transducer,900,I-GeneOrGeneProduct
and,900,I-GeneOrGeneProduct
activator,900,I-GeneOrGeneProduct
of,900,I-GeneOrGeneProduct
transcription,900,I-GeneOrGeneProduct
3,900,I-GeneOrGeneProduct
(,900,O
STAT3,900,B-GeneOrGeneProduct
),900,O
and,900,O
apoptotic,900,O
pathways,900,O
as,900,O
the,900,O
potential,900,O
mechanism,900,O
underlying,900,O
the,900,O
drug,900,O
effect,900,O
.,900,O
Male,901,O
Sprague,901,O
Dawley,901,O
rats,901,B-OrganismTaxon
were,901,O
treated,901,O
with,901,O
betaine,901,B-ChemicalEntity
(,901,O
100,901,O
",",901,O
200,901,O
",",901,O
and,901,O
400,901,O
mg/kg,901,O
),901,O
orally,901,O
for,901,O
40,901,O
days,901,O
.,901,O
Acute,902,O
myocardial,902,B-DiseaseOrPhenotypicFeature
ischemic,902,I-DiseaseOrPhenotypicFeature
injury,902,I-DiseaseOrPhenotypicFeature
was,902,O
induced,902,O
in,902,O
rats,902,B-OrganismTaxon
by,902,O
subcutaneous,902,O
injection,902,O
of,902,O
isoproterenol,902,B-ChemicalEntity
(,902,O
85,902,O
mg/kg,902,O
),902,O
",",902,O
for,902,O
two,902,O
consecutive,902,O
days,902,O
.,902,O
Serum,903,O
cardiac,903,O
marker,903,O
enzyme,903,O
",",903,O
histopathological,903,O
variables,903,O
and,903,O
expression,903,O
of,903,O
protein,903,O
levels,903,O
were,903,O
analyzed,903,O
.,903,O
Oral,904,O
administration,904,O
of,904,O
betaine,904,B-ChemicalEntity
(,904,O
200,904,O
and,904,O
400,904,O
mg/kg,904,O
),904,O
significantly,904,O
reduced,904,O
the,904,O
level,904,O
of,904,O
cardiac,904,O
marker,904,O
enzyme,904,O
in,904,O
the,904,O
serum,904,O
and,904,O
prevented,904,O
left,904,O
ventricular,904,B-DiseaseOrPhenotypicFeature
remodeling,904,I-DiseaseOrPhenotypicFeature
.,904,O
Western,905,O
blot,905,O
analysis,905,O
showed,905,O
that,905,O
isoproterenol-induced,905,B-ChemicalEntity
phosphorylation,905,O
of,905,O
STAT3,905,B-GeneOrGeneProduct
was,905,O
maintained,905,O
or,905,O
further,905,O
enhanced,905,O
by,905,O
betaine,905,B-ChemicalEntity
treatment,905,O
in,905,O
myocardium,905,O
.,905,O
Furthermore,906,O
",",906,O
betaine,906,B-ChemicalEntity
(,906,O
200,906,O
and,906,O
400,906,O
mg/kg,906,O
),906,O
treatment,906,O
increased,906,O
the,906,O
ventricular,906,O
expression,906,O
of,906,O
Bcl-2,906,B-GeneOrGeneProduct
and,906,O
reduced,906,O
the,906,O
level,906,O
of,906,O
Bax,906,B-GeneOrGeneProduct
",",906,O
therefore,906,O
causing,906,O
a,906,O
significant,906,O
increase,906,O
in,906,O
the,906,O
ratio,906,O
of,906,O
Bcl-2/Bax,906,B-GeneOrGeneProduct
.,906,O
The,907,O
protective,907,O
role,907,O
of,907,O
betaine,907,B-ChemicalEntity
on,907,O
myocardial,907,B-DiseaseOrPhenotypicFeature
damage,907,I-DiseaseOrPhenotypicFeature
was,907,O
further,907,O
confirmed,907,O
by,907,O
histopathological,907,O
examination,907,O
.,907,O
In,908,O
summary,908,O
",",908,O
our,908,O
results,908,O
showed,908,O
that,908,O
betaine,908,B-ChemicalEntity
pretreatment,908,O
attenuated,908,O
isoproterenol-induced,908,B-ChemicalEntity
acute,908,O
myocardial,908,B-DiseaseOrPhenotypicFeature
ischemia,908,I-DiseaseOrPhenotypicFeature
via,908,O
the,908,O
regulation,908,O
of,908,O
STAT3,908,B-GeneOrGeneProduct
and,908,O
apoptotic,908,O
pathways,908,O
.,908,O
Curcumin,909,B-ChemicalEntity
prevents,909,O
maleate-induced,909,B-ChemicalEntity
nephrotoxicity,909,B-DiseaseOrPhenotypicFeature
:,909,O
relation,909,O
to,909,O
hemodynamic,909,O
alterations,909,O
",",909,O
oxidative,909,O
stress,909,O
",",909,O
mitochondrial,909,O
oxygen,909,B-ChemicalEntity
consumption,909,O
and,909,O
activity,909,O
of,909,O
respiratory,909,B-ChemicalEntity
complex,909,I-ChemicalEntity
I,909,I-ChemicalEntity
.,909,O
The,910,O
potential,910,O
protective,910,O
effect,910,O
of,910,O
the,910,O
dietary,910,O
antioxidant,910,O
curcumin,910,B-ChemicalEntity
(,910,O
120,910,O
mg/Kg/day,910,O
for,910,O
6,910,O
days,910,O
),910,O
against,910,O
the,910,O
renal,910,B-DiseaseOrPhenotypicFeature
injury,910,I-DiseaseOrPhenotypicFeature
induced,910,O
by,910,O
maleate,910,B-ChemicalEntity
was,910,O
evaluated,910,O
.,910,O
Tubular,911,O
proteinuria,911,B-DiseaseOrPhenotypicFeature
and,911,O
oxidative,911,O
stress,911,O
were,911,O
induced,911,O
by,911,O
a,911,O
single,911,O
injection,911,O
of,911,O
maleate,911,B-ChemicalEntity
(,911,O
400,911,O
mg/kg,911,O
),911,O
in,911,O
rats,911,B-OrganismTaxon
.,911,O
Maleate-induced,912,B-ChemicalEntity
renal,912,B-DiseaseOrPhenotypicFeature
injury,912,I-DiseaseOrPhenotypicFeature
included,912,O
increase,912,O
in,912,O
renal,912,O
vascular,912,O
resistance,912,O
and,912,O
in,912,O
the,912,O
urinary,912,O
excretion,912,O
of,912,O
total,912,O
protein,912,O
",",912,O
glucose,912,B-ChemicalEntity
",",912,O
sodium,912,B-ChemicalEntity
",",912,O
neutrophil,912,B-GeneOrGeneProduct
gelatinase-associated,912,I-GeneOrGeneProduct
lipocalin,912,I-GeneOrGeneProduct
(,912,O
NGAL,912,B-GeneOrGeneProduct
),912,O
and,912,O
N-acetyl,912,B-GeneOrGeneProduct
b-D-glucosaminidase,912,I-GeneOrGeneProduct
(,912,O
NAG,912,B-GeneOrGeneProduct
),912,O
",",912,O
upregulation,912,O
of,912,O
kidney,912,B-GeneOrGeneProduct
injury,912,I-GeneOrGeneProduct
molecule,912,I-GeneOrGeneProduct
(,912,I-GeneOrGeneProduct
KIM,912,I-GeneOrGeneProduct
),912,I-GeneOrGeneProduct
-1,912,I-GeneOrGeneProduct
",",912,O
decrease,912,O
in,912,O
renal,912,O
blood,912,O
flow,912,O
and,912,O
claudin-2,912,B-GeneOrGeneProduct
expression,912,O
besides,912,O
of,912,O
necrosis,912,B-DiseaseOrPhenotypicFeature
and,912,I-DiseaseOrPhenotypicFeature
apoptosis,912,I-DiseaseOrPhenotypicFeature
of,912,I-DiseaseOrPhenotypicFeature
tubular,912,I-DiseaseOrPhenotypicFeature
cells,912,I-DiseaseOrPhenotypicFeature
on,912,O
24,912,O
h.,912,O
Oxidative,912,O
stress,912,O
was,912,O
determined,912,O
by,912,O
measuring,912,O
the,912,O
oxidation,912,O
of,912,O
lipids,912,B-ChemicalEntity
and,912,O
proteins,912,O
and,912,O
diminution,912,O
in,912,O
renal,912,O
Nrf2,912,B-GeneOrGeneProduct
levels,912,O
.,912,O
Studies,913,O
were,913,O
also,913,O
conducted,913,O
in,913,O
renal,913,O
epithelial,913,O
LLC-PK1,913,B-CellLine
cells,913,O
and,913,O
in,913,O
mitochondria,913,O
isolated,913,O
from,913,O
kidneys,913,O
of,913,O
all,913,O
the,913,O
experimental,913,O
groups,913,O
.,913,O
Maleate,914,B-ChemicalEntity
induced,914,O
cell,914,O
damage,914,O
and,914,O
reactive,914,B-ChemicalEntity
oxygen,914,I-ChemicalEntity
species,914,I-ChemicalEntity
(,914,O
ROS,914,B-ChemicalEntity
),914,O
production,914,O
in,914,O
LLC-PK1,914,B-CellLine
cells,914,O
in,914,O
culture,914,O
.,914,O
In,915,O
addition,915,O
",",915,O
maleate,915,B-ChemicalEntity
treatment,915,O
reduced,915,O
oxygen,915,B-ChemicalEntity
consumption,915,O
in,915,O
ADP-stimulated,915,B-ChemicalEntity
mitochondria,915,O
and,915,O
diminished,915,O
respiratory,915,O
control,915,O
index,915,O
when,915,O
using,915,O
malate/glutamate,915,B-ChemicalEntity
as,915,O
substrate,915,O
.,915,O
The,916,O
activities,916,O
of,916,O
both,916,O
complex,916,O
I,916,O
and,916,O
aconitase,916,B-GeneOrGeneProduct
were,916,O
also,916,O
diminished,916,O
.,916,O
All,917,O
the,917,O
above-described,917,O
alterations,917,O
were,917,O
prevented,917,O
by,917,O
curcumin,917,B-ChemicalEntity
.,917,O
It,918,O
is,918,O
concluded,918,O
that,918,O
curcumin,918,B-ChemicalEntity
is,918,O
able,918,O
to,918,O
attenuate,918,O
in,918,O
vivo,918,O
maleate-induced,918,B-ChemicalEntity
nephropathy,918,B-DiseaseOrPhenotypicFeature
and,918,O
in,918,O
vitro,918,O
cell,918,O
damage,918,O
.,918,O
The,919,O
in,919,O
vivo,919,O
protection,919,O
was,919,O
associated,919,O
to,919,O
the,919,O
prevention,919,O
of,919,O
oxidative,919,O
stress,919,O
and,919,O
preservation,919,O
of,919,O
mitochondrial,919,O
oxygen,919,B-ChemicalEntity
consumption,919,O
and,919,O
activity,919,O
of,919,O
respiratory,919,B-ChemicalEntity
complex,919,I-ChemicalEntity
I,919,I-ChemicalEntity
",",919,O
and,919,O
the,919,O
in,919,O
vitro,919,O
protection,919,O
was,919,O
associated,919,O
to,919,O
the,919,O
prevention,919,O
of,919,O
ROS,919,B-ChemicalEntity
production,919,O
.,919,O
The,920,O
androgen,920,B-GeneOrGeneProduct
receptor,920,I-GeneOrGeneProduct
confers,920,O
protection,920,O
against,920,O
diet-induced,920,O
atherosclerosis,920,B-DiseaseOrPhenotypicFeature
",",920,O
obesity,920,B-DiseaseOrPhenotypicFeature
",",920,O
and,920,O
dyslipidemia,920,B-DiseaseOrPhenotypicFeature
in,920,O
female,920,O
mice,920,B-OrganismTaxon
.,920,O
Androgens,921,B-ChemicalEntity
have,921,O
important,921,O
cardiometabolic,921,O
actions,921,O
in,921,O
males,921,O
",",921,O
but,921,O
their,921,O
metabolic,921,O
role,921,O
in,921,O
females,921,O
is,921,O
unclear,921,O
.,921,O
To,922,O
determine,922,O
the,922,O
physiologic,922,O
androgen,922,B-GeneOrGeneProduct
receptor,922,I-GeneOrGeneProduct
(,922,O
AR,922,B-GeneOrGeneProduct
),922,O
-dependent,922,O
actions,922,O
of,922,O
androgens,922,B-ChemicalEntity
on,922,O
atherogenesis,922,B-DiseaseOrPhenotypicFeature
in,922,O
female,922,O
mice,922,B-OrganismTaxon
",",922,O
we,922,O
generated,922,O
female,922,O
AR-knockout,922,B-GeneOrGeneProduct
(,922,O
ARKO,922,B-GeneOrGeneProduct
),922,O
mice,922,B-OrganismTaxon
on,922,O
an,922,O
atherosclerosis-prone,922,B-DiseaseOrPhenotypicFeature
apolipoprotein,922,B-GeneOrGeneProduct
E,922,I-GeneOrGeneProduct
(,922,O
apoE,922,B-GeneOrGeneProduct
),922,O
-deficient,922,O
background,922,O
.,922,O
After,923,O
8,923,O
weeks,923,O
on,923,O
a,923,O
high-fat,923,O
diet,923,O
",",923,O
but,923,O
not,923,O
on,923,O
a,923,O
normal,923,O
chow,923,O
diet,923,O
",",923,O
atherosclerosis,923,B-DiseaseOrPhenotypicFeature
in,923,O
aorta,923,O
was,923,O
increased,923,O
in,923,O
ARKO,923,B-GeneOrGeneProduct
females,923,O
(,923,O
+59,923,O
%,923,O
vs.,923,O
control,923,O
apoE-deficient,923,B-GeneOrGeneProduct
mice,923,B-OrganismTaxon
with,923,O
intact,923,O
AR,923,B-GeneOrGeneProduct
gene,923,O
),923,O
.,923,O
They,924,O
also,924,O
displayed,924,O
increased,924,O
body,924,O
weight,924,O
(,924,O
+18,924,O
%,924,O
),924,O
",",924,O
body,924,O
fat,924,O
percentage,924,O
(,924,O
+62,924,O
%,924,O
),924,O
",",924,O
and,924,O
hepatic,924,O
triglyceride,924,B-GeneOrGeneProduct
levels,924,O
",",924,O
reduced,924,O
insulin,924,B-GeneOrGeneProduct
sensitivity,924,O
",",924,O
and,924,O
a,924,O
marked,924,O
atherogenic,924,B-DiseaseOrPhenotypicFeature
dyslipidemia,924,B-DiseaseOrPhenotypicFeature
(,924,O
serum,924,O
cholesterol,924,B-ChemicalEntity
",",924,O
+52,924,O
%,924,O
),924,O
.,924,O
Differences,925,O
in,925,O
atherosclerosis,925,B-DiseaseOrPhenotypicFeature
",",925,O
body,925,O
weight,925,O
",",925,O
and,925,O
lipid,925,B-ChemicalEntity
levels,925,O
between,925,O
ARKO,925,B-GeneOrGeneProduct
and,925,O
control,925,O
mice,925,B-OrganismTaxon
were,925,O
abolished,925,O
in,925,O
mice,925,B-OrganismTaxon
that,925,O
were,925,O
ovariectomized,925,O
before,925,O
puberty,925,O
",",925,O
consistent,925,O
with,925,O
a,925,O
protective,925,O
action,925,O
of,925,O
ovarian,925,O
androgens,925,B-ChemicalEntity
mediated,925,O
via,925,O
the,925,O
AR,925,B-GeneOrGeneProduct
.,925,O
Furthermore,926,O
",",926,O
the,926,O
AR,926,B-GeneOrGeneProduct
agonist,926,O
dihydrotestosterone,926,B-ChemicalEntity
reduced,926,O
atherosclerosis,926,B-DiseaseOrPhenotypicFeature
(,926,O
-41,926,O
%,926,O
;,926,O
thoracic,926,O
aorta,926,O
),926,O
",",926,O
subcutaneous,926,O
fat,926,O
mass,926,O
(,926,O
-44,926,O
%,926,O
),926,O
",",926,O
and,926,O
cholesterol,926,B-ChemicalEntity
levels,926,O
(,926,O
-35,926,O
%,926,O
),926,O
in,926,O
ovariectomized,926,O
mice,926,B-OrganismTaxon
",",926,O
reduced,926,O
hepatocyte,926,O
lipid,926,B-ChemicalEntity
accumulation,926,O
in,926,O
hepatoma,926,B-DiseaseOrPhenotypicFeature
cells,926,O
in,926,O
vitro,926,O
",",926,O
and,926,O
regulated,926,O
mRNA,926,O
expression,926,O
of,926,O
hepatic,926,O
genes,926,O
pivotal,926,O
for,926,O
lipid,926,B-ChemicalEntity
homeostasis,926,O
.,926,O
In,927,O
conclusion,927,O
",",927,O
we,927,O
demonstrate,927,O
that,927,O
the,927,O
AR,927,B-GeneOrGeneProduct
protects,927,O
against,927,O
diet-induced,927,O
atherosclerosis,927,B-DiseaseOrPhenotypicFeature
in,927,O
female,927,O
mice,927,B-OrganismTaxon
and,927,O
propose,927,O
that,927,O
this,927,O
is,927,O
mediated,927,O
by,927,O
modulation,927,O
of,927,O
body,927,O
composition,927,O
and,927,O
lipid,927,B-ChemicalEntity
metabolism,927,O
.,927,O
Pharmacogenetic,928,O
Analysis,928,O
of,928,O
INT,928,O
0144,928,O
Trial,928,O
:,928,O
Association,928,O
of,928,O
Polymorphisms,928,O
with,928,O
Survival,928,O
and,928,O
Toxicity,928,B-DiseaseOrPhenotypicFeature
in,928,O
Rectal,928,B-DiseaseOrPhenotypicFeature
Cancer,928,I-DiseaseOrPhenotypicFeature
Patients,928,B-OrganismTaxon
Treated,928,O
with,928,O
5-FU,928,B-ChemicalEntity
and,928,O
Radiation,928,O
.,928,O
PURPOSE,929,O
:,929,O
We,929,O
tested,929,O
whether,929,O
18,929,O
polymorphisms,929,O
in,929,O
16,929,O
genes,929,O
(,929,O
GSTP1,929,B-GeneOrGeneProduct
",",929,O
COX2,929,B-GeneOrGeneProduct
",",929,O
IL10,929,B-GeneOrGeneProduct
",",929,O
EGFR,929,B-GeneOrGeneProduct
",",929,O
EGF,929,B-GeneOrGeneProduct
",",929,O
FGFR4,929,B-GeneOrGeneProduct
",",929,O
CCDN1,929,B-GeneOrGeneProduct
",",929,O
VEGFR2,929,B-GeneOrGeneProduct
",",929,O
VEGF,929,B-GeneOrGeneProduct
",",929,O
CXCR2,929,B-GeneOrGeneProduct
",",929,O
IL8,929,B-GeneOrGeneProduct
",",929,O
MMP3,929,B-GeneOrGeneProduct
",",929,O
ICAM1,929,B-GeneOrGeneProduct
",",929,O
ERCC1,929,B-GeneOrGeneProduct
",",929,O
RAD51,929,B-GeneOrGeneProduct
",",929,O
and,929,O
XRCC3,929,B-GeneOrGeneProduct
),929,O
would,929,O
predict,929,O
disease-free,929,O
survival,929,O
(,929,O
DFS,929,O
),929,O
",",929,O
overall,929,O
survival,929,O
(,929,O
OS,929,O
),929,O
",",929,O
and,929,O
toxicity,929,B-DiseaseOrPhenotypicFeature
in,929,O
the,929,O
INT0144,929,O
trial,929,O
",",929,O
which,929,O
was,929,O
designed,929,O
to,929,O
investigate,929,O
different,929,O
postoperative,929,O
regimens,929,O
of,929,O
5-fluorouracil,929,B-ChemicalEntity
(,929,O
5-FU,929,B-ChemicalEntity
),929,O
-based,929,O
chemoradiation,929,O
(,929,O
CRT,929,O
),929,O
in,929,O
locally,929,O
advanced,929,O
rectal,929,B-DiseaseOrPhenotypicFeature
cancers,929,I-DiseaseOrPhenotypicFeature
:,929,O
Arm,929,O
1,929,O
consisted,929,O
of,929,O
bolus,929,O
5-FU,929,B-ChemicalEntity
followed,929,O
by,929,O
5-FU,929,B-ChemicalEntity
protracted,929,O
venous,929,O
infusion,929,O
(,929,O
PVI,929,O
),929,O
with,929,O
radiotherapy,929,O
;,929,O
arm,929,O
2,929,O
was,929,O
induction,929,O
and,929,O
concomitant,929,O
PVI,929,O
5-FU,929,B-ChemicalEntity
with,929,O
radiotherapy,929,O
and,929,O
arm,929,O
3,929,O
was,929,O
induction,929,O
and,929,O
concomitant,929,O
bolus,929,O
5-FU,929,B-ChemicalEntity
with,929,O
radiotherapy,929,O
.,929,O
EXPERIMENTAL,930,O
DESIGN,930,O
:,930,O
DNA,930,O
from,930,O
746,930,O
stage,930,O
II/III,930,O
rectal,930,O
patients,930,B-OrganismTaxon
enrolled,930,O
in,930,O
the,930,O
Southwest,930,O
Oncology,930,O
Group,930,O
(,930,O
SWOG,930,O
),930,O
S9304,930,O
phase,930,O
III,930,O
trial,930,O
was,930,O
analyzed,930,O
.,930,O
Genomic,931,O
DNA,931,O
was,931,O
extracted,931,O
from,931,O
formalin-fixed,931,B-ChemicalEntity
",",931,O
paraffin-embedded,931,B-ChemicalEntity
(,931,O
FFPE,931,O
),931,O
tumor,931,B-DiseaseOrPhenotypicFeature
tissue,931,O
.,931,O
The,932,O
polymorphisms,932,O
were,932,O
analyzed,932,O
using,932,O
direct,932,O
DNA-sequencing,932,O
or,932,O
polymerase,932,O
chain,932,O
reaction-restriction,932,O
fragment,932,O
length,932,O
polymorphism,932,O
(,932,O
PCR-RFLP,932,O
),932,O
.,932,O
RESULTS,933,O
:,933,O
GSTP1-Ile105Val,933,B-GeneOrGeneProduct
(,933,O
rs1695,933,B-SequenceVariant
),933,O
was,933,O
significantly,933,O
associated,933,O
with,933,O
DFS,933,O
and,933,O
OS,933,O
and,933,O
its,933,O
effect,933,O
did,933,O
not,933,O
vary,933,O
by,933,O
treatment,933,O
arm,933,O
.,933,O
The,934,O
five-year,934,O
DFS,934,O
and,934,O
OS,934,O
were,934,O
53,934,O
%,934,O
and,934,O
58,934,O
%,934,O
",",934,O
respectively,934,O
",",934,O
for,934,O
G/G,934,O
",",934,O
66,934,O
%,934,O
and,934,O
72,934,O
%,934,O
for,934,O
G/A,934,O
",",934,O
and,934,O
57,934,O
%,934,O
and,934,O
66,934,O
%,934,O
for,934,O
A/A,934,O
patients,934,B-OrganismTaxon
.,934,O
In,935,O
arm,935,O
2,935,O
",",935,O
IL8-251A/A,935,B-GeneOrGeneProduct
genotype,935,O
(,935,O
rs4073,935,B-SequenceVariant
),935,O
was,935,O
associated,935,O
with,935,O
a,935,O
lower,935,O
risk,935,O
of,935,O
toxicities,935,B-DiseaseOrPhenotypicFeature
(,935,O
P,935,O
=,935,O
0.04,935,O
),935,O
.,935,O
The,936,O
VEGFR2,936,B-GeneOrGeneProduct
H472Q,936,B-SequenceVariant
Q/Q,936,O
genotype,936,O
(,936,O
rs1870377,936,B-SequenceVariant
),936,O
was,936,O
associated,936,O
with,936,O
a,936,O
higher,936,O
risk,936,O
of,936,O
grade,936,O
3-5,936,O
proximal,936,O
upper,936,O
gastrointestinal,936,O
tract,936,O
(,936,O
PUGIT,936,O
),936,O
mucositis,936,B-DiseaseOrPhenotypicFeature
(,936,O
P,936,O
=,936,O
0.04,936,O
),936,O
in,936,O
arm,936,O
2,936,O
.,936,O
However,937,O
",",937,O
in,937,O
arm,937,O
1,937,O
",",937,O
this,937,O
genotype,937,O
was,937,O
associated,937,O
with,937,O
a,937,O
lower,937,O
risk,937,O
of,937,O
PUGIT,937,O
mucositis,937,B-DiseaseOrPhenotypicFeature
(,937,O
P,937,O
=,937,O
0.004,937,O
),937,O
.,937,O
CONCLUSION,938,O
:,938,O
rs1695,938,B-SequenceVariant
may,938,O
be,938,O
prognostic,938,O
in,938,O
patients,938,B-OrganismTaxon
with,938,O
rectal,938,B-DiseaseOrPhenotypicFeature
cancer,938,I-DiseaseOrPhenotypicFeature
treated,938,O
with,938,O
adjuvant,938,O
CRT,938,O
.,938,O
rs4073,939,B-SequenceVariant
and,939,O
rs1870377,939,B-SequenceVariant
may,939,O
exhibit,939,O
different,939,O
associations,939,O
with,939,O
toxicity,939,B-DiseaseOrPhenotypicFeature
",",939,O
according,939,O
to,939,O
the,939,O
5-FU,939,B-ChemicalEntity
schedule,939,O
.,939,O
Identification,940,O
of,940,O
the,940,O
BRAF,940,B-GeneOrGeneProduct
V600E,940,B-SequenceVariant
mutation,940,O
in,940,O
gastroenteropancreatic,940,B-DiseaseOrPhenotypicFeature
neuroendocrine,940,I-DiseaseOrPhenotypicFeature
tumors,940,I-DiseaseOrPhenotypicFeature
.,940,O
Genomic,941,O
profiles,941,O
of,941,O
gastroenteropancreatic,941,B-DiseaseOrPhenotypicFeature
neuroendocrine,941,I-DiseaseOrPhenotypicFeature
tumors,941,I-DiseaseOrPhenotypicFeature
(,941,O
GEP-NETs,941,B-DiseaseOrPhenotypicFeature
),941,O
are,941,O
still,941,O
insufficiently,941,O
understood,941,O
",",941,O
and,941,O
the,941,O
genetic,941,O
alterations,941,O
associated,941,O
with,941,O
drug,941,O
responses,941,O
have,941,O
not,941,O
been,941,O
studied,941,O
.,941,O
Here,942,O
",",942,O
we,942,O
performed,942,O
whole,942,O
exome,942,O
sequencing,942,O
of,942,O
12,942,O
GEP-NETs,942,B-DiseaseOrPhenotypicFeature
from,942,O
patients,942,B-OrganismTaxon
enrolled,942,O
in,942,O
a,942,O
nonrandomized,942,O
",",942,O
open-labeled,942,O
",",942,O
single-center,942,O
phase,942,O
II,942,O
study,942,O
for,942,O
pazopanib,942,B-ChemicalEntity
",",942,O
and,942,O
integrated,942,O
our,942,O
results,942,O
with,942,O
previously,942,O
published,942,O
results,942,O
on,942,O
pancreas,942,O
(,942,O
n,942,O
=,942,O
12,942,O
),942,O
and,942,O
small,942,O
intestine,942,B-DiseaseOrPhenotypicFeature
NETs,942,I-DiseaseOrPhenotypicFeature
(,942,O
n,942,O
=,942,O
50,942,O
),942,O
.,942,O
The,943,O
mean,943,O
numbers,943,O
of,943,O
somatic,943,O
mutations,943,O
in,943,O
each,943,O
case,943,O
varied,943,O
widely,943,O
from,943,O
20,943,O
to,943,O
4682,943,O
.,943,O
Among,944,O
12,944,O
GEP-NETs,944,B-DiseaseOrPhenotypicFeature
",",944,O
eight,944,O
showed,944,O
mutations,944,O
of,944,O
more,944,O
than,944,O
one,944,O
cancer-related,944,B-DiseaseOrPhenotypicFeature
gene,944,O
",",944,O
including,944,O
TP53,944,B-GeneOrGeneProduct
",",944,O
CNBD1,944,B-GeneOrGeneProduct
",",944,O
RB1,944,B-GeneOrGeneProduct
",",944,O
APC,944,B-GeneOrGeneProduct
",",944,O
BCOR,944,B-GeneOrGeneProduct
",",944,O
BRAF,944,B-GeneOrGeneProduct
",",944,O
CTNNB1,944,B-GeneOrGeneProduct
",",944,O
EGFR,944,B-GeneOrGeneProduct
",",944,O
EP300,944,B-GeneOrGeneProduct
",",944,O
ERBB3,944,B-GeneOrGeneProduct
",",944,O
KDM6A,944,B-GeneOrGeneProduct
",",944,O
KRAS,944,B-GeneOrGeneProduct
",",944,O
MGA,944,B-GeneOrGeneProduct
",",944,O
MLL3,944,B-GeneOrGeneProduct
",",944,O
PTEN,944,B-GeneOrGeneProduct
",",944,O
RASA1,944,B-GeneOrGeneProduct
",",944,O
SMARCB1,944,B-GeneOrGeneProduct
",",944,O
SPEN,944,B-GeneOrGeneProduct
",",944,O
TBC1D12,944,B-GeneOrGeneProduct
",",944,O
and,944,O
VHL,944,B-GeneOrGeneProduct
.,944,O
TP53,945,B-GeneOrGeneProduct
was,945,O
recurrently,945,O
mutated,945,O
in,945,O
three,945,O
cases,945,O
",",945,O
whereas,945,O
CNBD1,945,B-GeneOrGeneProduct
and,945,O
RB1,945,B-GeneOrGeneProduct
mutations,945,O
were,945,O
identified,945,O
in,945,O
two,945,O
cases,945,O
.,945,O
Three,946,O
GEP-NET,946,B-DiseaseOrPhenotypicFeature
patients,946,B-OrganismTaxon
with,946,O
TP53,946,B-GeneOrGeneProduct
mutations,946,O
demonstrated,946,O
a,946,O
durable,946,O
response,946,O
and,946,O
one,946,O
small,946,O
intestinal,946,B-DiseaseOrPhenotypicFeature
grade,946,I-DiseaseOrPhenotypicFeature
(,946,I-DiseaseOrPhenotypicFeature
G,946,I-DiseaseOrPhenotypicFeature
),946,I-DiseaseOrPhenotypicFeature
1,946,I-DiseaseOrPhenotypicFeature
NET,946,I-DiseaseOrPhenotypicFeature
patient,946,B-OrganismTaxon
with,946,O
BRAF,946,B-GeneOrGeneProduct
V600E,946,B-SequenceVariant
mutation,946,O
showed,946,O
progression,946,O
after,946,O
pazopanib,946,B-ChemicalEntity
treatment,946,O
.,946,O
We,947,O
found,947,O
BRAF,947,B-GeneOrGeneProduct
V600E,947,B-SequenceVariant
(,947,O
G1,947,O
NET,947,B-DiseaseOrPhenotypicFeature
from,947,O
rectum,947,O
and,947,O
two,947,O
G3,947,O
NETs,947,B-DiseaseOrPhenotypicFeature
from,947,O
colon,947,O
),947,O
and,947,O
BRAF,947,B-GeneOrGeneProduct
G593S,947,B-SequenceVariant
(,947,O
G2,947,O
NET,947,B-DiseaseOrPhenotypicFeature
from,947,O
pancreas,947,O
),947,O
missense,947,O
mutations,947,O
(,947,O
9.1,947,O
%,947,O
),947,O
in,947,O
an,947,O
independent,947,O
cohort,947,O
of,947,O
44,947,O
GEP-NETs,947,B-DiseaseOrPhenotypicFeature
from,947,O
the,947,O
rectum,947,O
(,947,O
n,947,O
=,947,O
26,947,O
),947,O
",",947,O
colon,947,O
(,947,O
n,947,O
=,947,O
7,947,O
),947,O
",",947,O
pancreas,947,O
(,947,O
n,947,O
=,947,O
4,947,O
),947,O
",",947,O
small,947,O
intestine,947,O
(,947,O
n,947,O
=,947,O
3,947,O
),947,O
",",947,O
stomach,947,O
(,947,O
n,947,O
=,947,O
3,947,O
),947,O
and,947,O
appendix,947,O
(,947,O
n,947,O
=,947,O
1,947,O
),947,O
by,947,O
Sanger,947,O
sequencing,947,O
.,947,O
All,948,O
tumor,948,B-DiseaseOrPhenotypicFeature
specimens,948,O
were,948,O
obtained,948,O
before,948,O
chemotherapy,948,O
.,948,O
In,949,O
conclusion,949,O
",",949,O
BRAF,949,B-GeneOrGeneProduct
V600E,949,B-SequenceVariant
mutation,949,O
is,949,O
likely,949,O
to,949,O
result,949,O
in,949,O
resistance,949,O
to,949,O
pazopanib,949,B-ChemicalEntity
but,949,O
may,949,O
be,949,O
a,949,O
potentianally,949,O
actionable,949,O
mutation,949,O
in,949,O
metastatic,949,O
GEP-NETs,949,B-DiseaseOrPhenotypicFeature
patients,949,B-OrganismTaxon
.,949,O
Circulating,950,O
Fatty,950,B-GeneOrGeneProduct
Acid,950,I-GeneOrGeneProduct
Synthase,950,I-GeneOrGeneProduct
in,950,O
pregnant,950,O
women,950,B-OrganismTaxon
:,950,O
Relationship,950,O
to,950,O
blood,950,O
pressure,950,O
",",950,O
maternal,950,O
metabolism,950,O
and,950,O
newborn,950,O
parameters,950,O
.,950,O
The,951,O
enzyme,951,O
FASN,951,B-GeneOrGeneProduct
(,951,O
fatty,951,B-GeneOrGeneProduct
acid,951,I-GeneOrGeneProduct
synthase,951,I-GeneOrGeneProduct
),951,O
is,951,O
potentially,951,O
related,951,O
with,951,O
hypertension,951,B-DiseaseOrPhenotypicFeature
and,951,O
metabolic,951,B-DiseaseOrPhenotypicFeature
dysfunction,951,I-DiseaseOrPhenotypicFeature
.,951,O
FASN,952,B-GeneOrGeneProduct
is,952,O
highly,952,O
expressed,952,O
in,952,O
the,952,O
human,952,B-OrganismTaxon
placenta,952,O
.,952,O
We,953,O
aimed,953,O
to,953,O
investigate,953,O
the,953,O
relationship,953,O
circulating,953,O
FASN,953,B-GeneOrGeneProduct
has,953,O
with,953,O
blood,953,O
pressure,953,O
",",953,O
maternal,953,O
metabolism,953,O
and,953,O
newborn,953,O
parameters,953,O
in,953,O
healthy,953,O
pregnant,953,O
women,953,B-OrganismTaxon
.,953,O
Circulating,954,O
FASN,954,B-GeneOrGeneProduct
was,954,O
assessed,954,O
in,954,O
115,954,O
asymptomatic,954,O
pregnant,954,O
women,954,B-OrganismTaxon
in,954,O
the,954,O
second,954,O
trimester,954,O
of,954,O
gestation,954,O
along,954,O
with,954,O
C-peptide,954,B-ChemicalEntity
",",954,O
fasting,954,O
glucose,954,B-ChemicalEntity
and,954,O
insulin,954,B-GeneOrGeneProduct
",",954,O
post-load,954,O
glucose,954,B-ChemicalEntity
lipids,954,B-ChemicalEntity
",",954,O
HMW-adiponectin,954,B-GeneOrGeneProduct
and,954,O
blood,954,O
pressure,954,O
(,954,O
the,954,O
latter,954,O
was,954,O
assessed,954,O
in,954,O
each,954,O
trimester,954,O
of,954,O
gestation,954,O
),954,O
.,954,O
At,955,O
birth,955,O
",",955,O
newborns,955,O
and,955,O
placentas,955,O
were,955,O
weighed,955,O
.,955,O
FASN,956,B-GeneOrGeneProduct
expression,956,O
was,956,O
also,956,O
able,956,O
to,956,O
be,956,O
assessed,956,O
in,956,O
80,956,O
placentas,956,O
.,956,O
Higher,957,O
circulating,957,O
FASN,957,B-GeneOrGeneProduct
was,957,O
associated,957,O
with,957,O
lower,957,O
systolic,957,O
blood,957,O
pressure,957,O
(,957,O
SBP,957,O
),957,O
",",957,O
with,957,O
a,957,O
more,957,O
favourable,957,O
metabolic,957,O
phenotype,957,O
(,957,O
lower,957,O
fasting,957,O
glucose,957,B-ChemicalEntity
and,957,O
insulin,957,B-GeneOrGeneProduct
",",957,O
post,957,O
load,957,O
glucose,957,B-ChemicalEntity
",",957,O
HbAc1,957,B-GeneOrGeneProduct
",",957,O
HOMA-IR,957,O
and,957,O
C-peptide,957,B-ChemicalEntity
),957,O
",",957,O
and,957,O
with,957,O
lower,957,O
placental,957,O
and,957,O
birth,957,O
weight,957,O
(,957,O
all,957,O
p,957,O
<,957,O
0.05,957,O
to,957,O
p,957,O
<,957,O
0.001,957,O
),957,O
.,957,O
Placental,958,O
FASN,958,B-GeneOrGeneProduct
expression,958,O
related,958,O
positively,958,O
to,958,O
circulating,958,O
FASN,958,B-GeneOrGeneProduct
(,958,O
p,958,O
<,958,O
0.005,958,O
),958,O
and,958,O
negatively,958,O
to,958,O
placental,958,O
weight,958,O
(,958,O
p,958,O
<,958,O
0.05,958,O
),958,O
.,958,O
Our,959,O
observations,959,O
suggest,959,O
a,959,O
physiological,959,O
role,959,O
of,959,O
placental,959,O
FASN,959,B-GeneOrGeneProduct
in,959,O
human,959,B-OrganismTaxon
pregnancy,959,O
.,959,O
Future,960,O
studies,960,O
will,960,O
clarify,960,O
whether,960,O
circulating,960,O
FASN,960,B-GeneOrGeneProduct
of,960,O
placental,960,O
origin,960,O
does,960,O
actually,960,O
regulate,960,O
placental,960,O
and,960,O
fetal,960,O
growth,960,O
",",960,O
and,960,O
(,960,O
thereby,960,O
),960,O
has,960,O
a,960,O
favourable,960,O
influence,960,O
on,960,O
the,960,O
pregnant,960,O
mother,960,O
's,960,O
insulin,960,B-GeneOrGeneProduct
sensitivity,960,O
and,960,O
blood,960,O
pressure,960,O
.,960,O
On,961,O
the,961,O
pivotal,961,O
role,961,O
of,961,O
PPARa,961,B-GeneOrGeneProduct
in,961,O
adaptation,961,O
of,961,O
the,961,O
heart,961,O
to,961,O
hypoxia,961,B-DiseaseOrPhenotypicFeature
and,961,O
why,961,O
fat,961,O
in,961,O
the,961,O
diet,961,O
increases,961,O
hypoxic,961,B-DiseaseOrPhenotypicFeature
injury,961,O
.,961,O
The,962,O
role,962,O
of,962,O
peroxisome,962,B-GeneOrGeneProduct
proliferator-activated,962,I-GeneOrGeneProduct
receptor,962,I-GeneOrGeneProduct
a,962,I-GeneOrGeneProduct
(,962,O
PPARa,962,B-GeneOrGeneProduct
),962,O
-mediated,962,O
metabolic,962,O
remodeling,962,O
in,962,O
cardiac,962,O
adaptation,962,O
to,962,O
hypoxia,962,B-DiseaseOrPhenotypicFeature
has,962,O
yet,962,O
to,962,O
be,962,O
defined,962,O
.,962,O
Here,963,O
",",963,O
mice,963,B-OrganismTaxon
were,963,O
housed,963,O
in,963,O
hypoxia,963,B-DiseaseOrPhenotypicFeature
for,963,O
3,963,O
wk,963,O
before,963,O
in,963,O
vivo,963,O
contractile,963,O
function,963,O
was,963,O
measured,963,O
using,963,O
cine,963,O
MRI,963,O
.,963,O
In,964,O
isolated,964,O
",",964,O
perfused,964,O
hearts,964,O
",",964,O
energetics,964,O
were,964,O
measured,964,O
using,964,O
(,964,O
31,964,O
),964,O
P,964,O
magnetic,964,O
resonance,964,O
spectroscopy,964,O
(,964,O
MRS,964,O
),964,O
",",964,O
and,964,O
glycolysis,964,O
and,964,O
fatty,964,B-ChemicalEntity
acid,964,I-ChemicalEntity
oxidation,964,O
were,964,O
measured,964,O
using,964,O
[,964,O
(,964,B-ChemicalEntity
3,964,I-ChemicalEntity
),964,I-ChemicalEntity
H,964,I-ChemicalEntity
],964,O
labeling,964,O
.,964,O
Compared,965,O
with,965,O
a,965,O
normoxic,965,O
",",965,O
chow-fed,965,O
control,965,O
mouse,965,B-OrganismTaxon
heart,965,O
",",965,O
hypoxia,965,B-DiseaseOrPhenotypicFeature
decreased,965,O
PPARa,965,B-GeneOrGeneProduct
expression,965,O
",",965,O
fatty,965,B-ChemicalEntity
acid,965,I-ChemicalEntity
oxidation,965,O
",",965,O
and,965,O
mitochondrial,965,B-GeneOrGeneProduct
uncoupling,965,I-GeneOrGeneProduct
protein,965,I-GeneOrGeneProduct
3,965,I-GeneOrGeneProduct
(,965,O
UCP3,965,B-GeneOrGeneProduct
),965,O
levels,965,O
",",965,O
while,965,O
increasing,965,O
glycolysis,965,O
",",965,O
all,965,O
of,965,O
which,965,O
served,965,O
to,965,O
maintain,965,O
normal,965,O
ATP,965,B-ChemicalEntity
concentrations,965,O
(,965,O
[,965,O
ATP,965,B-ChemicalEntity
],965,O
),965,O
and,965,O
thereby,965,O
",",965,O
ejection,965,O
fractions,965,O
.,965,O
A,966,O
high-fat,966,O
diet,966,O
increased,966,O
cardiac,966,O
PPARa,966,B-GeneOrGeneProduct
expression,966,O
",",966,O
fatty,966,B-ChemicalEntity
acid,966,I-ChemicalEntity
oxidation,966,O
",",966,O
and,966,O
UCP3,966,B-GeneOrGeneProduct
levels,966,O
with,966,O
decreased,966,O
glycolysis,966,O
.,966,O
Hypoxia,967,B-DiseaseOrPhenotypicFeature
was,967,O
unable,967,O
to,967,O
alter,967,O
the,967,O
high,967,O
PPARa,967,B-GeneOrGeneProduct
expression,967,O
or,967,O
reverse,967,O
the,967,O
metabolic,967,O
changes,967,O
caused,967,O
by,967,O
the,967,O
high-fat,967,O
diet,967,O
",",967,O
with,967,O
the,967,O
result,967,O
that,967,O
[,967,O
ATP,967,B-ChemicalEntity
],967,O
and,967,O
contractile,967,O
function,967,O
decreased,967,O
significantly,967,O
.,967,O
The,968,O
adaptive,968,O
metabolic,968,O
changes,968,O
caused,968,O
by,968,O
hypoxia,968,B-DiseaseOrPhenotypicFeature
in,968,O
control,968,O
mouse,968,B-OrganismTaxon
hearts,968,O
were,968,O
found,968,O
to,968,O
have,968,O
occurred,968,O
already,968,O
in,968,O
PPARa-deficient,968,B-GeneOrGeneProduct
(,968,O
PPARa,968,B-GeneOrGeneProduct
(,968,O
-/-,968,O
),968,O
),968,O
mouse,968,B-OrganismTaxon
hearts,968,O
and,968,O
sustained,968,O
function,968,O
in,968,O
hypoxia,968,B-DiseaseOrPhenotypicFeature
despite,968,O
an,968,O
inability,968,O
for,968,O
further,968,O
metabolic,968,O
remodeling,968,O
.,968,O
We,969,O
conclude,969,O
that,969,O
decreased,969,O
cardiac,969,O
PPARa,969,B-GeneOrGeneProduct
expression,969,O
is,969,O
essential,969,O
for,969,O
adaptive,969,O
metabolic,969,O
remodeling,969,O
in,969,O
hypoxia,969,B-DiseaseOrPhenotypicFeature
",",969,O
but,969,O
is,969,O
prevented,969,O
by,969,O
dietary,969,O
fat.-Cole,969,O
",",969,O
M.,969,O
A.,969,O
",",969,O
Abd,969,O
Jamil,969,O
",",969,O
A.,969,O
H.,969,O
",",969,O
Heather,969,O
",",969,O
L.,969,O
C.,969,O
",",969,O
Murray,969,O
",",969,O
A.,969,O
J.,969,O
",",969,O
Sutton,969,O
",",969,O
E.,969,O
R.,969,O
",",969,O
Slingo,969,O
",",969,O
M.,969,O
",",969,O
Sebag-Montefiore,969,O
",",969,O
L.,969,O
",",969,O
Tan,969,O
",",969,O
S.,969,O
C.,969,O
",",969,O
Aksentijevic,969,O
",",969,O
D.,969,O
",",969,O
Gildea,969,O
",",969,O
O.,969,O
S.,969,O
",",969,O
Stuckey,969,O
",",969,O
D.,969,O
J.,969,O
",",969,O
Yeoh,969,O
",",969,O
K.,969,O
K.,969,O
",",969,O
Carr,969,O
",",969,O
C.,969,O
A.,969,O
",",969,O
Evans,969,O
",",969,O
R.,969,O
D.,969,O
",",969,O
Aasum,969,O
",",969,O
E.,969,O
",",969,O
Schofield,969,O
",",969,O
C.,969,O
J.,969,O
",",969,O
Ratcliffe,969,O
",",969,O
P.,969,O
J.,969,O
",",969,O
Neubauer,969,O
",",969,O
S.,969,O
",",969,O
Robbins,969,O
",",969,O
P.,969,O
A.,969,O
",",969,O
Clarke,969,O
",",969,O
K.,969,O
On,969,O
the,969,O
pivotal,969,O
role,969,O
of,969,O
PPARa,969,B-GeneOrGeneProduct
in,969,O
adaptation,969,O
of,969,O
the,969,O
heart,969,O
to,969,O
hypoxia,969,B-DiseaseOrPhenotypicFeature
and,969,O
why,969,O
fat,969,O
in,969,O
the,969,O
diet,969,O
increases,969,O
hypoxic,969,B-DiseaseOrPhenotypicFeature
injury,969,O
.,969,O
Gartanin,970,B-ChemicalEntity
induces,970,O
cell,970,O
cycle,970,O
arrest,970,O
and,970,O
autophagy,970,O
and,970,O
suppresses,970,O
migration,970,O
involving,970,O
PI3K/Akt/mTOR,970,B-GeneOrGeneProduct
and,970,O
MAPK,970,B-GeneOrGeneProduct
signalling,970,O
pathway,970,O
in,970,O
human,970,B-OrganismTaxon
glioma,970,B-DiseaseOrPhenotypicFeature
cells,970,O
.,970,O
In,971,O
central,971,O
nervous,971,O
system,971,O
",",971,O
glioma,971,B-DiseaseOrPhenotypicFeature
is,971,O
the,971,O
most,971,O
common,971,O
primary,971,B-DiseaseOrPhenotypicFeature
brain,971,I-DiseaseOrPhenotypicFeature
tumour,971,I-DiseaseOrPhenotypicFeature
.,971,O
The,972,O
diffuse,972,O
migration,972,O
and,972,O
rapid,972,O
proliferation,972,O
are,972,O
main,972,O
obstacles,972,O
for,972,O
successful,972,O
treatment,972,O
.,972,O
Gartanin,973,B-ChemicalEntity
",",973,O
a,973,O
natural,973,O
xanthone,973,B-ChemicalEntity
of,973,O
mangosteen,973,B-OrganismTaxon
",",973,O
suppressed,973,O
proliferation,973,O
",",973,O
migration,973,O
and,973,O
colony,973,O
formation,973,O
in,973,O
a,973,O
time-,973,O
and,973,O
concentration-dependent,973,O
manner,973,O
in,973,O
T98G,973,B-CellLine
glioma,973,B-DiseaseOrPhenotypicFeature
cells,973,O
but,973,O
not,973,O
in,973,O
mouse,973,B-OrganismTaxon
normal,973,O
neuronal,973,O
HT22,973,B-CellLine
cells,973,O
.,973,O
Gartanin,974,B-ChemicalEntity
",",974,O
at,974,O
low,974,O
micromole,974,O
",",974,O
led,974,O
to,974,O
cell,974,O
cycle,974,O
arrest,974,O
in,974,O
G1,974,O
phase,974,O
accompanied,974,O
by,974,O
inhibited,974,O
expression,974,O
level,974,O
of,974,O
G1,974,O
cell,974,O
cycle,974,O
regulatory,974,O
proteins,974,O
cyclin,974,B-GeneOrGeneProduct
D1,974,I-GeneOrGeneProduct
",",974,O
while,974,O
increased,974,O
expression,974,O
level,974,O
of,974,O
cyclin-dependent,974,B-GeneOrGeneProduct
kinase,974,I-GeneOrGeneProduct
inhibitor,974,O
p27Kip1,974,B-GeneOrGeneProduct
.,974,O
In,975,O
addition,975,O
",",975,O
the,975,O
secretion,975,O
and,975,O
activity,975,O
of,975,O
matrix,975,B-GeneOrGeneProduct
metalloproteinases,975,I-GeneOrGeneProduct
2/9,975,I-GeneOrGeneProduct
(,975,O
MMP-2/-9,975,B-GeneOrGeneProduct
),975,O
were,975,O
significantly,975,O
suppressed,975,O
in,975,O
T98G,975,B-CellLine
cells,975,O
treated,975,O
with,975,O
gartanin,975,B-ChemicalEntity
",",975,O
and,975,O
it,975,O
might,975,O
result,975,O
from,975,O
modulating,975,O
mitogen-activated,975,B-GeneOrGeneProduct
protein,975,I-GeneOrGeneProduct
kinases,975,I-GeneOrGeneProduct
(,975,O
MAPK,975,B-GeneOrGeneProduct
),975,O
signalling,975,O
pathway,975,O
in,975,O
T98G,975,B-CellLine
glioma,975,B-DiseaseOrPhenotypicFeature
cells,975,O
.,975,O
Moreover,976,O
",",976,O
gartanin,976,B-ChemicalEntity
significantly,976,O
induced,976,O
autophagy,976,O
in,976,O
T98G,976,B-CellLine
cells,976,O
and,976,O
increased,976,O
GFP-LC3,976,O
punctate,976,O
fluorescence,976,O
accompanied,976,O
by,976,O
the,976,O
increased,976,O
expression,976,O
level,976,O
of,976,O
Beclin,976,B-GeneOrGeneProduct
1,976,I-GeneOrGeneProduct
and,976,O
LC3-II,976,B-GeneOrGeneProduct
",",976,O
while,976,O
suppressed,976,O
expression,976,O
level,976,O
of,976,O
p62,976,B-GeneOrGeneProduct
.,976,O
Gartanin,977,B-ChemicalEntity
treatment,977,O
resulted,977,O
in,977,O
obvious,977,O
inhibition,977,O
of,977,O
PI3K/Akt/mTOR,977,B-GeneOrGeneProduct
signalling,977,O
pathway,977,O
",",977,O
which,977,O
is,977,O
important,977,O
in,977,O
modulating,977,O
autophagy,977,O
.,977,O
Notably,978,O
",",978,O
gartanin-mediated,978,B-ChemicalEntity
anti-viability,978,O
was,978,O
significantly,978,O
abrogated,978,O
by,978,O
autophagy,978,O
inhibitors,978,O
including,978,O
3-methyladenine,978,B-ChemicalEntity
(,978,O
3-MA,978,B-ChemicalEntity
),978,O
and,978,O
chloroquine,978,B-ChemicalEntity
(,978,O
CQ,978,B-ChemicalEntity
),978,O
.,978,O
These,979,O
results,979,O
indicate,979,O
that,979,O
anti-proliferation,979,O
effect,979,O
of,979,O
gartanin,979,B-ChemicalEntity
in,979,O
T98G,979,B-CellLine
cells,979,O
is,979,O
most,979,O
likely,979,O
via,979,O
cell,979,O
cycle,979,O
arrest,979,O
modulated,979,O
by,979,O
autophagy,979,O
",",979,O
which,979,O
is,979,O
regulated,979,O
by,979,O
PI3K/Akt/mTOR,979,B-GeneOrGeneProduct
signalling,979,O
pathway,979,O
",",979,O
while,979,O
anti-migration,979,O
effect,979,O
is,979,O
most,979,O
likely,979,O
via,979,O
suppression,979,O
of,979,O
MMP-2/-9,979,B-GeneOrGeneProduct
activity,979,O
which,979,O
is,979,O
involved,979,O
in,979,O
MAPK,979,B-GeneOrGeneProduct
signalling,979,O
pathway,979,O
.,979,O
Combination,980,O
of,980,O
the,980,O
histone,980,B-GeneOrGeneProduct
deacetylase,980,I-GeneOrGeneProduct
inhibitor,980,O
depsipeptide,980,B-ChemicalEntity
and,980,O
5-fluorouracil,980,B-ChemicalEntity
upregulates,980,O
major,980,B-GeneOrGeneProduct
histocompatibility,980,I-GeneOrGeneProduct
complex,980,I-GeneOrGeneProduct
class,980,I-GeneOrGeneProduct
II,980,I-GeneOrGeneProduct
and,980,O
p21,980,B-GeneOrGeneProduct
genes,980,O
and,980,O
activates,980,O
caspase-3/7,980,B-GeneOrGeneProduct
in,980,O
human,980,B-OrganismTaxon
colon,980,B-DiseaseOrPhenotypicFeature
cancer,980,I-DiseaseOrPhenotypicFeature
HCT-116,980,B-CellLine
cells,980,O
.,980,O
Epigenetic,981,O
anticancer,981,O
drugs,981,O
such,981,O
as,981,O
histone,981,B-GeneOrGeneProduct
deacetylase,981,I-GeneOrGeneProduct
(,981,O
HDAC,981,B-GeneOrGeneProduct
),981,O
inhibitors,981,O
have,981,O
been,981,O
combined,981,O
with,981,O
existing,981,O
anticancer,981,O
drugs,981,O
for,981,O
synergistic,981,O
or,981,O
additive,981,O
effects,981,O
.,981,O
In,982,O
the,982,O
present,982,O
study,982,O
",",982,O
we,982,O
found,982,O
that,982,O
a,982,O
very,982,O
low,982,O
concentration,982,O
of,982,O
depsipeptide,982,B-ChemicalEntity
",",982,O
an,982,O
HDAC,982,B-GeneOrGeneProduct
inhibitor,982,O
",",982,O
potentiated,982,O
the,982,O
antitumor,982,O
activity,982,O
of,982,O
5-fluorouracil,982,B-ChemicalEntity
(,982,O
5-FU,982,B-ChemicalEntity
),982,O
in,982,O
a,982,O
human,982,B-OrganismTaxon
colon,982,B-DiseaseOrPhenotypicFeature
cancer,982,I-DiseaseOrPhenotypicFeature
cell,982,O
model,982,O
using,982,O
HCT-116,982,B-CellLine
",",982,O
HT29,982,B-CellLine
",",982,O
and,982,O
SW48,982,B-CellLine
cells,982,O
via,982,O
the,982,O
inhibition,982,O
of,982,O
colony,982,O
formation,982,O
ability,982,O
or,982,O
cellular,982,O
viability,982,O
.,982,O
Exposure,983,O
to,983,O
a,983,O
combination,983,O
of,983,O
5-FU,983,B-ChemicalEntity
(,983,O
1.75,983,O
uM,983,O
),983,O
and,983,O
1,983,O
nM,983,O
depsipeptide,983,B-ChemicalEntity
for,983,O
24,983,O
and,983,O
48,983,O
h,983,O
resulted,983,O
in,983,O
a,983,O
3-,983,O
to,983,O
4-fold,983,O
increase,983,O
in,983,O
activated,983,O
caspase-3/7,983,B-GeneOrGeneProduct
",",983,O
while,983,O
5-FU,983,B-ChemicalEntity
alone,983,O
failed,983,O
to,983,O
activate,983,O
caspase-3/7,983,B-GeneOrGeneProduct
.,983,O
Microarray,984,O
and,984,O
subsequent,984,O
gene,984,O
ontology,984,O
analyses,984,O
revealed,984,O
that,984,O
compared,984,O
to,984,O
5-FU,984,B-ChemicalEntity
or,984,O
depsipeptide,984,B-ChemicalEntity
alone,984,O
",",984,O
the,984,O
combination,984,O
treatment,984,O
of,984,O
5-FU,984,B-ChemicalEntity
and,984,O
depsipeptide,984,B-ChemicalEntity
upregulated,984,O
genes,984,O
related,984,O
to,984,O
cell,984,O
death,984,O
and,984,O
the,984,O
apoptotic,984,O
process,984,O
consistent,984,O
with,984,O
the,984,O
inhibition,984,O
of,984,O
colony,984,O
formation,984,O
and,984,O
caspase-3/7,984,B-GeneOrGeneProduct
activation,984,O
.,984,O
These,985,O
analyses,985,O
indicated,985,O
marked,985,O
upregulation,985,O
of,985,O
antigen,985,O
processing,985,O
and,985,O
presentation,985,O
of,985,O
peptide,985,O
or,985,O
polysaccharide,985,B-ChemicalEntity
antigen,985,O
via,985,O
major,985,B-GeneOrGeneProduct
histocompatibility,985,I-GeneOrGeneProduct
complex,985,I-GeneOrGeneProduct
(,985,I-GeneOrGeneProduct
MHC,985,I-GeneOrGeneProduct
),985,I-GeneOrGeneProduct
class,985,I-GeneOrGeneProduct
(,985,O
GO:0002504,985,O
),985,O
and,985,O
MHC,985,B-GeneOrGeneProduct
protein,985,I-GeneOrGeneProduct
complex,985,I-GeneOrGeneProduct
(,985,O
GO:0042611,985,O
),985,O
.,985,O
Compared,986,O
with,986,O
vehicle,986,O
controls,986,O
",",986,O
the,986,O
cells,986,O
treated,986,O
with,986,O
the,986,O
combination,986,O
of,986,O
5-FU,986,B-ChemicalEntity
and,986,O
depsipeptide,986,B-ChemicalEntity
showed,986,O
marked,986,O
induction,986,O
(,986,O
3-,986,O
to,986,O
8.5-fold,986,O
),986,O
of,986,O
expression,986,O
of,986,O
MHC,986,B-GeneOrGeneProduct
class,986,I-GeneOrGeneProduct
II,986,I-GeneOrGeneProduct
genes,986,I-GeneOrGeneProduct
",",986,O
but,986,O
not,986,O
of,986,O
MHC,986,B-GeneOrGeneProduct
class,986,I-GeneOrGeneProduct
I,986,I-GeneOrGeneProduct
genes,986,I-GeneOrGeneProduct
.,986,O
Furthermore,987,O
",",987,O
our,987,O
global,987,O
analysis,987,O
of,987,O
gene,987,O
expression,987,O
",",987,O
which,987,O
was,987,O
focused,987,O
on,987,O
genes,987,O
involved,987,O
in,987,O
the,987,O
molecular,987,O
regulation,987,O
of,987,O
MHC,987,B-GeneOrGeneProduct
class,987,I-GeneOrGeneProduct
II,987,I-GeneOrGeneProduct
genes,987,I-GeneOrGeneProduct
",",987,O
showed,987,O
enhancement,987,O
of,987,O
pro-apoptotic,987,O
PCAF,987,B-GeneOrGeneProduct
and,987,O
CIITA,987,B-GeneOrGeneProduct
after,987,O
the,987,O
combination,987,O
of,987,O
5-FU,987,B-ChemicalEntity
and,987,O
depsipeptide,987,B-ChemicalEntity
.,987,O
These,988,O
results,988,O
may,988,O
indicate,988,O
a,988,O
closer,988,O
relationship,988,O
between,988,O
elevation,988,O
of,988,O
MHC,988,B-GeneOrGeneProduct
class,988,I-GeneOrGeneProduct
II,988,I-GeneOrGeneProduct
expression,988,O
and,988,O
cellular,988,O
apoptosis,988,O
induced,988,O
by,988,O
the,988,O
combination,988,O
of,988,O
depsipeptide,988,B-ChemicalEntity
and,988,O
5-FU,988,B-ChemicalEntity
.,988,O
To,989,O
the,989,O
best,989,O
of,989,O
our,989,O
knowledge,989,O
",",989,O
this,989,O
is,989,O
the,989,O
first,989,O
study,989,O
to,989,O
report,989,O
that,989,O
the,989,O
combination,989,O
of,989,O
5-FU,989,B-ChemicalEntity
and,989,O
depsipeptide,989,B-ChemicalEntity
induces,989,O
human,989,B-OrganismTaxon
colon,989,B-DiseaseOrPhenotypicFeature
cancer,989,I-DiseaseOrPhenotypicFeature
cell,989,O
apoptosis,989,O
in,989,O
a,989,O
concerted,989,O
manner,989,O
with,989,O
the,989,O
induction,989,O
of,989,O
MHC,989,B-GeneOrGeneProduct
class,989,I-GeneOrGeneProduct
II,989,I-GeneOrGeneProduct
gene,989,O
expression,989,O
.,989,O
Role,990,O
of,990,O
angiotensin,990,B-GeneOrGeneProduct
II,990,I-GeneOrGeneProduct
type,990,I-GeneOrGeneProduct
1a,990,I-GeneOrGeneProduct
receptor,990,I-GeneOrGeneProduct
in,990,O
renal,990,B-DiseaseOrPhenotypicFeature
injury,990,I-DiseaseOrPhenotypicFeature
induced,990,O
by,990,O
deoxycorticosterone,990,B-ChemicalEntity
acetate-salt,990,O
hypertension,990,B-DiseaseOrPhenotypicFeature
.,990,O
The,991,O
aim,991,O
of,991,O
this,991,O
study,991,O
was,991,O
to,991,O
investigate,991,O
the,991,O
in,991,O
vivo,991,O
role,991,O
of,991,O
angiotensin,991,B-GeneOrGeneProduct
II,991,I-GeneOrGeneProduct
type,991,I-GeneOrGeneProduct
1a,991,I-GeneOrGeneProduct
(,991,I-GeneOrGeneProduct
AT1a,991,I-GeneOrGeneProduct
),991,I-GeneOrGeneProduct
receptor,991,I-GeneOrGeneProduct
in,991,O
renal,991,B-DiseaseOrPhenotypicFeature
damage,991,I-DiseaseOrPhenotypicFeature
as,991,O
a,991,O
result,991,O
of,991,O
hypertension,991,B-DiseaseOrPhenotypicFeature
by,991,O
using,991,O
transgenic,991,O
mice,991,B-OrganismTaxon
with,991,O
AT1a,991,B-GeneOrGeneProduct
receptor,991,I-GeneOrGeneProduct
gene,991,O
disruption,991,O
.,991,O
Transgenic,992,O
mice,992,B-OrganismTaxon
that,992,O
express,992,O
human,992,B-OrganismTaxon
liver-type,992,B-GeneOrGeneProduct
fatty,992,I-GeneOrGeneProduct
acid,992,I-GeneOrGeneProduct
binding,992,I-GeneOrGeneProduct
protein,992,I-GeneOrGeneProduct
(,992,O
L-FABP,992,B-GeneOrGeneProduct
),992,O
with,992,O
or,992,O
without,992,O
disruption,992,O
of,992,O
the,992,O
AT1a,992,B-GeneOrGeneProduct
receptor,992,I-GeneOrGeneProduct
gene,992,O
(,992,O
L-FABP,992,B-GeneOrGeneProduct
(,992,O
+/-,992,O
),992,O
AT1a,992,B-GeneOrGeneProduct
(,992,O
-/-,992,O
),992,O
",",992,O
and,992,O
L-FABP,992,B-GeneOrGeneProduct
(,992,O
+/-,992,O
),992,O
AT1a,992,B-GeneOrGeneProduct
(,992,O
+/+,992,O
),992,O
",",992,O
respectively,992,O
),992,O
were,992,O
used,992,O
with,992,O
urinary,992,O
L-FABP,992,B-GeneOrGeneProduct
as,992,O
an,992,O
indicator,992,O
of,992,O
tubulointerstitial,992,B-DiseaseOrPhenotypicFeature
damage,992,I-DiseaseOrPhenotypicFeature
.,992,O
Those,993,O
female,993,O
mice,993,B-OrganismTaxon
were,993,O
administered,993,O
subcutaneously,993,O
deoxycorticosterone,993,B-ChemicalEntity
acetate,993,I-ChemicalEntity
(,993,O
DOCA,993,B-ChemicalEntity
),993,O
-salt,993,O
tablets,993,O
plus,993,O
drinking,993,O
water,993,O
that,993,O
contained,993,O
1,993,O
%,993,O
saline,993,O
for,993,O
28,993,O
d,993,O
after,993,O
uninephrectomy,993,O
.,993,O
In,994,O
L-FABP,994,B-GeneOrGeneProduct
(,994,O
+/-,994,O
),994,O
AT1a,994,B-GeneOrGeneProduct
(,994,O
+/+,994,O
),994,O
mice,994,B-OrganismTaxon
that,994,O
received,994,O
DOCA-salt,994,B-ChemicalEntity
treatment,994,O
",",994,O
hypertension,994,B-DiseaseOrPhenotypicFeature
was,994,O
induced,994,O
and,994,O
slight,994,O
expansion,994,O
of,994,O
glomerular,994,O
area,994,O
",",994,O
glomerular,994,B-DiseaseOrPhenotypicFeature
sclerosis,994,I-DiseaseOrPhenotypicFeature
",",994,O
and,994,O
tubulointerstitial,994,B-DiseaseOrPhenotypicFeature
damage,994,I-DiseaseOrPhenotypicFeature
were,994,O
observed,994,O
.,994,O
In,995,O
L-FABP,995,B-GeneOrGeneProduct
(,995,O
+/-,995,O
),995,O
AT1a,995,B-GeneOrGeneProduct
(,995,O
-/-,995,O
),995,O
mice,995,B-OrganismTaxon
that,995,O
received,995,O
DOCA-salt,995,B-ChemicalEntity
treatment,995,O
",",995,O
hypertension,995,B-DiseaseOrPhenotypicFeature
was,995,O
similarly,995,O
induced,995,O
and,995,O
the,995,O
degree,995,O
of,995,O
glomerular,995,B-DiseaseOrPhenotypicFeature
damage,995,I-DiseaseOrPhenotypicFeature
was,995,O
significantly,995,O
more,995,O
severe,995,O
than,995,O
in,995,O
L-FABP,995,B-GeneOrGeneProduct
(,995,O
+/-,995,O
),995,O
AT1a,995,B-GeneOrGeneProduct
(,995,O
+/+,995,O
),995,O
-DOCA,995,O
mice,995,B-OrganismTaxon
.,995,O
Urinary,996,O
L-FABP,996,B-GeneOrGeneProduct
levels,996,O
were,996,O
significantly,996,O
higher,996,O
in,996,O
L-FABP,996,B-GeneOrGeneProduct
(,996,O
+/-,996,O
),996,O
AT1a,996,B-GeneOrGeneProduct
(,996,O
-/-,996,O
),996,O
-DOCA,996,O
mice,996,B-OrganismTaxon
compared,996,O
with,996,O
those,996,O
in,996,O
L-FABP,996,B-GeneOrGeneProduct
(,996,O
+/-,996,O
),996,O
AT1a,996,B-GeneOrGeneProduct
(,996,O
+/+,996,O
),996,O
-DOCA,996,O
mice,996,B-OrganismTaxon
.,996,O
Hydralazine,997,B-ChemicalEntity
treatment,997,O
significantly,997,O
attenuated,997,O
renal,997,B-DiseaseOrPhenotypicFeature
damage,997,I-DiseaseOrPhenotypicFeature
that,997,O
was,997,O
found,997,O
in,997,O
L-FABP,997,B-GeneOrGeneProduct
(,997,O
+/-,997,O
),997,O
AT1a,997,B-GeneOrGeneProduct
(,997,O
-/-,997,O
),997,O
-DOCA,997,O
mice,997,B-OrganismTaxon
along,997,O
with,997,O
a,997,O
reduction,997,O
in,997,O
blood,997,O
pressure,997,O
.,997,O
In,998,O
summary,998,O
",",998,O
activation,998,O
of,998,O
the,998,O
AT1a,998,B-GeneOrGeneProduct
receptor,998,I-GeneOrGeneProduct
may,998,O
contribute,998,O
to,998,O
maintenance,998,O
of,998,O
the,998,O
glomerular,998,O
structure,998,O
against,998,O
hypertensive,998,B-DiseaseOrPhenotypicFeature
renal,998,I-DiseaseOrPhenotypicFeature
damage.-Hisamichi,998,O
",",998,O
M.,998,O
",",998,O
Kamijo-Ikemori,998,O
",",998,O
A.,998,O
",",998,O
Sugaya,998,O
",",998,O
T.,998,O
",",998,O
Ichikawa,998,O
",",998,O
D.,998,O
",",998,O
Natsuki,998,O
",",998,O
T.,998,O
",",998,O
Hoshino,998,O
",",998,O
S.,998,O
",",998,O
Kimura,998,O
",",998,O
K.,998,O
",",998,O
Shibagaki,998,O
",",998,O
Y,998,O
.,998,O
Role,999,O
of,999,O
angiotensin,999,B-GeneOrGeneProduct
II,999,I-GeneOrGeneProduct
type,999,I-GeneOrGeneProduct
1a,999,I-GeneOrGeneProduct
receptor,999,I-GeneOrGeneProduct
in,999,O
renal,999,B-DiseaseOrPhenotypicFeature
injury,999,I-DiseaseOrPhenotypicFeature
induced,999,O
by,999,O
deoxycorticosterone,999,B-ChemicalEntity
acetate-salt,999,O
hypertension,999,B-DiseaseOrPhenotypicFeature
.,999,O
MicroRNA,1000,O
deep,1000,O
sequencing,1000,O
in,1000,O
two,1000,O
adult,1000,O
stem,1000,O
cell,1000,O
populations,1000,O
identifies,1000,O
miR-501,1000,B-GeneOrGeneProduct
as,1000,O
a,1000,O
novel,1000,O
regulator,1000,O
of,1000,O
myosin,1000,B-GeneOrGeneProduct
heavy,1000,I-GeneOrGeneProduct
chain,1000,I-GeneOrGeneProduct
during,1000,O
muscle,1000,O
regeneration,1000,O
.,1000,O
MicroRNAs,1001,O
(,1001,O
miRNAs,1001,O
),1001,O
are,1001,O
important,1001,O
regulators,1001,O
of,1001,O
skeletal,1001,O
muscle,1001,O
regeneration,1001,O
",",1001,O
but,1001,O
the,1001,O
underlying,1001,O
mechanisms,1001,O
are,1001,O
still,1001,O
incompletely,1001,O
understood,1001,O
.,1001,O
Here,1002,O
",",1002,O
comparative,1002,O
miRNA,1002,O
sequencing,1002,O
analysis,1002,O
of,1002,O
myogenic,1002,O
progenitor,1002,O
cells,1002,O
(,1002,O
MPs,1002,O
),1002,O
and,1002,O
non-myogenic,1002,O
fibroblast-adipocyte,1002,O
progenitors,1002,O
(,1002,O
FAPs,1002,O
),1002,O
during,1002,O
cardiotoxin,1002,B-ChemicalEntity
(,1002,O
CTX,1002,B-ChemicalEntity
),1002,O
-induced,1002,O
muscle,1002,B-DiseaseOrPhenotypicFeature
injury,1002,I-DiseaseOrPhenotypicFeature
uncovered,1002,O
miR-501,1002,B-GeneOrGeneProduct
as,1002,O
a,1002,O
novel,1002,O
muscle-specific,1002,O
miRNA,1002,O
.,1002,O
miR-501,1003,B-GeneOrGeneProduct
is,1003,O
an,1003,O
intronic,1003,O
miRNA,1003,O
and,1003,O
its,1003,O
expression,1003,O
levels,1003,O
in,1003,O
MPs,1003,O
correlated,1003,O
with,1003,O
its,1003,O
host,1003,O
gene,1003,O
",",1003,O
chloride,1003,B-GeneOrGeneProduct
channel,1003,I-GeneOrGeneProduct
",",1003,I-GeneOrGeneProduct
voltage-sensitive,1003,I-GeneOrGeneProduct
5,1003,I-GeneOrGeneProduct
(,1003,O
Clcn5,1003,B-GeneOrGeneProduct
),1003,O
.,1003,O
Pharmacological,1004,O
inhibition,1004,O
of,1004,O
miR-501,1004,B-GeneOrGeneProduct
dramatically,1004,O
blunted,1004,O
the,1004,O
induction,1004,O
of,1004,O
embryonic,1004,O
myosin,1004,B-GeneOrGeneProduct
heavy,1004,I-GeneOrGeneProduct
chain,1004,I-GeneOrGeneProduct
(,1004,O
MYH3,1004,B-GeneOrGeneProduct
),1004,O
and,1004,O
",",1004,O
to,1004,O
a,1004,O
lesser,1004,O
extent,1004,O
",",1004,O
adult,1004,B-GeneOrGeneProduct
myosin,1004,I-GeneOrGeneProduct
isoforms,1004,I-GeneOrGeneProduct
during,1004,O
muscle,1004,O
regeneration,1004,O
",",1004,O
and,1004,O
promoted,1004,O
small-diameter,1004,O
neofibers,1004,O
.,1004,O
An,1005,O
unbiased,1005,O
target,1005,O
identification,1005,O
approach,1005,O
in,1005,O
primary,1005,O
myoblasts,1005,O
validated,1005,O
gigaxonin,1005,B-GeneOrGeneProduct
as,1005,O
a,1005,O
target,1005,O
of,1005,O
miR-501,1005,B-GeneOrGeneProduct
that,1005,O
mimicked,1005,O
the,1005,O
effect,1005,O
of,1005,O
miR-501,1005,B-GeneOrGeneProduct
inhibition,1005,O
on,1005,O
MYH3,1005,B-GeneOrGeneProduct
expression,1005,O
.,1005,O
In,1006,O
the,1006,O
mdx,1006,O
mouse,1006,B-OrganismTaxon
model,1006,O
",",1006,O
which,1006,O
models,1006,O
a,1006,O
pathological,1006,O
disease,1006,O
state,1006,O
",",1006,O
not,1006,O
only,1006,O
was,1006,O
miR-501,1006,B-GeneOrGeneProduct
induced,1006,O
in,1006,O
regenerating,1006,O
skeletal,1006,O
muscle,1006,O
",",1006,O
but,1006,O
also,1006,O
its,1006,O
serum,1006,O
levels,1006,O
were,1006,O
increased,1006,O
",",1006,O
which,1006,O
correlated,1006,O
with,1006,O
the,1006,O
disease,1006,O
state,1006,O
of,1006,O
the,1006,O
animals,1006,O
.,1006,O
Our,1007,O
results,1007,O
suggest,1007,O
that,1007,O
miR-501,1007,B-GeneOrGeneProduct
plays,1007,O
a,1007,O
key,1007,O
role,1007,O
in,1007,O
adult,1007,O
muscle,1007,O
regeneration,1007,O
and,1007,O
might,1007,O
serve,1007,O
as,1007,O
a,1007,O
novel,1007,O
serum,1007,O
biomarker,1007,O
for,1007,O
the,1007,O
activation,1007,O
of,1007,O
adult,1007,O
muscle,1007,O
stem,1007,O
cells,1007,O
.,1007,O
Reduced,1008,O
adiponectin,1008,B-GeneOrGeneProduct
expression,1008,O
after,1008,O
high-fat,1008,O
diet,1008,O
is,1008,O
associated,1008,O
with,1008,O
selective,1008,O
up-regulation,1008,O
of,1008,O
ALDH1A1,1008,B-GeneOrGeneProduct
and,1008,O
further,1008,O
retinoic,1008,B-GeneOrGeneProduct
acid,1008,I-GeneOrGeneProduct
receptor,1008,I-GeneOrGeneProduct
signaling,1008,O
in,1008,O
adipose,1008,O
tissue,1008,O
.,1008,O
Adiponectin,1009,B-GeneOrGeneProduct
is,1009,O
an,1009,O
adipocyte-derived,1009,O
adipokine,1009,B-GeneOrGeneProduct
with,1009,O
potent,1009,O
antidiabetic,1009,O
",",1009,O
anti-inflammatory,1009,O
",",1009,O
and,1009,O
antiatherogenic,1009,O
activity,1009,O
.,1009,O
Long-term,1010,O
",",1010,O
high-fat,1010,O
diet,1010,O
results,1010,O
in,1010,O
gain,1010,O
of,1010,O
body,1010,O
weight,1010,O
",",1010,O
adiposity,1010,B-DiseaseOrPhenotypicFeature
",",1010,O
further,1010,O
inflammatory-based,1010,B-DiseaseOrPhenotypicFeature
cardiovascular,1010,B-DiseaseOrPhenotypicFeature
diseases,1010,I-DiseaseOrPhenotypicFeature
",",1010,O
and,1010,O
reduced,1010,O
adiponectin,1010,B-GeneOrGeneProduct
secretion,1010,O
.,1010,O
Vitamin,1011,B-ChemicalEntity
A,1011,I-ChemicalEntity
derivatives/retinoids,1011,O
are,1011,O
involved,1011,O
in,1011,O
several,1011,O
of,1011,O
these,1011,O
processes,1011,O
",",1011,O
which,1011,O
mainly,1011,O
take,1011,O
place,1011,O
in,1011,O
white,1011,O
adipose,1011,O
tissue,1011,O
(,1011,O
WAT,1011,O
),1011,O
.,1011,O
In,1012,O
this,1012,O
study,1012,O
",",1012,O
we,1012,O
examined,1012,O
adiponectin,1012,B-GeneOrGeneProduct
expression,1012,O
as,1012,O
a,1012,O
function,1012,O
of,1012,O
dietary,1012,O
high-fat,1012,O
and,1012,O
high-vitamin,1012,O
A,1012,I-ChemicalEntity
conditions,1012,O
in,1012,O
mice,1012,B-OrganismTaxon
.,1012,O
A,1013,O
decrease,1013,O
of,1013,O
adiponectin,1013,B-GeneOrGeneProduct
expression,1013,O
in,1013,O
addition,1013,O
to,1013,O
an,1013,O
up-regulation,1013,O
of,1013,O
aldehyde,1013,B-GeneOrGeneProduct
dehydrogenase,1013,I-GeneOrGeneProduct
A1,1013,I-GeneOrGeneProduct
(,1013,O
ALDH1A1,1013,B-GeneOrGeneProduct
),1013,O
",",1013,O
retinoid,1013,O
signaling,1013,O
",",1013,O
and,1013,O
retinoic,1013,B-ChemicalEntity
acid,1013,I-ChemicalEntity
response,1013,O
element,1013,O
signaling,1013,O
was,1013,O
selectively,1013,O
observed,1013,O
in,1013,O
WAT,1013,O
of,1013,O
mice,1013,B-OrganismTaxon
fed,1013,O
a,1013,O
normal-vitamin,1013,O
A,1013,I-ChemicalEntity
",",1013,O
high-fat,1013,O
diet,1013,O
.,1013,O
Reduced,1014,O
adiponectin,1014,B-GeneOrGeneProduct
expression,1014,O
in,1014,O
WAT,1014,O
was,1014,O
also,1014,O
observed,1014,O
in,1014,O
mice,1014,B-OrganismTaxon
fed,1014,O
a,1014,O
high-vitamin,1014,O
A,1014,I-ChemicalEntity
diet,1014,O
.,1014,O
Adipocyte,1015,O
cell,1015,O
culture,1015,O
revealed,1015,O
that,1015,O
endogenous,1015,O
and,1015,O
synthetic,1015,O
retinoic,1015,B-GeneOrGeneProduct
acid,1015,I-GeneOrGeneProduct
receptor,1015,I-GeneOrGeneProduct
(,1015,I-GeneOrGeneProduct
RAR,1015,I-GeneOrGeneProduct
),1015,I-GeneOrGeneProduct
a-,1015,O
and,1015,O
RARg-selective,1015,B-GeneOrGeneProduct
agonists,1015,O
",",1015,O
as,1015,O
well,1015,O
as,1015,O
a,1015,O
synthetic,1015,O
retinoid,1015,B-GeneOrGeneProduct
X,1015,I-GeneOrGeneProduct
receptor,1015,I-GeneOrGeneProduct
agonist,1015,O
",",1015,O
efficiently,1015,O
reduced,1015,O
adiponectin,1015,B-GeneOrGeneProduct
expression,1015,O
",",1015,O
whereas,1015,O
ALDH1A1,1015,B-GeneOrGeneProduct
expression,1015,O
only,1015,O
increased,1015,O
with,1015,O
RAR,1015,B-GeneOrGeneProduct
agonists,1015,O
.,1015,O
We,1016,O
conclude,1016,O
that,1016,O
reduced,1016,O
adiponectin,1016,B-GeneOrGeneProduct
expression,1016,O
under,1016,O
high-fat,1016,O
dietary,1016,O
conditions,1016,O
is,1016,O
dependent,1016,O
on,1016,O
1,1016,O
),1016,O
increased,1016,O
ALDH1A1,1016,B-GeneOrGeneProduct
expression,1016,O
in,1016,O
adipocytes,1016,O
",",1016,O
which,1016,O
does,1016,O
not,1016,O
increase,1016,O
all-trans-retinoic,1016,O
acid,1016,I-ChemicalEntity
levels,1016,O
;,1016,O
2,1016,O
),1016,O
further,1016,O
RAR,1016,B-GeneOrGeneProduct
ligand-induced,1016,O
",",1016,O
WAT-selective,1016,O
",",1016,O
increased,1016,O
retinoic,1016,B-ChemicalEntity
acid,1016,I-ChemicalEntity
response,1016,O
element-mediated,1016,O
signaling,1016,O
;,1016,O
and,1016,O
3,1016,O
),1016,O
RAR,1016,B-GeneOrGeneProduct
ligand-dependent,1016,O
reduction,1016,O
of,1016,O
adiponectin,1016,B-GeneOrGeneProduct
expression.-Landrier,1016,O
",",1016,O
J.-F.,1016,O
",",1016,O
Kasiri,1016,O
",",1016,O
E.,1016,O
",",1016,O
Karkeni,1016,O
",",1016,O
E.,1016,O
",",1016,O
Mihaly,1016,O
",",1016,O
J.,1016,O
",",1016,O
Beke,1016,O
",",1016,O
G.,1016,O
",",1016,O
Weiss,1016,O
",",1016,O
K.,1016,O
",",1016,O
Lucas,1016,O
",",1016,O
R.,1016,O
",",1016,O
Aydemir,1016,O
",",1016,O
G.,1016,O
",",1016,O
Salles,1016,O
",",1016,O
J.,1016,O
",",1016,O
Walrand,1016,O
",",1016,O
S.,1016,O
",",1016,O
de,1016,O
Lera,1016,O
",",1016,O
A.,1016,O
R.,1016,O
",",1016,O
Ruhl,1016,O
",",1016,O
R.,1016,O
Reduced,1016,O
adiponectin,1016,B-GeneOrGeneProduct
expression,1016,O
after,1016,O
high-fat,1016,O
diet,1016,O
is,1016,O
associated,1016,O
with,1016,O
selective,1016,O
up-regulation,1016,O
of,1016,O
ALDH1A1,1016,B-GeneOrGeneProduct
and,1016,O
further,1016,O
retinoic,1016,B-GeneOrGeneProduct
acid,1016,I-GeneOrGeneProduct
receptor,1016,I-GeneOrGeneProduct
signaling,1016,O
in,1016,O
adipose,1016,O
tissue,1016,O
.,1016,O
PTPN22,1017,B-GeneOrGeneProduct
Is,1017,O
a,1017,O
Critical,1017,O
Regulator,1017,O
of,1017,O
Fcg,1017,B-GeneOrGeneProduct
Receptor-Mediated,1017,O
Neutrophil,1017,O
Activation,1017,O
.,1017,O
Neutrophils,1018,O
act,1018,O
as,1018,O
a,1018,O
first,1018,O
line,1018,O
of,1018,O
defense,1018,O
against,1018,O
bacterial,1018,O
and,1018,O
fungal,1018,B-DiseaseOrPhenotypicFeature
infections,1018,I-DiseaseOrPhenotypicFeature
",",1018,O
but,1018,O
they,1018,O
are,1018,O
also,1018,O
important,1018,O
effectors,1018,O
of,1018,O
acute,1018,B-DiseaseOrPhenotypicFeature
and,1018,I-DiseaseOrPhenotypicFeature
chronic,1018,I-DiseaseOrPhenotypicFeature
inflammation,1018,I-DiseaseOrPhenotypicFeature
.,1018,O
Genome-wide,1019,O
association,1019,O
studies,1019,O
have,1019,O
established,1019,O
that,1019,O
the,1019,O
gene,1019,O
encoding,1019,O
the,1019,O
protein,1019,B-GeneOrGeneProduct
tyrosine,1019,I-GeneOrGeneProduct
phosphatase,1019,I-GeneOrGeneProduct
nonreceptor,1019,I-GeneOrGeneProduct
22,1019,I-GeneOrGeneProduct
(,1019,O
PTPN22,1019,B-GeneOrGeneProduct
),1019,O
makes,1019,O
an,1019,O
important,1019,O
contribution,1019,O
to,1019,O
susceptibility,1019,O
to,1019,O
autoimmune,1019,B-DiseaseOrPhenotypicFeature
disease,1019,I-DiseaseOrPhenotypicFeature
",",1019,O
notably,1019,O
rheumatoid,1019,B-DiseaseOrPhenotypicFeature
arthritis,1019,I-DiseaseOrPhenotypicFeature
.,1019,O
Although,1020,O
PTPN22,1020,B-GeneOrGeneProduct
is,1020,O
most,1020,O
highly,1020,O
expressed,1020,O
in,1020,O
neutrophils,1020,O
",",1020,O
its,1020,O
function,1020,O
in,1020,O
these,1020,O
cells,1020,O
remains,1020,O
poorly,1020,O
characterized,1020,O
.,1020,O
We,1021,O
show,1021,O
in,1021,O
this,1021,O
article,1021,O
that,1021,O
neutrophil,1021,O
effector,1021,O
functions,1021,O
",",1021,O
including,1021,O
adhesion,1021,O
",",1021,O
production,1021,O
of,1021,O
reactive,1021,B-ChemicalEntity
oxygen,1021,I-ChemicalEntity
species,1021,I-ChemicalEntity
",",1021,O
and,1021,O
degranulation,1021,O
induced,1021,O
by,1021,O
immobilized,1021,O
immune,1021,O
complexes,1021,O
",",1021,O
were,1021,O
reduced,1021,O
in,1021,O
Ptpn22,1021,B-GeneOrGeneProduct
(,1021,O
-/-,1021,O
),1021,O
neutrophils,1021,O
.,1021,O
Tyrosine,1022,O
phosphorylation,1022,O
of,1022,O
Lyn,1022,B-GeneOrGeneProduct
and,1022,O
Syk,1022,B-GeneOrGeneProduct
was,1022,O
altered,1022,O
in,1022,O
Ptpn22,1022,B-GeneOrGeneProduct
(,1022,O
-/-,1022,O
),1022,O
neutrophils,1022,O
.,1022,O
On,1023,O
stimulation,1023,O
with,1023,O
immobilized,1023,O
immune,1023,O
complexes,1023,O
",",1023,O
Ptpn22,1023,B-GeneOrGeneProduct
(,1023,O
-/-,1023,O
),1023,O
neutrophils,1023,O
manifested,1023,O
reduced,1023,O
activation,1023,O
of,1023,O
key,1023,O
signaling,1023,O
intermediates,1023,O
.,1023,O
Ptpn22,1024,B-GeneOrGeneProduct
(,1024,O
-/-,1024,O
),1024,O
mice,1024,B-OrganismTaxon
were,1024,O
protected,1024,O
from,1024,O
immune,1024,O
complex-mediated,1024,O
arthritis,1024,B-DiseaseOrPhenotypicFeature
",",1024,O
induced,1024,O
by,1024,O
the,1024,O
transfer,1024,O
of,1024,O
arthritogenic,1024,O
serum,1024,O
.,1024,O
In,1025,O
contrast,1025,O
",",1025,O
in,1025,O
vivo,1025,O
neutrophil,1025,O
recruitment,1025,O
following,1025,O
thioglycollate-induced,1025,B-ChemicalEntity
peritonitis,1025,B-DiseaseOrPhenotypicFeature
and,1025,O
in,1025,O
vitro,1025,O
chemotaxis,1025,O
were,1025,O
not,1025,O
affected,1025,O
by,1025,O
lack,1025,O
of,1025,O
PTPN22,1025,B-GeneOrGeneProduct
.,1025,O
Our,1026,O
data,1026,O
suggest,1026,O
an,1026,O
important,1026,O
role,1026,O
for,1026,O
PTPN22-dependent,1026,B-GeneOrGeneProduct
dephosphorylation,1026,O
events,1026,O
",",1026,O
which,1026,O
are,1026,O
required,1026,O
to,1026,O
enable,1026,O
full,1026,O
FcgR-induced,1026,B-GeneOrGeneProduct
activation,1026,O
",",1026,O
pointing,1026,O
to,1026,O
an,1026,O
important,1026,O
role,1026,O
for,1026,O
this,1026,O
molecule,1026,O
in,1026,O
neutrophil,1026,O
function,1026,O
.,1026,O
Seven,1027,O
novel,1027,O
and,1027,O
six,1027,O
de,1027,O
novo,1027,O
PHEX,1027,B-GeneOrGeneProduct
gene,1027,O
mutations,1027,O
in,1027,O
patients,1027,B-OrganismTaxon
with,1027,O
hypophosphatemic,1027,B-DiseaseOrPhenotypicFeature
rickets,1027,I-DiseaseOrPhenotypicFeature
.,1027,O
Inactivating,1028,O
mutations,1028,O
in,1028,O
phosphate-regulating,1028,B-GeneOrGeneProduct
gene,1028,I-GeneOrGeneProduct
with,1028,I-GeneOrGeneProduct
homologies,1028,I-GeneOrGeneProduct
to,1028,I-GeneOrGeneProduct
endopeptidase,1028,I-GeneOrGeneProduct
on,1028,I-GeneOrGeneProduct
the,1028,I-GeneOrGeneProduct
X,1028,I-GeneOrGeneProduct
chromosome,1028,I-GeneOrGeneProduct
(,1028,O
PHEX,1028,B-GeneOrGeneProduct
),1028,O
have,1028,O
been,1028,O
identified,1028,O
as,1028,O
a,1028,O
cause,1028,O
of,1028,O
X-linked,1028,B-DiseaseOrPhenotypicFeature
hypophosphatemic,1028,I-DiseaseOrPhenotypicFeature
rickets,1028,I-DiseaseOrPhenotypicFeature
(,1028,O
XLH,1028,B-DiseaseOrPhenotypicFeature
;,1028,O
OMIM,1028,B-DiseaseOrPhenotypicFeature
307800,1028,I-DiseaseOrPhenotypicFeature
),1028,O
.,1028,O
In,1029,O
the,1029,O
present,1029,O
study,1029,O
",",1029,O
we,1029,O
enrolled,1029,O
43,1029,O
patients,1029,B-OrganismTaxon
from,1029,O
18,1029,O
unrelated,1029,O
families,1029,O
clinically,1029,O
diagnosed,1029,O
with,1029,O
hypophosphatemic,1029,B-DiseaseOrPhenotypicFeature
rickets,1029,I-DiseaseOrPhenotypicFeature
and,1029,O
250,1029,O
healthy,1029,O
controls,1029,O
.,1029,O
For,1030,O
each,1030,O
available,1030,O
individual,1030,O
",",1030,O
all,1030,O
22,1030,O
exons,1030,O
with,1030,O
their,1030,O
exon-intron,1030,O
boundaries,1030,O
of,1030,O
the,1030,O
PHEX,1030,B-GeneOrGeneProduct
gene,1030,O
were,1030,O
directly,1030,O
sequenced,1030,O
.,1030,O
The,1031,O
levels,1031,O
of,1031,O
serum,1031,O
fibroblast,1031,B-GeneOrGeneProduct
growth,1031,I-GeneOrGeneProduct
factor,1031,I-GeneOrGeneProduct
23,1031,I-GeneOrGeneProduct
(,1031,O
FGF23,1031,B-GeneOrGeneProduct
),1031,O
were,1031,O
measured,1031,O
as,1031,O
well,1031,O
.,1031,O
Sequencing,1032,O
analysis,1032,O
detected,1032,O
17,1032,O
different,1032,O
PHEX,1032,B-GeneOrGeneProduct
gene,1032,O
mutations,1032,O
",",1032,O
and,1032,O
7,1032,O
of,1032,O
these,1032,O
were,1032,O
identified,1032,O
as,1032,O
novel,1032,O
:,1032,O
3,1032,O
missense,1032,O
mutations,1032,O
",",1032,O
including,1032,O
c.304G,1032,B-SequenceVariant
>,1032,I-SequenceVariant
A,1032,I-SequenceVariant
(,1032,O
p.Gly102Arg,1032,B-SequenceVariant
),1032,O
in,1032,O
exon,1032,O
3,1032,O
",",1032,O
c.229T,1032,B-SequenceVariant
>,1032,I-SequenceVariant
C,1032,I-SequenceVariant
(,1032,O
p.Cys77Arg,1032,B-SequenceVariant
),1032,O
in,1032,O
exon,1032,O
3,1032,O
and,1032,O
c.824T,1032,B-SequenceVariant
>,1032,I-SequenceVariant
C,1032,I-SequenceVariant
(,1032,O
p.Leu275Pro,1032,B-SequenceVariant
),1032,O
in,1032,O
exon,1032,O
7,1032,O
;,1032,O
2,1032,O
deletion,1032,O
mutations,1032,O
",",1032,O
including,1032,O
c.528delT,1032,B-SequenceVariant
(,1032,O
p.Glu177LysfsX44,1032,B-SequenceVariant
),1032,O
in,1032,O
exon,1032,O
5,1032,O
and,1032,O
c.1234delA,1032,B-SequenceVariant
(,1032,O
p.Ser412ValfsX12,1032,B-SequenceVariant
),1032,O
in,1032,O
exon,1032,O
11,1032,O
;,1032,O
and,1032,O
2,1032,O
alternative,1032,O
splicing,1032,O
mutations,1032,O
",",1032,O
including,1032,O
c.436_436+1delAG,1032,B-SequenceVariant
in,1032,O
intron,1032,O
4,1032,O
at,1032,O
splicing,1032,O
donor,1032,O
sites,1032,O
and,1032,O
c.1483-1G,1032,B-SequenceVariant
>,1032,I-SequenceVariant
C,1032,I-SequenceVariant
in,1032,O
intron,1032,O
13,1032,O
at,1032,O
splicing,1032,O
acceptor,1032,O
sites,1032,O
.,1032,O
Moreover,1033,O
",",1033,O
6,1033,O
mutations,1033,O
were,1033,O
proven,1033,O
to,1033,O
be,1033,O
de,1033,O
novo,1033,O
in,1033,O
6,1033,O
sporadic,1033,O
cases,1033,O
and,1033,O
the,1033,O
probands,1033,O
were,1033,O
all,1033,O
females,1033,O
.,1033,O
No,1034,O
mutations,1034,O
were,1034,O
found,1034,O
in,1034,O
the,1034,O
250,1034,O
healthy,1034,O
controls,1034,O
.,1034,O
The,1035,O
serum,1035,O
levels,1035,O
of,1035,O
FGF23,1035,B-GeneOrGeneProduct
varied,1035,O
widely,1035,O
among,1035,O
the,1035,O
patients,1035,B-OrganismTaxon
with,1035,O
XLH,1035,B-DiseaseOrPhenotypicFeature
",",1035,O
and,1035,O
no,1035,O
significant,1035,O
difference,1035,O
was,1035,O
found,1035,O
when,1035,O
compared,1035,O
with,1035,O
those,1035,O
of,1035,O
the,1035,O
healthy,1035,O
controls,1035,O
.,1035,O
On,1036,O
the,1036,O
whole,1036,O
",",1036,O
the,1036,O
findings,1036,O
of,1036,O
this,1036,O
study,1036,O
provide,1036,O
new,1036,O
insight,1036,O
into,1036,O
the,1036,O
spectrum,1036,O
of,1036,O
PHEX,1036,B-GeneOrGeneProduct
mutations,1036,O
and,1036,O
provide,1036,O
potential,1036,O
evidence,1036,O
of,1036,O
a,1036,O
critical,1036,O
domain,1036,O
in,1036,O
PHEX,1036,B-GeneOrGeneProduct
protein,1036,O
.,1036,O
In,1037,O
addition,1037,O
",",1037,O
the,1037,O
finding,1037,O
of,1037,O
an,1037,O
overlap,1037,O
of,1037,O
the,1037,O
serum,1037,O
FGF23,1037,B-GeneOrGeneProduct
levels,1037,O
between,1037,O
the,1037,O
patients,1037,B-OrganismTaxon
with,1037,O
XLH,1037,B-DiseaseOrPhenotypicFeature
and,1037,O
the,1037,O
healthy,1037,O
controls,1037,O
indicates,1037,O
its,1037,O
limited,1037,O
diagnostic,1037,O
value,1037,O
in,1037,O
XLH,1037,B-DiseaseOrPhenotypicFeature
.,1037,O
Sildenafil,1038,B-ChemicalEntity
attenuates,1038,O
hypoxic,1038,B-DiseaseOrPhenotypicFeature
pulmonary,1038,I-DiseaseOrPhenotypicFeature
remodelling,1038,I-DiseaseOrPhenotypicFeature
by,1038,O
inhibiting,1038,O
bone,1038,O
marrow,1038,O
progenitor,1038,O
cells,1038,O
.,1038,O
The,1039,O
recruitment,1039,O
of,1039,O
bone,1039,O
marrow,1039,O
(,1039,O
BM,1039,O
),1039,O
-derived,1039,O
progenitor,1039,O
cells,1039,O
to,1039,O
the,1039,O
lung,1039,O
is,1039,O
related,1039,O
to,1039,O
pulmonary,1039,B-DiseaseOrPhenotypicFeature
remodelling,1039,I-DiseaseOrPhenotypicFeature
and,1039,O
the,1039,O
pathogenesis,1039,O
of,1039,O
pulmonary,1039,B-DiseaseOrPhenotypicFeature
hypertension,1039,I-DiseaseOrPhenotypicFeature
(,1039,O
PH,1039,B-DiseaseOrPhenotypicFeature
),1039,O
.,1039,O
Although,1040,O
sildenafil,1040,B-ChemicalEntity
is,1040,O
a,1040,O
known,1040,O
target,1040,O
in,1040,O
PH,1040,B-DiseaseOrPhenotypicFeature
treatment,1040,O
",",1040,O
the,1040,O
underlying,1040,O
molecular,1040,O
mechanism,1040,O
is,1040,O
still,1040,O
elusive,1040,O
.,1040,O
To,1041,O
test,1041,O
the,1041,O
hypothesis,1041,O
that,1041,O
the,1041,O
therapeutic,1041,O
effect,1041,O
of,1041,O
sildenafil,1041,B-ChemicalEntity
is,1041,O
linked,1041,O
to,1041,O
the,1041,O
reduced,1041,O
recruitment,1041,O
of,1041,O
BM-derived,1041,O
progenitor,1041,O
cells,1041,O
",",1041,O
we,1041,O
induced,1041,O
pulmonary,1041,B-DiseaseOrPhenotypicFeature
remodelling,1041,I-DiseaseOrPhenotypicFeature
in,1041,O
rats,1041,B-OrganismTaxon
by,1041,O
two-week,1041,O
exposure,1041,O
to,1041,O
chronic,1041,O
hypoxia,1041,B-DiseaseOrPhenotypicFeature
(,1041,O
CH,1041,B-DiseaseOrPhenotypicFeature
",",1041,O
10,1041,O
%,1041,O
oxygen,1041,B-ChemicalEntity
),1041,O
",",1041,O
a,1041,O
trigger,1041,O
of,1041,O
BM-derived,1041,O
progenitor,1041,O
cells,1041,O
.,1041,O
Rats,1042,B-OrganismTaxon
were,1042,O
treated,1042,O
with,1042,O
either,1042,O
placebo,1042,O
(,1042,O
saline,1042,O
),1042,O
or,1042,O
sildenafil,1042,B-ChemicalEntity
(,1042,O
1.4,1042,O
mg/kg/day,1042,O
ip,1042,O
),1042,O
during,1042,O
CH,1042,B-DiseaseOrPhenotypicFeature
.,1042,O
Control,1043,O
rats,1043,B-OrganismTaxon
were,1043,O
kept,1043,O
in,1043,O
room,1043,O
air,1043,O
(,1043,O
21,1043,O
%,1043,O
oxygen,1043,B-ChemicalEntity
),1043,O
with,1043,O
no,1043,O
treatment,1043,O
.,1043,O
As,1044,O
expected,1044,O
",",1044,O
sildenafil,1044,B-ChemicalEntity
attenuated,1044,O
the,1044,O
CH-induced,1044,B-DiseaseOrPhenotypicFeature
increase,1044,O
in,1044,O
right,1044,O
ventricular,1044,O
systolic,1044,O
pressure,1044,O
and,1044,O
right,1044,B-DiseaseOrPhenotypicFeature
ventricular,1044,I-DiseaseOrPhenotypicFeature
hypertrophy,1044,I-DiseaseOrPhenotypicFeature
.,1044,O
However,1045,O
",",1045,O
sildenafil,1045,B-ChemicalEntity
suppressed,1045,O
the,1045,O
CH-induced,1045,B-DiseaseOrPhenotypicFeature
increase,1045,O
in,1045,O
c-kit,1045,B-GeneOrGeneProduct
(,1045,O
+,1045,O
),1045,O
cells,1045,O
in,1045,O
the,1045,O
adventitia,1045,O
of,1045,O
pulmonary,1045,O
arteries,1045,O
.,1045,O
Moreover,1046,O
",",1046,O
sildenafil,1046,B-ChemicalEntity
reduced,1046,O
the,1046,O
number,1046,O
of,1046,O
c-kit,1046,B-GeneOrGeneProduct
(,1046,O
+,1046,O
),1046,O
cells,1046,O
that,1046,O
colocalize,1046,O
with,1046,O
tyrosine,1046,B-GeneOrGeneProduct
kinase,1046,I-GeneOrGeneProduct
receptor,1046,I-GeneOrGeneProduct
2,1046,I-GeneOrGeneProduct
(,1046,O
VEGF-R2,1046,B-GeneOrGeneProduct
),1046,O
and,1046,O
CD68,1046,B-GeneOrGeneProduct
(,1046,O
a,1046,O
marker,1046,O
for,1046,O
macrophages,1046,O
),1046,O
",",1046,O
indicating,1046,O
a,1046,O
positive,1046,O
effect,1046,O
on,1046,O
moderating,1046,O
hypoxia-induced,1046,B-DiseaseOrPhenotypicFeature
smooth,1046,O
muscle,1046,O
cell,1046,O
proliferation,1046,O
and,1046,O
inflammation,1046,B-DiseaseOrPhenotypicFeature
without,1046,O
affecting,1046,O
the,1046,O
pulmonary,1046,O
levels,1046,O
of,1046,O
hypoxia-inducible,1046,B-GeneOrGeneProduct
factor,1046,I-GeneOrGeneProduct
(,1046,I-GeneOrGeneProduct
HIF,1046,I-GeneOrGeneProduct
),1046,I-GeneOrGeneProduct
-1a,1046,I-GeneOrGeneProduct
.,1046,O
Furthermore,1047,O
",",1047,O
sildenafil,1047,B-ChemicalEntity
depressed,1047,O
the,1047,O
number,1047,O
of,1047,O
CXCR4,1047,B-GeneOrGeneProduct
(,1047,O
+,1047,O
),1047,O
cells,1047,O
.,1047,O
Collectively,1048,O
",",1048,O
these,1048,O
findings,1048,O
indicate,1048,O
that,1048,O
the,1048,O
improvement,1048,O
in,1048,O
pulmonary,1048,O
haemodynamic,1048,O
by,1048,O
sildenafil,1048,B-ChemicalEntity
is,1048,O
linked,1048,O
to,1048,O
decreased,1048,O
recruitment,1048,O
of,1048,O
BM-derived,1048,O
c-kit,1048,B-GeneOrGeneProduct
(,1048,O
+,1048,O
),1048,O
cells,1048,O
in,1048,O
the,1048,O
pulmonary,1048,O
tissue,1048,O
.,1048,O
The,1049,O
attenuation,1049,O
of,1049,O
the,1049,O
recruitment,1049,O
of,1049,O
BM-derived,1049,O
c-kit,1049,B-GeneOrGeneProduct
(,1049,O
+,1049,O
),1049,O
cells,1049,O
by,1049,O
sildenafil,1049,B-ChemicalEntity
may,1049,O
provide,1049,O
novel,1049,O
therapeutic,1049,O
insights,1049,O
into,1049,O
the,1049,O
control,1049,O
of,1049,O
pulmonary,1049,B-DiseaseOrPhenotypicFeature
remodelling,1049,I-DiseaseOrPhenotypicFeature
.,1049,O
Repeated,1050,O
otilonium,1050,B-ChemicalEntity
bromide,1050,I-ChemicalEntity
administration,1050,O
prevents,1050,O
neurotransmitter,1050,B-ChemicalEntity
changes,1050,O
in,1050,O
colon,1050,O
of,1050,O
rats,1050,B-OrganismTaxon
underwent,1050,O
to,1050,O
wrap,1050,O
restraint,1050,O
stress,1050,O
.,1050,O
Otilonium,1051,B-ChemicalEntity
bromide,1051,I-ChemicalEntity
(,1051,O
OB,1051,B-ChemicalEntity
),1051,O
is,1051,O
a,1051,O
spasmolytic,1051,O
drug,1051,O
successfully,1051,O
used,1051,O
for,1051,O
the,1051,O
treatment,1051,O
of,1051,O
irritable,1051,B-DiseaseOrPhenotypicFeature
bowel,1051,I-DiseaseOrPhenotypicFeature
syndrome,1051,I-DiseaseOrPhenotypicFeature
(,1051,O
IBS,1051,B-DiseaseOrPhenotypicFeature
),1051,O
.,1051,O
Its,1052,O
efficacy,1052,O
has,1052,O
been,1052,O
attributed,1052,O
to,1052,O
the,1052,O
block,1052,O
of,1052,O
L-,1052,B-GeneOrGeneProduct
and,1052,I-GeneOrGeneProduct
T-type,1052,I-GeneOrGeneProduct
Ca,1052,I-GeneOrGeneProduct
(,1052,I-GeneOrGeneProduct
2+,1052,I-GeneOrGeneProduct
),1052,I-GeneOrGeneProduct
channels,1052,I-GeneOrGeneProduct
and,1052,O
muscarinic,1052,B-GeneOrGeneProduct
and,1052,I-GeneOrGeneProduct
tachykinin,1052,I-GeneOrGeneProduct
receptors,1052,I-GeneOrGeneProduct
in,1052,O
the,1052,O
smooth,1052,O
muscle,1052,O
.,1052,O
Furthermore,1053,O
",",1053,O
in,1053,O
healthy,1053,O
rats,1053,B-OrganismTaxon
",",1053,O
repeated,1053,O
OB,1053,B-ChemicalEntity
administration,1053,O
modified,1053,O
neurotransmitter,1053,B-ChemicalEntity
expression,1053,O
and,1053,O
function,1053,O
suggesting,1053,O
other,1053,O
mechanisms,1053,O
of,1053,O
action,1053,O
.,1053,O
On,1054,O
this,1054,O
basis,1054,O
",",1054,O
we,1054,O
investigated,1054,O
whether,1054,O
repeated,1054,O
OB,1054,B-ChemicalEntity
treatment,1054,O
prevented,1054,O
the,1054,O
functional,1054,O
and,1054,O
neurochemical,1054,O
changes,1054,O
observed,1054,O
in,1054,O
the,1054,O
colon,1054,O
of,1054,O
rats,1054,B-OrganismTaxon
underwent,1054,O
to,1054,O
wrap,1054,O
restrain,1054,O
stress,1054,O
(,1054,O
WRS,1054,O
),1054,O
a,1054,O
psychosocial,1054,O
stressor,1054,O
considered,1054,O
suitable,1054,O
to,1054,O
reproduce,1054,O
the,1054,O
main,1054,O
IBS,1054,B-DiseaseOrPhenotypicFeature
signs,1054,O
and,1054,O
symptoms,1054,O
.,1054,O
In,1055,O
control,1055,O
",",1055,O
WRS,1055,O
and,1055,O
OB/WRS,1055,B-ChemicalEntity
rats,1055,B-OrganismTaxon
functional,1055,O
parameters,1055,O
were,1055,O
measured,1055,O
in,1055,O
vivo,1055,O
and,1055,O
morphological,1055,O
investigations,1055,O
were,1055,O
done,1055,O
ex,1055,O
vivo,1055,O
in,1055,O
the,1055,O
colon,1055,O
.,1055,O
The,1056,O
results,1056,O
showed,1056,O
that,1056,O
OB,1056,B-ChemicalEntity
counteracts,1056,O
most,1056,O
of,1056,O
the,1056,O
neurotransmitters,1056,B-ChemicalEntity
changes,1056,O
caused,1056,O
by,1056,O
WRS,1056,O
.,1056,O
In,1057,O
particular,1057,O
",",1057,O
the,1057,O
drug,1057,O
prevents,1057,O
the,1057,O
decrease,1057,O
in,1057,O
SP-,1057,B-GeneOrGeneProduct
",",1057,O
NK1r-,1057,B-GeneOrGeneProduct
",",1057,O
nNOS-,1057,B-GeneOrGeneProduct
",",1057,O
VIP-,1057,B-GeneOrGeneProduct
",",1057,O
and,1057,O
S100b-immunoreactivity,1057,B-GeneOrGeneProduct
(,1057,O
IR,1057,O
),1057,O
and,1057,O
the,1057,O
increase,1057,O
in,1057,O
CGRP-,1057,B-GeneOrGeneProduct
",",1057,O
and,1057,O
CRF1r-IR,1057,B-GeneOrGeneProduct
.,1057,O
On,1058,O
the,1058,O
contrary,1058,O
",",1058,O
OB,1058,B-ChemicalEntity
does,1058,O
not,1058,O
affect,1058,O
the,1058,O
increase,1058,O
in,1058,O
CRF2r-IR,1058,B-GeneOrGeneProduct
neurons,1058,O
observed,1058,O
in,1058,O
WRS,1058,O
rats,1058,B-OrganismTaxon
and,1058,O
does,1058,O
not,1058,O
interfere,1058,O
with,1058,O
the,1058,O
mild,1058,O
mucosal,1058,B-DiseaseOrPhenotypicFeature
inflammation,1058,I-DiseaseOrPhenotypicFeature
due,1058,O
to,1058,O
WRS,1058,O
.,1058,O
Finally,1059,O
",",1059,O
OB,1059,B-ChemicalEntity
per,1059,O
se,1059,O
increases,1059,O
the,1059,O
Mr2,1059,B-GeneOrGeneProduct
expression,1059,O
in,1059,O
the,1059,O
muscle,1059,O
wall,1059,O
and,1059,O
decreases,1059,O
the,1059,O
number,1059,O
of,1059,O
the,1059,O
myenteric,1059,O
ChAT-IR,1059,B-GeneOrGeneProduct
neurons,1059,O
.,1059,O
Functional,1060,O
findings,1060,O
show,1060,O
a,1060,O
significantly,1060,O
reduction,1060,O
in,1060,O
the,1060,O
number,1060,O
of,1060,O
spontaneous,1060,O
abdominal,1060,O
contraction,1060,O
in,1060,O
OB,1060,B-ChemicalEntity
treated,1060,O
rats,1060,B-OrganismTaxon
.,1060,O
The,1061,O
ability,1061,O
of,1061,O
OB,1061,B-ChemicalEntity
to,1061,O
block,1061,O
L-type,1061,B-GeneOrGeneProduct
Ca,1061,I-GeneOrGeneProduct
(,1061,I-GeneOrGeneProduct
2+,1061,I-GeneOrGeneProduct
),1061,I-GeneOrGeneProduct
channels,1061,I-GeneOrGeneProduct
",",1061,O
also,1061,O
expressed,1061,O
by,1061,O
enteric,1061,O
neurons,1061,O
",",1061,O
might,1061,O
represent,1061,O
a,1061,O
possible,1061,O
mechanism,1061,O
through,1061,O
which,1061,O
OB,1061,B-ChemicalEntity
exerts,1061,O
its,1061,O
actions,1061,O
.,1061,O
Pleomorphic,1062,B-GeneOrGeneProduct
adenoma,1062,I-GeneOrGeneProduct
gene,1062,I-GeneOrGeneProduct
like-2,1062,I-GeneOrGeneProduct
induces,1062,O
epithelial-mesenchymal,1062,O
transition,1062,O
via,1062,O
Wnt/b-catenin,1062,B-GeneOrGeneProduct
signaling,1062,O
pathway,1062,O
in,1062,O
human,1062,B-OrganismTaxon
colorectal,1062,B-DiseaseOrPhenotypicFeature
adenocarcinoma,1062,I-DiseaseOrPhenotypicFeature
.,1062,O
Epithelial-mesenchymal,1063,O
transition,1063,O
(,1063,O
EMT,1063,O
),1063,O
is,1063,O
a,1063,O
critical,1063,O
step,1063,O
in,1063,O
the,1063,O
acquisition,1063,O
of,1063,O
metastatic,1063,O
and,1063,O
invasive,1063,O
power,1063,O
for,1063,O
tumor,1063,B-DiseaseOrPhenotypicFeature
cells,1063,O
.,1063,O
Colorectal,1064,B-DiseaseOrPhenotypicFeature
adenocarcinoma,1064,I-DiseaseOrPhenotypicFeature
(,1064,O
CRC,1064,B-DiseaseOrPhenotypicFeature
),1064,O
is,1064,O
a,1064,O
common,1064,O
cancer,1064,B-DiseaseOrPhenotypicFeature
where,1064,O
metastasis,1064,B-DiseaseOrPhenotypicFeature
is,1064,O
directly,1064,O
linked,1064,O
to,1064,O
patient,1064,B-OrganismTaxon
survival,1064,O
.,1064,O
Recent,1065,O
studies,1065,O
show,1065,O
that,1065,O
pleomorphic,1065,B-GeneOrGeneProduct
adenoma,1065,I-GeneOrGeneProduct
gene,1065,I-GeneOrGeneProduct
like-2,1065,I-GeneOrGeneProduct
(,1065,O
PLAGL2,1065,B-GeneOrGeneProduct
),1065,O
could,1065,O
induce,1065,O
tumor,1065,B-DiseaseOrPhenotypicFeature
EMT,1065,O
and,1065,O
is,1065,O
an,1065,O
independent,1065,O
predictive,1065,O
factor,1065,O
associated,1065,O
with,1065,O
poor,1065,O
prognosis,1065,O
in,1065,O
cancer,1065,B-DiseaseOrPhenotypicFeature
.,1065,O
In,1066,O
the,1066,O
present,1066,O
study,1066,O
",",1066,O
we,1066,O
confirmed,1066,O
the,1066,O
role,1066,O
of,1066,O
PLAGL2,1066,B-GeneOrGeneProduct
in,1066,O
the,1066,O
prognosis,1066,O
of,1066,O
CRC,1066,B-DiseaseOrPhenotypicFeature
patients,1066,B-OrganismTaxon
and,1066,O
provide,1066,O
molecular,1066,O
evidence,1066,O
of,1066,O
PLAGL2,1066,B-GeneOrGeneProduct
promoted,1066,O
EMT,1066,O
in,1066,O
CRC,1066,B-DiseaseOrPhenotypicFeature
cell,1066,O
line,1066,O
SW480,1066,B-CellLine
.,1066,O
We,1067,O
found,1067,O
that,1067,O
PLAGL2,1067,B-GeneOrGeneProduct
expression,1067,O
was,1067,O
upregulated,1067,O
in,1067,O
the,1067,O
paraffin-embedded,1067,B-ChemicalEntity
CRC,1067,B-DiseaseOrPhenotypicFeature
tissues,1067,O
compared,1067,O
to,1067,O
borderline,1067,O
or,1067,O
benign,1067,O
tissues,1067,O
.,1067,O
Experimental,1068,O
EMT,1068,O
induced,1068,O
by,1068,O
PLAGL2,1068,B-GeneOrGeneProduct
plasmid,1068,O
transfection,1068,O
proved,1068,O
PLAGL2,1068,B-GeneOrGeneProduct
protein,1068,O
overexpression,1068,O
could,1068,O
enhance,1068,O
the,1068,O
cell,1068,O
scratch,1068,O
wound-healing,1068,O
and,1068,O
transwell,1068,O
ability,1068,O
and,1068,O
significantly,1068,O
upregulated,1068,O
mesenchymal,1068,O
marker,1068,O
proteins,1068,O
",",1068,O
N-cadherin,1068,B-GeneOrGeneProduct
and,1068,O
vimentin,1068,B-GeneOrGeneProduct
and,1068,O
concurrently,1068,O
downregulated,1068,O
epithelial,1068,O
marker,1068,O
of,1068,O
E-cadherin,1068,B-GeneOrGeneProduct
.,1068,O
Subsequently,1069,O
",",1069,O
through,1069,O
western,1069,O
blot,1069,O
assay,1069,O
",",1069,O
we,1069,O
found,1069,O
that,1069,O
PLAGL2,1069,B-GeneOrGeneProduct
could,1069,O
activate,1069,O
the,1069,O
wnt-signaling,1069,B-GeneOrGeneProduct
component,1069,O
b-catenin,1069,B-GeneOrGeneProduct
in,1069,O
the,1069,O
nuclei,1069,O
.,1069,O
More,1070,O
CRC,1070,B-DiseaseOrPhenotypicFeature
cell,1070,O
metastasis,1070,B-DiseaseOrPhenotypicFeature
to,1070,O
the,1070,O
lungs,1070,O
was,1070,O
observed,1070,O
when,1070,O
the,1070,O
PLAGL2,1070,B-GeneOrGeneProduct
overexpressing,1070,O
SW480,1070,B-CellLine
cells,1070,O
were,1070,O
injected,1070,O
into,1070,O
the,1070,O
tail,1070,O
vein,1070,O
of,1070,O
rats,1070,B-OrganismTaxon
",",1070,O
compared,1070,O
with,1070,O
the,1070,O
cell,1070,O
control,1070,O
and,1070,O
PLAGL2,1070,B-GeneOrGeneProduct
silence,1070,O
group,1070,O
.,1070,O
Our,1071,O
findings,1071,O
indicated,1071,O
that,1071,O
PLAGL2,1071,B-GeneOrGeneProduct
might,1071,O
be,1071,O
a,1071,O
very,1071,O
upstream,1071,O
key,1071,O
molecule,1071,O
regulating,1071,O
EMT,1071,O
involved,1071,O
in,1071,O
Wnt/b-catenin,1071,B-GeneOrGeneProduct
signaling,1071,O
pathway,1071,O
.,1071,O
Psoriasin,1072,B-GeneOrGeneProduct
promotes,1072,O
invasion,1072,O
",",1072,O
aggregation,1072,O
and,1072,O
survival,1072,O
of,1072,O
pancreatic,1072,B-DiseaseOrPhenotypicFeature
cancer,1072,I-DiseaseOrPhenotypicFeature
cells,1072,O
;,1072,O
association,1072,O
with,1072,O
disease,1072,O
progression,1072,O
.,1072,O
Psoriasin,1073,B-GeneOrGeneProduct
(,1073,O
S100A7,1073,B-GeneOrGeneProduct
),1073,O
is,1073,O
an,1073,O
11-kDa,1073,O
small,1073,O
calcium,1073,B-GeneOrGeneProduct
binding,1073,I-GeneOrGeneProduct
protein,1073,I-GeneOrGeneProduct
initially,1073,O
isolated,1073,O
from,1073,O
psoriatic,1073,B-DiseaseOrPhenotypicFeature
skin,1073,I-DiseaseOrPhenotypicFeature
lesions,1073,I-DiseaseOrPhenotypicFeature
.,1073,O
It,1074,O
belongs,1074,O
to,1074,O
the,1074,O
S100,1074,B-GeneOrGeneProduct
family,1074,O
of,1074,O
proteins,1074,O
which,1074,O
play,1074,O
an,1074,O
important,1074,O
role,1074,O
in,1074,O
a,1074,O
range,1074,O
of,1074,O
cell,1074,O
functions,1074,O
including,1074,O
proliferation,1074,O
",",1074,O
differentiation,1074,O
",",1074,O
migration,1074,O
and,1074,O
apoptosis,1074,O
.,1074,O
Aberrant,1075,O
Psoriasin,1075,B-GeneOrGeneProduct
expression,1075,O
has,1075,O
been,1075,O
implicated,1075,O
in,1075,O
a,1075,O
range,1075,O
of,1075,O
cancers,1075,B-DiseaseOrPhenotypicFeature
and,1075,O
is,1075,O
often,1075,O
associated,1075,O
with,1075,O
poor,1075,O
prognosis,1075,O
.,1075,O
This,1076,O
study,1076,O
examined,1076,O
the,1076,O
role,1076,O
of,1076,O
Psoriasin,1076,B-GeneOrGeneProduct
on,1076,O
pancreatic,1076,B-DiseaseOrPhenotypicFeature
cancer,1076,I-DiseaseOrPhenotypicFeature
cell,1076,O
functions,1076,O
and,1076,O
the,1076,O
implication,1076,O
in,1076,O
progression,1076,O
of,1076,O
the,1076,O
disease,1076,O
.,1076,O
Expression,1077,O
of,1077,O
Psoriasin,1077,B-GeneOrGeneProduct
was,1077,O
determined,1077,O
in,1077,O
a,1077,O
cohort,1077,O
of,1077,O
pancreatic,1077,O
tissues,1077,O
comprised,1077,O
of,1077,O
126,1077,O
pancreatic,1077,B-DiseaseOrPhenotypicFeature
tumours,1077,I-DiseaseOrPhenotypicFeature
and,1077,O
114,1077,O
adjacent,1077,O
non-tumour,1077,O
pancreatic,1077,O
tissues,1077,O
.,1077,O
Knockdown,1078,O
and,1078,O
overexpression,1078,O
of,1078,O
Psoriasin,1078,B-GeneOrGeneProduct
in,1078,O
pancreatic,1078,B-DiseaseOrPhenotypicFeature
cancer,1078,I-DiseaseOrPhenotypicFeature
cells,1078,O
was,1078,O
performed,1078,O
using,1078,O
specifically,1078,O
constructed,1078,O
plasmids,1078,O
",",1078,O
which,1078,O
either,1078,O
had,1078,O
anti-Psoriasin,1078,O
ribozyme,1078,O
transgene,1078,O
or,1078,O
the,1078,O
full,1078,O
length,1078,O
human,1078,B-OrganismTaxon
Psoriasin,1078,B-GeneOrGeneProduct
coding,1078,O
sequence,1078,O
.,1078,O
Psoriasin,1079,B-GeneOrGeneProduct
knockdown,1079,O
and,1079,O
overexpression,1079,O
was,1079,O
verified,1079,O
using,1079,O
conventional,1079,O
RT-PCR,1079,O
and,1079,O
qPCR,1079,O
.,1079,O
The,1080,O
effect,1080,O
of,1080,O
manipulating,1080,O
Psoriasin,1080,B-GeneOrGeneProduct
expression,1080,O
on,1080,O
pancreatic,1080,B-DiseaseOrPhenotypicFeature
cancer,1080,I-DiseaseOrPhenotypicFeature
cell,1080,O
functions,1080,O
was,1080,O
assessed,1080,O
using,1080,O
several,1080,O
in,1080,O
vitro,1080,O
cell,1080,O
function,1080,O
assays,1080,O
.,1080,O
Local,1081,O
invasive,1081,O
pancreatic,1081,B-DiseaseOrPhenotypicFeature
cancers,1081,I-DiseaseOrPhenotypicFeature
extended,1081,O
beyond,1081,O
the,1081,O
pancreas,1081,O
expressed,1081,O
higher,1081,O
levels,1081,O
of,1081,O
Psoriasin,1081,B-GeneOrGeneProduct
transcripts,1081,O
compared,1081,O
with,1081,O
the,1081,O
cancers,1081,B-DiseaseOrPhenotypicFeature
confined,1081,O
to,1081,O
the,1081,O
pancreas,1081,O
.,1081,O
Primary,1082,B-DiseaseOrPhenotypicFeature
tumours,1082,I-DiseaseOrPhenotypicFeature
with,1082,O
distant,1082,O
metastases,1082,B-DiseaseOrPhenotypicFeature
exhibited,1082,O
a,1082,O
reduced,1082,O
expression,1082,O
of,1082,O
Psoriasin,1082,B-GeneOrGeneProduct
.,1082,O
Psoriasin,1083,B-GeneOrGeneProduct
overexpression,1083,O
cell,1083,O
lines,1083,O
exhibited,1083,O
significantly,1083,O
increased,1083,O
growth,1083,O
and,1083,O
migration,1083,O
compared,1083,O
to,1083,O
control,1083,O
cells,1083,O
.,1083,O
In,1084,O
addition,1084,O
",",1084,O
Psoriasin,1084,B-GeneOrGeneProduct
overexpression,1084,O
resulted,1084,O
in,1084,O
increased,1084,O
pancreatic,1084,B-DiseaseOrPhenotypicFeature
cancer,1084,I-DiseaseOrPhenotypicFeature
cell,1084,O
invasion,1084,O
which,1084,O
was,1084,O
associated,1084,O
with,1084,O
upregulation,1084,O
of,1084,O
matrix,1084,B-GeneOrGeneProduct
metalloproteinase-2,1084,I-GeneOrGeneProduct
(,1084,O
MMP-2,1084,B-GeneOrGeneProduct
),1084,O
and,1084,O
MMP-9,1084,B-GeneOrGeneProduct
.,1084,O
Overexpression,1085,O
of,1085,O
Psoriasin,1085,B-GeneOrGeneProduct
also,1085,O
promoted,1085,O
aggregation,1085,O
and,1085,O
survival,1085,O
of,1085,O
pancreatic,1085,B-DiseaseOrPhenotypicFeature
cancer,1085,I-DiseaseOrPhenotypicFeature
cells,1085,O
when,1085,O
they,1085,O
lost,1085,O
anchorage,1085,O
.,1085,O
Taken,1086,O
together,1086,O
",",1086,O
higher,1086,O
expression,1086,O
of,1086,O
Psoriasin,1086,B-GeneOrGeneProduct
was,1086,O
associated,1086,O
with,1086,O
local,1086,O
invasion,1086,O
in,1086,O
pancreatic,1086,B-DiseaseOrPhenotypicFeature
cancers,1086,I-DiseaseOrPhenotypicFeature
.,1086,O
Psoriasin,1087,B-GeneOrGeneProduct
expression,1087,O
is,1087,O
associated,1087,O
with,1087,O
pancreatic,1087,B-DiseaseOrPhenotypicFeature
cancer,1087,I-DiseaseOrPhenotypicFeature
cell,1087,O
growth,1087,O
",",1087,O
migration,1087,O
",",1087,O
cell-matrix,1087,O
adhesion,1087,O
",",1087,O
and,1087,O
invasion,1087,O
via,1087,O
regulation,1087,O
of,1087,O
MMPs,1087,B-GeneOrGeneProduct
.,1087,O
As,1088,O
such,1088,O
",",1088,O
the,1088,O
proposed,1088,O
implications,1088,O
of,1088,O
Psoriasin,1088,B-GeneOrGeneProduct
in,1088,O
invasion,1088,O
",",1088,O
disease,1088,O
progression,1088,O
and,1088,O
as,1088,O
a,1088,O
potential,1088,O
therapeutic,1088,O
target,1088,O
warrant,1088,O
further,1088,O
investigation,1088,O
.,1088,O
Calcium,1089,B-GeneOrGeneProduct
sensing,1089,I-GeneOrGeneProduct
receptor,1089,I-GeneOrGeneProduct
protects,1089,O
high,1089,O
glucose-induced,1089,B-ChemicalEntity
energy,1089,O
metabolism,1089,B-DiseaseOrPhenotypicFeature
disorder,1089,I-DiseaseOrPhenotypicFeature
via,1089,O
blocking,1089,O
gp78-ubiquitin,1089,B-GeneOrGeneProduct
proteasome,1089,O
pathway,1089,O
.,1089,O
Diabetic,1090,B-DiseaseOrPhenotypicFeature
cardiomyopathy,1090,I-DiseaseOrPhenotypicFeature
(,1090,O
DCM,1090,B-DiseaseOrPhenotypicFeature
),1090,O
is,1090,O
a,1090,O
major,1090,O
complication,1090,O
and,1090,O
fatal,1090,O
cause,1090,O
of,1090,O
the,1090,O
patients,1090,B-OrganismTaxon
with,1090,O
diabetes,1090,B-DiseaseOrPhenotypicFeature
.,1090,O
The,1091,O
calcium,1091,B-GeneOrGeneProduct
sensing,1091,I-GeneOrGeneProduct
receptor,1091,I-GeneOrGeneProduct
(,1091,O
CaSR,1091,B-GeneOrGeneProduct
),1091,O
is,1091,O
a,1091,O
G,1091,B-GeneOrGeneProduct
protein-coupled,1091,I-GeneOrGeneProduct
receptor,1091,I-GeneOrGeneProduct
",",1091,O
which,1091,O
is,1091,O
involved,1091,O
in,1091,O
maintaining,1091,O
calcium,1091,B-ChemicalEntity
homeostasis,1091,O
",",1091,O
regulating,1091,O
cell,1091,O
proliferation,1091,O
and,1091,O
apoptosis,1091,O
",",1091,O
and,1091,O
so,1091,O
on,1091,O
.,1091,O
In,1092,O
our,1092,O
previous,1092,O
study,1092,O
",",1092,O
we,1092,O
found,1092,O
that,1092,O
CaSR,1092,B-GeneOrGeneProduct
expression,1092,O
",",1092,O
intracellular,1092,O
calcium,1092,B-ChemicalEntity
levels,1092,O
and,1092,O
cardiac,1092,O
function,1092,O
were,1092,O
all,1092,O
significantly,1092,O
decreased,1092,O
in,1092,O
DCM,1092,B-DiseaseOrPhenotypicFeature
rats,1092,B-OrganismTaxon
;,1092,O
however,1092,O
",",1092,O
the,1092,O
exact,1092,O
mechanism,1092,O
are,1092,O
not,1092,O
clear,1092,O
yet,1092,O
.,1092,O
The,1093,O
present,1093,O
study,1093,O
revealed,1093,O
the,1093,O
protective,1093,O
role,1093,O
of,1093,O
CaSR,1093,B-GeneOrGeneProduct
in,1093,O
myocardial,1093,B-DiseaseOrPhenotypicFeature
energy,1093,I-DiseaseOrPhenotypicFeature
metabolism,1093,I-DiseaseOrPhenotypicFeature
disorder,1093,I-DiseaseOrPhenotypicFeature
induced,1093,O
by,1093,O
high,1093,O
glucose,1093,B-ChemicalEntity
(,1093,O
HG,1093,O
),1093,O
as,1093,O
well,1093,O
as,1093,O
the,1093,O
underlying,1093,O
mechanism,1093,O
.,1093,O
Here,1094,O
",",1094,O
we,1094,O
demonstrated,1094,O
that,1094,O
HG,1094,O
decreased,1094,O
the,1094,O
expression,1094,O
of,1094,O
CaSR,1094,B-GeneOrGeneProduct
",",1094,O
mitochondrial,1094,O
fusion,1094,O
proteins,1094,O
(,1094,O
Mfn1,1094,B-GeneOrGeneProduct
",",1094,O
Mfn2,1094,B-GeneOrGeneProduct
),1094,O
",",1094,O
cell,1094,O
gap,1094,O
junction,1094,O
related,1094,O
proteins,1094,O
(,1094,O
Cx43,1094,B-GeneOrGeneProduct
",",1094,O
beta-catenin,1094,B-GeneOrGeneProduct
",",1094,O
N-cadherin,1094,B-GeneOrGeneProduct
),1094,O
",",1094,O
and,1094,O
intracellular,1094,O
ATP,1094,B-ChemicalEntity
concentration,1094,O
.,1094,O
In,1095,O
contrast,1095,O
",",1095,O
HG,1095,O
increased,1095,O
extracellular,1095,O
ATP,1095,B-ChemicalEntity
concentration,1095,O
",",1095,O
the,1095,O
expression,1095,O
of,1095,O
gp78,1095,B-GeneOrGeneProduct
",",1095,O
mitochondrial,1095,O
fission,1095,O
proteins,1095,O
(,1095,O
Fis1,1095,B-GeneOrGeneProduct
",",1095,O
Drp1,1095,B-GeneOrGeneProduct
),1095,O
",",1095,O
and,1095,O
the,1095,O
ubiquitination,1095,O
levels,1095,O
of,1095,O
Mfn1,1095,B-GeneOrGeneProduct
",",1095,O
Mfn2,1095,B-GeneOrGeneProduct
and,1095,O
Cx43,1095,B-GeneOrGeneProduct
.,1095,O
Moreover,1096,O
",",1096,O
CaSR,1096,B-GeneOrGeneProduct
agonist,1096,O
and,1096,O
gp78-siRNA,1096,B-GeneOrGeneProduct
significantly,1096,O
reduced,1096,O
the,1096,O
above,1096,O
changes,1096,O
.,1096,O
Taken,1097,O
together,1097,O
",",1097,O
these,1097,O
results,1097,O
suggest,1097,O
that,1097,O
HG,1097,O
induces,1097,O
myocardial,1097,B-DiseaseOrPhenotypicFeature
energy,1097,I-DiseaseOrPhenotypicFeature
metabolism,1097,I-DiseaseOrPhenotypicFeature
disorder,1097,I-DiseaseOrPhenotypicFeature
via,1097,O
decrease,1097,O
of,1097,O
CaSR,1097,B-GeneOrGeneProduct
expression,1097,O
",",1097,O
and,1097,O
activation,1097,O
of,1097,O
gp78-ubiquitin,1097,B-GeneOrGeneProduct
proteasome,1097,O
system,1097,O
.,1097,O
In,1098,O
turn,1098,O
",",1098,O
these,1098,O
effects,1098,O
disrupt,1098,O
the,1098,O
structure,1098,O
and,1098,O
function,1098,O
of,1098,O
the,1098,O
mitochondria,1098,O
and,1098,O
the,1098,O
cell,1098,O
gap,1098,O
junction,1098,O
",",1098,O
result,1098,O
in,1098,O
the,1098,O
reduced,1098,O
ATP,1098,B-ChemicalEntity
synthesis,1098,O
and,1098,O
the,1098,O
increased,1098,O
ATP,1098,B-ChemicalEntity
leakage,1098,O
.,1098,O
Stimulation,1099,O
of,1099,O
CaSR,1099,B-GeneOrGeneProduct
significantly,1099,O
attenuates,1099,O
HG-induced,1099,O
abnormal,1099,B-DiseaseOrPhenotypicFeature
myocardial,1099,I-DiseaseOrPhenotypicFeature
energy,1099,I-DiseaseOrPhenotypicFeature
metabolism,1099,I-DiseaseOrPhenotypicFeature
",",1099,O
suggesting,1099,O
CaSR,1099,B-GeneOrGeneProduct
would,1099,O
be,1099,O
a,1099,O
promising,1099,O
potential,1099,O
therapeutic,1099,O
target,1099,O
for,1099,O
DCM,1099,B-DiseaseOrPhenotypicFeature
.,1099,O
An,1100,O
inducible,1100,O
mouse,1100,B-OrganismTaxon
model,1100,O
of,1100,O
podocin-mutation-related,1100,B-GeneOrGeneProduct
nephrotic,1100,B-DiseaseOrPhenotypicFeature
syndrome,1100,I-DiseaseOrPhenotypicFeature
.,1100,O
Mutations,1101,O
in,1101,O
the,1101,O
NPHS2,1101,B-GeneOrGeneProduct
gene,1101,O
",",1101,O
encoding,1101,O
podocin,1101,B-GeneOrGeneProduct
",",1101,O
cause,1101,O
hereditary,1101,O
nephrotic,1101,B-DiseaseOrPhenotypicFeature
syndrome,1101,I-DiseaseOrPhenotypicFeature
.,1101,O
The,1102,O
most,1102,O
common,1102,O
podocin,1102,B-GeneOrGeneProduct
mutation,1102,O
",",1102,O
R138Q,1102,B-SequenceVariant
",",1102,O
is,1102,O
associated,1102,O
with,1102,O
early,1102,O
disease,1102,O
onset,1102,O
and,1102,O
rapid,1102,O
progression,1102,O
to,1102,O
end-stage,1102,O
renal,1102,B-DiseaseOrPhenotypicFeature
disease,1102,I-DiseaseOrPhenotypicFeature
.,1102,O
Knock-in,1103,O
mice,1103,B-OrganismTaxon
carrying,1103,O
a,1103,O
R140Q,1103,B-SequenceVariant
mutation,1103,O
",",1103,O
the,1103,O
mouse,1103,B-OrganismTaxon
analogue,1103,O
of,1103,O
human,1103,B-OrganismTaxon
R138Q,1103,B-SequenceVariant
",",1103,O
show,1103,O
developmental,1103,O
arrest,1103,O
of,1103,O
podocytes,1103,O
and,1103,O
lethal,1103,O
renal,1103,B-DiseaseOrPhenotypicFeature
failure,1103,I-DiseaseOrPhenotypicFeature
at,1103,O
neonatal,1103,O
age,1103,O
.,1103,O
Here,1104,O
we,1104,O
created,1104,O
a,1104,O
conditional,1104,O
podocin,1104,B-GeneOrGeneProduct
knock-in,1104,O
model,1104,O
named,1104,O
NPHS2,1104,B-GeneOrGeneProduct
R140Q/-,1104,B-SequenceVariant
",",1104,O
using,1104,O
a,1104,O
tamoxifen-inducible,1104,B-ChemicalEntity
Cre,1104,O
recombinase,1104,O
",",1104,O
which,1104,O
permits,1104,O
to,1104,O
study,1104,O
the,1104,O
effects,1104,O
of,1104,O
the,1104,O
mutation,1104,O
in,1104,O
postnatal,1104,O
life,1104,O
.,1104,O
Within,1105,O
the,1105,O
first,1105,O
week,1105,O
of,1105,O
R140Q,1105,B-SequenceVariant
hemizygosity,1105,O
induction,1105,O
the,1105,O
animals,1105,O
developed,1105,O
proteinuria,1105,B-DiseaseOrPhenotypicFeature
",",1105,O
which,1105,O
peaked,1105,O
after,1105,O
4-5,1105,O
weeks,1105,O
.,1105,O
Subsequently,1106,O
the,1106,O
animals,1106,O
developed,1106,O
progressive,1106,O
renal,1106,B-DiseaseOrPhenotypicFeature
failure,1106,I-DiseaseOrPhenotypicFeature
",",1106,O
with,1106,O
a,1106,O
median,1106,O
survival,1106,O
time,1106,O
of,1106,O
12,1106,O
(,1106,O
95,1106,O
%,1106,O
CI,1106,O
:,1106,O
11-13,1106,O
),1106,O
weeks,1106,O
.,1106,O
Foot,1107,O
process,1107,O
fusion,1107,O
was,1107,O
observed,1107,O
within,1107,O
one,1107,O
week,1107,O
",",1107,O
progressing,1107,O
to,1107,O
severe,1107,O
and,1107,O
global,1107,O
effacement,1107,O
in,1107,O
the,1107,O
course,1107,O
of,1107,O
the,1107,O
disease,1107,O
.,1107,O
The,1108,O
number,1108,O
of,1108,O
podocytes,1108,O
per,1108,O
glomerulus,1108,O
gradually,1108,O
diminished,1108,O
to,1108,O
18,1108,O
%,1108,O
compared,1108,O
to,1108,O
healthy,1108,O
controls,1108,O
12-16,1108,O
weeks,1108,O
after,1108,O
induction,1108,O
.,1108,O
The,1109,O
fraction,1109,O
of,1109,O
segmentally,1109,O
sclerosed,1109,O
glomeruli,1109,O
was,1109,O
25,1109,O
%,1109,O
",",1109,O
85,1109,O
%,1109,O
and,1109,O
97,1109,O
%,1109,O
at,1109,O
2,1109,O
",",1109,O
4,1109,O
and,1109,O
8,1109,O
weeks,1109,O
",",1109,O
respectively,1109,O
.,1109,O
Severe,1110,O
tubulointerstitial,1110,B-DiseaseOrPhenotypicFeature
fibrosis,1110,I-DiseaseOrPhenotypicFeature
was,1110,O
present,1110,O
at,1110,O
later,1110,O
disease,1110,O
stage,1110,O
and,1110,O
was,1110,O
correlated,1110,O
quantitatively,1110,O
with,1110,O
the,1110,O
level,1110,O
of,1110,O
proteinuria,1110,B-DiseaseOrPhenotypicFeature
at,1110,O
early,1110,O
disease,1110,O
stages,1110,O
.,1110,O
While,1111,O
R140Q,1111,B-SequenceVariant
podocin,1111,B-GeneOrGeneProduct
mRNA,1111,O
expression,1111,O
was,1111,O
elevated,1111,O
",",1111,O
protein,1111,O
abundance,1111,O
was,1111,O
reduced,1111,O
by,1111,O
more,1111,O
than,1111,O
50,1111,O
%,1111,O
within,1111,O
one,1111,O
week,1111,O
following,1111,O
induction,1111,O
.,1111,O
Whereas,1112,O
miRNA21,1112,B-GeneOrGeneProduct
expression,1112,O
persistently,1112,O
increased,1112,O
during,1112,O
the,1112,O
first,1112,O
4,1112,O
weeks,1112,O
",",1112,O
miRNA-193a,1112,B-GeneOrGeneProduct
expression,1112,O
peaked,1112,O
2,1112,O
weeks,1112,O
after,1112,O
induction,1112,O
.,1112,O
In,1113,O
conclusion,1113,O
",",1113,O
the,1113,O
inducible,1113,O
R140Q-podocin,1113,B-SequenceVariant
mouse,1113,B-OrganismTaxon
model,1113,O
is,1113,O
an,1113,O
auspicious,1113,O
model,1113,O
of,1113,O
the,1113,O
most,1113,O
common,1113,O
genetic,1113,O
cause,1113,O
of,1113,O
human,1113,B-OrganismTaxon
nephrotic,1113,B-DiseaseOrPhenotypicFeature
syndrome,1113,I-DiseaseOrPhenotypicFeature
",",1113,O
with,1113,O
a,1113,O
spontaneous,1113,O
disease,1113,O
course,1113,O
strongly,1113,O
reminiscent,1113,O
of,1113,O
the,1113,O
human,1113,B-OrganismTaxon
disorder,1113,O
.,1113,O
This,1114,O
model,1114,O
constitutes,1114,O
a,1114,O
valuable,1114,O
tool,1114,O
to,1114,O
test,1114,O
the,1114,O
efficacy,1114,O
of,1114,O
novel,1114,O
pharmacological,1114,O
interventions,1114,O
aimed,1114,O
to,1114,O
improve,1114,O
podocyte,1114,O
function,1114,O
and,1114,O
viability,1114,O
and,1114,O
attenuate,1114,O
proteinuria,1114,B-DiseaseOrPhenotypicFeature
",",1114,O
glomerulosclerosis,1114,B-DiseaseOrPhenotypicFeature
and,1114,O
progressive,1114,O
renal,1114,B-DiseaseOrPhenotypicFeature
failure,1114,I-DiseaseOrPhenotypicFeature
.,1114,O
Arginase,1115,B-GeneOrGeneProduct
1,1115,I-GeneOrGeneProduct
deletion,1115,O
in,1115,O
myeloid,1115,O
cells,1115,O
affects,1115,O
the,1115,O
inflammatory,1115,B-DiseaseOrPhenotypicFeature
response,1115,O
in,1115,O
allergic,1115,O
asthma,1115,B-DiseaseOrPhenotypicFeature
",",1115,O
but,1115,O
not,1115,O
lung,1115,O
mechanics,1115,O
",",1115,O
in,1115,O
female,1115,O
mice,1115,B-OrganismTaxon
.,1115,O
BACKGROUND,1116,O
:,1116,O
(,1116,O
Over-,1116,O
),1116,O
expression,1116,O
of,1116,O
arginase,1116,B-GeneOrGeneProduct
may,1116,O
limit,1116,O
local,1116,O
availability,1116,O
of,1116,O
arginine,1116,O
for,1116,O
nitric,1116,B-ChemicalEntity
oxide,1116,I-ChemicalEntity
synthesis,1116,O
.,1116,O
We,1117,O
investigated,1117,O
the,1117,O
significance,1117,O
of,1117,O
arginase1,1117,B-GeneOrGeneProduct
(,1117,O
ARG1,1117,B-GeneOrGeneProduct
),1117,O
for,1117,O
the,1117,O
development,1117,O
of,1117,O
airway,1117,O
hyperresponsiveness,1117,O
(,1117,O
AHR,1117,O
),1117,O
and,1117,O
lung,1117,B-DiseaseOrPhenotypicFeature
inflammation,1117,I-DiseaseOrPhenotypicFeature
in,1117,O
female,1117,O
mice,1117,B-OrganismTaxon
with,1117,O
ovalbumin,1117,B-GeneOrGeneProduct
(,1117,O
OVA,1117,B-GeneOrGeneProduct
),1117,O
-induced,1117,O
allergic,1117,O
asthma,1117,B-DiseaseOrPhenotypicFeature
.,1117,O
METHODS,1118,O
:,1118,O
Arg1,1118,B-GeneOrGeneProduct
was,1118,O
ablated,1118,O
in,1118,O
the,1118,O
lung,1118,O
by,1118,O
crossing,1118,O
Arg1,1118,B-GeneOrGeneProduct
fl/fl,1118,O
and,1118,O
Tie2Cre,1118,O
tg/-,1118,O
mice,1118,B-OrganismTaxon
.,1118,O
OVA,1119,B-GeneOrGeneProduct
sensitization,1119,O
and,1119,O
challenge,1119,O
were,1119,O
conducted,1119,O
",",1119,O
and,1119,O
AHR,1119,O
to,1119,O
methacholine,1119,B-ChemicalEntity
was,1119,O
determined,1119,O
using,1119,O
the,1119,O
Flexivent,1119,O
system,1119,O
.,1119,O
Changes,1120,O
in,1120,O
gene,1120,O
expression,1120,O
",",1120,O
chemokine,1120,O
and,1120,O
cytokine,1120,O
secretion,1120,O
",",1120,O
plasma,1120,O
IgE,1120,B-GeneOrGeneProduct
",",1120,O
and,1120,O
lung,1120,O
histology,1120,O
were,1120,O
quantified,1120,O
using,1120,O
RT-qPCR,1120,O
",",1120,O
ELISA,1120,O
",",1120,O
and,1120,O
immunohistochemistry,1120,O
",",1120,O
respectively,1120,O
.,1120,O
RESULTS,1121,O
:,1121,O
Arg1,1121,B-GeneOrGeneProduct
ablation,1121,O
had,1121,O
no,1121,O
influence,1121,O
on,1121,O
the,1121,O
development,1121,O
of,1121,O
OVA-induced,1121,B-GeneOrGeneProduct
AHR,1121,O
",",1121,O
but,1121,O
attenuated,1121,O
OVA-induced,1121,B-GeneOrGeneProduct
increases,1121,O
in,1121,O
expression,1121,O
of,1121,O
Arg2,1121,B-GeneOrGeneProduct
and,1121,O
Nos2,1121,B-GeneOrGeneProduct
",",1121,O
Slc7a1,1121,B-GeneOrGeneProduct
",",1121,O
Slc7a2,1121,B-GeneOrGeneProduct
",",1121,O
and,1121,O
Slc7a7,1121,B-GeneOrGeneProduct
(,1121,O
arginine,1121,B-GeneOrGeneProduct
transporters,1121,I-GeneOrGeneProduct
),1121,O
",",1121,O
Il4,1121,B-GeneOrGeneProduct
",",1121,O
Il5,1121,B-GeneOrGeneProduct
and,1121,O
Il13,1121,B-GeneOrGeneProduct
(,1121,O
TH2-type,1121,B-GeneOrGeneProduct
cytokines,1121,I-GeneOrGeneProduct
),1121,O
",",1121,O
Ccl2,1121,B-GeneOrGeneProduct
and,1121,O
Ccl11,1121,B-GeneOrGeneProduct
(,1121,O
chemokines,1121,B-GeneOrGeneProduct
),1121,O
",",1121,O
Ifng,1121,B-GeneOrGeneProduct
(,1121,O
TH1-type,1121,B-GeneOrGeneProduct
cytokine,1121,I-GeneOrGeneProduct
),1121,O
",",1121,O
Clca3,1121,B-GeneOrGeneProduct
and,1121,O
Muc5ac,1121,B-GeneOrGeneProduct
(,1121,O
goblet,1121,O
cell,1121,O
markers,1121,O
),1121,O
",",1121,O
and,1121,O
OVA-specific,1121,B-GeneOrGeneProduct
IgE,1121,B-GeneOrGeneProduct
.,1121,O
Pulmonary,1122,O
IL-10,1122,B-GeneOrGeneProduct
protein,1122,O
content,1122,O
increased,1122,O
",",1122,O
but,1122,O
IL-4,1122,B-GeneOrGeneProduct
",",1122,O
IL-5,1122,B-GeneOrGeneProduct
",",1122,O
IL-13,1122,B-GeneOrGeneProduct
",",1122,O
TNFalpha,1122,B-GeneOrGeneProduct
and,1122,O
IFNgamma,1122,B-GeneOrGeneProduct
content,1122,O
",",1122,O
and,1122,O
lung,1122,O
histopathology,1122,O
",",1122,O
were,1122,O
not,1122,O
affected,1122,O
.,1122,O
Arg1,1123,B-GeneOrGeneProduct
elimination,1123,O
also,1123,O
decreased,1123,O
number,1123,O
and,1123,O
tightness,1123,O
of,1123,O
correlations,1123,O
between,1123,O
adaptive,1123,O
changes,1123,O
in,1123,O
lung,1123,O
function,1123,O
and,1123,O
inflammatory,1123,B-DiseaseOrPhenotypicFeature
parameters,1123,O
in,1123,O
OVA/OVA-treated,1123,B-GeneOrGeneProduct
female,1123,O
mice,1123,B-OrganismTaxon
.,1123,O
OVA/OVA-treated,1124,B-GeneOrGeneProduct
female,1124,O
mice,1124,B-OrganismTaxon
mounted,1124,O
a,1124,O
higher,1124,O
OVA-IgE,1124,B-GeneOrGeneProduct
response,1124,O
than,1124,O
males,1124,O
",",1124,O
but,1124,O
the,1124,O
correlation,1124,O
between,1124,O
lung,1124,O
function,1124,O
and,1124,O
inflammation,1124,B-DiseaseOrPhenotypicFeature
was,1124,O
lower,1124,O
.,1124,O
Arg1-deficient,1125,B-GeneOrGeneProduct
OVA/OVA-treated,1125,B-GeneOrGeneProduct
females,1125,O
differed,1125,O
from,1125,O
males,1125,O
in,1125,O
a,1125,O
more,1125,O
pronounced,1125,O
decline,1125,O
of,1125,O
arginine-metabolizing,1125,O
and,1125,O
-transporting,1125,O
genes,1125,O
",",1125,O
higher,1125,O
plasma,1125,O
arginine,1125,O
levels,1125,O
",",1125,O
a,1125,O
smaller,1125,O
OVA-specific,1125,B-GeneOrGeneProduct
IgE,1125,B-GeneOrGeneProduct
response,1125,O
",",1125,O
and,1125,O
no,1125,O
improvement,1125,O
of,1125,O
peripheral,1125,O
lung,1125,O
function,1125,O
.,1125,O
CONCLUSION,1126,O
:,1126,O
Complete,1126,O
ablation,1126,O
of,1126,O
Arg1,1126,B-GeneOrGeneProduct
in,1126,O
the,1126,O
lung,1126,O
affects,1126,O
mRNA,1126,O
abundance,1126,O
of,1126,O
arginine-transporting,1126,O
and,1126,O
-metabolizing,1126,O
genes,1126,O
",",1126,O
and,1126,O
pro-inflammatory,1126,O
genes,1126,O
",",1126,O
but,1126,O
not,1126,O
methacholine,1126,B-ChemicalEntity
responsiveness,1126,O
or,1126,O
accumulation,1126,O
of,1126,O
inflammatory,1126,B-DiseaseOrPhenotypicFeature
cells,1126,O
.,1126,O
